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ABSTRACT 
There is evidence that amyloid-beta (Aβ) toxicity is mediated through interactions and 
binding with neuronal surface sialic acids in Alzheimer’s disease (AD). The binding affinity is 
higher if the sialic acids are clustered and toxicity of Aβ was attenuated by removal of neuronal 
sialic acids. Thus, interfering with cell membrane-Aβ binding using biomimetics that could 
reproduce the clustered sialic acid structure could present us with a potential target for 
therapeutic intervention in AD. 
Based on this hypothesis, we developed several multifunctionalized sialic acid labeled 
chitosan compounds of different valency, or number of sialic acid per chitosan molecule, to 
attenuate Aβ toxicity. A cross-linker, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) was used, which provided control over the degree of labeling of chitosan. 
After characterization, the ability of the complexes to attenuate toxicity of Aβ(1-40) was 
investigated in vitro. We found that all linear polysialylated complexes showed significant ability 
to attenuate Aβ toxicity, with optimum balance between intrinsic toxicity and protection around 
37% labeling of chitosan. Moreover, unlabeled chitosan also showed some level of protective 
properties to the labeled compounds. 
Then, four biological sugars that are structural analogs of sialic acid (N-Acetylneuraminic 
acid) were used to decorate approximately 35% of the chitosan backbone using EDC chemistry. 
After characterization, the ability of these sugar complexes to attenuate toxicity of Aβ was 
investigated in vitro. We investigated whether sugars other than sialic acid provided better 
toxicity attenuation and attempted to understand the impact of sub-structures or unique –R 
groups of sialic acid and its analogs in Aβ toxicity attenuation. Our results show that oxygen 
substitution in the ring structure contributes to the intrinsic toxicity but also plays a role in Aβ 
xv 
 
toxicity attenuation. Similarly, the multi –OH tail present in sialic acid plays an important role in 
Aβ toxicity attenuation. 
This approach of designing effective biomimetics and of determining the structure-
activity relationship has relevance with respect to the development of new intelligent class of 
therapeutic agents for AD. Although this work focuses on AD, this approach can be extended to 
other diseases involving misfolded proteins. 
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1. OVERVIEW 
1.1. Introduction 
At a medical conference in 1906, a German neurologist, Dr. Alois Alzheimer described 
the autopsy findings of a 51 year old patient who had died from what he described as a course of 
progressive dementia[1, 2]. Today, more than a century after it was first described, this 
condition, called “Alzheimer’s disease”, affects almost 37 million people worldwide with an 
estimated cost of healthcare exceeding a staggering $600 billion, the bulk attributed to long-term 
care for patients unable to care for themselves[3, 4]. Statistics indicate that almost 10% of people 
above 65 years and 50% of people above 85 years will be affected by Alzheimer’s disease (AD). 
Additionally, AD has a very slow progression, so, with the rising life expectancy, the prevalence 
of AD continuously increases, leading to an untenable burden on the healthcare system in terms 
of both services and cost. 
At the present time, there are no absolute causal pathways defined or techniques available 
for definitive diagnosis of AD, although several theories are hypothesized. Plus, there is no 
known cure for AD, with the medicines currently available being simply symptom relieving and 
do not stop or hinder the progression of the disease. 
The only definite confirmation of AD comes from the autopsy of the affected brain. The 
affected brains show massive death of neurons and the loss of synaptic connections with the 
abnormal presence of neurofibrillary tangles and senile plaques [5-9]. The primary species 
identified in the senile plaques is a 39 to 43 amino acid long peptide, called amyloid-beta (Aβ). 
Even though Aβ is necessary for the proper functioning of the human brain, its level drastically 
rises in an AD patient. The enzymes γ-secretase and β-secretase cleave the amyloid precursor 
protein (APP) generating Aβ [10, 11]. The unique feature of Aβ is that the peptide is 
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amphipathic, with a hydrophobic region (C-terminal) with residues 24 to 42 and a hydrophilic 
region (N-terminal) with residues 1 to 28[12]. This allows Aβ to self-assemble and form 
aggregates with a host of different morphologies (dimers, trimers, dodecamers, filaments, 
protofibrils, amyloid-beta derived diffusible ligands (ADDLs), and fibrils). Numerous studies 
have confirmed that these Aβ species play a critical role in the pathogenesis of AD [8, 9, 13-16]. 
Earlier studies indicated that the insoluble fibrils were the toxic species. However, recent data is 
contrasting and suggests that the soluble small Aβ oligomers are the neurotoxic species, with the 
amyloid fibrils being the protective mechanism. However, the exact toxic species is not agreed 
upon, and currently, the aggregated Aβ species such as oligomers, ADDL’s and protofibrils are 
the most pursued targets for the diagnostic and therapeutic treatment of AD. 
Researchers have postulated several mechanisms and hypotheses to explain the pathways 
by which Aβ is toxic to the neurons. Aβ is known to cause synaptic dysfunction, 
neuroinflammation, oxidative stress, decrease membrane fluidity, lipid peroxidation and 
microglial inflammation, which leads to cell death. Evidence has shown that Aβ generates 
reactive oxygen species and nitric oxide that are extremely harmful to cells [17]. Aβ has been 
known to disrupt Ca2+ and K+ homeostasis leading to the formation of ion channels in the cells 
[17, 18]. It has been shown that Aβ binds to specific cell receptors that eventually prove 
detrimental to cells. Thus, evidence tells that the mechanism of Aβ toxicity is a very complex 
phenomenon with many interrelated or simultaneous mechanisms taking place. Another 
mechanism by which Aβ can exert toxicity is through interactions with the neuronal membrane. 
It is these interactions that will be the focus of this work.  
For Aβ to be toxic to cells, an interaction (either direct or indirect) between the toxic 
species and neuronal membrane must exist. Studies have linked cell membranes or their 
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components to Aβ generation, self-assembly and in toxicity to neurons[4]. Thus, there is a 
variety of evidence that points to the harmful interactions between the cell membranes and Aβ. 
Particularly, several glutamate receptors, as well as cellular prion protein (PrPc) have been 
identified to which Aβ oligomers bind. These receptors reside or partition into cholesterol rich 
microdomains that are a part of cell membranes called lipid-rafts. There is evidence that shows 
that membrane environment modulates the actions of secretases, with the decrease in membrane 
fluidity triggering the amyloidogenic processing of APP. It is hypothesized that Aβ interacts with 
the cell membranes through hydrogen bonding and electrostatic interactions in addition to 
specific receptor binding. The first physical evidence of this behavior result from the 
investigation by Yanagisawa et al., which showed a ganglioside bound Aβ, specifically, GM1 
ganglioside, in the brains of patients affected by AD [19-23]. This species was not detected in the 
brains of non-AD patients, pointing to the need of a more detailed investigation into ganglioside-
Aβ interactions. Gangliosides are very complex lipids demonstrating strong amphiphillic 
characteristics due to the presence of a double tailed hydrophobic moiety and a large saccharide 
hydrophilic head group. The saccharide head group is composed of a wide variety of sugars 
containing carboxylic groups, of which the sialic acid family of compounds are the most 
prominent and greatest in numbers compared to other sugars [24, 25]. Thus, gangliosides exhibit 
strong polar characteristics and are particularly abundant in neuronal cell membrane. Studies 
have shown that Aβ specifically interacts with the surface sialic acids present on the various 
gangliosides. Moreover, it is postulated that the interaction and binding affinity is higher if the 
gangliosides on the cell surface are clustered together [8, 26-30]. It is believed that Aβ interacts 
with the surface sialic acids leading to the formation of a ganglioside-Aβ moiety (GAβ) with an 
altered conformation that is highly prone to aggregation. This species (GAβ) then acts as a seed 
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for further amyloid aggregation [23, 31, 32]. Another argument in the favor of the importance of 
sialic acids in AD pathology is that the removal of surface sialic acids have been found to 
attenuate Aβ toxicity towards cells in culture[33].        
Now that the etiology of AD has been explained, there are a number of diagnostic and 
therapeutic approaches that are being investigated. Some major approaches are briefly described 
below. One approach is to target the secretases with different modulators and inhibitors. 
However, this is extremely risky, dangerous, and unproven as Aβ is required by the healthy brain 
and the exact roles of the different secretases have not been established. A number of Aβ 
aggregate inhibitors are also under review. However, this approach is still suspect, as the exact 
toxic species in AD has not been established. Thus, it suffices to say that most of the current 
approaches in AD suffer from the fact that the majority of mechanisms, causes, chain of events 
and agents involved have not been completely identified or understood. This makes designing 
effective therapeutics for AD a very difficult task. 
1.2. Rationale for This Project 
Looking at all the information provided, it is evident that membrane interactions with Aβ 
are critical in Alzheimer’s disease. Additionally, the fact remains that to be toxic to the cells, 
there has to be some sort of interaction between the neurons and the toxic species of Aβ. Thus, a 
novel therapeutic approach is being considered to target the theoretical “bottleneck” in the 
progression of Alzheimer’s disease, namely, the interaction of Aβ with neurons. It is our opinion 
that this is the bottleneck region as there are several theorized environmental conditions that lead 
to the excessive formation of Aβ species. Additionally, the exact form of Aβ (oligomers, 
protofibrils, ADDLs or fibrils) that is toxic to the cells is not yet proven. 
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Figure 1: Theoretical hypothesis for the progression of Alzheimer’s disease, showing the 
bottleneck region 
The hypothesis is that there are several conditions and factors in AD that are still unclear, 
unknown in the pathogenesis of AD. However, there must be some sort of Aβ-cell interaction for 
the toxic species to be fatal to cells. Thus, this represents the target bottleneck region, which we 
plan to attack. If we prevent cellular interaction with Aβ, we prevent toxicity associated with Aβ. 
Figure modified from [34]. 
It is possible that multiple species are toxic with interchangeability between them. Other 
factors such as APP cleavage, APP mutations, ApoE4 and other chaperons are not well 
understood and their exact role in AD unproven. However, what is certain is that Aβ interaction 
occurs through gangliosides or sialic acids and these gangliosides that are clustered. 
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Our first hypothesis is that aggregated Aβ interacts with neuronal cells and this 
interaction is eventually fatal. If this is true, then it would be beneficial to develop cell membrane 
mimicking materials that have antibody-like affinity towards Aβ. The design would be such that 
these biomimetic's would compete favorably with the cell surface for Aβ binding, reducing the 
free Aβ left to interact with the neurons,  and thus protecting them from Aβ neurotoxicity. 
With this postulate as the basis, the first part of the dissertation focuses on the synthesis of 
membrane mimicking compounds that are multivalent in sialic acid residues. To be multivalent 
and clustered, we need a backbone molecule on which these sialic acids or sugars can be 
successfully attached. The approach of using biomimetic’s against Aβ has been used earlier with 
limited success [8, 26]. Thus, as an improvement over previous works and to mimic sialic acids 
present on gangliosides (especially GM1); sialic acid was conjugated to a chitosan backbone. 
Chitosan was chosen as a backbone due to its biocompatibility, flexibility and non-toxic nature. 
Chitosan is also a FDA approved polymer for implantation. This conjugation was achieved using 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) chemistry which 
facilitated the conjugation of the amine groups of chitosan with the carboxylic acid groups 
present in sialic acid. Several sialic acid-chitosan complexes of different valency, number of 
sialic acids per chitosan molecule, were synthesized to attenuate the toxicity of Aβ in vitro. 
Numerous studies have stressed the importance of sialic acid clustering on neuronal cell 
membranes to be critical in Aβ binding. Thus, the use of a flexible backbone, such as chitosan, 
will allow for the necessary flexibility, allowing for the sialic acids to effectively cluster. This 
critical improvement will also allow us to predict the cluster size needed for the optimal 
protection from Aβ toxicity. Additionally, sialic acid decorated chitosan will closely mimic 
neuronal cell adhesion molecules (NCAM), providing another mimetic target for Aβ. The 
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hypothesis is presented in Figure 2. The development of such novel sialic acid conjugated 
chitosan complexes and their toxicity studies with and without Aβ are described in Chapter 3. 
 
Figure 2: Our hypothesis to prevent Aβ toxicity  
Aggregated Aβ peptide recognizes the sialic acids on cell membranes and binds to them causing 
cell death. Introduction of a biomimetic compound having higher affinity towards Aβ interferes 
with the cellular-Aβ binding thereby preventing toxicity. Introduction of a biomimetic allows us 
to target the bottleneck region in AD pathology. 
The results from the work with sialic acid conjugated chitosan complexes indicated that 
we were successful in mimicking the neuronal cell membrane as all the compounds tested 
showed significant ability to attenuate the toxicity of Aβ. The study also allowed us to predict the 
sialic acid clustering, or the degree of sialylation, necessary for optimum toxicity attenuation of 
Aβ. Interestingly, unlabeled chitosan also showed toxicity attenuation properties which prompted 
us to investigate other biological sugars that might show similar or greater protective properties 
against Aβ.  
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The second part of the project, described in Chapter 4, will serve multiple purposes. 
Chitosan is again selected as the backbone molecules because of excellent results shown in 
earlier results (see Chapter 3). By conjugating sugars to a chitosan backbone, we will be able to 
benefit from its protective effects, its flexibility, and biocompatibility. The criteria for selecting 
the biological sugars are based on the structure of sialic acid. Thus, in this work, in addition to 
sialic acid (N-acetylneuraminic acid); 2-Keto-3-deoxy-nononic acid (KDN), Galacturonic acid 
(GA), Tetrahydropyran-2-carboxylic acid (Pyran) and Cyclohexanecarboxylic acid (CHC) were 
conjugated to chitosan and characterized. 
The work described from Chapter 4 will also help to identify which unique -R groups, or 
core structures of N-Acetylneuraminic acid, are involved in toxicity attenuation. This is critical 
as it will be possible to predict which subgroup of sialic acid on neuronal membranes is 
necessary for Aβ binding. It also addresses the question whether sugars other than sialic acid can 
be effectively used to attenuate the toxicity of Aβ. This will shed more light on the type of 
interactions that occur between Aβ and cell membranes. It will allow for the development of 
specific polysaccharide therapeutic targets against the Aβ peptide in AD. The major conclusions 
from all the studies are presented in Chapter 5. Lastly, Chapter 6 suggests possible future 
directions that could be investigated based on this work.  
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2. LITERATURE REVIEW 
According to the latest statistics from Alzheimer’s Association, AD is the 5th leading 
cause of death in Americans over the age of 65 years with an estimated 5.4 million people 
currently suffering from this fatal disease. Total payments in 2011 for health care, long-term 
care, and hospice services for people aged ≥65years with AD and other dementias are expected 
to be $183 billion (not including the contributions of unpaid caregivers). Projections estimate 11 
to 16 million people will be affected in the US alone with AD by the mid-century 2050[35]. 
Thus, unless medical breakthroughs identify ways to treat or cure AD, the burden it will place on 
the healthcare system will be tremendous. Alzheimer’s disease has a long and stressful clinical 
course in which the patients need special attention, ranging from home care to special nursing 
homes. Apart from its impact on the patients, this disease puts a significant physical, emotional 
and financial burden to the families and relatives of the patients as well. Due to advances in 
science and medicine, the general life expectancy is increasing; making AD a problem of epic 
proportions that needs to be addressed.  
Despite over a century of research, AD still remains a complex disease which is not fully 
understood. There is no definitive cause and no known cure. The challenge now is to identify the 
cascade of events that lead to AD. The progression of the disease is slow and the average period 
of survival is eight years, with some patients surviving in excess of twenty years[36]. The course 
of the disease depends on the health issues and the age at which diagnosis was done for the 
individual. The progression of the disease can be subcategorized into three stages [37]: In the 
first stage, some change in personality with decline in short term memory and beginning of 
faulty judgment is observed. The patient becomes less productive and spontaneous in everyday 
activities. The next stage results in more memory loss, impairment of language, attention and 
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visual-spatial and executive functions. Ability of a patient to perform day-to-day activities 
(eating, washing, grooming) start declining and the patient becomes more dependent on others. 
Short term memory becomes drastically impaired and only long established memories persist. 
Sleeping disorders, aggression, verbal outbursts and other troublesome behavior sets in. In the 
third stage, only fragments of memory remain. All cognitive functions are lost and the patient 
becomes mute, incontinent and eventually unresponsive to communication. The patient is at the 
mercy of the caregivers at this stage. Loss of immunity is the typical outcome making patients 
susceptible to infections which leads to death [38]. 
Simply put, aging is the main risk factor of the disease [39]. Mutations in the amyloid 
precursor protein (APP) gene on chromosome 21, the presenilin 1 (PS1) gene on chromosome 14 
and the presenilin 2 (PS2) gene on chromosome 1 have been implicated in AD [40, 41]. Presence 
of apolipoprotein E (ApoE) e4 allele was shown to increase the risk of getting AD in conjunction 
with lowering the age of onset of the disease [36, 42]. Other risk factors include decreased 
reserve capacity of brain [43], poor linguistic ability in early life [44], low mental and leisure 
activity, traumatic head injury, cardiovascular diseases like hyperlipidemia, hypertension, 
diabetes, obesity etc. See [41] for additional review. 
The affected brain in AD shows the presence of massive neuronal death and the loss of 
synaptic connections [45]. The progression of AD starts in the hippocampus (an area of brain 
responsible for new memories) [36], then spreads to the association areas of the cerebral 
complex (responsible for language and reasoning) and finally to the neocortex (responsible for 
the sensory and motor area functionalities). This progression results in tissue loss throughout the 
brain thereby causing the brain to shrink in size and also the enlargement of the ventricles (fluid 
filled spaces within the brain). Proteinaceous deposits are observed in both the intracellular and 
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extracellular compartments of the brain. Researchers have shown that the intracellular deposits 
are composed of neurofibrillary tangles (NFT) which are primarily formed due to the hyper-
phosphorylation of the tau protein [5, 46]. NFTs are intra-neuronal bundles of paired helical 
filaments formed by the microtubules, but they are not specific to AD and are found in various 
other neurodegenerative conditions such as Frontotemporal dementia, Hallervorden-Spatz 
disease etc. [47]. Amyloid plaques are extracellular aggregates of the Aβ peptide and many 
researchers have found a direct correlation between the presence of these plaques and the 
severity of AD [10, 48]. Earlier, the large insoluble plaques were thought as the toxic species, but 
recent evidence suggests that it is the small oligomers that may be the toxic species. The real 
insight into the disease was after 1984, when Glenner and Wong identified the amino acid 
sequence of Aβ peptides [49]. 
In the treatment of AD, many researchers are targeting the production and the 
aggregation process of Aβ. Since the identification of AD as a unique condition, a number of 
theories and hypotheses have been put forward. The two major hypotheses that have been 
postulated to explain the molecular mechanisms of AD are the cholinergic hypothesis and the 
amyloid cascade hypothesis [10, 48]. The amyloid cascade hypothesis is relevant to the work 
done in this thesis and is discussed in the later sections. Also, there is much evidence that points 
to the central role of Aβ in AD that supports the amyloid cascade hypothesis. As of now, none of 
the hypotheses are perfect and can satisfactorily explain AD but, they provide a conceptual 
framework and a valuable roadmap for all researchers. With more and more advances in science, 
the missing links and pieces are being identified. This will be a valuable tool which will aid 
researchers in accurate diagnosis and in designing therapeutics for the treatment and cure of AD. 
Finally, progress in defeating this disease is hampered by the fact that AD is a very complex 
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disease whose exact mechanisms and pathways still remain a mystery. The following sections 
will be devoted to understanding some of the aspects of AD with an aim to design better 
therapeutic for its treatment. 
2.1. Hallmarks of Alzheimer’s Disease 
Researchers have identified the two main hallmarks of AD: the deposition of 
neurofibrillary tangles (NFT) composed of tau protein and the aggregation deposition of senile 
plaques comprised majorly of the amyloid-β peptide. 
2.1.1. Tau Protein 
Microtubules play an important role in maintaining the structural and physiological 
integrity of neurons. The biological activity of tau in promoting assembly and stability of the 
microtubules is regulated by its degree of phosphorylation [46]. Evidence has shown that 
abnormal hyperphosphorylation of tau protein disrupts the microtubule structure resulting in the 
aggregation of tau into bundles of paired helical filaments (PHF), twisted ribbons and/or straight 
filaments collectively called neurofibrillary tangles [46, 50]. Glycogen synthase kinase-3 (GSK-
3) and cyclin dependent protein kinase-5 (cdk5) are the major protein kinases that have been 
implicated in the abnormal hyperphosphorylation of tau [7, 46, 50].This abnormal deposition of 
tau is observed in several other human neurodegenerative disorders and not just in AD. The 
NFTs are known to be toxic to the neurons, which slowly and progressively lead to their death. 
Studies from different groups suggests that hyperphosphorylation of tau can be considered as one 
of the primary cause of AD, but not the fundamental one [7, 46, 51, 52]. Thus, inhibition of 
abnormal hyperphorphorylation of tau protein is a promising, but not ideal approach for the 
development of therapeutic drugs [53]. Drugs which inhibit GSK-3 and cdk5 have been 
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developed by the industry and many of them are at different phases of clinical trials. Other 
strategies include inhibiting the misfolding of tau and to directly stabilize the microtubules. As 
hyperphosphorylated tau is toxic by sequestering, normal mitogen activated proteins (MAPs), 
small molecules that can compete with this sequestering are being developed that can effectively 
attenuate toxicity of tau [7, 53]. For review see [46, 53-56]. 
2.1.2. Amyloid-beta Peptide 
A common pathogenic mechanism in many different neurodegenerative disorders 
including AD is the aggregation and deposition of misfolded proteins, mostly in the brain. As 
summarized in Table 1, nearly every major neurodegenerative disease is characterized by the 
insidious accumulation of insoluble filamentous aggregates of normally soluble proteins in the 
central nervous system (CNS). These diseases are usually grouped together as the filamentous 
aggregates show similar ultra-structural and tinctorial (staining or coloring) properties of 
amyloid (i.e. ~10nm wide fibrils with crossed β-sheet structures which stain with congo red, 
thioflavin-S or other related dyes). Hence, they are collectively known as brain amyloidosis. 
Glenner and Wong first identified the major protein component of vascular amyloid, an 
approximately 4kDa polypeptide now referred to as β-amyloid protein [12, 49]. This protein was 
also found to be a major component of amyloid plaques [57, 58] which led to the identification 
of its precursor, the amyloid precursor protein (APP). Soon after the discovery, the APP gene 
was cloned allowing the disease to be examined at molecular levels. Subsequently, mapping of 
mutations in APP gene, the association of AD with Down’s syndrome (People with Down’s 
syndrome have an extra copy of chromosome 21, which also contains APP), higher prevalence of 
AD with increased copy number of APP and the identification of mutations in presenilin 1 (PS1) 
all confirmed the central role of Aβ peptide and APP in Alzheimer’s disease [9, 13, 14]. 
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Table 1: Common neurodegenerative diseases caused by deposition of misfolded or 
aggregated proteins 
 
Disease Microscopic lesion Location Aggregated protein 
Alzheimer’s 
Disease 
Amyloid 
Plaque Extracellular 
Amyloid-β 
(Aβ) 
 Neurofibrillary Tangle 
Intracytoplasmic 
(neurons) Tau 
 Lewy bodies (seen in Lewy body variant) 
Intracytoplasmic 
(neurons) α-synuclein 
Amyotrophic 
lateral sclerosis 
Hyaline 
Inclusions 
Intracytoplasmic 
(neurons) 
Superoxide dismutase-1 
(SOD-1) 
Cortical basel 
degeneration/ 
progressive 
supranuclear palsy 
Tau 
positive 
inclusions 
Intracytoplasmic 
(neurons, 
oligodendroglia 
and astrocyes) 
Tau 
Dementia with 
Lewy bodies Lewy bodies 
Intracytoplasmic 
(neurons) α-synuclein 
Huntington 
Disease 
Neuronal 
Inclusions 
Intranuclear 
(neurons) 
Huntington 
(With Polyglutamine 
repeat expansion) 
Multiple system 
atrophy 
Glial cytoplasmic 
inclusions 
Intracytoplasmic 
(oligodendroglia) α-synuclein 
Parkinson’s 
Disease 
Lewy 
Bodies 
Intracytoplasmic  
(neutrons) α-synuclein 
Pick’s 
Disease 
Pick 
Bodies 
Intracytoplasmic 
(neutrons) Tau 
Prion 
Diseases 
Prion 
Plaques Extracellular 
Protease-resistant 
prion protein (PrP),  
Creutzfeldt Jakob 
disease, Kuru 
Amylin (IAPP)   Type 2 diabetes 
Calcitonin   Finnish amyloidosis 
Transthyretin   Peripheral amyloidosis 
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2.2. Characteristics of Aβ Peptide 
Amyloid-β, a 39 to 43 amino acid long peptide, is cleaved from the C-terminal region of 
the membrane spanning glycoprotein, the amyloid precursor protein (APP). APP is found in 
tissues throughout the body but its primary function is still unknown[11, 36]. A large part of the 
APP lies in the ectodomain and contains the N-terminus, whereas its C-terminus is located in the 
cytoplasmic domain. APP has the characteristics of a cell surface receptor and is located on 
chromosome 21. The Aβ sequence itself comprises part of the ectodomain of the APP and 
extends into, but not all the way through, the transmembrane domain[59]. Aβ contains 28 amino 
acids from the extracellular part of APP and the remaining 11 – 15 residues are located in the 
transmembrane domain [60]. 
The formation of Aβ peptide is shown in Figure 3. There are two pathways by which the 
APP can be metabolized in the cells and tissues: the non-amyloidogenic and amyloidogenic 
pathway [61]. In the non-amyloidogenic pathway, the APP is cleaved by α-secretase between 
residues 687 and 688, which releases a soluble extracellular sequence (α-sAPP) and a membrane 
attached C-terminal fragment (CTFα). The CTFα is further cleaved at a variable position 
(between the C-terminus and residue 712) by γ-secretase in the transmembrane region which 
releases the harmless, 3kDa, p3 fragment and the APP Intracellular C-terminal domain (ACID) 
[11, 61]. This cleavage of α-secretase takes place within the Aβ fragment, thereby preventing the 
release of the full-length Aβ polypeptide, hence referred to as the non-amyloidogenic 
pathway[10, 62].  
In the amyloidogenic pathway, the Aβ peptide is formed when the APP is cleaved by     
β-secretase in between residues 671 and 672 followed by cleavage in between the C-terminal and 
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Figure 3: Metabolism of APP and the formation of Aβ peptide 
In the amyloidogenic pathway, the Aβ peptide is formed when the APP is cleaved by β-secretase 
in between residues 671 and 672 followed by cleavage in between the C-terminal and residue 
712 by γ-secretase Reprinted [63] with permission from Elsevier Ltd. 
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residue 712 by γ-secretase [10]. Along with the soluble extracellular β-sAPP fragment, several 
isoforms of Aβ can be produced of which the 40 and 42 amino acid forms are the most common 
ones [11, 61]. Aβ (1-40) is the predominant species produced, whereas Aβ (1-42) accounts for 
only 10% of the total secreted Aβ. However, Aβ (1-42) is considerably more prone to 
aggregation and is regarded as more neurotoxic [57]. The levels of Aβ (1-42) are believed to be 
elevated in AD. The Aβ (1-40)/Aβ (1-42) ratio can be influenced by several factors such as 
substrate concentration, PS1, PS2 mutations and effect the formation of senile plaques. 
Three different proteases appear to be responsible for the α-secretase activity: TACE 
(TNF-α converting enzyme), ADAM-9 and ADAM-10 (a disintegrin and metalloprotease 
domain protein). The protein responsible for β-cleavage has been identified as a novel 
transmembrane aspartyl protease BACE1 (β-site APP cleaving enzyme 1) and it is posited that 
levels of BACE1 increase in AD. As β-secretase is the Aβ producing enzyme, it is the ideal 
therapeutic target, but complete abolishment of BACE1 has shown deleterious effects in 
knockout mice [64]. The enzyme γ-secretase is believed to be a complex of at least four proteins:  
Presenilin 1(PS1) or Presenilin 2 (PS2), Nicastrin, Pen-2 and Aph-1, but other protein 
components of this complex may also exist. Notch signaling is also affected by γ-secretase [61]. 
It is the γ-secretase dependent cleavage affected by missense mutations that is predominant cause 
of excess production of Aβ (1-42). However, all these enzymes have not been completely 
identified. Much is unknown about the different substrates that they act on. Research has shown 
that α-secretase and β-secretase compete for the APP substrate, as increase in one pathway has 
shown decrease in other pathway and vice-versa [64]. 
In the Aβ sequence, the first 16 residues (N-terminal region) are found to be largely 
hydrophilic whereas the remaining residues (C-terminal region) form the hydrophobic domain. 
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Thus, amphipathic Aβ has propensity towards self-aggregation and accumulation, which is 
hypothesized to initiate a cascade that triggers complex pathological reactions, eventually 
leading to AD. The Aβ peptide forms various structures such as dimers, 5-mers, oligomers, 
protofibrils and fibrils through the aggregation process. It is the central region of Aβ(12-23) that 
has been implicated as the self-recognition site for the formation of dimmers and higher 
oligomers [36]. 
 
 
Figure 4 : Sequences of Alzheimer’s Aβ peptides 
References [12, 36, 49, 65, 66] 
2.3. Evidence of Aβ Induced Neurotoxicity 
It was observed that AD patients showed evidence of extensive oxidative stress [36] 
caused by reactive oxygen species (ROS) present in the brains [67]. One of the sources of ROS is 
believed to be the Aβ peptide, which works in conjunction with metal ions and oxygen. It was 
also noted that oxidative stress also led to the over-expression and misprocessing of the APP 
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gene, which further led to more production of Aβ. This results in a dangerous cycle that 
eventually leads to neuronal death and brain degeneration [68].  
In addition to oxidative stress, cell membrane permeability is severely compromised by 
Aβ peptide when it forms calcium permeable ion channels in the plasma cell membrane [36]. 
These channels allow excess calcium influx and disrupt the normal calcium homeostasis. In vitro 
studies by Lin et.al showed that Aβ(1-42) induced rapid neuritic degeneration at physiological 
concentrations [69].  Recent evidences have suggested that formation of ion-permeable pores 
maybe the condition before Aβ is released in the extracellular space. 
Researchers have also shown that Aβ causes damage to the blood brain barrier (BBB) 
through the production of superoxide and the involvement of homocysteine [36]. There is 
evidence suggesting that Aβ binds to an intracellular polypeptide called ERAB, producing a 
toxicity level that is directly related to the expression of ERAB [70]. Aβ is involved in 
decreasing synaptic activity and causing progressive neuronal degradation. The fact that neuronal 
death is observed in the immediate vicinity of Aβ deposits further implicates Aβ in the 
pathogenesis of AD [71]. 
These factors have confirmed the central role of Aβ and APP in the etiology of the 
Alzheimer’s disease, resulting in much of the work in designing effective therapeutics for AD 
being focused on the Aβ peptide. A number of different hypotheses have been proposed, out of 
which, the amyloid cascade hypothesis presented by Hardy and Higgins [14] has received the 
most attention [9]. It is reviewed in the next section. 
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2.4. The Amyloid Cascade Hypothesis 
In 1992, Hardy and Higgins presented the “amyloid cascade hypothesis” which explained 
the pathogenesis of sporadic AD. The hypothesis proposes that the increased production or 
decreased clearance of Aβ peptide is the fundamental cause of AD. They proposed that Aβ 
causes the hyperphosphorylation of tau protein which starts the cascade of events leading to the 
formation of amyloid plaques and neurofibrillary tangles [14]. 
Since, the amyloid cascade hypothesis has undergone alterations as newer research 
finding are being presented. A decade after the hypothesis was originally presented, Hardy and 
Selkoe proposed an amended version which took into consideration mutations in the APP, PS1 
or PS2 genes which increases Aβ production. This results in the accumulation of Aβ followed by 
the oligomerization and deposition of Aβ as plaques. These Aβ plaques cause increased synapse 
destruction, altered neuronal ionic homoeostasis and oxidative injury, which leads to 
hyperphosphorylation of tau protein and causing the deposition of NFT’s and neuronal 
destruction [14, 43, 72]. Support for this theory includes the fact that AD brains demonstrate 
extensive Aβ deposition [8]; mutation in the genes implicated in familial forms are all related to 
APP processing, which increases Aβ production [9, 11, 43, 73]; Down’s syndrome patients (who 
have an extra APP gene) develop Aβ plaques early in life [17, 43, 74] and several in vitro studies 
have also demonstrated the neurotoxic nature of soluble Aβ oligomers in in vitro and in vivo 
studies [9, 75].  
Still, the amyloid cascade hypothesis is not perfect and the exact mechanism of Aβ 
toxicity remains elusive as the specific neurotoxic species of Aβ and the nature of its effects on 
neuronal function have not been defined in vivo. Earlier, it was thought that Aβ deposited as 
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plaques were neurotoxic. However, recent findings demonstrate that soluble pre-fibrillar 
oligomers of Aβ are likely to be the toxic species that initiate neurodegeneration [17].   
 
Figure 5: Mechanism of amyloid cascade hypothesis.  
The central event in the disease pathogenesis is an imbalance between Aβ production and 
clearance, with increased Aβ production in familial AD and decreased Aβ clearance in sporadic 
AD. This accumulation of Aβ leads to microglial activation and inflammatory response. The loss 
of homeostasis and oxidative stress leads to synaptic dysfunction, altered kinase activity 
affecting tau production. The NFTs and plaques lead to neuronal death and dementia. [43] 
Reprinted with permission from Elsevier Ltd. 
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2.5. Mechanisms of Aβ Neurotoxicity 
A number of mechanisms have been suggested to explain the pathway by which Aβ 
induces neurotoxicity. Some of them are explained in brief below: 
Studies have shown that Aβ binds to a metal substrate generating reactive oxygen species 
(ROS). Aβ also causes loss of calcium homeostasis, generating reactive nitrogen species (RNS). 
One plausible explanation is that the Aβ can enter the mitochondria, where it increases the 
production of ROS, significantly reducing the levels of antioxidants (e.g., vitamins E, C and 
gluthathione) thereby altering the balance in the brain [36]. Depending on the substrate attacked, 
oxidative stress will manifest as protein, DNA, RNA oxidation or lipid peroxidation [67]. These 
species are extremely reactive, causing damage to DNA, RNA, lipids and proteins via oxidation. 
This creates an imbalance which leads to oxidative stress and induces inflammation in the 
neurons, resulting in death [10, 36, 76].  
Another mechanism that has received considerable thought is that Aβ causes synaptic 
dysfunction. Neurons are connected to each other through junctions called as synapses, and tiny 
electrical pulses are transmitted through these junctions as a means of communication between 
two neurons. It is believed that synaptic terminals are critically dependent on levels of cortical 
Aβ. After the onset of AD, levels of Aβ start rising which leads to synaptic dysfunction, thereby 
inducing neurotoxicity [17, 77].  
Neuroinflammation and microglial activation is another possible mechanism of Aβ 
induced neurotoxicity. Aβ plaques have been found with clusters of microglia. Microglias are 
considered to be the brain resident macrophages responsible for the maintenance of homeostasis 
within the brain. They are activated when the brain detects signs of oxidative stress and neuronal 
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damage. It is believed that the microglia cells are activated to clear the Aβ by phagocytosis. This 
process involves the release of ROS, pro-inflammatory cytokines, excitotoxins and proteases; all 
potentially neurotoxic substances [17]. 
Interaction with tau protein is considered as another mechanism through which Aβ is 
thought to induce neurotoxicity. It is believed that Aβ(1-42) and ApoE4 activates various kinases 
that results in the hyperphosphorylation of the tau protein, which in turn form NFTs. 
Aβ also adheres to endothelial cell walls forming damaged tissues or lesions. Over time, 
accumulation of Aβ deposits can lead to a condition known as cerebral amyloid angiopathy 
(CAA), which leads to internal bleeding in the brain. Aβ causes pore formation in the 
membranes that lead to loss of calcium homeostasis and an influx of Ca2+ into the neurons. This 
is believed to start a cascade of events which ultimately leads to neuronal death [36, 69].  
Other mechanisms proposed for Aβ neurotoxicity include increased membrane fluidity 
[18], alteration of cytoskeleton and nucleus [78]; redox active iron [79], binding of Aβ to ApoE 
and catalases. It is believed that several mechanisms might be active simultaneously and could 
be interrelated and dependent on each other. However, no consensus has been reached on a 
perfect mechanism for Aβ neurotoxicity, which makes the design of therapeutics for AD a 
difficult task. 
2.6. Normal Roles of Aβ and APP 
The exact roles of APP and Aβ in the normal functioning of cells are not fully 
understood. Aβ is secreted by neuronal cells as a part of normal metabolism. Ill effects such as 
lower weight, reduced locomotor activity and impaired neuronal functions in brains are observed 
in experiments on APP knockout mice [80]. The APP intracellular domain (ACID) formed by 
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the γ-cleavage of APP, is believed to regulate phosphodinositide-mediated calcium signaling, 
which plays an important role in cell differentiation [81]. Studies have shown that Aβ(1-40) is 
produced as a cellular antioxidant [82], Aβ(1-40) modulates potassium channels in neurons with 
Aβ(1-42) and it also counteracts the effects of secretase inhibitors [83]. 
2.7. Neurotoxicity of Aβ: Who Is the Real Culprit? 
Aβ protein is derived from APP and is found to be present in the cerebrospinal fluid 
(CSF) and in brains of normal humans. Hence, the mere presence of Aβ cannot be the cause of 
dementia. However, ordered self-association of Aβ molecules seems to be the factor causing 
neuronal degradation [84]. Self-association and aggregation of Aβ can lead to various forms of 
aggregates such as monomeric species, small dimers, trimmers, oligomers, larger assemblies 
commonly referred to as Aβ-derived diffusible ligands (ADDL), protofibrils, Aβ*56 and large 
insoluble fibrils. [85] 
Initially, the large insoluble fibrils[86], which deposited as plaques were considered 
neurotoxic because these fibrils were detectable and characterization of the assemblies that 
formed in vitro were limited [84]. However, the fact that amyloid fibrils are the AD causing 
species is frequently challenged as a weak correlation is found between the amount of plaques 
deposited and the severity of dementia in patients. 
Recent evidence has suggested that soluble oligomers are likely to be the real culprits 
[87]. Studies have shown that oligomeric Aβ, in the absence of monomers and fibrils resulted in 
toxicity in vivo and oligomer-specific antibodies could block the toxicity in neurons. A strong 
correlation was found between the soluble Aβ levels, loss of synapses and severity of dementia, 
further implicating soluble Aβ as the toxic intermediate [84, 88]. The term, ‘soluble Aβ’ 
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describes the form of Aβ that can remain in solution even after high speed ultracentrifugation. 
Studies from synthetic Aβ peptides, APP over-expressed cell culture systems, APP transgenic 
mice, human CSF and postmortem brain have indicated that soluble non-fibrillar Aβ induces 
toxicity in cells [84]. Review on Aβ oligomers [89-93]. 
Protofibrils (PFs)[94] are a group of structures ranging from spheres (about 5nm in 
diameter) to curvilinear structures about 200nm in length. PFs are physically similar to amyloid 
fibrils but they have the ability to form both true amyloid fibrils or dissociate into low molecular 
weight species of Aβ. PFs and amyloid fibrils also have distinct biological activities [15, 16, 84]. 
Shortly after the discovery of protofibrils, Lambert et al. observed small (5-6nm) globular 
structures of synthetic Aβ(1-42) with the C-terminal region of Aβ forming a hydrophobic core, 
which they referred to as Amyloid-β derived diffusible ligands (ADDLs) [95]. The ADDLs are 
the smallest assemblies of  PFs, about 6nm and have been shown to cause neuronal death, block 
long-term potentiation (LTP), inhibit reduction of MTT in neural cells and avidly bind and 
decorate dendritic arbors of certain cultured neurons [84, 85]. A dodecamer, labeled Aβ*56 for 
its weight in kD, is proposed to induce memory loss independent of neuronal plaques before 
amyloid plaques started developing [85, 96]. However, no consensus has been reached on the 
exact toxic species and it is thought that toxicity can be induced by multiple assemblies rather 
than any particular form. However, the fact remains that the in vivo environment is quite 
different than the in vitro environment and the hydrophobic nature of the Aβ peptide makes it 
ambiguous whether the pathway observed would also work in vivo. 
Now that the different assemblies of Aβ have been discussed, the pathway by which Aβ 
aggregates needs to be addressed. It is proposed that Aβ aggregation is a nucleation dependent 
polymerization process, which is significantly affected by the presence of small peptide 
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aggregates or ‘seeds’ [97] and by the rate of elongation of the seeds [15]. Walsh et al. [15] 
showed that Aβ oligomers arise through a series of short lived intermediates that form PFs, 
which act as centers for the growth of mature insoluble fibers. Thus, the monomers can be in 
equilibrium with dimers to form fibril nuclei from which protofibrils emerge. The end to end or 
lateral association of PFs forms “self-templates”, onto which the monomers/dimers bind and 
polymerize. Most of the other models proposed are variation of what is depicted in figure 6. 
Huang et al. [97] suggested two pathways for Aβ aggregation. In one pathway, an 
ordered β-sheet conformation is observed, which leads to AD like symptoms and the formation 
of other, unstructured aggregates called diffuse amyloid or preamyloid. The preamyloid species 
exist in an amorphous form and are non-toxic to the neuronal cells. It is hypothesized that Aβ 
takes the ordered β-sheet pathway only when levels of total Aβ are above 10μM in the brain. 
This hypothesis explains why normal healthy brains do not develop AD like symptoms despite 
having Aβ present in them. 
 
Figure 6: Modes of Aβ aggregation: Believed to be a nucleation dependent process 
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2.8. Structure of Aggregated Aβ Peptide 
Elucidating the exact structure of aggregated Aβ could prove extremely useful in 
designing effective inhibitors for prevention of AD. However, previous studies have established 
that Aβ (1-40) and its different fragments Aβ (16-22), Aβ (11-25), Aβ (10-35) adopt different 
conformations depending on the environmental conditions [66, 98].  Also, Aβ (1-42) has a great 
propensity to aggregate because it has 2 extra residues, Ile at 41 and Ala at 42 at the C-terminus 
of the peptide[86]. At physiological conditions, the Aβ peptide displays an unstructured random 
coil structure in vitro. The first 16 residues of Aβ are largely hydrophilic and the remaining 
residues form a part of a largely hydrophobic domain. Residues 12-23 have been identified as the 
self-recognition sites for formation of dimers and higher oligomers. It is also posited that the 
hydrophobic stretch at residues 17-21 is critical in the formation of fibrillar structure [99].  The 
exact structure of monomeric Aβ in solution is still uncertain as the psychological environment is 
difficult to achieve under laboratory conditions. Aqueous Aβ (1-40) was analyzed using Circular 
Dichroism and the result showed a mixed coil, β-turn, β-sheet and α-helical content for Aβ 
structure. Also, other groups observed a  high β-sheet content at the air-water interface [100], 
whereas in sodium dodecyl sulphate (SDS) micelles and later in 40% trifluoroethanol, 
monomeric Aβ showed an extensive α-helical content [101]. However, the exact structure 
remains debated and it is postulated that Aβ adopts α-helical conformation in organic solvents 
whereas in aqueous environments it is predominantly β-sheet [102]. 
Intermolecular β-sheet structure of the Aβ peptide fibrils was confirmed by a variety of 
techniques such as electron microscopy, Fourier transform infrared spectroscopy (FTIR), and CD 
[102, 103]. The β-sheets are composed of cross-β-strands which are perpendicular to the axis of 
the fibril and intermolecular hydrogen bonding occurring parallel to its axis. Tjernberg et al. 
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suggested that the smallest fibril forming sequence was Aβ (14-23) and this was the core of the 
Aβ fibril [104]. It is proposed that residues 16-23 have a high propensity to form a β-sheet 
structure and residues 11-24 are implicated in α-helix to β-sheet conversion [102]. One study 
indicated the presence of anti-parallel β-sheets in the Aβ fibrils and a turn at positions 25-28 due 
to the presence of the amide-I band of the infrared absorption spectra. On the other hand, 
structural studies on Aβ (10-35) using solid-state NMR have established a parallel β-sheet 
structure. This has led to a conclusion that Aβ fibrils can adopt both parallel and anti-parallel 
structure depending on the sequences and composition of the amino acid residues [103]. By the 
use of solid-sate NMR, it was suggested that fibrils made from different lengths of Aβ peptide 
were the same [105]. In another study, it was proposed that the first 10 residues of Aβ (1-40) are 
structurally disordered. Petkova et al. presented a model in which residues 12-24 and 30-40 
formed the β-sheet structure. The two β-sheets are in contact through side chain-side chain 
interactions with residues 25-29 forming the bend of the peptide [106]. In the case of Aβ(1-40) 
fibrils, the side-chain interactions are intramolecular, whereas for Aβ(1-42) fibrils, the upper 
layer sheet is displaced relative to the lower sheet so that the two β strands of Aβ molecule ( i ) 
form intermolecular side-chain interactions with the strands of molecules ( i+1 ) and ( i-1 ) 
respectively [98]. Many models have been proposed having different configurations, number of 
turns and patterns, with each satisfying different constraints. Recent evidence suggests that the 
molecular structure formed by the Aβ fibrils in vitro depends on solvent composition, 
temperature, protein concentration, pH, ionic strength, and external mechanical forces such as 
agitation. Simple variation in these conditions can lead to the formation of fibrils with a 
completely different morphology [107]. Also, direct structural measurements of Aβ fibrils are 
not possible due to the small quantities and the lack of isotopic labeling in vivo. It was also 
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demonstrated by Paravastu et al. that the molecular structure of Aβ fibrils seeded from AD brain 
fibrils were markedly different than those seeded with synthetic Aβ [108]. Thus, even though in 
vitro studies on Aβ fibrils have provided a plethora of knowledge, the exact structure of Aβ 
fibrils formed in vivo remains uncertain. 
2.9. Interaction Between Aβ-Cell Membranes 
There have been studies that document the role of lipid rafts in the cell membranes and 
peptides in the loss of neuronal function and potentially cell death in AD, Parkinson’s disease 
[109, 110], Huntington’s, Prion diseases and amyotrophic lateral sclerosis (ALS)[111].  Focusing 
on AD, it is well documented from pathological, genetic and cell culture studies that Aβ 40/42 is 
the neurotoxic species in AD. Several investigators have postulated that the interaction of Aβ 
with cellular membranes may be the mechanism leading to cell death [28, 112-119]. Interactions 
of Aβ peptide with artificial and biological membranes is reviewed in [120]. Membrane rafts are 
implicated in Aβ production [121], aggregation and binding of peptide moieties. Aβ is known to 
interact with cell membranes and also with membranes of other subcellular components such as 
Golgi bodies, lysosomes and endoplasmic reticulum [119]. Aβ in the aggregated form binds to 
neuronal membranes via hydrogen bonding and electrostatic interactions. It has been posited that 
Aβ(40/42) decreases the fluidity of the fatty acyl and head groups of the plasma, lysosomal and 
endosomal membranes whereas it increases the Golgi membrane fluidity [122]. Investigations by 
Yanagisawa et al. showed the presence of monosialoganglioside GM1-bound Aβ (GM1-Aβ) in 
the brains of AD patients which is not detected in non-AD brains [21]. Terzi and co-workers 
showed that Aβ had higher binding affinity to the negatively charged phospholipids than 
zwitterionic and cationic lipids [123, 124]. It has been shown that cholesterol, gangliosides and 
membrane composition affect Aβ formation, Aβ aggregation and Aβ membrane association 
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[125]. It is postulated that hydrogen binding as well as hydrophobic interactions with sugar 
groups in the gangliosides are responsible to Aβ-membrane interactions [126]. Some of the 
mechanisms that have been postulated to induce membrane-related toxicity are as follows: 
Strong physiological interactions of Aβ with membranes can lead to detrimental change in the 
fluidity of the membranes; interaction of Aβ with membranes leads to alterations in ion 
permeability, formation of ion channels, changes in intracellular Ca2+ levels leading to disturbed 
homeostasis and membrane depolarization; interaction of Aβ with membranes leads to disruption 
of neuronal homeostasis and loss of neuronal function [117, 119]. Thus, it is of utmost 
importance to understand the mechanisms and pathways through which Aβ-membrane 
association induces toxicity. There can be several mechanisms working together that may be the 
cause of increased Aβ or polymerized Aβ. However, we know for sure that Aβ interacts with the 
cell membrane where it binds to membrane lipids and this somehow leads to or contributes to 
toxicity. It is this theoretical bottleneck region that we are going to target in this thesis. For this, 
the role of gangliosides in AD must be reviewed. Some of the experimental strategies to 
investigate membrane or lipids interaction with amyloidogenic proteins or peptides has been 
reviewed by Raz Jelinek [127]. 
2.10. Role of Gangliosides in Alzheimer’s Disease Pathology 
Lipid components such as glycerophospholipids, sphingolipids and cholesterol are the 
major components of cell membranes. Gangliosides are a type of glycosphingolipids containing 
one or more sialic acid residues, with sialic acid being a generic term for N-acetyl- or N-
glycoloyl-neuraminic acid [24, 128]. The hydrophilic characteristics of the big saccharidic 
headgroup and the hydrophobic characteristics of the double tailed sphingolipid, called ceramide, 
impart a strong amphiphilic nature to the gangliosides. The ceramide is composed by a long-
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chain amino alcohol, 2-amino-1,3-dihydroxy-octadec-4-ene, connected to  a fatty acid by an 
amide linkage [25]. The sugar structure, content, sequence, and bonding atoms in the 
oligosaccharide chain can vary along with the lipid moiety making gangliosides a very large 
family of compounds. Presence of sialic acid on the saccharidic headgroup differentiates 
gangliosides from neutral glycosphingolipids and sulfatides. The three main sialic acids known 
to be present in gangliosides are 5-N-acetyl-, 5-N-acetyl-9-O-acetyl and 5-N-glycolyl derivative. 
Due to their specific location, gangliosides are able to interact with a variety of biological entities 
such as glycoproteins, antibodies, peptides, hormones, growth factors etc. They are postulated to 
play an important role in cell differentiation, biosignaling, inducing neuritogenesis and play a 
protective role in the case of neuronal injury [129, 130]. GM1, GD1a, GD1b, and GT1b are the 
major gangliosides found in the human brain comprising almost 65% to 85% of the total content 
[111, 131]. The structures of the major gangliosides are given in Figure 7. It was observed that 
AD brains showed alterations in ganglioside levels and metabolism [129, 132] indicating that 
interactions between Aβ and membranes play a vital role in the pathology of AD. A novel 
ganglioside bound Aβ (GM1-Aβ) species was isolated from AD brains, which was postulated to 
function as a seed for amyloid fibril formation [19]. Terzi et al. first reported the conformational 
change in Aβ from random coil to β-sheet after binding to negatively charged lipid vesicles [129, 
133]. After that, many studies have reported the interaction between Aβ and gangliosides, 
especially GM1, which results in an altered secondary structure of the Aβ peptide [28, 112-114, 
116, 129]. Some studies have revealed that the Aβ attaches between the hydrophobic/hydrophilic 
interface of the ganglioside clusters, exhibiting an up- and down- topological mode in which the 
α-helices and particular segments of Aβ interact with the ganglioside clusters[31]. It is 
hypothesized that the hydrophobic side of the ganglioside cluster is responsible for the 
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conformational change in Aβ, whereas the sugar chains or the hydrophilic side is involved in the 
determination of the binding affinity between the Aβ and gangliosides [31]. 
 
Figure 7: Chemical structures of major gangliosides present in neurons 
Cer, ceramide; Glc, glucose; Gal, galactose; GalNAc, N-acetylgalactosamine; SA, sialic acid. 
[131] Reprinted with permission from Elsevier Ltd. 
In an important observation, Choo-Smith et al. showed that Aβ peptide interacts 
specifically with membrane gangliosides with affinities ranging from 10-6 to 10-7M depending on 
the ganglioside sugar moiety. However, isolated oligosaccharide moiety on the ganglioside was 
not sufficient to induce the conformational change in Aβ peptide which indicated the role of the 
lipid component in the binding. They posited that the gangliosides function as high affinity 
receptors towards Aβ which leads to conformational changes from random coil to ordered β-
sheet [134]. Another important observation came from the studies of McLaurin and 
Chakrabartty, who reported that Aβ peptide disrupted acidic phospholipid membranes and the 
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gangliosides induce Aβ40/42 to adopt a novel α/β conformation at neutral pH. They observed 
that the sialic acid moiety on the oligosaccharide chain was important for inducing this 
disruption of the membranes. They speculated that gangliosides could sequester Aβ and thereby 
prevent ordered β-sheet formation; alternatively, gangliosides may be involved in normal Aβ 
functioning and/or clearance [113]. McLaurin et al. suggested that the association with a 
carbohydrate backbone was necessary along with the sialic acid for binding to Aβ. The study 
showed that the binding of Aβ (1-40) to mixed gangliosides or GM1 induced α-helical structure 
at pH 7.0 and β-sheet structure at pH 6.0. They posited that increasing the number of sialic acid 
residues on the carbohydrate backbone leads to increased net negative surface charge on the lipid 
vesicles which favors the formation of an ordered β-sheet structure and inhibits the α-helical 
structure [112]. This observation was further supported by the work of Matsuzaki and Horikiri, 
who suggested that Aβ(1-40) peptide binds more strongly to a ganglioside-rich domain in which 
the binding site was the sialic acid moiety, with the Aβ peptide adopting an antiparallel β-sheet 
lying parallel to the lipid bilayer [116]. In another work by Ariga et al. it was found that GM1 
ganglioside had affinities in the following order of binding strengths: Aβ (1-42) > Aβ (40-1) > 
Aβ (1-40) > Aβ (1-38).  Aβ-APP analogs had very low binding affinities for gangliosides. They 
also showed that Aβ (1-40) binds to a number of gangliosides with the following order of 
binding strength: GQ1bα > GT1aα > GQ1b > GT1b > GD3 > GD1a = GD1b > LM1 > GM1 > 
GM2 = GM3 > GM4. Their results suggested that an α2,3NeuAc residue on the neutral 
oligosaccharide core of gangliosides was required for binding along with the α2,6NeuAc residue 
linked to the GalNAc in the α-series [135]. In another related study, researchers showed that Aβ 
has higher affinity towards clustered ganglioside GM1 and to gangliosides having higher number 
of sialic acid content, the formation of which is regulated by cholesterol content in the brain [27]. 
34 
 
In a study by Wang et al., reduction of cellular cholesterol and removal of cell surface sialic 
acids protected cells from Aβ toxicity, stressing the importance of surface sialic acids [125]. The 
clustering effect of gangliosides is supported by the theory of lipid rafts. Lipid rafts are 
membrane microdomains that are enriched in cholesterol, sphingomyelin and sphingolipids 
(especially GM1 ganglioside) [136]. These lipid rafts are more ordered and tightly packed than 
surrounding bilayers, have certain proteins, signaling molecules clustered in it and have the 
ability to float freely in the cell membrane. Willliamson et al. demonstrated with NMR studies 
that interaction of 15N-labeled Aβ(1-40) and Aβ(1-42) with GM1 micelles is localized to the N-
terminal and His13 to Leu17 region of the peptide. They showed that the fibrillogenic seed 
nucleus involves an interaction of His13 with the sialic acid moiety of GM1 ganglioside. This 
indicated that Aβ binds to the carboxylic acid group on sialic acid via a positively charged amino 
acid residue. However, they observed no binding to the isolated pentasaccharide headgroup, 
suggesting the need for a polyanionic membrane like surface [137]. Investigators found that the 
ability of fibrils binding to membranes was significantly affected when cells were treated with 
neuraminidase, which did not affect the membrane fluidity, but removed the negatively charged 
sialic acid residue in GM1 [23]. This suggests that Aβ fibrils interact with the negative charges in 
the sialic acids and demonstrates the importance of electrostatic interactions between fibrils and 
cellular membranes. 
A number of studies have observed the accumulation of specific ganglioside bound Aβ 
complex in the AD brain [19-21, 129]. Other studies showed the interaction between 
gangliosides and Aβ peptides in neuronal cells leading to the amyloid fibril formation. 
Glucosylcermidsynthase inhibition, one of the rate limiting steps in ganglioside synthesis, results 
in decreased Aβ production. AD brains have also shown elevated GM1 levels and increased 
35 
 
sialidase activity [62]. All of these results point to the pivotal role of gangliosides, especially 
GM1 in the pathogenesis of Alzheimer’s disease. Researchers propose that the initial step in AD 
is ganglioside binding with the Aβ peptide; the peptide then undergoes self-association on the 
membrane surface by undergoing a conformational change from random coil to ordered β-sheet. 
This surface associated, ordered β sheet peptide then acts as a specific template (“seed”) which 
causes additional soluble Aβ to form fibrils by β-sheet augmentation mechanism [129, 134]. 
[Please see [129] for excellent review]. In a related recent study of Aβ(1-40) fibrillation in the 
presence of lipid bilayers composed of GM1, cholesterol and sphingomyelin at low protein 
densities (Aβ:GM1 less than ~0.013 units concentration) the helical Aβ species was observed. At 
mid-level protein densities (Aβ:GM1 between ~0.013 and ~0.044), the helical species and 
aggregated β-sheet species were seen together. At higher densities (Aβ:GM1 more than ~0.044), 
the β-sheet structure had converted to  a second seed-prone β-structure [32]. Another study 
developed GM1-Aβ specific monoclonal antibody that specifically recognized the unique 
changed conformation shown by the GM1-Aβ in the AD affected brain, which in turn acts a seed 
for further aggregation [22]. In another recent study, the interaction of both model and living cell 
membranes with Aβ (1-40) and Aβ (1-42) was studied where they observed 10-fold more 
amyloidogenic activity from Aβ(1-42) compared to Aβ(1-40) [138]. 
 It was also observed that Aβ(1-40) fibrils grown on GM1 have different structural 
features and much higher toxicity due to their increased stability and ability to bind to neurons 
with respect to the same fibrils that are grown in the absence of GM1[23]. In a clinical study 
where 100mg of GM1 was administered for 18-32 days to patients with spinal cord injury, 
patient’s showed enhanced recovery of neurologic function. However, same studies on a much 
larger group of 760 patients did not show any significant benefit. In another related study, 
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administrating 200mg of GM1 per day for 18 weeks did not show any significant changes in the 
blood chemistry of patients [111]. This direct GM1 study further supports our approach given 
that GM1 administration is ineffective and we need a better biomimetic that can bind to Aβ. 
 
Figure 8: Hypothetical mechanism of ganglioside-mediated Aβ fibrillization.  
Enzymatic cleavage (γ- and β-secretase) of APP generates soluble Aβ in the lipid rafts composed 
of cholesterol and sphingolipids. Cholesterol mediates the formation of ganglioside clusters 
(especially GM1), Aβ binds to the clusters, forming a seed for further soluble amyloid deposition 
into ordered β-sheet form at higher peptide to ganglioside ratios [129]. Reprinted with 
permission from Elsevier Ltd. 
2.11. Current and Emerging Therapeutic Approaches in AD  
2.11.1. Approved Drugs Against Alzheimer’s Disease 
Currently available treatments for AD are merely symptom alleviating, providing 
temporary cognitive improvement and deferred decline. However, they show very little to no 
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evidence of slowing disease progression or curing AD [139]. Table 2 lists the drugs currently 
approved by the Food and Drug Administration (FDA).  
Most of the drugs approved today are cholinesterase inhibitors. The enzyme 
cholinesterase is responsible for the degradation of acetylcholine, which is released into the 
synaptic cleft after the firing of the synapses from one neuron to another [139].  As neurons are 
under attack in AD, they produce less acetylcholine and hence, inhibition of its destruction 
causing enzyme makes more neurotransmitters available for communication between neurons. 
Galantamine, Donepezil and Rivastigmine are the 3 inhibitors of cholinesterase available in the 
market today and are approved for mild to moderate treatment of AD [11, 43, 48, 139]. 
Galantamine and Donepezil selectively inhibit acetylcholinesterase hydrolysis in the brain, while 
Rivastigmine in addition to cholinesterases also inhibits butyrylcholinesterase, which has a 
similar role to that of cholinesterase. Based on their mechanism of action it is evident that these 
medications only temporarily mitigate symptoms and are not expected to change the course of 
AD [43]. All drugs reported positive effects in several randomized, double-blind, placebo-
controlled studies; however, a direct comparison of these three cholinesterase inhibitors has not 
been done. Another drug available is Memantine, an NMDA (N-methyl-D-aspatarte) -receptor, 
which is approved for the treatment of moderate to severe AD. In AD, it is observed that NMDA 
glutamate receptors are overactivated which leads to disturbed calcium homeostatis causing 
neurodegeneration. Memantine is a non-competitive NMDA-receptor antagonist with moderate 
affinity that appears to be able to protect neurons while leaving physiological NMDA-receptor 
activation unaffected [139]. Several other potential NMDA receptors are in active phases of 
development. Some researchers postulate that the use of Memantine with cholinesterase 
inhibitors might be a viable approach in treating AD. In a randomized, double-blind, placebo-
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controlled clinical trial of patients with moderate to severe AD, the combination therapy showed 
a statistically significant benefit over monotherapy of Donepezil, with regard to the measures of 
cognitive function, activities of daily living, and behavior [139]. However, this theory needs to 
be investigated further. Flurizan (Myriad Genetics, USA) is a γ-secretase inhibitor that showed 
promise but failed in Phase III trials [6]. Semagucestat (Eli Lilly & Company, USA) made 
patients worse with increased risk of skin cancer. Information on other drugs investigated is 
presented in [6]. 
Table 2: Characteristics of drugs approved for AD [43, 140, 141]. 
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2.11.2. Immunotherapy for AD 
Immunotherapy is an emerging and promising approach because it promotes the 
possibility of peripheral treatment of Aβ that eliminates the need to design molecules that can 
cross the blood-brain barrier (BBB). The idea behind immunotherapy is that by decreasing the 
Aβ levels in the blood, more Aβ can be removed from the brain. The use of Aβ immunotherapy 
was first reported by Schenk and co-workers from the study in APP transgenic mice, wherein 
active immunization with fibrillar Aβ attenuated Aβ deposition and improved behavior [139, 
142]. Similar results were obtained by the use of passive immunization with antibodies against 
Aβ [143]. This led to the clinical trials on mild AD patients with vaccine AN1792, composed of 
preaggregated Aβ(1-42). However, in phase II, it was found that 6% of the vaccinated cases had 
developed aseptic meningoencephalitis and the trail was discontinued [144]. The researchers 
attributed this side-effect due to the T-cell response against the mid-terminal and C-terminal part 
of the peptide [43, 48].  
Still, refined forms of active immunization are considered as a viable option and some 
clinical trials are in Phase I [145]. Researchers have also focused on the development of passive 
vaccinations for the treatment of AD. Several trials with passive immunization are underway 
with selective monoclonal antibodies which have been shown to decrease Aβ plaque pathology 
and reduce behavioral impairments in transgenic mice [11]. Phase III trials are under way for an 
anti-Aβ antibody named Bapineuzumab, which has shown affinity for both soluble and insoluble 
Aβ. One phase II and two phase I trials are also underway for other antibodies [145].  Thus, 
active/passive immunization or vaccination can prove to be a viable option for the treatment of 
Aβ. A very good strategy in immunotherapy is to develop an Aβ sequestering molecule that does 
not elicit an immune response. 
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2.11.3. Inhibition/Modulation of Secretases 
According to the amyloid cascade hypothesis, the production of Aβ is the root-cause of 
AD. Assuming this to be true, the inhibition/modulation of secretases would be the cleanest 
approach and would remove monomeric Aβ, therefore preventing the production of oligomers 
and fibrils. Thus, up-regulation of α-secretase, down-regulation/inhibition of β-secretase, and 
inhibition/ modulation of γ-secretase are some of the potentially viable approaches that are being 
investigated currently.  
γ-Secretase inhibitors can reduce Aβ synthesis, which can further inhibit the downstream 
cascade of events. DAPT, LY450139 dihydrate, MRK-560 and BMS-299897 are some of the γ-
secretase inhibitors that have shown marked reduction in Aβ levels in brains, CSF and plasma in 
transgenic mice [48, 139]. However, it was found that γ-secretase cleaves substrates other than 
APP such as Notch [11]. Thus, inhibition of γ-secretase can have adverse effects. Hence, 
modulating the activity of γ-secretase to produce less Aβ is a more viable strategy. Recently, a γ-
secretase inhibitor was developed that was able to inhibit Aβ production without affecting Notch 
signaling [146]. Another γ-secretase modulator that has entered phase III study is R-flurbiprofen, 
which is believed to lower the production of the more toxic Aβ(1-42) by shifting the cleavage of 
APP from producing Aβ(1-42) to other shorter, less toxic peptide fragments [147]. Several other 
γ-secretase modulators are currently being developed or undergoing phase I trials [11]. Also, β-
secretase appears to be the perfect therapeutic target as it represents the first step in Aβ 
production. Studies on β-secretase (BACE1) knockout mice revealed very small quantities of Aβ 
thereby establishing BACE1 as the primary β-secretase enzyme acting in vivo [139, 146]. 
However, the physiological roles of BACE1 and its homologue BACE2 are unknown even 
though they are expressed throughout the body. The complete inhibition of β-secretase has 
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displayed potentially deleterious effects in mice. It was observed that β-secretase can also act on 
other non-APP substrates [64, 148]. It has been difficult to develop potent brain penetrating 
BACE1 inhibitors as it was observed that most of BACE inhibitors showed nanomolar binding 
affinities in cell free assays but were unsuitable for in vivo experiments [48]. Recently, it was 
announced that a potent BACE1 inhibitor, named CTS-21166 [64] was safe and well-tolerated in 
Phase I study. In AD, it is believed that β and α-secretase compete for the APP substrate and 
there exists a balance between the two activities. For review see [149]. 
Progress in developing efficient inhibitors and modulators of secretases has been 
impeded as most of these secretases have not been fully identified and understood. Their 
psychological roles are unknown. Not everything is known about the different substrates they 
attack and it is believed that most secretases attack more than one substrate. Thus, there is a need 
for developing selective and highly targeted drugs that can only inhibit or modulate the APP 
cleavage process. Also, the compounds developed should be capable of crossing the blood-brain 
barrier. Such constraints make the development of specific drugs a challenging task. 
2.11.4. Aβ Aggregation Inhibitors 
Preventing the aggregation of Aβ, thereby preventing the formation of presumed toxic 
oligomers and fibrils by specifically binding molecules is another promising approach for the 
treatment of AD. Alzhemed (3-amino-1-propanesulphonic acid), a small molecule developed by 
Neurochem Inc., has been shown to inhibit the interaction of Aβ with glycosaminoglycans 
thereby inhibiting formation of Aβ aggregates. Clioquinol (PBT-1) developed by Prana 
Biotechnology, has shown good results in reducing Aβ deposition in APP transgenic mice by 
binding to zinc and copper, which are postulated to be involved in Aβ aggregation process [146]. 
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Also, another metal chelating agent, PBT-2 is in phase II trials [148]. Another approach is to 
design inhibitors based on histological dyes used to characterize amyloid in vitro and in vivo. A 
number of polyphenols such as Curcumin, Catechins, Gingo Biloba are also being investigates 
are potent inhibitors of Aβ aggregation and to prevent neurotoxicity [150].  
Compared to small molecules, several peptide based therapeutic strategies are under 
investigation, as they are thought to be more effective as they can interact with the extended 
regions of Aβ. Tjernberg et al. reported that a pentapeptide KLVFF of Aβ(16-20) binds to and 
disrupts fibrils formation [151]. Ghanta et al. reported a prototype inhibitor composed of residues 
15-25 of the Aβ peptide linked to an oligosine disrupting element [99]. The use of the 
recognition element helps in specificity whereas the disrupting element interferes with Aβ 
aggregation pathway. Selective substitution of proline at key positions on a peptide homologous 
to the central 17-21 regions of Aβ was shown to convert Aβ fibrils to amorphous aggregates and 
inhibit toxicity in vitro and in vivo [152]. The use of N-methylated peptides is another promising 
approach which is known to lock the residues into a β-conformation. N-methylated peptides 
function by binding to the face of the aggregating peptide through the amide -NH groups at the 
outer edge of the β-sheet, effectively blocking intermolecular hydrogen bonding, thus preventing 
aggregation and toxicity [150]. For reviews see [12]. 
However, most of these strategies are under development and their beneficial effects on 
AD patients are still not clear. Another major problem is that the most toxic species of Aβ has 
not been identified. Also, determining the correct chain of events in AD development is 
challenging and this is another major hurdle in the development of a specific Aβ inhibiting 
molecule. 
43 
 
2.11.5. Strategies Involving Metal Interactions of Aβ 
Researchers are investigating the role of metals in AD pathology. Abnormally high levels 
of metals such as Cu (~400μM), Zn (~1mM) and Fe (~1mM) have been found in AD brains with 
significant ROS and evidence of oxidative stress. One approach is to selectively inhibit the metal 
binding sites in an Aβ peptide to prevent Aβ metal interaction. Another approach is to synthesize 
metal-protein attenuating compounds (MPACs) which target the metal bound Aβ and restore the 
metals back to the synapses. MPAC Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) and 
MPAC PBT2 are in Phase II clinical trials. However, simply removing metals using chelators 
does not work as many metals play essential roles in neuronal function and chelators or metal 
complexes are very difficult to get a cross the BBB. For excellent review see [153]. 
2.11.6. Drugs Based On Epidemiology 
Epidemiological studies have observed the protective effect of different types of drugs 
and supplements on AD patients. One such class of drugs being investigated are anti-
inflammatory drugs as inflammation type characteristics are observed in the immediate vicinity 
of plaques. Hence, it is believed that use of anti-inflammatory drugs may have preventative 
effects in the development of AD either by the inhibition of cyclo-oxygenase (COX-1 or COX-2) 
or by direct action on γ-secretase  [43, 139]. However, clinical trials on drugs such as 
Prednisone, Hydroxychloroquine, Naproxen, Celecoxib and Rofecoxib were negative [148]. The 
use of cholesterol reducing drugs (statins) is suggested as a viable treatment option for AD as in 
vivo and in vitro studies showed altered levels of APP and Aβ along with cholesterol levels 
[154].  However, clinical trials of these drugs have showed ambiguous results [139, 154]. One of 
the reasons may be that the exact role of cholesterol in AD is unknown. Dietary intake of anti-
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oxidants such as Vitamin E has shown beneficial results as oxidative stress is lessened in an AD 
brain. However, most of these strategies target post-cell damage and are therefore not optimal 
disease modifying agents. 
2.11.7. Novel Aβ Sequestering Agents: OUR FOCUS 
In the earlier sections, we have already reviewed the interaction between Aβ, 
gangliosides and the neuronal membrane. We know that Aβ interacts with cells via binding to 
surface glycolipids and glycoproteins, and that the affinity of this interaction increases when the 
gangliosides or sialic acid molecules on the cell surface are clustered [8, 26-28, 118, 134, 135, 
137]. Based on these observations, the approach is to design membrane mimics that would 
reproduce the clustered sialic acid structure of the cell surface thus successfully competing with 
the cell surface for Aβ binding. Then, Aβ would have higher affinity towards the mimic, binding 
it instead of the cell membrane, and thus sequestering the Aβ, thereby reducing its neurotoxicity 
[8, 26, 143]. Such a strategy has already been applied with good results to many biological 
systems such as the prevention of influenza viral adhesion and infection both in vitro and in vivo 
[155-159]. Patel et al. synthesized sialic acid conjugated dendrimers which were more effective 
than unconjugated dendrimers alone at reducing Aβ toxicity. The reported binding affinities for 
Aβ to gangliosides in various literatures are in the order of 10-6M [114, 134, 135] whereas the 
observed binding affinities for Aβ to sialic acid conjugated dendrimers were on the order of 10-7 
to 10-9 M. The improved affinity was attributed to the clustering of sialic acids on dendrimers, or 
the combined effect of electrostatic interactions of Aβ with the dendrimer backbone and the 
interaction of Aβ with the surface sialic acids on the dendrimer [8]. However, the dendrimer 
backbone itself was toxic to the cells, leading to lower viability. This observation was in 
agreement with that observed in literature for dendrimer toxicity [158, 160]. Also, it is possible 
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that due to the rigid structure of the dendrimer used, the star burst type, it could have partly 
reduced the binding of labeled sialic acid to specific Aβ sites. In another related work by Patel et 
al., the difference in Aβ attenuation using physiologically relevant attachment (via anomeric 
hydroxyl) versus non-physiologically attached (carboxyl attached) chemistry of dendrimers was 
investigated. They found that though physiologically attached dendrimers attenuated Aβ toxicity 
at lower concentrations than non-physiologically attached dendrimers, there was no significant 
improvement in the binding affinities [161]. Furthermore, they postulated that, greater Aβ 
toxicity attenuation could be achieved by the use of a less highly charged polymer backbone and 
longer spacer between the charged polymer and sialic acid [26]. In the work by Cowan et al., use 
of photocrosslinked sialic acid containing oligosaccharides 3’–sialyl-N-acetyllactosamine 
(3’SLN) and disialyllacto-N-tetraose (DSLNT), showed almost complete attenuation of toxicity 
but at very high polymer concentration. Their results suggested that the mechanism of toxicity 
attenuation of Aβ might not be direct competition for Aβ binding and that, better attenuation of 
toxicity could be achieved at lower concentrations by increasing the valency of sialic acids on 
the polymers [156]. All these observations support the fact that multivalency can increase the 
binding affinity of a ligand to receptors [162]. By the use of mathematical models, Cowan et al. 
showed that the closest qualitative explanation for the membrane mimic attenuating toxicity was 
that the sialic acid mimic bound to Aβ, the Aβ-mimic complex was still toxic to the cells, but 
with a reduced toxicity compared to Aβ alone. It is predicted that at physiological ionic 
strengths, electrostatic effects are likely to play a role in sialic acid polymer toxicity attenuation 
of Aβ only for very highly charged polymers [162].  
All these observations certainly indicate that there are yet to be understood mechanisms 
that are possibly playing a role in attenuating Aβ toxicity such as the possibility of different –R 
46 
 
group sugars that have better properties. Since, a number of studies have highlighted the role of 
multivalent sialic acids in attenuating toxicity, it will be crucial to investigate how multivalency 
affects Aβ binding. In addition, the effect of different backbones on the Aβ needs to be 
investigated as backbone toxicity can significantly affect viability. This leaves the field open for 
the design of better membrane mimicking compounds that can attenuate toxicity at even lower 
concentration with higher affinity.  
Towards this goal, there is a need for a suitable backbone structure that is biocompatible, 
flexible, non-toxic and easy to label among other things. Chitosan is an aminopolysaccharide that 
seems ideal as a backbone for sialic acid labeling. We will aim to synthesize sugar labeled 
chitosan by the use of a suitable cross-linker and test the efficiency of this complex to attenuate 
Aβ toxicity. Next section describes the properties of chitosan. 
2.12. Chitosan, Backbone Molecule 
Throughout the project, chitosan was chosen as a backbone molecule for attaching different 
sugars. We expect excellent biological properties offered due to the use of chitosan, especially 
that it has been FDA approved for use in wound dressing [163]. Additionally, chitosan is one of 
the most extensively studied biopolymer or biomaterial. Chitosan, identified in 1884 [164],  is a 
natural amino-polysaccharide comprising copolymers of D-glucosamine and N-acetyl-D-
glucosamine linked together by β(1-4) glycosidic bonds [165]. The individual chains of chitosan 
assume a linear structure which undergoes one full twist every 10.1-10.5A0 along the chain axis. 
Each monosaccharide unit is chiral, the rotations of polymer chains show evident left or right. 
Three crystal types of chitosan are identified, α, β and γ- type, out of which α-type is the most 
common identified from X-ray models and NMR spectra [166]. It is derived by partial 
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deacetylation of chitin from crustacean shells. The content of glucosamine in chitosan is called 
the Degree of Deacetylation (DD), which affects its solubility [167]. In chitosan, the DD ranges 
from 40% to 98% and the molecular weight ranges between 300Da to over 1000kDa depending 
on the source and method of preparation [168, 169].  The distribution of the two monomer units 
that make up chitosan can be determined using various techniques such as IR, elemental analysis, 
enzymatic reaction, UV, 1H liquid state NMR and solid-state 13C-NMR [166]. Other important 
properties of chitosan include viscosity, molecular weight, DD, crystallinity index, number of 
monomeric units, water retention value, pKa and energy of hydration [170]. Generally, studies 
have shown greater solubility and faster degradation for chitosan with low molecular weights 
and low DD compared to high molecular weight chitosan[171].  The oral mean lethal dose of 
chitosan in mice was found to be in excess of 16g/day/kg, which is higher than sucrose [171, 
172]. 
 
Figure 9: Structure of Chitosan  
Also shown are the functional groups that can be modified for various applications. In our case, 
amine group at C2 position is used to couple sugars to chitosan 
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Chitosan is normally insoluble in aqueous solutions above pH 7 and in dilute acids (pH < 
6), the amino groups on glucosamine become protonated (positively charged) (pKa value of 6.3) 
facilitating solubility of chitosan, making it a cationic polyelectrolyte. There is a strong 
possibility of the interaction of the positive charges of chitosan polymer with the negatively 
charged surface of the cell membrane, particularly the sialic acid moieties [167, 173]. Chitosan 
exhibits high charge density which makes it adhere to negatively charged surfaces [170]. When 
chitosan solution pH increases above 6.0, the chitosan’s amines become deprotonated, chitosan 
loses its charge and becomes insoluble [163]. It has been reported that chitosan with higher DD 
shows low toxicity at low molecular weight [171]. This property of chitosan can be explored for 
drug adsorption enhancement. Generally, chitosan has three types of reactive functional groups, 
an amino group as well as both primary and secondary hydroxyl groups at the C2, C3 and C6 
positions, respectively, which allow modification of chitosan for various applications [168]. This 
large quantity of amines at C2 position compared to other biopolymers makes chitosan the target 
of a host of chemical modifications and potential applications.  
The amino functionality gives rise to chemical reactions such as acetylation, amide 
formation, quaternization, reactions with ketones and aldehydes, alkylation, grafting, chelation of 
metals, flocculation etc. Much work has been reported on chemical modifications of chitosan and 
the reactions have been reviewed extensively [165, 168, 169, 174, 175]. There have been 
extensive applications of chitosan in the field of controlled drug delivery. Chitosan nanoparticles 
offer better stability, low toxicity and simpler preparation methods with novel routes for delivery 
of drugs. For review on application of chitosan nanoparticles see [171, 176]. Thiol modification 
of chitosan has been extensively studied as non-invasive drug delivery applications [167]. The 
tissue engineering application of chitosan, applications in hydrogels, bone substitute has also 
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been studied extensively [177]. Commercial hemostatic dressing based on chitosan include 
HemCom and Chitoflex by HemCom, Chitoseal by Abbott, Clo-Sur by Scion, TraumaStat by 
Ore-Medix to name a few. Chitosan and its derivatives  have been shown to have several 
interesting properties such as biocompatibility, biodegradability to harmless products, 
physiological inertness, remarkable affinity to proteins, nontoxicity, antibacterial, hemostatic 
behavior [166], wound healing, fungistatic, antitumoral, anti-acid, non-allergic, antiviral and 
anticholesteremic properties [165, 168, 169, 175]. Such unique properties of chitosan make it a 
very interesting topic of research with a host of applications [165-169, 174, 175]. Summary of 
applications of chitosan and drug are presented in [170]. Another excellent source on chitosan 
applications is the latest review (published in 2011) published by Dash et. al. that gives 
information about the toxicity, biological properties, biomedical applications (types and 
methods), drug delivery, wound healing, tissue engineering, gene therapy, green chemistry and 
pharmaceutical applications of chitosan [163]. 
2.13. Biological Sugars Selected for Conjugation with Chitosan 
A host of sugars, particularly, sialic acids, polysialic acids and oligosialic acid chains 
discovered so far are directly or indirectly connected to membrane chemistry. The action of sialic 
acids/poly/oligosialic compounds [178] results from the combination of: 
Repulsive interactions: in-between sugars or between sugars and membrane proteins. 
Attractive interactions: between poly/oligosialic chains and membrane protein, or lipids or 
soluble peptides/proteins/proteoglycans 
Modulation of surface charge density: due to negative charge associated with sugar monomers 
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Modulation of pH at the membrane surface: the carboxylic groups on the sugar chains affect the 
pH at the microenvironment 
Sialic acid or N-Acetylneuraminic acid (SA): In the sialic acid family of compounds, N-
acetylneuraminic acid (SA), is one of the most frequently occurring member. It is an 
electronegatively charged monossacharide, and is a major component of most proteins and lipids 
of cell membranes. SA is conveniently positioned on the outer end of these molecules, which 
implies a strong influence on cell biology. Its role in AD is well documented in the earlier pages 
of the report. Thus, SA, is studied first in this research and will enable us to use SA as a standard. 
Structure of SA is shown in figure 10. 
2-Keto-3-deoxy-nononic acid (KDN): KDN is another electro-negatively charged member of 
the sialic acid family occurring most frequently in cell membranes after N-acetylneuraminic acid 
(SA). The only difference between SA and KDN is the substitution at the C-5 position. This 
critical difference will help us to isolate the effect of the –R group at C-5 position. The structure 
of KDN is shown in figure 10. 
Galacturonic acid (GA): GA is a monobasic carboxylic acid derived from the oxidation of D-
galactose. It is found in many natural polymers such as pectins and is a common component of 
cells walls. It has hydroxyl substitutions at C-5 and C-6 position instead of the –R groups found 
in sialic acids. The structure of GA is shown in figure 10. 
Tetrahydropyran-2-carboxylic acid (Pyran): This compound was selected to test the ability of 
the ring structure in Aβ attenuation properties. Pyran has no substitutions that are present in sialic 
acid family. It has a conveniently located carboxylic acid group at the C-2 location which can be 
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coupled with the amines in chitosan via EDC chemistry. Structure is shown in figure 10. 
However, to the best of knowledge, Pyran has not been studied in a neuronal cell system. 
Cyclohexanecarboxylic Acid (CHC): CHC is a cyclohexane with a carboxylic acid group 
conveniently attached for coupling with amines of chitosan. This will help us to understand the 
difference due to the cyclic ring structure. Also, the difference in properties shown by CHC and 
Pyran ring will help to identify the role of –O substitution found in the Pyran structure. However, 
to the best of knowledge, CHC has not been studied in a neuronal cell system. 
 
 
Figure 10: Structure of different sugars conjugated to chitosan 
The structural differences from sialic acid are indicated by the shaded region.  (A) Sialic acid (N-
Acetylneuraminic acid), (B) Keto-deoxynonulosonic acid (KDN), (C) D(+)-Galacturonic acid 
(GA), (D) Tetrahydropyran-2-carboxylic acid (Pyran), and (E) Cyclohexanecarboxylic acid 
(CHC) structures are shown to elucidate these differences. 
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2.14. Conjugation Chemistry Using EDC with Sulfo-NHS 
We envisioned the synthesis of cyclic sugar labeled chitosan biomaterials that can mimic 
the sialic acid structure present on the cell membrane.  For this reason, a suitable conjugation 
chemistry should be investigated that can attach these sugars to chitosan with control over the 
degree of labeling. As it can be seen from figure 10, there is a carboxylic acid group at the C1 
position on each of the sugars that are coupled with the amines on chitosan. A number of 
chemistry methods have been developed that can couple –NH2 group to a –COOH group 
resulting in amide linkage. The sugars that will be conjugated to chitosan are shown in figure 10 
and the structure of chitosan is shown in figure 9. 
Crosslinking reagents are commonly used to couple two molecules together. 
Homobifunctional crosslinkers (e.g. Imidoesters to couple amines) are used when the two 
crosslinking molecules have the same functional groups and heterobifunctional crosslinkers (eg. 
carbodiimides to from amide linkages) are used when the two targeted molecules have different 
functional groups. In using conjugation chemistry, the length of the spacer arm or bridge is an 
important consideration as it can affect the steric interactions and affinity between linked 
molecules  [179].  
EDC or 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride is a zero-length, 
water soluble crosslinker used commonly to couple carboxylic acids with primary amines. EDC 
first reacts with the carboxyl groups to form a highly reactive, O-acylisourea intermediate. This 
active species then reacts with an amino group to form an amide bond by release of an isourea    
derivative as by-product. However, the intermediate is unstable in aqueous solutions and 
therefore, a two-step conjugation procedure is preferred using N-hydroxysuccinimide (NHS) or 
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N-hydroxysulfosuccinimide (Sulfo-NHS) for stabilization. Sulfo-NHS esters are water soluble 
hydrophilic active groups that react rapidly with amino groups on target molecules. This two-
step procedure of using EDC and Sulfo-NHS has advantages such as enhanced coupling 
efficiency, slow hydrolysis in water, extension of the half-life of activated carboxylate from 
seconds to hours and increased stability in coupling. Thus, in the first step, EDC reacts with the 
carboxyl group on first target compound forming the unstable O-acylisourea ester intermediate. 
Sulfo-NHS, added at the same time as EDC, reacts with the unstable intermediate to form semi-
stable amine reactive NHS ester with improved stability. In the second step, the amino group 
containing molecules are added. In the presence of amino groups that can attack the carbonyl 
group of the ester, the N-hydroxysulfosuccinimide group rapidly leaves, creating a stable amide 
linkage with the amine molecule. Failure to react with an amine results in hydrolysis of the 
intermediate, regeneration of the carboxyl groups and release of N-substituted urea [179-181]. 
The mechanism of EDC chemistry is given in figure 11. 
The EDC coupling reaction is dependent of temperature, pH and buffer composition 
[179]. Studies have found that reactions with EDC and Sulfo-NHS are most efficient at pH 
between 4.7 and 6. At low pH, MES buffer (2-[morpholino]ethanesulfonic acid) at 0.1M is 
recommended whereas for neutral pH reactions, phosphate buffers can be used. Amine or 
carboxylate containing buffers can interfere with the EDC chemical pathway and hence should 
be avoided. For the two step conjugation process, the first reaction is usually performed in MES 
buffer (or other non-amine, non-carboxylate buffer) at pH 5.0-6.0. After activation is complete, 
the pH is raised by using phosphate buffer (or other non-amine buffer) to 7.0-7.5 immediately 
before addition of amine containing compound (Ref: NHS, Sulfo-NHS product information 
sheet, Pierce Biotechnology, IL, USA) [180, 181]. Thus, EDC chemistry is extensively used to 
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couple two proteins, haptens to carrier proteins, surface molecule attachment and a host of other 
applications. Practically, any two molecules having a carboxyl group and amine group can be 
conjugated by this chemistry.  The disadvantages of this chemistry include unwanted 
polymerization, precipitation of conjugating molecules, hydrolysis and unwanted side reactions 
in presence of certain compounds. 
 
Figure 11: Conjugation Mechanism using EDC chemistry with Sulfo-NHS 
This chemistry is used to couple carboxylate containing molecules (Sugars in this case) with 
amine containing molecules (Chitosan in this case) showing intermediate steps in the reaction 
[180] (http://www.piercenet.com/products/browse.cfm?fldID=02040114) 
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2.15. Experimental Design 
The therapeutic development in Alzheimer’s disease (AD) is hampered by the fact that 
the amyloid-beta (Aβ) peptide is amphiphillic and highly prone to aggregation. Until now, the 
exact structure of aggregated Aβ has not been agreed upon (section 2.8 gives literature on the 
structures of Aβ, its aggregated states and the work done in those fields). For the Aβ experiments 
done in vitro, in this work, it is important that the protocols and design followed are consistent 
with that in the community. The following sections describe the work of other researchers with 
aggregated Aβ and its toxicity attenuation studies. 
2.15.1. Brief Background 
Aβ peptide is highly prone to aggregation and exhibits dual nature in many studies. Aβ is 
an amphiphillic peptide whose aggregation is dependent on a host of factors such as length of the 
peptide, solvent hydrophobicity, peptide counter ions (CF3COO- vs. Cl-), pH, temperature, 
peptide concentration, type of solvent, salt concentration and pretreatment [182, 183]. There are 
a host of conformational forms that Aβ can take and all these forms have shown different 
behavior and toxicity profiles depending on several environmental factors. Additionally, 
depending on the commercial source, peptide batch, particular aggregation conditions, there are 
significant discrepancies observed across different studies [182].  Before making the aggregated 
Aβ peptide that is neurotoxic, the lyophilized powder of Aβ peptide is dissolved in a highly polar 
solvent such as dimethyl sulfoxide (DMSO), 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) or 
trifluoroacetic acid (TFA), aqueous TFA, aqueous acetonitrile with TFA etc. so that no 
aggregated Aβ species preexist that can act as a seed for aggregation. For the Aβ(40) peptide, 
solvents such as DMSO and HFIP are more suitable [182]. This addition of a polar solvent 
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makes each Aβ monomer into a single species which is then added to the cell culture medium for 
aggregation over different periods of time (depending on the type of study to be done). Amyloid-
beta Aβ(40), Aβ(1-42) and Aβ(25-35) are the most widely used Aβ species that are investigated 
for their neurotoxic effects. In the human body, more than 90% of the Aβ produced from the 
amyloid precursor protein is the Aβ(40) compared to other species, namely Aβ(42), which is 
more neurotoxic Aβ(42). Aβ(42) has two additional residues in the hydrophobic domain 
compared to Aβ(40), thus, it is more prone to aggregation and has been proved to be more toxic 
to cells in culture[184-187]. Aβ(25-35) is the small fragment isolated from APP, one of the 
active part of Aβ(1-42) that has shown similar neurotoxic effects (compared to Aβ fragements) 
to cells in cultures [188, 189]. Additionally, section 2.7 lists the type of aggregated species that 
are isolated and identified. Each of these species exhibits their own morphology, aggregation 
states and toxicity profiles. Till this date, the exact toxic species in AD has not been agreed upon.  
Given below are the studies done with Aβ peptides and its different protocols regarding 
aggregation or cell culture or viability assessment. Details include, type of peptide used, 
concentration of Aβ used, time of aggregation, protocol of aggregation, cell culture system used, 
toxicity assay used to assess viability and the time of Aβ incubated with cells is mentioned. 
Finally, the viabilities (Percentage of cell surviving) obtained from each experiment are 
mentioned. Only the Aβ control viability is will be given. The Aβ control represents the viability 
obtained after the addition of Aβ peptide solution (in any aggregated form) to cells in the absence 
of any other test or experimental compound. Thus, viability of cells with just toxic aggregated 
Aβ added represents the Aβ control. All values are relative to the live control, which are 100% 
cells, with no Aβ or any other test/experimental compound added to them. 
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2.15.2. Review of Aβ Studies from Published Literature 
The issue of variability and unpredictable nature of the in vitro toxicity of synthetic 
Aβ(40) was investigated by using different batches of Aβ(40) and a model system of PC-12 cells 
[190]. Aβ(40) peptides obtained from different sources were aggregated under similar conditions 
and the viability assessed by the trypan-blue assay. To form aggregated solutions, Aβ(40) 
powders were dissolved in either 10% DMSO or 100% DMSO and sonicated, then centrifuged at 
14000rpm for 5min. Then, these stock solutions were diluted into the serum free media for cell 
culture studies. For comparing toxicity studies, Aβ(40) solutions were added to PC-12 cells for 
24h after which viability assessed with the trypan blue assay. Viable cells exclude trypan dye. 
All Aβ(40) peptide protocols and cell studies were done in a consistent manner to minimize 
variations in the study. Control cells were cell treated with either 0.1 or 1% DMSO as that was 
the solvent in which Aβ was initially dissolved. First, from 18 PC-12 cell toxicity experiments 
(with 18 different batches of Aβ(40)), statistically significant cell death was observed in 67% of 
the experiments. On the other hand, no toxicity was seen in 37% of the tests, indicating that 6 out 
of 18 Aβ(40) batches were non-toxic to cells. These results show lot-to-lot variability in toxicity 
from Aβ(40) solutions even under consistent conditions. See (figure 12 C.) below for detailed 
explanation on the results seen from the publication. In the next experiment, 46µM Aβ(40) from 
the same lot, (ZK568) was used in each experiment performed on separate days. In these two 
experiments, same numbers of cells were added to the plates. Two experiments, done on two 
separate dates, with the same batch (ZK568) of Aβ(40) and with the same number of cells gave 
very high toxicity (~24% viability of cells were in Aβ control) in one experiment whereas no 
toxicity ( ~91% viability in Aβ control) in the other. The actual result, adapted from the 
publication is shown in figure 12(A). This indicates the within lot variability of Aβ(40) peptides. 
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Figure 12: Results from typical PC-12 cell toxicity tests illustrated to denote lot-by-lot 
variability 
Figure 12.A: Amyloid-β(40) at 46µM concentration of the same lot (#ZK568) of Aβ(40) was 
used in each experiment. Cell toxicity was defined relative to control cells that had received 
vehicle only (DMSO). All dishes started out with the same number of cells. Results of cell 
counting on the third day after addition of Aβ(40).  Comparison of these results illustrates the 
within-lot variability documented in Figure 12. C, experiments dated 7-15 are shown in (12.A) 
and the 10-12 results in (12.B). Figure (12.A) A typical result in which Lot#568 Aβ(40) was 
toxic to PC-12 cells Figure (12.B) A typical result in which same lot# 568 Aβ(40) was not toxic 
to PC-12 cells.  
Figure 12.C: The numbers (#) refer to lot numbers of Aβ(40) (note that there are no lot numbers 
for the privately obtained material, dates 9-15 and 10-7). Yes refers to experiments in which the 
Aβ(40) was toxic and NO indicates experiments in which Aβ(40) was not toxic. In 67% of the 
cases, Aβ(40) was toxic to PC-12 cells and it was not toxic in 33% of the experiments. These 
results demonstrate the lot-to-lot variability and the within-lot variability in toxicity of Aβ(40) 
solutions. Figures adapted from publication [190], with permission from Elsevier Science Inc.) 
 
59 
 
In a study by Jarvis et al., a dose-dependent study to decide optimum Aβ concentration 
was performed before other cytotoxicity experiments [191]. Briefly, neurons from the septal 
nucleus of the rat were treated with 0.1μM, 1μM and 10μM concentrations of aggregated Aβ 
fragment (25-35). In the dose-dependent study, live control (no Aβ) was ~87% cell survival, the 
addition of 0.1μM Aβ(25-35) gave ~79% viability, 1μM gave ~73% cell survival, and 10μM 
Aβ(25-35) gave ~64% cell survival. The study determined 10µM Aβ(25-25) to be the 
concentration for later studies. However, in the later experiments under similar conditions of 
aggregation and cell culture, the control value was around ~66% and the % cell survival with the 
same 10μM Aβ(25-35) was ~21%. This indicates that even after a dose-dependent study with the 
same Aβ fragment, same aggregation protocol, same cell culture system and same experimental 
conditions gives completely different viabilities and cell survival due to variability in the toxicity 
of aggregated Aβ. This difference between the viability from dose-dependent study (~64%) and 
later experiments (~21%) indicates that dose-dependent studies are not a good predictor of Aβ 
toxicity values for subsequent studies. 
The protective effect of TEMPOL, a cyclic nitroxide to prevent Aβ(42) induced oxidative 
injury in SH-SY5Y cells was investigated by Chonpathompikunlert & Nagasaki et al. [192]. 
Aggregated Aβ(42) was prepared by dissolving the peptide in cell culture medium and 
incubating at 370C for 72h prior to the addition to cells. In all experiments, the incubation time of 
Aβ(42) with SH-SY5Y cells was 48h after which the viability was determined by the WST-8 
assay. The WSY-8 reduction by the cells gives a spectrophotometric reading that is proportional 
to the number of viable cells in the sample. In the dose-dependent study with aggregated Aβ(42), 
compared to 100% live cells, 1.5µM Aβ(42) gave ~72% viability, 10µM Aβ(42) gave ~56% 
viability, 12.5µM Aβ(42) gave ~40% viability, 15µM and 20µM Aβ(42) gave ~26% viability of 
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SH-SY5Y cells after 48h of incubation with Aβ(42) peptide. From this study, 20µM Aβ(42) was 
chosen for the next experiments. When 20µM of aggregated Aβ(42) prepared by same methods 
was used, the Aβ control viability was observed to be ~40%. Thus, using the same concentration 
of Aβ(42) and the same aggregation and cell culture protocols, different viabilities in SH-SY5Y 
cultures were observed. This indicates that the viabilities from a dose-dependent study are not an 
accurate predictor of the viabilities obtained in later studies.  
The protective effect of TEMPOL, a cyclic nitroxide to prevent Aβ(42) induced oxidative 
injury in SH-SY5Y cells was investigated by Chonpathompikunlert & Nagasaki et al. [192]. 
Aggregated Aβ(42) was prepared by dissolving the peptide in cell culture medium and 
incubating at 370C for 72h prior to the addition to cells. In all experiments, the incubation time of 
Aβ(42) with SH-SY5Y cells was 48h after which the viability was determined by the WST-8 
assay. The WSY-8 reduction by the cells gives a spectrophotometric reading that is proportional 
to the number of viable cells in the sample. In the dose-dependent study with aggregated Aβ(42), 
compared to 100% live cells, 1.5µM Aβ(42) gave ~72% viability, 10µM Aβ(42) gave ~56% 
viability, 12.5µM Aβ(42) gave ~40% viability, 15µM and 20µM Aβ(42) gave ~24% viability of 
SH-SY5Y cells after 48h of incubation with Aβ(42) peptide. From this study, 20µM Aβ(42) was 
chosen for the next experiments. When 20µM of aggregated Aβ(42) prepared by same methods 
was used, the Aβ control viability was observed to be ~40%. Thus, using the same concentration 
of Aβ(42) and the same aggregation and cell culture protocols, different viabilities in SH-SY5Y 
cultures were observed. This indicates that the viabilities from a dose-dependent study (~24% at 
20μM) are not an accurate predictor of the viabilities obtained in later studies (~40% at 20μM).  
Lee et al., [193] investigated different hybrid molecules to reduce the effects of 
aggregated Aβ(42) on the model human neuroblastoma cell line SH-SY5Y. The SH-SY5Y cells 
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were differentiated for 8 days prior to use in the experiments using trans-retinoic acid in 96-well 
plates. Aβ(42) was dissolved in DMSO to make 500μM and 1mM stock solutions and then 
diluted to their final concentration in cell media. After addition of aggregated Aβ(42) and other 
hybrid molecules, the cells were incubated for 24h and then viability assessed by the 3(4,5-
dimethylthiazol-2yl)2,5-diphenyl-2H-tertrazolium bromide (MTT) assay. This is the same assay 
used in our experiments. In this study, no dose-response studies with aggregated Aβ are done 
before toxicity studies. Using a concentration of 5μM Aβ(42), the results show a viability of 
~77% when no other molecule in added to the wells except 5μM Aβ (figure 1 in ref [193] ). In 
the same publication, the effect of 0.5μM Aβ(42) was assessed on SH-SY5Y cells along with 4 
different hybrid complexes. In these four separate experiment’s, differentiated SH-SY5Y showed 
viability ranging from ~56% to ~64% after treatment with 0.5μM Aβ(42). It is interesting to note 
that in this study, treatment with 0.5μM Aβ(42) showed ~56% to ~64% SH-SY5Y viability, 
whereas treatment with a higher 5μM concentration of toxic Aβ(42) showed a contradictory 
~77% viability even when the aggregation protocols were the same.  
In a publication in PEDS [194], a new protocol for the solubilization of Aβ peptide is 
presented along with the toxicity studies with neuroblastoma SH-SY5Y cells. The protocol to 
give seed free Aβ for aggregation involves a series of solubilizations in organic solvents such as 
DMSO and hexafluoroisopropanol. 1μM to 50μM of Aβ(40) and Aβ(42) aggregated solutions 
were added to SH-SY5Y cells and the viability assessed after 48h using the Cell Titer-Blue 
(Promega) cell viability assay. The results show that no toxicity is seen at 1µM to 20µM of the 
aggregated Aβ(40) species and Aβ(40) displays toxicity towards SH-SY5Y after 30μM (~22% 
viability) concentration. Also, there is a huge drop in viability between 20μM (~90% viability) 
and 30μM (~22% viability). SH-SY5Y cells are completely killed above the concentration of 
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30μM till 50μM Aβ(40) concentration. In the case of Aβ(42) prepared by the proposed method, 
aggregated Aβ(42) species show toxicity from 7.5μM to 10μM. At concentrations of 10μM and 
30μM, the observed viability is ~12% with complete loss of viability at higher concentrations. 
This study shows that very high toxicities (0% viability at ≥ 30µM Aβ) can be achieved from 
lower concentrations to Aβ peptides (higher limit is ~100µM). Also, the no toxicity observed 
from Aβ(40) up to 20μM is in contrast to other studies that have used even less concentration of 
Aβ (40) with significant toxicity seen in toxicity studies [195, 196]. 
Milton and group studied the effects of compounds, cannabinoids and noladin ether, on 
the toxicity of Aβ(1-40) induced in human neuronal NT-2 and mouse myeloma SP2 cell cultures 
[195]. Aβ aggregated solutions were prepared by dissolving in PBS and incubating for 24h to 
prepare cytotoxic species. In this study, no dose-dependent study on aggregated Aβ peptides was 
done. Focusing only on the neuronal cell line NT-2, addition of 5μM aggregated Aβ(40) to NT-2 
cells gave ~42% viability (seen from figure 1 in publication) determined by the 3(4,5-
dimethylthiazol-2yl)2,5-diphenyl-2H-tertrazolium bromide (MTT) assay. In a contradictory 
results, addition of 25μM aggregated Aβ(40) by the same aggregation protocol to NT-2 cells 
gave ~48% viability (refer figure 2 in publication), which ideally should be lower than the 
viability obtained at 5μM Aβ. In this study, two different Aβ concentrations are used out of 
which the lower concentration of toxic Aβ has higher toxicity compared to higher concentration 
of Aβ, which indicates different toxicity profiles at different concentrations of the same peptide. 
Studies have shown that Aβ is a random coil monomer, well solvated in DMSO [197] or 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) [15], forms a “seedless” monomer, which renatures 
when diluted to buffers or cell media solutions. These studies show that using a strong polar 
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solvent such as DMSO will eliminate any preexisting aggregation that may lead to inconsistent 
results after aggregation.  
Mie, Liu et al. studied the effects of cryptotanshinione on the inhibition of aggregated 
fibril Aβ(42) toxicity was studied in an SH-SY5Y cell system [198]. Aβ was solubilized in 
distilled water to a concentration of 200μM and stored at -20oC. The viability of SH-SY5Y was 
assessed by the MTT assay after 24h of addition of Aβ peptides. In the dose dependent study, a 
gradient of 1μM to 10μM of Aβ(42) was applied and viability assessed 24h later via MTT assay. 
The viability of SH-SY5Y ranged from 100% viability (0.0μM Aβ) to ~70% viability (10μM 
Aβ). Later, in the same study, the viability with 10μM Aβ was ~66% after 24h. This study 
indicates that dose-dependent study viabilities do not match exactly with viabilities observed in 
later studies. Also, 10μM Aβ(42) in another study gave ~12% viability in SH-SY5Y cell cultures 
[194]. This indicates that, at the same concentration of Aβ and same cultures, different viabilities 
can be obtained based on individual protocols used. 
The effect of peptide based aggregation inhibitors were investigated on fresh and aged 
Aβ peptide solutions [196]. The effect of these inhibitors in a system of different concentrations 
of Aβ and SH-SY5Y cells was investigated. Aggregated Aβ(40) and Aβ(42) were made by 
dissolving peptides in water and then in PBS to give 100μM of the peptides. SH-SY5Y viability 
was assessed after 24h of the addition of peptide inhibitors and aggregated Aβ peptides 40 and 
42 by using the 3(4,5-dimethylthiazol-2yl)2,5-diphenyl-2H-tertrazolium bromide (MTT) assay. 
The different concentrations of fresh Aβ(40), aged Aβ(40) and aged Aβ(42) studied were 
3.125μM, 6.25μM, 12.5μM and 25μM. The SH-SY5Y viabilities assessed after 24h for Aβ 
control is given below. The table indicates that when different types of procedures or conditions 
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of aging are used, the Aβ species give completely different viabilities for SH-SY5Y cells. These 
viability values are different than those obtained by other researchers [190, 199, 200]. 
Table 3: SH-SY5Y viabilities after 24h incubation for different Aβ concentrations and 
different Aβ aggregation times, from ref. [196] 
Aβ Species 
Concentration of Aβ applied 
for 24h to SH-SY5Y 
% of average control obtained 
from MTT assay: Aβ control 
Fresh Aβ(40) 
3.12μM 
6.25μM 
12.5μM 
25μM 
~90% 
~87% 
~70% 
~52% 
Aged Aβ(40) 
3.12μM 
6.25μM 
12.5μM 
25μM 
~72% 
~60% 
~56% 
~42% 
Aged Aβ(42) 
0.3125μM 
3.12μM 
6.25μM 
12.5μM 
25μM 
~84% 
~60% 
~58% 
~52% 
~39% 
In the study presented by Wang et al.[201], synthetic Aβ(40) was aggregated by 
dissolving in a strong polar solvent TFA and  rotated for 24h. Then, aggregated Aβ(40) was 
diluted to its final concentration and added to SH-SY5Y cell culture. The viability was assessed 
using the MTT reduction assay. This procedure is consistent with that followed in our work in 
this dissertation. The toxicity of Aβ(40) peptide was determined as a function of time (20h, 41h, 
65h) at different concentration of Aβ protein. As the aggregation protocol, cell culture systems 
are consistent (except time of incubation, in our work, 24h) with that of this work, the viabilities 
obtained for Aβ control are given in the table below. The viabilities indicate that different 
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incubation times of the Aβ peptide with SH-SY5Y cells give completely different viabilities. 
Thus, time of incubation of cells with Aβ influences the toxicity profile observed. In our case, 
24h is the incubation time with 50μM Aβ.  
Table 4: SH-SY5Y viabilities after different incubation times with Aβ at different 
concentrations, from ref. [201] 
For 20h incubation with Aβ For 41h incubation with Aβ For 65h incubation with Aβ 
Conc. of Aβ Viability Conc. of Aβ Viability Conc. of Aβ Viability 
10μM Aβ(40) ~79% 10μM Aβ(40) ~62% 10μM Aβ(40) ~50% 
20μM Aβ(40) ~75% 20μM Aβ(40) ~58% 20μM Aβ(40) ~40% 
30μM Aβ(40) ~70% 30μM Aβ(40) ~48% 30μM Aβ(40) ~30% 
In this study [202], aggregated Aβ(42) concentrations at 25μM and 100μM were added to 
a system of SH-SY5Y cells to evaluate the ability of ectoine and hydroectoine to inhibit 
aggregate formation. The aggregates were prepared by dissolving in HCl and DMSO for 3 days. 
To observe the effect on SH-SY5Y viability, Aβ(42) seed samples were made by incubating 
25μM or 100μM solution at 370C for 24h. The viability of SH-SY5Y was assessed after 48h 
incubation with the seed-aggregated Aβ(42) peptide using the 3(4,5-dimethylthiazol-2yl)2,5-
diphenyl-2H-tertrazolium bromide  (MTT) assay. For the same concentration of Aβ(42), the 
viabilities obtained at 25μM Aβ(42) are different in the same experiment. In one case, the SH-
SY5Y viability was ~75% and in the other ~65% (see figure 4A in the publication). Thus, at the 
same concentration and at the same experiment, different SH-SY5Y viabilities were observed, 
which is most likely due to the differences in toxicities of the aggregates formed. Addition of 
100μM Aβ(42) gave around ~53% viability. It can be seen that researchers use Aβ 
concentrations as high as 100μM and the viabilities of Aβ peptide, at the same concentration and 
the same conditions can be different. 
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Green et al. investigated the use of estradiol to attenuate the toxicity of Aβ(25-35) in a 
human neuroblastoma cell line SK-N-SH using the MTT assay[203]. The lyophilized peptide 
Aβ(25-35) was suspended in PBS and incubated for 1h prior to use by diluting to its final 
concentration in culture media. The SK-N-SH cells were exposed to varying concentration of Aβ 
for 24h. Compared to 100% live control, 5µM Aβ(25-35) gave ~95% viability, 10µM Aβ gave 
~85% viability and 20µM Aβ gave ~66% viability. The paper reports that incubation times of Aβ 
with cells up 96h did not further increase attenuation in MTT reduction (i.e. did not cause further 
toxicity in cells), however, other studies have shown that as the incubation time of cells with Aβ 
increase, changes in toxicity are observed. See [199-201, 204] for conflicting reports. This 
indicates contradictory results with respect to toxicity observed in cells incubated for various 
time periods with Aβ peptides. 
A study with estrogen to protect human neuroblastoma SH-SY5Y cells from Aβ(42) 
toxicity is presented below [205]. A 10µM concentration of Aβ(42) was prepared by “aging” the 
dissolved peptide for 24h. Before selecting this concentration, no dose dependent study with Aβ 
was done. In the first experiment, the viability of SH-SY5Y was assessed after incubating the 
cells with 10µM Aβ(42) for 5h, 24h and 48h using the MTT assay. The viability of cells are as 
follows: 5h incubation with 10µM Aβ(42): ~70% viability, 24h incubation with 10µM Aβ(42): 
~78% cell viability, 48h incubation with 10µM Aβ(42): ~75% viability. Thus, in this case, the 
viability observed is less after 5h incubation with the toxic peptide but increases at 24h (and 
remains almost the same at 48h incubation) which is in contrast with other studies (see 
publication with [203]). In the next experiment with estrogen receptor agonists, 10µM Aβ(42) 
control viability was ~60% after 24h of incubation with SH-SY5Y. Thus, SH-SY5Y viabilities 
have a wide difference (~78% and ~60% viability) for the experiments done at the same 
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concentration (10µM) of Aβ(42) with the same incubation time (24h) at the same condition in 
the single publication. This indicates that even with the same likely batch of Aβ peptide 
(although this cannot be proved looking at the data presented) and the same experimental 
conditions, it is possible to have different toxicities associated with the peptide.  
Zhang et al. studied the protective effect of galantamine on Aβ(40) induced toxicity in 
human neuroblatoma cells SH-SY5Y [206]. A 5µM Aβ(40) solution was prepared by incubating 
the peptides in DI water for 24h at 370C. No dose dependent study was done before choosing this 
concentration to work in the experiments. After incubating a solution of 5µM Aβ(40) with SH-
SY5Y cells for 24h, the viability observed was (~63.23% ± 1.2%). Again, other studies with 
Aβ(40) concentration upto 20μM applied to SH-SY5Y showed ~100% viability [194]. 
This publication demonstrated the use of Hsp20, novel α-crystallin heat shock protein, to 
attenuate the toxicity of Aβ(40) in a system of SH-SY5Y cell line and PC12 cell line[207]. 
Aβ(40) was dissolved in trifluoroacetic acid (TFA) and then diluted to its final concentration in 
cell culture media for testing with cells in vitro. The Aβ peptides were rotated for 24h to ensure 
aggregation. A concentration of 100µM aggregated Aβ(40) was tested on SH-SY5Y cells and the 
viability after 24h was found to be around ~42% assessed by the MTT assay. On the other hand, 
in the same experiment and same aggregation protocol but with PC12 cells, 2µM of aggregated 
Aβ(40) gave viability of ~38% using the MTT assay after 24h. As there is no dose dependent 
study done on Aβ toxicity, it is unclear why different Aβ values that were very different apart 
were chosen in the same experiment for different cell cultures. In the next set of experiment with 
a modified shock protein, 100µM aggregated Aβ(40) gave viability of ~50% after 24h treatment 
of SH-SY5Y cells. There are two important observations from this study: Different cell cultures 
give widely different toxicities towards Aβ (2µM Aβ to PC12 and 100µM Aβ to SH-SY5Y gave 
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almost same viabilities). Secondly, in Aβ studies, the range of Aβ studies can vary from as low 
as 2µM to as high as 100µM Aβ in the same publication. Additionally, same aggregation 
protocol, same cell type, same experimental methodology gave different set of viabilities at 
100µM Aβ (~42% and ~50%). In our work, the aggregation protocol has same methodology as 
in this publication. The cell culture experiments as well as Aβ studies done in our work are also 
consistent with this publication. 
The interactions of different heat shock proteins with Aβ(40) was studied in a system of 
human neuroblastoma SH-SY5Y cells by Lee, Good et al [204]. To prepare aggregated Aβ(40), 
lyophilized Aβ(40) was dissolved in trifluoroacetic acid (TFA) and incubated for 20-30min to 
completely dissolve the Aβ. Then, the TFA-Aβ solution was directly added to the cell media to 
its final concentration and mixed at 370C for different times. Different rotation times were used 
to get different aggregated Aβ(40) species. The aggregated Aβ(40) was added to SH-SY5Y for 
2h and the viability determined using the Annexin-PE-7AAD dye. Viable cell exclude both dyes. 
In the first experiment in a system of hsp20, 100µM of aggregated Aβ(40) gave ~45% of Aβ 
control & hsp27, 100µM of aggregated Aβ(40) gave ~47% of Aβ control. Next, in a system of 
hsp17.7, 20µM Aβ(40) had ~65% viability. As no dose dependent study was done, it is unclear 
why different concentrations of Aβ(40) were used. Also, the time of aggregation of Aβ(40) was 
varied. Specifically, 100µM Aβ(40) was aged for 2h, 4d, 8h and 24h. These differently aged 
peptides were added to Aβ and toxicity assessed after 2h. The viabilities are as follows: after 2h 
aggregation: ~66% viability. 4h aggregation time: ~62% viability, 8h aggregation time: ~53% 
viability and after 24h aggregation time: ~48% viability of SH-SY5Y was observed. Important 
points can be observed from this publication: 1) Different Aβ concentrations (20µM and 100µM) 
of the same peptide are used in the same study without a dose-dependent study done beforehand. 
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2) Concentrations as high as 100µM are used for Aβ toxicity studies. 3) With increased aging, 
Aβ peptide shows increasing toxicity, whereas other studies show conflicting results for ageing 
and toxicity data [208, 209]. The aggregation methodology for Aβ used in our work is consistent 
with this publication. 
Yang et al studied the effect of citrate on the inhibition of Aβ(40) peptide aggregation 
using SH-SY5Y cells [210]. Stock solution of Aβ(40) peptide was prepared by solubilizing the 
lyophilized Aβ(40) by shaking in NaOH solution. SH-SY5Y cell viability was assessed by the 
WST-1 assay. It is an assay in which viable cells metabolize tetrazolium salts to formazan that 
can be detected spectrophotometrically. When SH-SY5Y cells were incubated with 20µM 
Aβ(40) for 3 days, cell viability of Aβ control was (~65.3% ± 5.2%) compared to live control of 
100% cells. 
In a system of cultured fetal rat cortical neurons, the effects of laminin 1 and laminin 2 on 
aggregated Aβ(40) was investigated by Drouet et al [211]. Stock solutions of Aβ were prepared 
by dissolving the Aβ in hexafluoro-2-propanol. Then, fibrillar aggregated Aβ was prepared by 
incubation the peptide in culture medium for 48h. For the Aβ studies, 5µM aggregated Aβ was 
added to the cultured neurons for 48h and the viability assessed by MTT assay. In this study, no 
dose-dependent study for aggregated Aβ was done before other toxicity studies. The cortical 
neuron viability was ~38.1% after 24h incubation and ~30.2% after 48h incubation with 5µM 
Aβ(40). In the next experiment (refer to Fig 1.A. in the publication), with 5µM Aβ(40) 
aggregated by the same procedure and the same cell culture experiment, the neuronal viability 
was ~40% of control (live control is 100%) after 48h incubation. In table 2 of the publication, in 
the experiment with laminin 2, the 5µM Aβ(40) gave 34% viability compared to control after 
48h. Further, in another experiment with different compound (see figure 4A in publication), the 
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Aβ control value was ~20% viability compared to live control after 48h incubation. The 
aggregated protocol was the same, concentration of Aβ was 5µM and the cortical neurons were 
used. In this publication, for the same peptide Aβ(40), with the same aggregation protocol, same 
concentration of Aβ(40) used (i.e. 5µM), and the same incubation time with cortical neurons 
(48h), the ranges of viability obtained are from ~20%, 30%, 34% and 40%. This may point to the 
fact that even with the same batch of Aβ, in the same publication and similar conditions, the 
toxicities of the aggregated Aβ formed could differ significantly. Also, it is interesting to note 
that a low concentration (5µM) of Aβ(40) is showing about 20% to 40% viabilities.  
To investigate the effect of mortalin overexpression on Aβ(42) toxicity was investigated 
in a human neuroblastoma cell line SH-SY5Y[212]. Aβ was dissolved in ice-cold cell culture 
medium and incubated for 24h to form aggregated Aβ(42) and the supernatant used for 
subsequent experiments. The viability was assessed by the CCK-8 assay that gives 
spectrophotometric reading similar to the MTT assay. From a dose dependent study, SH-SY5Y 
viabilities at different concentrations of Aβ(42) after 24h incubation were: 1µM Aβ(42): ~92%, 
5µM Aβ(42): ~75%, 10µM Aβ(42): 64%, 20µM Aβ(42): 42% viability. Later experiments with 
10µM Aβ(42) gave ~65% viabilities. 
Coenzyme Q10 was studied in a system of SH-SY5Y cells exposed to 5µM Aβ(42) for 
24h [213]. After 24h incubation of 5µM Aβ(42) with SH-SY5Y cells, the viability of SH-SY5Y 
with MTT assay was ~63% compared to 100% viability for live control. In earlier publication 
[212], 10µM Aβ(42) gave ~64% viability, whereas in this publication, 5µM Aβ(42) gave ~63% 
viability. In another publication, use of the same 10μM Aβ(42) gave ~12% viability of SH-SY5Y 
cells [194]. Thus, there are many variables in Aβ studies that influence the toxicity profiles seen 
on cultured cells. 
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The neuroprotective effect of cannabidiol was investigated in a system of cultured rat 
pheochromocytoma PC-12 cells [214]. Briefly, 1µg/ml of Aβ(42) = 0.2215µM Aβ(42) was 
added to PC12 cells and incubated for 24h after which viability was determined by the MTT 
assay. It is interesting to note that incubation of PC12 cells with 0.2215µM Aβ(42) for 24h gave 
~61.2% viability compared to 100% live control. This publication indicates that Aβ peptide 
values as low as 0.221µM are used and that such low concentration of Aβ peptide can give ~61% 
cell viability towards cells in culture. 
The effect of genistein was investigated using aggregated Aβ(42) was studied in a system 
of SH-SY5Y cell cultures [215]. A dose-dependent study to determine the effective 
concentration (1μM, 2μM, 5μM, 10µM) and duration (24h, 48h, 72h) of Aβ(42) was assessed by 
using the MTT assay. After 24h incubation, 1µM, 2µM, 5µM, 10µM all gave around ~70% 
viability of SH-SY5Y using the MTT assay. After 72h, 5µM and 10µM of Aβ(42) gave ~50% 
viabilities of SH-SY5Y using the MTT assay. Following this study, a concentration of 5µM 
Aβ(42) was chosen with 72h incubation time. At the same conditions and same aggregation 
protocols, the viability of SH-SY5Y was ~62% using the MTT assay. This study indicates that 
performing a dose-dependent study with Aβ (~50% at 5μM Aβ) is not a very good predictor of 
the viabilities obtained in later experiments (~62% at 5μM Aβ) with the same experimental 
conditions. Also, at an incubation time of 24h, Aβ concentrations from 1µM till 10µM exhibited 
the same toxicity which is not seen in other studies [212, 213, 216]. 
Neuroprotective effects of salidroside against Aβ(25-35) were investigated in a system of 
SH-SY5Y cells in vitro using the trypan blue dye assay [216]. The assay is based on the 
exclusion of trypan dye from viable cells which can be counted on the hemocytometer as stained 
and unstained cells separately. The viable cell ratio is the non-stained cells divided by the total 
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cells (stained + unstained counted). Aβ(25-35) was dissolved in DI water and then the stock 
solution was diluted to final concentration in the cell medium prior to use. Additionally, the 
CCK-8 assay was also used to measure cell viability by giving a spectrophotometric output 
corresponding to viable cells. In the dose dependent study with Aβ(25-35), a concentration of 
5µM, 15µM and 25µM was studied by incubating the peptide for 24h with SH-SY5Y and 
assessing the viability by the CCK-8 assay. The viabilities at 5µM = ~90%, 15µM= ~80% and 
25µM= ~54.9% of the control. Later, using the same conditions with 25µM Aβ(25-35) the 
viability was 50.0%. In another experiment, with different Aβ fragment, namely Aβ(42), the 
viabilities of SH-SY5Y cells assessed by CCK-8 assay after 24h incubation with Aβ(42) are as 
follows: 5µM Aβ(42): ~83% viability, 10µM Aβ(42): ~58% viability, 25µM Aβ(42): 42% 
viability. This indicates that even after a dose-dependent study, exact values of toxicity are 
difficult to achieve. Also, compared to other Aβ(25-35) viability values to other publications, the 
viabilities are different at same concentration of Aβ [217].  
The role of N-truncated Aβ oligomers was investigated in a system of primary mouse 
neurons [218]. Fresh peptide stock solutions were made by dissolving in hexafluoro-2-propanol. 
These stock solutions were dried under nitrogen and directly added to the culture medium and 
incubated for 1hr prior to use in the experiments. This procedure was used to generate Aβ 
peptide oligomers. The toxicity of Aβ peptides was assessed by the MTT assay after incubation 
of the mouse neurons for 24h and 48h with Aβ peptides (see figure 6A in publication). After 24h 
incubation with 1µM Aβ(40) the viability of SH-SY5Y with MTT assay was ~80% and that of 
1µM Aβ(42) was ~72%. After 48h, viability of SH-SY5Y with 1µM Aβ(40) was ~60% while 
that of 1µM Aβ(42) was ~53%. This study is interesting because, a lower concentration of Aβ 
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peptides (1µM) was used for all studies which showed significant toxicities towards mouse 
neurons. 
The effect of cholesterol and Aβ/Aβ-metal complexes was investigated in human 
neuroblastoma cell line SH-SY5Y [219]. This study elucidates the use of a low concentration of 
Aβ in toxicity studies in vitro. Aβ(42) was dissolved in hexafluorisopropanol (HFIP) for 40min 
and then HFIP removed. Finally, dialysis was performed with Aβ(42) for 24h and used in 
toxicity studies for Aβ control. After addition of 0.5µM Aβ(42) for 24h to SH-SY5Y cells, the 
viability for Aβ control was observed to be ~ 82% as assessed by the MTT assay. This is 
significant because the study uses a low concentration of Aβ and 0.5µM concentration killed 
only ~18% cells which was their range of study. 
The ability of pregnenolone and its ester to attenuate the toxicity of Aβ(25-35) was 
investigated using a rat pheochromocytoma cell line PC-12 [217]. A concentration of 20µM 
Aβ(25-35) was added to PC-12 cultures and viability assessed with the MTT assay after 24h, 48h 
and 72h treatment. After 24h, viability of PC-12 was ~96%, indicating no toxicity of the 20µM 
Aβ(25-35) fragment. After 48h exposure time, viability decreased to ~65% and after 72h to 
~55%. This no toxicity shown by Aβ(25-35) after 24h exposure is inconsistent with other studies 
[216].  
The effect of aggregation/incubation conditions on the toxicity of Aβ(40) fibrils on SH-
SY5Y cells was studied by T. Good et.al.[200]. Aβ(40) solutions are prepared by dissolving 
lyophilized Aβ(40) in trifluoroacetic acid (TFA) at room temperature and then adding the Aβ-
TFA to its final concentration in cell culture media. In this study, the incubation conditions are 
gentle agitation and no agitation for different periods of time to get aggregated Aβ(40) species. 
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The viability of differentiated SH-SY5Y cells were examined after treatment with Aβ samples 
prepared with and without agitation using the annexin-PE, 7-AAD cell assay. In this assay, 
viable cells are both annexin-PE and 7-AAD negative. When fresh 100µM Aβ(40) was tested on 
SH-SY5Y, no toxicity was observed. This observation is in contrast with other studies [190, 
196]. The assay was run after 2h incubation with aggregated Aβ(40) peptides using flow 
cytometry. The study indicated that toxicity with 100µM Aβ(40) aggregated with gentle agitation 
(24h) was significantly greater than the toxicity of fibrils formed under no agitation conditions 
(72h). The study shows that Aβ fibrils formed via different methods do not have the same 
toxicity or even the same stability. Additionally, this study demonstrates the use of high 
concentration (100µM) of aggregated Aβ(40) used on SH-SY5Y cells. The protocols and 
methods used in this study are similar to those used in our work.  
 
Table 5: SH-SY5Y viabilities assessed after 24h of addition of 100μM Aβ(40) aggregated 
according to different conditions, from ref. [200] 
100µM aggregated Aβ(40) prepared with 
gentle agitation 
100µM aggregated Aβ(40) prepared with no 
agitation 
Time of aggregation 
of Aβ 
Approx. SH-SY5Y 
cell viability 
Time of aggregation 
of Aβ 
Approx. SH-SY5Y 
cell viability 
Control (no Aβ) 100% Control (no Aβ) 100% 
0h (fresh Aβ) 102% 0h (fresh Aβ) 102% 
2h 68% 1h 78% 
4h 65% 4h 51% 
8h 52% 8h 35% 
24h 50% 24h 62% 
  72h 75% 
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The ability of the oriental medicine, Jangwonhwan, to inhibit oxidative stress induced 
due to Aβ peptides in human neuroblastoma cells SH-SY5Y was investigated by Seo, Han et al 
[220].  The viability of SH-SY5Y was assessed by the WST-1 assay spectrophotometrically to 
give the proportion of viable cells. Aβ(42)  was dissolved in DMSO after which they were 
diluted down in Phosphate buffered saline or cell media and incubated 24h before addition to 
cells. After addition of 80µM Aβ(42) to SH-SY5Y and incubation for 24h, the viability of Aβ 
control was observed to be ~30% compared to 100% live control from the WST-1 assay.  
The neuroprotective potential of salvianolic acid B (Sal B) against Aβ-induced toxicity 
human neuroblastoma SH-SY5Y and rat PC-12 cultures is explored using aggregated Aβ(40), 
Aβ(42) peptides [208]. Toxicity of the aggregated peptides was studied using the MTT assay. Aβ 
was dissolved in DMSO prior to the assay and Aβ aggregation was performed in PBS at 370C. 
Aβ seed samples in PBS were preincubated for 3-7days for fibril aging at 370C. Differentiated 
SH-SY5Y cells were incubated with aggregated Aβ for 24h after which the viability was 
assessed using the MTT assay. In the first experiment, using 15µM aggregated Aβ(40), PC-12 
cultures has ~15% viability of Aβ control. The viability of differentiated SH-SY5Y when treated 
with 50µM aggregated preformed Aβ(42) was ~25% assessed by the MTT viability assay. 
Finally, 15µM aggregated preformed Aβ(42) added to PC-12 cells gave ~27% viability in MTT 
viability assay (see figure 2 for those results in the publication). In the next sets of experiments 
with SH-SY5Y cells, 50µM preformed Aβ(42) gave ~21.1% viability, 50µM of 3 day aggregated 
Aβ(42) gave 25.1% viability and 50µM of 7 day aggregated Aβ(42) gave 28.1% viability. This 
study demonstrates that aggregated Aβ shows different toxicity on different cultures. Also, it is 
interesting to note that 15µM Aβ(40) gave ~15% viability whereas 15µM preformed Aβ(42) 
gave ~27% viabilities in the same cell system of PC-12 cells. It is a well-established fact that 
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although Aβ(40) constitutes to 90% Aβ in the plasma, Aβ(42) is significantly more toxic species 
compared to Aβ(40), however this study is in contrast to that fact [184-187, 221]. 
The interaction of a Aβ(39-42) fragment of Aβ peptide with 10µM Aβ(42) and 25µM 
Aβ(40) to prevent toxicity in PC-12 cells was assessed using the MTT assay [222]. Peptides 
were dissolved in DMSO and diluted to their final concentration in the cell culture media. PC12 
cells were incubated for 15h with the peptides [222, 223]. The PC-12 viability after treatment 
with 10µM Aβ(42) and 25µM Aβ(40) was ~78% of live control (100%). Here, an uncommon 
incubation time of 15h was used to assess toxicity of PC-12 cells. Also, viabilities of cells at 
same concentration in other studies were significantly different than this study. Another study 
using the same protocols and experimental conditions reported ~49% viability at 10μM Aβ(42) 
[223]. 
The ability of different Aβ fragments to protect rat pheochromocytoma PC-12 cells from 
toxicity was investigated using the MTT assay [223]. For the peptide Aβ(42) incubated with PC-
12 cells for 15h, concentration of 0.1µM gave ~90% viability, 1µM Aβ(42) gave ~78% viability, 
5µM Aβ(42) gave ~60% viability and 10µM Aβ(42) gave ~49% viability by the MTT assay. In 
another publication [222], using the same Aβ(42) protocol, the viability of PC-12 cells was 
~78% for 10µM Aβ(42). Thus, in the same cell line, using same concentration of Aβ peptide, 
different viabilities are observed from different publications. 
Interesting results are presented in the study by Zhang et. al. where intracellular and 
extracellular Aβ peptides were investigated with human neuronal cells [187]. Aβ peptides were 
dissolved in sterile DI water and incubated at room temperature for 5days.  The same batch of 
peptides when injected inside the neurons caused significant toxicity (100,000 times greater) for 
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the Aβ(42) compared to extracellular incubation. The same human neurons were incubated with 
the same batch of aged 10µM Aβ(40) and aged 10µM Aβ(42) for 24h and they showed no 
toxicity to neurons at these conditions (a concentration known to induce cell death in a variety of 
cell lines). The results are in contrast to other studies where significant toxicity is observed from 
Aβ peptides at these concentrations (or even lower). Almost all other studies show toxicity at 
these concentrations or even lower concentrations of Aβ(40) and Aβ(42). Also, Aβ(42) is known 
to be more toxic to cells than Aβ(40). 
The protective effect of quinone compound against Aβ(25-35) toxicity was investigated 
in an SH-SY5Y cell culture and viability assessed by the MTT assay [224]. Aβ(25-35) was 
dissolved in DI water and incubated for 3 days to form aggregates. SH-SY5Y cells incubated 
with 25µM Aβ(25-35) for 24h gave around ~65% of SH-SY5Y cells compared to live control 
(100% cells).  
Human α2-macroglobulin was studied in an system of aggregated Aβ(42) using human 
neuroblastoma SH-SY5Y cell line, SK-N-AS cell line, LAN5 cell line and SMS-KCNR cell line 
[225]. After incubation of 10µM Aβ(42) for 24h the viability assessed by MTT assays is as 
follows: SH-SY5Y cells: ~65% viability, SK-N-AS cells : ~70% viability, LAN5 cell line: ~60% 
viability  and SMS-KCNR: ~62% compared to 100% viability of the live control. This study 
demonstrates that a variety of cell culture systems are used in one publication for Aβ studies. 
Howlett, Roberts et al. investigated the neurotoxic behavior of two synthetic batches of 
Aβ(1-40) peptide having > 99% purity by HPLC [199]. The Aβ(40) was dissolved in pure water 
and ageing was carried out at 370C to achieve aggregation. The two batches of Aβ(40) as TFA 
salt, lot# ZK051 and lot#ZK600, were studied in rat PC-12 cultures. After ageing, the peptides 
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were added to PC-12 cells and viability was assessed with the MTT assay after 2h incubation 
with the peptides. A comparison between batches #ZK051 and #ZK066 of Aβ(40) is given below 
from the publication. Neurotoxicity is assessed as the decrease in the conversion of MTT to a 
formazan product in the presence of 1µg/ml and 10µg/ml of Aβ(40). Live control has 0% 
toxicity. For comparison, the PC-12 culture conditions, aggregation protocols, ageing times for 
different Aβ batches were all consistent for comparison purposes.  
Table 6: PC-12 viabilities exposed to two batches to Aβ(40) aggregated under similar 
conditions, from ref [199] 
Ageing of the Aβ(40) peptide Neurotoxicity observed in PC-12 cultures in (%) 
(h) Batch ZK051 of Aβ(40) Batch ZK600 of Aβ(40) 
0h (No ageing) 10 ± 2 @ 10µg/ml 32 ± 1 @ 10µg/ml 
24h ageing 
36 ± 4 @ 10µg/ml 
26 ± 4 @ 1µg/ml 
52 ± 7 @ 10µg/ml 
53 ± 3 @ 1µg/ml 
168h ageing 
43 ± 4 @10µg/ml 
42 ± 6 @ 1 µg/ml 
51 ± 2 @ 10µg/ml 
44 ± 5 @ 1µg/ml 
The results from table 6 show that batch ZK600 produced significantly greater toxicity at 
0 and 24h of ageing time. Thus, the use of fresh Aβ(40) peptide (with no ageing) and the use of 
aged peptide (24h) shows very different toxic profiles between the two batches compared. In the 
ideal case, since they both are Aβ(40), have >99% purity and are studied at the same 
culture/experimental conditions, the toxicity shown by both batches should be consistent. 
However, this is not true for these two batches of Aβ(40) and neurotoxic behavior of Aβ(40) 
varies between synthetic batches of Aβ.  The likely reason given by the researchers is that the 
differences result from conformational variations. 
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In this study, low concentrations of Aβ(40) and Aβ(42) were used to study neuronal 
apoptosis induced in human neuron primary cultures [209]. A control peptide with the reverse 
sequence Aβ(40-1) is also included for comparison purposes as it is the in-active control against 
Aβ(40). This reverse fragment is frequently used as the negative control in experiments. Fibrillar 
Aβ(40) and Aβ(42) were prepared by incubating freshly solubilized peptides in sterile DI water 
at 370C for 5 days. The peptides were then diluted down to 100nM concentration in the cell 
media. Neurons were treated with 100nM of Aβ(40) and Aβ(42) for 6, 12, 24, 48 and 72h after 
which viability was assessed by the MTT assay. According to the study, the normal 
concentration of Aβ in cerebrospinal fluid is 4nM which represents a 25X times concentration 
added to the cells. Compared to 100% control of live cells, viability after 12h treatment was ~ 
100% for Aβ(40), ~90% for Aβ(42) and surprisingly, ~72% for Aβ(40-1). At 24h, the viabilities 
are increases to ~100% for all the 3 types of Aβ peptides. At 48h, the viability is ~90% for all the 
peptides. At 72h incubation, Aβ(40) viability is 72%, Aβ(42) viability is ~90% and Aβ(40-1) is 
~81%. This indicates highly irregular viabilities in contrast with trend observed [204]. There is 
strong evidence that Aβ(42) is significantly more toxic than Aβ(40). However, at most 
incubation times, Aβ(42) toxicity was either equal to Aβ(40) or lower. Also, it is interesting to 
see that Aβ(40-1), the reverse control peptide is showing toxicity and also more than the active 
parts of Aβ in some cases. This indicates that there are yet understood mechanisms involved in 
Aβ toxicity. Also, 100nM is a low concentration that the researchers have used in this study. 
New inhibitors were investigated on the Aβ(1-39) fragment in a system of PC-12 cells 
[99]. Aβ(39) was dissolved in trifluoroacetic acid (TFA) then diluted to PBS, incubated for 7 
days, the diluted to the cell medium and incubated again for 1 day. PC-12 cells were incubated 
with 24µM concentration of above prepared Aβ(39) and viability assessed after 24h using the 
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MTT assay. The viability of PC-12 cells was about ~65% of the live control (100%). This study 
indicates that Aβ studies are done with a wide variety of fragments or different lengths of Aβ 
peptides each having its own variability in biological and physical activity.  
The role of G protein activation in Aβ peptide toxicity was investigated using Aβ(1-16) 
fragment, Aβ(1-40) and Aβ(25-25) in a system of PC-12 cell culture[226]. Aβ peptide aggregates 
were formed by dissolving the peptides in trifluoroacetic acid (TFA) water solution. After 
incubation for 1h at 370C, the dissolved peptides were diluted to their final concentration of 
20µM in cell median and rotated for 24 hours prior to addition to cells. After 24h treatment of 
PC-12 cells with these peptides, the viability was determined by the MTT assay. Compared to 
100% live control, 20µM of aggregated Aβ(1-16) gave ~100% viability indicating that the Aβ(1-
16) was not biologically active. 20µM of aggregated Aβ(40) gave ~52% viability and 20µM of 
Aβ(25-35) gave ~45% PC-12 viabilities. The aggregation protocol used in our work is consistent 
with this publication except for the use of DMSO instead of TFA. In the same study, different 
Aβ fragments are used and results compared. 
Wang et al. investigated the effect of cholesterol and sialic acid content on the toxicity 
induced by Aβ(40), Aβ(25-35) and in-active Aβ(1-16) in different cell lines[125]. The lyophilize 
peptide was treated dissolved in trifluoroacetic acid (TFA)-water solution. After incubation for 
1h at 250C, the peptide stock solutions were further diluted in PBS and rotated for 24h. Finally, 
the peptides were diluted to their final concentration of 20µM in cell media and rotated for 24h 
prior to addition to cells. The aggregated peptides were added to human neuroblastoma SH-
SY5Y cells, C-6 glioma cells and rat pheochromocytoma PC12 cells and the viability assessed 
by the MTT assay after 24h of treatment. For rat PC-12 cells, the viabilities after 24h of 
treatment with 20µM Aβ(40) were ~55%, 20µM Aβ(25-35) were ~48% and 20µMAβ(1-16) 
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showed no toxicity. In case of SH-SY5Y cells, after 24h, viabilities were, 20µM Aβ(40) = ~52% 
viability, 20µM Aβ(25-35) = ~45% viability and Aβ(1-16) showed no toxicity towards SH-
SY5Y. However, when C6 glioma cells were treated with 20µM Aβ(40), there was no toxicity 
induced by Aβ peptides on C6 cells. However, this no toxicity seen in C6 glioma’s is in contrast 
with other studies, where 25µM Aβ(42) gave around 48% viability after 24h treatment as 
assessed by MTT assay [227]. This is significant as one study observes no toxicity in Aβ-C6 cell 
study (this publication), whereas the other study has observed almost ~50% viability when Aβ is 
exposed to C-6 cells [227]. Additionally, in the same publication, 3 different cell types and 3 
different Aβ fragments are used. 
Patel and Good et al. investigated a new rapid viability assay to assess Aβ induced 
neurotoxicity in SH-SY5Y cell cultures [183]. The new viability assay required an incubation 
time of 2h to see the toxic effects of Aβ compared to the conventional viability assays such as 
MTT reduction assay, lactate dehydrogenase assay, trypan blue assay, propidium iodide assay 
and the TUNEL assay which require 24h or more to get toxicity profiles. Thus, a rapid apoptosis 
assay using annexin-PE and 7AAD was studied using 100µM Aβ and SH-SY5Y cells. 
Lyophilized Aβ(40) was dissolved in dimethyl sulfoxide (DMSO) or trifluoroacetic acid-water 
solution. After complete dissolution, the peptides were diluted to their final concentration in cell 
media and rotated for 24h at 250C to get fibrillar aggregated Aβ.  To get different Aβ aggregated 
intermediate species, samples of Aβ were incubated at 370C for different periods of time (0h, 4h, 
8h, 24h or 72h). In the first experiment, 100µM Aβ(40) was aggregated for 24h and then the 
viability of SH-SY5Y cells was assessed as a function of time of incubation with 100µM Aβ(40). 
(the results are shown in table 7) For 6h incubation with 100µM Aβ(40): viability was ~110%, 
12h incubation: viability was ~84%, 24h incubation: viability was ~70% and 48h incubation: 
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viability was ~60%. In the same type of experiment but with different viability assay, annexin-
PE+7AAD assay, the effect of different incubation times gave completely different viabilities. 
See figure 13. below (adapted from [183], with permission from Elsevier Inc.):  
For the next result, Aβ(40) was aggregated for 24h prior to the addition to SH-SY5Y 
cells. After aggregation, 100µM Aβ(40) was added to the cells, and the viability measured using 
different assays, PI assay after 24 and 48h incubation and the new proposed assay, annexin-
V+7AAD, which required 2h incubation of cells with Aβ. So, 15min incubation with 100µM 
Aβ(40) gave ~94% SH-SY5Y viability, 30min incubation gave ~89% viability, 1h incubation 
gave ~68% viability, 2h gave ~93% viability, 4h gave ~83% viability and 8h gave ~80% 
viability (results are shown in figure 13). The results adapted [183] (with permission from 
Elsevier Inc.) from the publication are shown below: 
 
Table 7: SH-SY5Y viability after 24h aggregation with different concentration of Aβ and 
different viability assays, from ref. [183] 
24h aggregated 
Aβ(40) 
Normalized Viability of SH-SY5Y cells (%) 
Concentration of 
aggregated Aβ (40) 
added to cells 
24h incubation and PI 
assay used 
24h incubation and PI 
assay used 
2h incubation and 
annexin V-7-AAD 
assay used 
10µM ~81% ~72% ~95% 
20µM ~96% ~89% ~74% 
50µM ~88% ~72% ~90% 
75µM ~85% ~71% ~83% 
100µM ~70% ~60% ~73% 
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Figure 13: Normalized viability of SH-SY5Y cells as a function of time of incubation of cells 
with 100µM Aβ(40), viability from different assays 
Figure 13 A: Normalized viability of SH-SY5Y cells as a function of time of incubation of cells 
with 100μM Aβ, as assessed by the Annexin-PE and 7AAD assay. Aβ was aggregated for 24 h 
with mixing prior to addition to cells. The mean viability of three or more measurements is 
plotted. Statistically significant changes in cell viability were detected at all times measured after 
0 time (p < 0.05). 
Figure 13 B: Normalized viability of SH-SY5Y cells as a function of time of incubation with 
100μM Aβ as assessed by the PI assay. Aβ was aggregated for 24 h with mixing prior to addition 
to cells. Mean viability measurements plus or minus their standard deviation (error bars) are 
shown for three or more independent measurements. 
(results adapted from publication [183], with permission from Elsevier Inc.) 
 
Also, from figure 14.B, it can be seen that in the PI assay, 10µM Aβ(40) concentration 
gave higher toxicity compared to 20µM, 30µM and 75µM in the 24h PI assay. Also, 10µM 
Aβ(40) gave higher toxicity compared to 20µM Aβ(40) in the 48h PI assay. Coming to the 
annexin-PE+7-AAD assay (figure 14.A.), the 20µM Aβ(40) showed deviations from normality. 
Thus, from the table 7 and figure 13, it can be seen that with the same solution of aggregated 
Aβ(40) at the same concentration (100µM) and the same culture conditions, just the use of 
different assays and different incubation times give completely different toxicity profiles. This 
possibly indicates that the dynamic structure of aggregated Aβ could be changing in solution and 
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the toxicity must be dependent on the concentration and the incubation time used. Hence, it is 
possibly the best if we shift our focus away from these assays. As such, the MTT assay is widely 
used and established for Aβ studies. 
 
Figure 14: Normalized viability of SH-SY5Y cells as a function of Aβ concentration 
assessed by different assays 
Figure 14.A: Normalized viability of SH-SY5Ycells assessed by the annexin-PE and 7AAD two-
color assay as a function of Aβ concentration. Aβ samples were aggregated for 24 h with mixing 
prior to addition to cells. Cells were incubated with Aβ for 2 h. 
Figure 14.B: Normalized viability of SH-SY5Y cells as a function of Aβ concentration as 
assessed by the PI assay. Aβ samples were aggregated for 24 h with mixing prior to addition to 
cells. Cells were incubated with Aβ for 24 h (■) and 48 h (●). 
(results adapted from publication [183], with permission from Elsevier Inc.) 
 
Additionally, when the two assays, PI and annexin-PE/7AAD are compared head-to-
head, 100µM of Aβ(40) samples were incubated for various periods of time (0h=fresh Aβ 
sample, 4h, 8h, 72h incubation) and the toxicity assessed by the two assays. The results adapted 
from the publication are given in figure 15:  
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We can see that, sample 100µM Aβ samples give different viability values from different 
assays even when all other conditions such as Aβ concentration, cell culture, method of 
aggregation of Aβ(40) were consistent. Additionally, in this publication, 100µM of fresh Aβ(40) 
did not show any toxicity towards SH-SY5Y cells, whereas other publications show toxicity of 
the fresh, un-aggregated Aβ peptide. See [190, 196, 199, 200] for conflicting reports on the 
toxicity of fresh Aβ(40). 
 
Figure 15: Normalized viability of Aβ(40) incubated for various periods of time as obtained 
from the PI (A) and annexin-PE/7AAD (B) assay 
Figure 15 A: Normalized viability of Aβ species as assessed by PI assay. 100μM Aβ was 
incubated at 370C without mixing for various periods of time (0, 4, 8, and 72 h) prior to addition 
to cells. Cells were exposed to Aβ for 24 h prior to staining with PI. Only cell viability 
associated with the Aβ sample that was aggregated for 72 h prior to cell addition was statistically 
different from that of the fresh peptide sample (p < 0.05).  
Figure 15B: Normalized viability of Aβ species incubated at 370C without mixing for various 
periods of time as obtained from the annexin-PE and 7AAD two-color assay. 100μM Aβ was 
used. Peptide was aggregated for 0, 4, 8 and 72 h in MEM prior to addition to cells without 
further dilution of peptide. Cells were exposed to Aβ for 2 h prior to staining with annexin-PE 
and 7AAD. Cell viability associated with Aβ species preincubated for 4 and 8 h prior to addition 
to cells were statistically different from viability associated with fresh and the 72 h fibrillar 
samples (p < 0.05). 
(results adapted from publication [183], with permission from Elsevier Inc.) 
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The ability of sialic acid conjugated dendrimers to attenuate the toxicity of Aβ(40) was 
investigated in a model human  neuroblastoma SH-SY5Y cell culture [8]. Lyophilized Aβ(40) 
was dissolved in DMSO to make 10mg/ml stock solutions. After incubation for 1h to 30min, the 
stock were diluted to their final concentration to cell media and rotated for 24h to form 
aggregated Aβ fibrils and other aggregated Aβ species. Peptides were added to SH-SY5Y cells 
and toxicity assessed after 24h incubation by the PI toxicity assay. At a concentration of 5µM 
aggregated Aβ(40), the viability after 24h was ~60%. At a concentration of 20µM aggregated 
Aβ(40), the viability after 24h was ~90% in the same experiment (refer figure 2 in publication). 
In the next experiments with 50µM Aβ(40), the Aβ control viability observed was ~55% and 
~60% in experiments after 24h (refer figure 4 in publication). This indicates that concentration of 
aggregated Aβ(40) does not give proportional toxicity in SH-SY5Y cells, even if all other 
protocols are consistent in all experiments. Also, in the same publication, even though no dose-
dependent study is done, a total of 3 different concentrations of Aβ(40) are used to evaluate 
toxicity profiles for different compounds. The protocols in our work are consistent with this 
publication. 
The ability of sialic acids attached to dendrimers via different functional groups to reduce 
the toxicity of Aβ(40) was investigated in a model human neuroblastoma SH-SY5Y cell line 
[26]. Lyophilized Aβ(40) was dissolved in DMSO to make 10mg/ml stock solutions. After 
incubation for 1h to 30min, the stock were diluted to their final concentration to cell media and 
rotated for 24h to forms aggregated Aβ fibrils and other aggregated Aβ species. Peptides were 
added to SH-SY5Y cells and toxicity assessed after 24h incubation by the PI toxicity assay. After 
incubation 50µM aggregated Aβ(40) with SH-SY5Y cells for 24 hours, the Aβ control values 
obtained were ~55% viability, ~60% viability and ~64% viability in three separate experiments. 
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Even if the toxicity given by same Aβ(40) peptide, by the same aggregation protocol and same 
cell system, results for these experiments are compared to one another. This indicates that in 
spite of variability in Aβ toxicity, results can be compared to one another (the difference in Aβ 
toxicity these experiments was of 9%).  
Photopolymerized sialic acid polymers were developed to protect mouse neuroblastoma 
N2A cells from neurotoxicity induced by aggregated Aβ(40) by Cowan et al [162]. Lyophilized 
Aβ(40) was dissolved in DMSO to make 10mg/ml stock solutions. After incubation for 1h to 
30min, the stock were diluted to their final concentration to cell media and rotated for 24h to 
forms aggregated Aβ fibrils and other aggregated Aβ species. Peptides were added to N2A cells 
and toxicity assessed after 24h incubation by the PI toxicity assay. After incubation 20µM 
aggregated Aβ(40) with N2A cells for 24 hours, the Aβ control values obtained were ~70% 
viability and ~78% viability in the same experiments with different compounds. This indicates 
that even with the same batch of Aβ(40) and same aggregation protocol and same cell culture 
experiments, different viabilities of N2A cell can be observed. 
To address the conflicting results from neurotoxicity studies, May et al. investigated 
Aβ(40) peptides from different sources for neurotoxicity expressed in rat hippocampal cell 
culture system [228]. Stock solutions of 1mM were prepared by dissolving in 10% DMSO and 
used in cell cultures studies at 10μM Aβ concentrations. The viability of the cells after 4 days of 
incubation with Aβ(40) was measured by the Lactate Dehydrogenase Assay (results from that 
publications are shown in figure 16). Lactate dehydragenase (LDH) is a stable enzyme, present 
in all cell types, and rapidly released into the cell culture medium upon damage of the plasma 
membrane. Cell death or cytotoxicity can be quantified by the measurement of plasma membrane 
damage. Thus, amount of LDH released directly correlates to cytotoxicity observed. For this 
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study, all the cytotoxicity experiments were run at similar conditions to ensure consistency. 
Aβ(40) lots investigated were #Z1682, #Z1960,  #Z1424 from Bachem, Inc.,   1 lot of Aβ(40) 
was from Multiple Peptides System (MPS), one Aβ(40) from Athena Lot # 164-OA-P232-1, one 
lot from Eli Lilly. Thus, in total 6 lots were investigated out of which 3 were from Bachem Inc. 
The results from the cytotoxicity assay for 10μM Aβ(40) with cell cultures are given in the figure 
16 below. Significant lot-to-lot variations were observed. The results show that only lot #Z1682 
was toxic to hippocampal cultures. All other lots were non-toxic. Another significant mention in 
the publication was that their initial biochemical characterization by reverse phase HPLC, 
electrospray mass spectroscopy, and amino acid sequence analysis did not reveal any obvious 
differences in all these lots. This shows that some but not all preparations of Aβ are neurotoxic 
even under identical in vitro culture conditions [228]. 
 
Figure 16: Direct toxicity of Aβ(40) in high density rat hippocampal cultures.  
Aβ(40) from various sources was added at 10μM Aβ(40) concentration to cultures and viability 
assessed after 4 days later by Lactate Dehydrogenase Assay. Results are expressed at units/ml of 
LDH (mean ±SD). CTL represent the control LDH level. Result shows that only Aβ lot # Z1682 
showed toxicity to cultures. All other lots were non-toxic under identical in vitro conditions. 
(result adapted from publication [228], with permission from Elsevier Inc.) 
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2.15.2. Summary 
In this section, almost 47-50 studies involving different fragments of Aβ, namely, 
Aβ(42), Aβ(40), Aβ(25-25), reverse peptide Aβ(40-1), Aβ fragments Aβ(1-16) etc. have been 
reviewed. It is evident that there is a wide variability in experimental methodology, for example, 
on the type of peptide used, aggregation protocol used, concentration of the peptide used, cell 
culture model used, Aβ-cell incubation time used, cytotoxicity assay used and most importantly, 
the viabilities reported from all these different studies.   
Researchers have used aggregated as well as fresh Aβ peptides in their toxicity studies. 
However, there are conflicting reports on the toxicity of fresh peptides (No ageing, No 
aggregation). In some studies, fresh peptides have shown non-toxicity whereas they have shown 
toxicity in other studies [183, 190, 196, 199, 200]. On the other hand, most of the studies 
reviewed in this section used aggregated Aβ peptides. Also, there are a significant number of 
researchers working on the different Aβ aggregates, their binding, physical characterization and 
so on (see section 2.7 and 2.8 in dissertation). Thus, in our study, we will use aggregated Aβ 
peptides because there is a plethora to evidence to suggest that aggregated Aβ is toxic to cells in 
culture. 
From the different studies, it can be seen that there are multiple protocols used to induce 
aggregation in the Aβ peptide. Reviewing the literature, the most used approach is to dissolve the 
lyophilized Aβ powder in a strong polar solvent such as DMSO, HFIP or TFA[15, 88, 190, 193, 
194, 197, 201]. The peptide stock is then diluted into the cell media or PBS or water depending 
on the type of study [8, 26, 161, 183, 190, 196, 201, 229]. Then, the Aβ-cell media solution is 
incubated or rotated for different periods of time depending on the type of application or the type 
of aggregated Aβ species desired. The time of incubation with cells as well as time of 
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aggregation before addition to cells is an important aspect in Aβ-cell studies. Additionally, 
different incubation times and different aggregation times have shown different effects on 
different cell systems [201, 204, 205, 211]. 
The concentration of Aβ used in vitro spans over the nanomolar to the micromolar range. 
Studies have used concentrations as low as 0.1µM Aβ [191, 209], 0.5µM Aβ [193]. Other groups 
have used concentration as high as 100µM [200, 202, 204, 207] Aβ in cell studies with all 
concentrations in between. Looking at the literature reviewed, all the studies fall in the 
micromolar range, from 0.1μM to 100μM. There are publications that have used different 
concentrations of Aβ in the same study and used the results for further comparisons. 
It appears that several different cell lines can be used in Aβ studies. A survey of literature 
shows that rat PC-12 and human neuroblastoma SH-SY5Y are the most commonly used cell 
lines. There are also studies on neuronal NT-2 [195], septal rat neurons [191], human 
neuroblastoma SK-N-SH [203], neuroblastoma N2A [229], neuroblastoma SJ-N-AS, LAN5, 
SMS-KCNR [225], cortical neurons etc. Out of these, human neuroblastoma SH-SY5Y was 
chosen as the model cell line as most of the studies reviewed here used SH-SY5Y in toxicity 
studies.  
In most of the studies reviewed here, the cytotoxicity of the cells is measured by the MTT 
assay. Other assays such as lactate dehydrogenase assay, trypan blue assay, CCK-8 assay [212, 
216], propidium iodide assay, WAST-1 assay [220]  and the TUNEL assay are also popular. 
From these studies, it can be seen that the viabilities assessed from these assays vary among the 
different assays for the same concentration of Aβ species. E.g. Aβ(40) toxicity assessed by an 
assay in one study is different than the Aβ(40) toxicity assessed in same study by the same assay 
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[8, 26, 183] or among different studies by the same assay. Additionally, the viabilities of the cells 
treated with the same Aβ peptide gives different values if assessed by different assays [183]. 
There is a wide variability between the viabilities of the cultures treated with Aβ under 
similar conditions. This is aptly explored by a study that investigated 18 batches of Aβ and found 
37% were non-toxic to PC-12 cells under similar conditions. Two experiments, done on two 
separate dates, with the same batch (ZK568) of Aβ(40) and with the same number of cells gave 
very high toxicity (~24% viability of cells were in Aβ control) in one experiment whereas no 
toxicity ( ~91% viability in Aβ control) in the other [190]. In another study, only 1 out of 6 
batches of Aβ(40) evaluated showed toxicity to hippocampal cultures under consistent conditions 
[228]. This shows that some but not all preparations of Aβ are neurotoxic even under identical in 
vitro culture conditions. Also, it appears that toxicity of Aβ is not directly proportions to the 
concentration of Aβ added to the cells [8, 183]. One study reported that 0.5µM Aβ(42) gave 
~56% viability compared to 5µM Aβ(42) that gave ~77% viability of cells [193] under exact 
same conditions and aggregation protocols. Another study observed no toxicity towards cells at 
concentrations of Aβ(40) from 1µM to 20µM, but observed ~22% viability at 30µM Aβ(40) 
concentration [194]. Other studies have routinely used less than 20μM Aβ(40) with high 
toxicities [196, 208, 214]. Higher concentration of 100µM Aβ gave ~50% viability in SH-SY5Y 
cells, whereas the similar or even lower viabilities is observed in the low concentration range of 
Aβ in other studies [194, 196, 215, 218, 223]. In a publication, 2μM Aβ(40) on PC-12 cells and 
100μM Aβ(40) on SH-SY5Y cells gave almost the same viabilities (~50%) under similar Aβ 
aggregation protocols. In one study, it was observed that 20μM Aβ(40) induced no toxicity in C6 
glioma cells whereas other study reported 25μM Aβ(42) giving ~48% viability after 24h [125, 
227]. Thus, it can be seen that in almost every publication, different viabilities are obtained for 
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concentrations depending on the type of model culture system used for the study. The viabilities 
of SH-SY5Y cells treated with the same 100μM Aβ samples show completely different toxicities 
when evaluated with two different assays [183]. 
Finally, due to its amphiphilic nature, Aβ peptide shows high unpredictability and high 
variability in toxicity profiles [190]. In 1997, a new method to predict toxicity of Aβ(40) was 
investigated where the researcher found 33% of the 18 batches of synthetic Aβ to be non-toxic to 
cells. This dual nature of Aβ is the precise reason why there has been limited progress towards 
development of a therapeutic against AD. 
Additionally, there are several more observations done from each done at the end of each 
reviewed publication. The main observation is that the toxicity behavior of the Aβ peptide is 
dependent on multiple factors and hence it is very difficult to observe consistency across the 
studies. Also, this is the precise reason why even after 100 years since its discovery, the exact 
cause, exact mechanism, and exact diagnosis is still unclear or unknown. This has made 
developing therapeutics for AD very difficult.  
2.15.3. Design of Experiments: Guidelines 
Since there are a vast number of variables when it comes to Aβ studies, each part of the 
Aβ toxicity experiments is considered separately. 
Choice of Aβ Peptide 
Almost all Aβ studies are done with Aβ(40), Aβ(42) or Aβ(25-35) peptides. In our 
experiments, we chose Aβ(40) for toxicity attenuation studies with SH-SY5Y cells. More than 
90% of the Aβ in the human CSF is Aβ(40) compared to its other fragment Aβ(42). Also, more 
than 90% of the Aβ produced from the amyloid precursor protein is Aβ(40) [11, 61]. Among the 
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reviewed papers, Aβ(40) has been used in the following studies [8, 26, 125, 183, 190, 194-196, 
200, 201, 206-208, 210, 226, 229].  
Choice of Aβ(40) Concentration for Toxicity Studies 
Multiple groups have used concentrations of Aβ peptides ranging from 0.1µM [209], 
0.5µM [219]  to 100µM [200, 202, 207]. In most biological fluids, cerebrospinal fluid, plasma, 
Aβ exists in the nanomolar concentrations [230, 231]. At lower concentrations of Aβ(40) 
conflicting results were observed at 10µM and 20µM in a publication whose protocols with Aβ 
were consistent to our own [183]. Hence, to avoid that range, a concentration of 50µM was 
chosen to study the toxic effects of Aβ in cells.  Also, 50µM falls within the biological range 
(0.1µM to 100µM) of Aβ peptides that are studied in vitro. Additionally, the closest research 
publications that are parallel to this study used 50µM Aβ(40) concentration for those studies. [8, 
26]. Other publications have also used 50µM concentration of Aβ are [183, 190, 194, 208].  
Choice of 50μM Aβ(40) Aggregation Protocol 
Stock solutions of Aβ(1-40) at concentrations of 10mg/ml were prepared by dissolving 
the lyophilized peptide in anhydrous dimethyl sulfoxide (DMSO). Aβ peptides are dissolved in a 
strong polar solvent to prevent any preexisting seeds that may affect aggregation. This protocol 
is consistent with other studies [15, 88, 190, 193, 194, 197, 200, 201, 204, 207, 222, 226, 229, 
232]. After incubating for 30min to 1h at 250C to ensure complete dissolution, the stock 
solutions of Aβ were diluted directly to their final concentration in sterile cell culture media and 
rotated at 250C for 24h prior to the addition to the cells. This protocol of diluting the stock 
directly to cell media is consistent with the following studies [8, 26, 161, 183, 190, 193, 196, 
200, 201, 203, 204, 207, 222, 226, 229, 232]. 
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Choice of Time of Incubation with SH-SY5Y Cells 
The time of incubation of the aggregated Aβ peptide was chosen to be 24h after which 
the viability was assessed. Multiple groups have used 24h incubation time in their Aβ toxicity 
studies [8, 26, 125, 190, 193, 195, 196, 200, 203, 205-208, 211-214, 216, 218, 219, 224, 226, 
229].  
Choice of Dose Dependent Study 
Out of around 50 publications reviewed, only a few studies [190-192, 198, 215, 216] 
have performed dose-dependent or cell-death calibration curves using different Aβ peptide 
concentrations. In most cases, dose-dependent studies were done when a new aggregation 
protocol [194] or a new viability assay [183] was proposed. Studies have shown that viabilities 
from a dose-dependent curve are not a very good predictor of the viability obtained by using the 
same concentration and conditions in subsequent experiments [190-192, 198, 215, 216]. The 
general trend observed is that a suitable concentration of Aβ peptide is picked and toxicity 
studies are done directly using that concentration. Also, there are studies that indicate lot-to-lot 
and within-lot variability in the toxicity shown by Aβ peptides [190, 199]. Thus, in our work, we 
chose not to perform the dose-dependent studies with aggregated Aβ(40). 
Choice of Cytotoxicity assay 
The 3(4,5-dimethylthiazol-2yl)2,5-diphenyl-2H-tetrazolium bromide (MTT assay) was 
chosen for evaluation of the viabilities of SH-SY5Y cells. As it can be seen from this document, 
MTT is a common viability assay that is routinely used in Aβ studies by several research groups. 
As the MTT is a very established assay, the protocol used is consistent with literature. After 24h 
incubation with the peptides or test compounds, the media from the wells was replaced with 
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100μl of culture media without phenol red. 10μl of 5mg/ml MTT solution was freshly prepared 
in culture media without phenol red and added to all the wells. After incubation for 2h, the cells 
were checked for purple crystals and the media was replaced with 200μl of DMSO. After 20min 
on the shaker, absorbance at 570nm and 690nm was measured using a standard microplate 
reader. Normalized viability values were obtained by dividing the percentage of viable cells in 
the sample by that in the control samples with no Aβ or other agent added. 
Viabilities Observed from Toxicity Studies 
The issue with variable viabilities seen in Aβ studies is discussed in detail in the 
summary section. Multiple groups have seen extremely wide range of viabilities with Aβ 
peptides. There are entire publications which investigate the unpredictability of different batches 
of Aβ [190, 199, 228] studied under consistent aggregation and in vitro conditions.  The entire 
focus of this experimental design section was to illustrate and understand the differences in the 
studies done with Aβ in vitro. From this document, it is evident that viability of a cell culture 
incubated with Aβ depends upon multiple factors such as, Aβ peptide chosen [99, 125, 187, 194, 
196, 208], Aβ concentration chosen [193, 194, 196, 201-203, 214, 215], Aβ aggregation protocol 
chosen, time of Aβ aggregation [196, 199-201, 204, 215], type of cell culture model used [125, 
207, 208, 225], time of incubation with cells [192, 203, 222], type of viability assay used [183] 
and so on. In the same experiment, at the same conditions and same concentrations of Aβ, 
different viabilities have been observed from Aβ peptide treated cells [199, 205, 211, 223, 229]. 
Additionally, different concentrations of Aβ peptides have been used in the same study giving 
different viabilities [8, 187, 204, 207]. In another study, 5μM Aβ(42) gave viabilities ranging 
from 20% to 40% under exact same conditions [211]. Under the exact same conditions, different 
viabilities of cells treated with Aβ have been reported [8, 26, 191, 202, 205, 207, 211, 229]. 
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Thus, in our case, the different viabilities obtained from different batches of Aβ(40) are 
within reasonable limit. In this work, Aβ studies were run with different batches for Aβ(40) for 
the two parts of this work. What is important is that the Aβ control value does not vary within 
each part, i.e., within sialic acid-complex part and within biological-sugar-complex part. Even 
though the aggregation protocol and cell culture protocols are consistent, the difference in 
toxicity could be the result of different Aβ batch or a difference in the aggregated species formed 
after 24h aggregation protocol. It is for this precise reason why we are treating the sialic acid 
complex study and sugar-analogs complex study as individual pieces of publications. Within 
each study, we still have just one Aβ control value against which we are doing comparisons. The 
only link between the sialic acid-chitosan complex part and biological sugar-complex part is the 
35% labeling we used as the labeling percentage of chitosan. Thus, we are not comparing any of 
the Aβ results from sialic-acid chitosan complex study with that of the sugar-analog study. If the 
viabilities of Aβ control from the two parts of this dissertation were close together, it would have 
made the comparison between sialic acid-complex and KDN-complex possible. 
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3. SIALIC ACID CONJUGATED CHITOSAN FOR THE ATTENUATION OF 
AMYLOID-BETA TOXICITY: DEGREE OF LABELING STUDY 
 
3.1. Introduction 
Alzheimer’s disease (AD) is the leading cause of neurodegeneration, affecting almost 37 
million people worldwide with an estimated cost of healthcare of over $600 billion, the bulk 
attributed to long-term care for patients unable to care for themselves[3, 4].  While there are 
numerous hallmarks of AD (including neurofibrillary tangles and amyloid plaques), we will 
focus on fibrils, whose main protein component is the amyloid-beta peptide (Aβ). We chose this 
target as it is widely hypothesized that Aβ is the primary causative agent in AD-related 
neurodegeneration. 
A number of investigators, including the ourselves, have suggested that Aβ binds to 
neuronal cell membranes through interaction with cell surface gangliosides or glycoproteins 
containing sialic acid [8, 114, 233-235]. Gangliosides are glycosphingolipids with one or more 
sialic acid moieties attached to a sugar chain.  Numerous studies have shown that the binding 
affinity of Aβ to the membrane is higher when multiple sialic acids are present, either because of 
clustering of gangliosides or because of the degree of sialylation of the gangliosides. [8, 29, 113, 
118, 234, 235]. Evidence suggests that Aβ interacts specifically with the sialic acids present on 
gangliosides such as GM1[4, 29, 112], and this GM1-Aβ moiety can act as a seed for further 
amyloid deposition thus becoming the key step in the initiation of AD [29, 31, 129, 135, 
236].Additionally, reduction of cell surface sialic acids has been found to protect cells from Aβ 
toxicity[33].  
Thus, it would be beneficial to develop membrane mimicking materials that could 
compete favorably with the cell surface for Aβ binding, thereby reducing the free Aβ that 
interacts with neurons thus protecting them from Aβ toxicity. The aim is recreate the clustered 
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sialic acid structure seen on cell membranes by the design of novel conjugated compounds that 
have antibody-like affinity towards Aβ. Previously synthesized membrane mimetic multivalent 
sialic acid polymers were found to attenuate toxicity [8, 26]. These materials also bound to Aβ 
with high affinity (on the order of 107 to 108 M-1 association binding constants, compared to 106-
107 M-1 for sialic acid containing neuronal membranes to Aβ) [8, 26, 237]. A major issue in those 
studies was core polymer toxicity and inflexibility. This shortcoming is addressed in this work 
using chitosan as the core backbone polymer, as chitosan is an FDA approved polymer for 
implantation. Chitosan is a natural amino-polysaccharide comprising of copolymers of D-
glucosamine and N-acetyl glucosamine units linked together by β-(1-4) glycosidic bonds. 
Chitosan has an amino group present at C2 position, which allows for its modification using 
EDC chemistry. Detailed reviews on the chitosan, its host of biological properties, and chemical 
modifications have been published elsewhere [163, 164, 168, 169, 174, 175, 238]. 
In this study, we have designed several sialic acid (N-acetyl neuraminic acid) conjugated 
chitosan molecules of different valency, or different number of sialic acid residues per chitosan 
molecule, using EDC chemistry. By using chitosan, we will benefit from its biocompatibility and 
non-toxicity as a backbone. Also, chitosan is a flexible, linear molecule; hence, we expect better 
clustering effect when sialic acid is attached to it. Using a model cell-line SH-SY5Y, along with 
aggregated Aβ(40) peptide, it will be possible to predict the clustering of sialic acids necessary to 
achieve optimum protection from Aβ toxicity. Since other studies have seen binding of the Aβ to 
sialic acid complexes, we hope to make a biomimetic that Aβ can bind to, and therefore prevent 
Aβ-cell interaction. Thus, sialic acid decorated chitosan will more closely mimic neuronal cell 
adhesion molecules (NCAM), providing another mimetic target for Aβ.  
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3.2. Materials and Methods 
3.2.1. Materials 
Aβ(1-40).HCl peptide was purchased from Anaspec Inc. (San Jose, CA).  Human 
neuroblastoma SH-SY5Y cells were purchased from ATCC (Manassas, VA).  Cell dissociation 
buffer and cell culture reagents were purchased from Gibco-Invitrogen (Grand Island, NY).  
Chitosan powder (MW~15000, DD~84%) was purchased from Polysciences Inc. (Warrington, 
PA). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (Sulfo-NHS) were purchased from Pierce Biotechnology (Rockford, 
IL).  Ultrafiltration membranes were purchased from Millipore (Billerica, MA).  Human 
recombinant nerve growth factor-β (NGF-β), (3-[4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT), Sialic acid (N-Acetylneuraminic acid), chemicals for Warren assay 
and all other reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
3.2.2. Peptide Preparation 
The Aβ peptides were prepared analogously to established methods in structural and 
toxicity literature for forming β-sheet and Aβ fibrils. Aβ(1-40) stock solutions were prepared by 
dissolving the lyophilized peptide in anhydrous dimethyl sulfoxide (DMSO) to make 10mg/ml 
stock solutions. After incubating for 30 min to 1h at 25oC, stock solutions of Aβ were diluted to 
their final concentrations in cell culture medium and rotated at 25oC for 24h prior to addition to 
the cells. This method of peptide preparation has been found to produce Aβ fibrils that were 
consistently toxic to the cells in in vitro at concentrations between 20μM and 100μM [8, 226]. 
3.2.3. Cell Culture 
Human neuroblastoma SH-SY5Y cells were cultured in a humidified 5% CO2/air 
incubator at 37oC in Minimum Essential Media (MEM), supplemented with 10% (v/v) fetal 
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bovine serum, 2.2 mg/ml NaHCO3, 100 U/ml penicillin, 100 μg/ml streptomycin and 2.5 μg/ml 
amphotericin-B (fungizone). SH-SY5Y cells were NGF differentiated prior to use in toxicity 
experiments by addition of 20ng/ml NGF to cells for 5-7 days in 96 well plates.  All the cells 
used in experiments were under the 10th passage to ensure consistent metabolic response and 
stability. 
3.2.4. Synthesis and Purification of Sialic Acid Labeled Chitosan 
Sialic acid was conjugated with chitosan using EDC chemistry following the 
manufacturer’s suggested protocol with minor modifications.  Chitosan (MW~ 15000, DD~ 
84%) at concentration of 8 mg/ml, was dissolved in 1X Phosphate Buffer Solution (PBS) and 5% 
HCl solution. The molar concentrations of sialic acid and EDC were based on the theoretical 
calculation of the number of primary amines in one mole of chitosan calculated from the number 
of glucosamine units. To achieve different percentage labeling, the ratio of the amount of sialic 
acid added to primary amines in reaction was varied in each case. For the conjugation 
experiment, sialic acid at different molar concentrations was dissolved in 1ml of activation buffer 
(0.1M of 2-[morpholino]ethanesulfonic acid (MES) and 0.5M NaCl at pH 6.0). To this activated 
buffer solution, 0.3626mM of EDC (10 Fold excess to the moles of primary amines in chitosan) 
and 5mM of Sulfo-NHS (1.1mg) were added. The pH was maintained in between 5.0 to 6.0 by 
the use of 0.1M phosphate buffer (at pH 7.2). The reaction mixture was continuously rotated at 
room temperature for 15 min. Thereafter, 1.4μl of 2-mercaptoethanol was added to deactivate the 
unreacted EDC. The reaction mixture was stirred for 2min and then, 1 ml of chitosan solution 
was added; pH increased to 7.0 by the use of phosphate buffer and mixture allowed to react 
overnight. After 24h, the reaction mixture was checked for precipitation. If observed, the 
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resulting precipitate was dissolved by drop-wise addition of 10% (v/v) acetic acid solution before 
purification. 
To remove the unreacted sialic acid and EDC, the reaction volume was ultrafiltered using 
10000 NMWL cutoff Amicon Ultra Centrifugal filter unit. Six washes of DI water were done 
each time, assuming that the final concentration of the free sialic acid in the mixture was less 
than 6% of the total sialic acid (free and covalently bound to chitosan) [8]. After purification, the 
sialic acid labeled chitosan was stored at -4oC for later use. 
3.2.5. Verification and Quantification of the Extent of Sialic Acid Conjugation 
The verification of the presence of sialic acid on chitosan was performed using Thermo 
Electron Nicolet 380 FTIR with Smart Orbit attachment (Thermo Electron Corporation, 
Waltham, MA). For the FTIR analysis, samples of sialic acid-chitosan conjugates (called 
complex) were lyophilized using Labconco FreeZone 1 Liter Benchtop Freeze Dry Systems. Dry 
lyophilized complex powders were stored at -4oC before and after use in the FTIR. For the FTIR 
analysis of chitosan, dry powder obtained directly from the manufacturer was used.  
The extent of sialic acid labeling was determined by a procedure described by Warren 
[239].   In this method, the free sialic acid undergoes periodic oxidation resulting in the 
formation of β-formylpyruvic acid. This acid reacts with 2 molecules of thiobarbituric acid to 
give a red chromophore with a maximum absorbance at 549nm [240].  The Warren assay uses 
the following reagents, Solution A) 0.2M Sodium (meta) periodate in 9M phosphoric acid 
(prepared fresh each time); Solution B) 10% (w/v) Sodium arsenite in a solution of 0.5M sodium 
sulphate-0.1M H2SO4 and Solution C) 0.6% (w/v) Thiobarbituric acid in a solution of 0.5M 
sodium sulphate  
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The procedure to determine the extent of sialic acid labeling is as follows [241]. 
Assuming that the complex synthesized was 100% labeled, a sample containing 0.3mM of sialic 
acid concentration was hydrolyzed by 0.1N hydrochloric acid at 80oC for 1h. Then, to a 0.2ml 
hydrolyzed sample, 0.1ml of periodate solution (A) was added, tubes shaken and allowed to 
stand for 20min. After that, 1ml of arsenite solution (B) was added and the tube vortexed till the 
yellow-brown color disappeared. Care was taken to completely make the yellow-brown color 
disappear. This was done by immediately vortexing after adding the arsenite, allowing the 
solution to stand for a few minutes and again vortexing. Thiobarbituric acid solution (C), 3ml 
was added, the solution intensely mixed and the sample immersed in a vigorously boiling water 
bath for 15min. Samples which showed the presence of white coloration were discarded as it 
indicated that the yellow-brown color was not completely removed in the earlier step. Next, the 
sample was placed in cold water for 5min to develop the chromophore. Then, 4.3ml of 
cyclohexanone was added and then tubes shaken vigorously. The sample was then centrifuged at 
1500g for 7min at 25oC to extract the resulting chromophore into the cyclohexanone. The 
precipitate-free upper organic phase was taken in a 10mm path-length quartz fluorometer cell 
(Starna Cells Inc.) and the absorbance measured at 549nm.  Each reading was repeated four 
times.  
Using the same procedure, the assay was performed on pure sialic acid samples to get the 
standard curve and on pure chitosan to determine whether chitosan interfered with the 
chromophore production. The standarad curve will allow us to calculate the degree of labeling of 
our compounds. Three independent measurements were taken in each case. 
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3.2.6. MTT Toxicity Assay 
SH-SY5Y cells were plated at a density of 2x104 cells/well in 96 well plates and NGF 
differentiated. After 5-7 days differentiation, culture medium was replaced with medium 
containing NGF to which the compound to be tested was added, either Aβ, chitosan, sialic acid 
conjugated chitosan complex, or a combination of the above. Aβ peptide at a concentration of 
50μM was prepared by methods described in earlier sections. In all experiments, Aβ was added 
to the cells approximately 30min prior to the addition of chitosan or conjugated complex. A 
gradient of chitosan and conjugated complex from 30μM to 1μM was applied on the 96 well 
plate. After 24h, of the addition of Aβ, chitosan, sialic acid conjugated chitosan; the viability of 
cells was determined by using the MTT assay. The media from the wells was replaced with 
100μl of culture media without phenol red. 10μl of 5mg/ml MTT solution was freshly prepared 
in culture media without phenol red and added to all the wells. After incubation for 2h, the cells 
were checked for purple crystals and the media was replaced with 200μl of DMSO. After 20min 
on the shaker, absorbance at 570nm and 690nm was measured using a standard microplate 
reader. Normalized viability values were obtained by dividing the percentage of viable cells in 
the sample by that in the control samples with no Aβ or other agent added[242, 243]. 
3.2.7. Statistical Analysis 
We used ANOVA followed by the Tukey’s test for the complete analysis of the intrinsic 
toxicity and Aβ studies data. The results were significant if p < 0.05. Detailed statistical analysis 
of the results is presented after the results and discussion section. The p-values for every 
comparison are given in the appendix. The detailed analysis of the results with statistical analysis 
is provided in later sections. 
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3.3. Results and Discussion 
3.3.1. Verification of Sialic Acid Conjugation to Chitosan 
Figure 17 shows the FTIR results for complex B (moles of primary amines in chitosan/ 
moles of sialic acid = 1), Figure 18 shows spectra for complex F (moles of primary amines in 
chitosan/ moles of sialic acid = 4) and figure 19 shows complex G (moles of primary 
amines/moles of sialic acid =10) spectra. The FTIR result for pure chitosan is also included for 
comparison purposes.  The dashed line indicates the sialic acid-chitosan complex spectra 
whereas the solid line shows the pure chitosan spectra.  
In the region from 3000 to 3500cm-1, the FTIR of pure chitosan shows two weak peaks 
that are indicative of the primary amines present in chitosan. These two peaks are absent in 
complex spectra and instead a broad band for amide –NH stretching frequency is observed. A 
strong peak around ~1650cm-1 for the complex spectra, indicates the presence of amide bond. 
The loss of primary amines and the formation of amide bonds confirm the complex of SA with 
chitosan. Sialic acid has carboxylic acid group which is used to couple with the amine in 
chitosan. In the complex spectra, the characteristic strong peak of C=O of carboxylic acid in 
between 1700 to 1725cm-1 is not observed. The complex also shows peaks at ~1030cm-1 and 
~1380cm-1 that indicates the presence of alcohols and acids consistent with sugar molecule 
attached to chitosan. Thus, all the three spectra indicate the presence of sialic acid on chitosan. 
The spectra for intermediate concentrations of sialic acid (i.e. Complex A, C, D, E) are not 
shown (but verified). From these results, we can qualitatively say that the EDC chemistry was 
successful for the synthesis of sialic acid conjugated chitosan. This is significant as it validates 
EDC as a crosslinking technique for future works.  
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Figure 17: FTIR results of sialic acid conjugated chitosan complex B (dashed line) and 
pure chitosan (solid line).  
Complex B (having ratio of moles of primary amines in chitosan/ moles of sialic acid = 1). The 
x-axis is wavenumber (cm-1) and the y-axis is normalized absorbance. 
 
Figure 18:  FTIR results of sialic acid conjugated chitosan complex F (dashed line) and 
pure chitosan (solid line) 
Complex F (having ratio of moles of primary amines in chitosan/ moles of sialic acid = 4), The 
x-axis is wavenumber (cm-1) and the y-axis is normalized absorbance. 
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Figure 19: FTIR results of sialic acid conjugated chitosan complex G (dashed line) and 
pure chitosan (solid line) 
Complex G (having ratio of moles of primary amines in chitosan/moles of sialic acid = 10). The 
x-axis is wavenumber (cm-1) and the y-axis is normalized absorbance. 
3.3.2. Quantification of Sialic Acid Conjugation to Chitosan 
The Warren assay was performed on pure sialic acid to generate the standard curve. As 
seen from figure 20, the Warren assay gives very accurate, linear and reproducible results with 
very low standard deviation. The standard curve was useful in the calculation of the degree of 
labeling of chitosan. The assay gave accurate results if the concentration of sialic acid (SA) in 
the sample was in between 0.05mM to 0.3mM. The assay was also performed on higher SA 
concentrations, but the curve saturated limiting the highest concentration that can be tested to 
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0.3mM (results not shown). Pure chitosan was also evaluated using the Warren assay but the 
results were negative (results not shown) indicating that chitosan did not interfere with the assay.  
The moles of primary amines in reaction mixture were determined theoretically from the degree 
of deacetylation of the chitosan sample. The extent of sialic acid (SA) labeling was effectively 
determined by using the Warren assay as the FTIR results were insufficient for the quantitative 
estimate of the amount of SA present on chitosan. The percentage of SA labeling was calculated  
by dividing the absorbance of the sample by the estimated absorbance for 100% labeling of the 
amine terminals of the chitosan with sialic acid. The percentage of sialic acid conjugation for 
different samples of complex synthesized by the EDC chemistry is shown in Table 8. Using EDC 
chemistry, it was possible to achieve 8% to 48% labeling (sample A to sample G) of the amines 
of chitosan by sialic acid. 
Table 8: Percentage labeling of chitosan by sialic acid from EDC chemistry 
Sample [Sialic Acid]:[Primary Amines] 
in reaction solution 
Degree of Labeling (%) 
A 1:4 7.8 + 1.1 
B 1:1 14.1 + 1.9 
C 1.33:1 17.6 ± 0.4 
D 1.66:1 24.5 ± 0.5 
E 2:1 37.3 + 1.5 
F 4:1 40.7 + 1.4 
G 10:1 48.0 + 2.5 
  
From figure 21, we observe that the conjugation chemistry follows a classic saturation 
curve for sialic acid labeling. As the concentration of sialic acid increases, the degree of labeling 
increases until the curve starts saturating. The results also indicate that the saturation 
characteristic appear after sample E (with ratio of moles of amines to moles of SA =2). It may be 
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possible that as more and more sialic acids get attached to chitosan via amine groups, it becomes 
increasingly difficult to accommodate additional sialic acids due to steric hindrance. It seems 
unlikely that we would achieve a higher degree of labeling of chitosan by sialic acid (SA) as the 
bulk of SA’s already present on the chitosan would prevent free SA from interacting with the 
amines on chitosan. The different percentage labeling of chitosan will allow us to study the effect 
of SA concentration on Aβ binding. It will also allow us to predict the labeling at which 
optimum protection will be achieved. Now, our compounds range from unlabeled chitosan (0% 
labeled, flexible and linear) to complex G (48% labeled, saturated SA concentration on the 
surface, rigid and inflexible). This will allow us to test the Aβ attenuating properties of the 
labeled compounds on all ends of the spectrum. 
 
Figure 20: Results of Warren assay on pure sialic acid – standard curve  
Data is represented as mean ± SD, n=3 
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Figure 21: Saturation curve for EDC labeling of chitosan 
Data is represented as mean ± SD, n=4 
 
3.3.3. Intrinsic Toxicity of Sialic Acid-Chitosan Complexes and Unlabeled Chitosan 
The compounds, unlabeled chitosan and sialic acid-chitosan complexes A to G, were 
tested for intrinsic toxicity using the MTT assay described earlier by varying the concentration of 
the compounds from 1μM to 30uM.  This will allow us to determine the toxicity of the 
compounds compared to chitosan toxicity in the absence of Aβ. The toxicity values are 
normalized to live control containing no complex or chitosan. The results for toxicity studies are 
shown in Figure 22. The statistical analysis is presented later. The bar at 0μM complex 
concentration represents the normalized control viability with no complex or chitosan in the 
system. It can be observed that chitosan, complex A (1/4Fold), complex B (1 Fold), complex C 
(1.33Fold), complex D (1.66Fold) and complex E (2 Fold) show little to no toxicity towards SH-
SY5Y cultures. The range of toxicity for the compounds tested range from no apparent toxicity 
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(chitosan and complexes A,B,C,D,E) to 20% toxicity for complex F (4 Fold) to 40% toxicity for 
complex G (10 Fold). For detailed analysis of the results see the statistical analysis section. 
As no toxicity is observed for chitosan at even higher concentrations (30μM), it supports 
the fact that the backbone selected is biocompatible and non-toxic to cells in culture. This is an 
improvement over earlier works where the issue was core backbone toxicity [8, 26]. As it is 
apparent from figure 22, there is a distinct increase in toxicity that occurs between complex E (2 
Fold) and complex F (4 Fold).  This follows the transition to saturation found from the labeling 
evaluation (refer figure 21). 
 
Figure 22: Intrinsic toxicity of sialic acid chitosan complexes (A to G) and naïve chitosan 
exposed to SH-SY5Y   
The bar charts are labeled according to the sialic acid-chitosan complexes and their respective 
sialic acid labeling. Viability at 0µM represents the normalized control viability with no complex 
or chitosan in the system.  Data is represented as mean ±SD, n=4 in each case. 
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This indicates that there is likely a link between compound toxicity and molecular 
rigidity. We know this from EDC chemistry that it was difficult to achieve higher degree of 
labeling of chitosan by sialic acid. We believe this might be the factor affecting the transition 
into toxicity. There is a direct relation between intrinsic toxicity and molecular weight of the 
compound. Thus, the 40% toxicity of complex G (10 Fold) can be as a result of the high 
molecular weight due to higher number of sialic acid molecules present on the chitosan backbone 
(48% labeling shown by Warren assay). 
3.3.4. Aβ Toxicity Attenuation Studies of Sialic Acid-Chitosan Complexes and 
Unlabeled Chitosan 
 
The ability of chitosan and complexes to attenuate the toxicity of aggregated Aβ peptide 
was investigated in vitro using the MTT assay. A gradient of 0μM to 30μM of chitosan and 
complexes was applied and the results with 50μM Aβ can be found in figure 23. The statistical 
analysis is given later. The toxicity attenuation values are normalized to control containing 50μM 
Aβ with no chitosan or complex added. The bars at 0μM concentration represents the Aβ control 
value (i.e. wells with only Aβ in media but no compounds added) used for normalization. 
Looking at the results, all compounds (including chitosan) showed significant protective 
properties against Aβ. The levels of Aβ toxicity attenuation by the compounds are as follows: 
Complex A (1/4 Fold) shows the least protective effect against Aβ toxicity. The reason can be 
explained by the fact that due to least sialic acid labeling, there is a loss of the protective effect 
shown by naïve chitosan plus there is insufficient sialic acid present to effectively cluster. Earlier 
studies have shown that free sialic acid did not show any significant protective properties [8]. . 
Now, as the degree of labeling increases, higher viabilities in SH-SY5Y cells are observed. The 
highest protection can be seen for labeling from ~17.6% to ~37.6% of chitosan (i.e. complex C, 
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D, E). This transition may indicate that the mechanism of protection has now shifted to our 
complex sequestering Aβ away from the cells. This is a strong possibility, as the biomimetics 
were synthesized with sialic acids labeled on chitosan. On the neuronal membrane, Aβ has 
affinity towards clustered sialic acids and binds to them. If our complexes are showing toxicity 
attenuation, it is most likely that the protection is due to binding of Aβ to the complex. In the 
study with sialic acid labeled dendrimers, Aβ had binding affinities to the sialic acid dendrimers 
complexes on the order of 10-7M to 10-9M[8, 26], which were at least an order of magnitude 
higher than Aβ binding to gangliosides (10-6M [8, 26, 156]) on neuronal membranes.  Looking at 
the data, it is difficult to predict whether one or multiple mimics bind to Aβ. Binding studies 
should be done to prove the exact mechanism of protection (e.g. to prove binding of complex 
with Aβ). This sequestering of the Aβ away from the cell is the mechanism of protection that we 
aimed for. It is difficult to elucidate whether the complex acts via competitive or non-
competitive mechanism in attenuating the toxicity of Aβ. It is also possible that the complex 
binds with Aβ, and alters the rate at which Aβ interacts with the cells, and induces toxic effect. 
This may be the reason why we see protection at all concentrations studied but not complete 
protection (or 100% cell survival). Additionally, we do not see any type of dose-dependent 
behavior from the complexes. Thus, the mechanism of protection needs to be investigated in 
much more detail in later studies. While all compounds (including chitosan) showed protective 
properties (in all cases, p < 0.05, by Tukey’s test), there was a distinct transition between 
complex E (2 Fold) and complex F (4 Fold). This indicates that an optimum can be achieved that 
balances the degree of sialation and backbone flexibility (which is critical in the effectiveness of 
the sialic acid to ‘cluster’). Similar transition was also seen in figure 17 in the case of intrinsic 
toxicity of the complexes E and F.  Even of more interest is the effectiveness of chitosan to 
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exhibit protective properties similar to that for sialic acid complexes. It also suggests that the 
sialic acid mimic interaction with Aβ and cells must be more than just competitive binding or 
electrostatic interactions. It has been suggested that lysine or histidine residues on the toxic Aβ 
species interact with the negatively charged groups on the cell membranes, possibly sialic 
acids[162]. Thus, the presence of another charged species in solution could shield the cell from 
the harmful interactions with Aβ. This could possibly explain the protective effect shown by 
chitosan in solution. The results from this study indicate that the sugar structure could play a 
critical role in Aβ binding, thus raising the possibility that other biological sugars could prove to 
be equally or even more effective than sialic acid in binding and sequestering the pathogenic Aβ 
peptide. 
 
Figure 23: Attenuation of 50μM Aβ toxicity by sialic acid chitosan complexes (A to G) and 
Naïve chitosan  
The bar charts are labeled according to the sialic acid-chitosan complexes and their respective 
sialic acid labeling. Viability at 0µM represents the system with 50µM Aβ(40) with no complex 
or chitosan in the system.  Data is represented as mean ±SD, n=4 in each case. 
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Nevertheless, this type of protection also works in our favor, that if we can delay or alter 
the rate of toxicity of Aβ towards neurons, we can essentially aim to delay the age of onset or the 
time of progression of Alzheimer’s disease. This the reason why we need to investigate structural 
analogs of sialic acid, to understand which groups or subgroups of sialic acid are interacting with 
or have higher affinity towards Aβ. This information coupled with binding studies will prove 
beneficial from the therapeutic point of view. 
3.4. Statistical Analysis of Intrinsic Toxicity and Aβ Toxicity Attenuation Data 
Every value in the bar charts are expressed as normalized viabilities plotted on the y-axis 
with the test compound concentration on the x-axis. Each mean is calculated from the average of 
the viabilities observed from at least four replicates of each complex/compound concentration. 
For the statistical analysis, we are interested to understand how each compound performed at all 
the concentrations we tested. Hence, each compound, starting with 0μM concentration, the 
viabilities obtained at all concentrations is compared to one another. This is the statistical 
analysis for each compound. Similarly, at each concentration, we wanted to compare the 
viabilities obtained from all compounds tested at that concentration. This will allow us to 
compare the effects of different compounds at the same concentration. This is the statistical 
analysis for each concentration. 
As this is a case of multiple comparisons, we use ANOVA followed by a suitable post-
hoc test. For the post-hoc test, Tukey’s Honest Significant Difference (HSD) test (shorthand 
“Tukey’s test” in later texts) is used. For every case or comparison, we are keeping the constant 
error rate of α equal to 0.05. All our measurements are done independently. The two important 
assumptions of ANOVA test is that the population is normally distributed and the variances for 
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all populations are equal. A sample dataset was run with the Levene’s test in SAS to check for 
equality of variances. The output from Levene’s test is attached in the Appendix. Thus, the 
homogeneity of the variance is verified and our data fits the requirements for ANOVA. 
However, this is a common assumptions in such kind of toxicity studies [8, 26, 162, 203, 229]. 
Furthermore, as a post hoc test, the analysis is done by Tukey’s test. The null hypothesis is that 
the two means (i.e. the means of the two normalized viabilities being compared) are equal. When 
the null hypothesis is rejected, post hoc comparisons are done using Tukey’s test to investigate 
further which groups/means differ. 
Tukey’s Test 
Tukey’s test allows for all possible pairwise tests and is based on the studentized range 
statistics. It also keeps a constant experimental error rate (α) for all possible pairwise tests. The 
sample size is equal in Tukey’s method. The differences between the means is calculated and 
compared to the critical value to see if the difference is significant. This critical value is the 
“Honestly Significant Difference” and that value is computed from SAS. The adjusted p-values 
for all pairwise comparisons are given in the output. 
Guide to Interpreting the Statistical Information on the Bar Chart 
Data for normalized viability is presented as mean ±SD of at least four replicates on the 
bar chart. The statistical significance of differences between groups was estimated by ANOVA. 
Further, any differences between the means group were analyzed by Tukey's test. Each graph 
shows the results and the statistical outputs obtained from the Tukey’s test. Different letters 
across the graphs indicate statistically-significant differences (p < 0.05); the same letter indicates 
no statistical difference between those groups. This assignment of letters is done using a macro 
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for SAS program developed by Saxton M.A [244]. This macro is run after the analysis by 
Tukey’s test. The macro groups similar means together and assigns a letter. The figure 24 shows 
the statistical analysis of the KDN-Chitosan complex intrinsic toxicity data. The table (24.A) in 
the figure 24 below shows the output from the macro by the Tukey’s test (at p < 0.05). The 
means are sorted and ranked starting with the highest to the lowest mean. Each mean represents 
the normalized viability at each concentration of the compound studied. Using SAS, the 
calculation for the critical value of the “Least Significant Difference” (LSD) is done. When the 
analysis is done by the Tukey's test, SAS applies the adjustment on the LSD based on Tukey's 
test and the critical value is adjusted. The highest mean is assigned the letter group A. If the 
critical value of the LSD = “X”, then means below that differ by less than “X” do not differ 
statistically. This is represented by giving them a common letter so that they share a letter. 
 
Figure 24: Grouping example- Statistical analysis and graph for KDN complex intrinsic 
toxicity data 
The table 24.A. represents the output using the macro which gives letter grouping for the means 
by Tukey’s test. The figure 24.B represents the normalized viabilities of KDN-complex plotted 
as a function of concentration. The similar letters above the bar indicate no statistical difference. 
Different letters indicates statistical difference at p < 0.05 by Tukey’s test. 
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As seen in figure 24-A, the difference between the means of 0μM and 10μM is not 
statistically significant. This is indicated by same letter A on 0µM and 10µM in figure 24.B. 
Here, each mean is the normalized viability obtained at each concentration. Hence, they both are 
assigned the letter A. However, the mean of 10μM is less than that of the mean at 0μM. Hence, 
10μM is assigned A and B (i.e. “AB”). Thus, 10µM indicated by “AB” is statistically the same 
as all other means that have the letter A or B above them. Moving on after 10μM, the next 
highest mean is 3μM. SAS determined that the mean of 10μM and 3μM were statistically 
different (working with the adjusted critical value for Tukey’s) and hence it is assigned a 
separate letter group “BC”. Looking at the output data in the appendix, the comparison between 
the 0μM and 10μM gives the p-value of 0.0106 using Tukey’s test. Coming back to 3μM, the 
letter “B” and “C” is shared with 10μM, 5μM, 20μM, 30μM. All these means do not differ 
statistically even if one is lower in value than the other. Looking back at the table, the 
normalized viability at 0μM is statistically different from all the viabilities at all other 
concentrations. Thus, means that share a letter are not statistically different. Example: As seen 
from figure 24.A, the normalized viability at 3μM (indicated by letter group “BC” is statistically 
different from the normalized viabilities at 0μM (indicated by A), 40μM (indicated by D) and 
48μM (indicated by D) as given by Tukey’s test (at p < 0.05). The comparison between each data 
point and the p-values obtained by Tukey’s test are attached in the appendix. Also, the output 
from macro is included along with the means compared in the appendix. 
3.4.1. Intrinsic Toxicity of Sialic Acid-Chitosan Complexes and Unlabeled Chitosan 
The following plots show the result of the intrinsic toxicity of the complexes and chitosan 
evaluated without Aβ in media. In all results, a gradient of 1μM to 30μM chitosan or complex 
concentration are applied and the viabilities evaluated. The viability at 0μM concentration 
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represents the untreated cells, i.e. live control with no test/experimental compound added to the 
control well. The normalized viability is calculated by dividing the viable cells in a sample by 
that of the live control, which represents 100% cells. Each point is represented as mean ± SD of 
the normalized viability values (with four replicates each). The statistical significance of 
differences between the means is estimated by ANOVA followed by the post hoc comparisons 
by the Tukey's test. Different letters above the groups indicates statistically different means at p 
< 0.05 as given by Tukey’s test. Similar letter or group of letter indicates no statistical 
significance between those groups. A macro in SAS programing was used to convert similar 
means into letter groups [244].  
Statistical Analysis Done for Each Compound 
The next set of graphs show the statistical analysis of each complex or compound done at 
all the concentrations studied. Thus, for this analysis each compound is considered separately. 
The graph below (figure 25) shows the analysis for the intrinsic toxicity of unlabeled 
chitosan compared at all concentrations from 1μM to 30μM. Essentially, it can be seen that 
unlabeled chitosan does not show any toxicity (statistically relevant) at all concentrations. Thus, 
unlabeled chitosan as a backbone is non-toxic to the cells. This is a significant improvement over 
previous works. Also, as chitosan has shown no toxicity, it will be possible to isolate the effects 
of just sialic acid in further results.  
In the result (figure 26) for sialic acid-chitosan complex A, which has around ~7.8% 
labeling of chitosan, we see that the non-toxic nature of the chitosan is maintained even after 
~7.8% labeling of the amine terminals by sialic acid moieties. At all concentrations studied, 
addition of the complex A shows no statistical difference from control at 0μM.  
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When the normalized viability means from complex B (having ~14.1% labeling) are 
compared to one another by Tukey’s test, we see no statistical differences in viabilities at all 
concentrations. Since, none of the compounds shows any statistical change from control 
viability, it indicates that complex B is non-toxic to the SH-SY5Y cells, see figure 27. 
 
 
 
 
Figure 25: Unlabeled chitosan=0%: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p < 0.05 
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Figure 26: Sialic acid-chitosan complex A =7.8% labeling: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
 
 
Figure 27: Sialic acid-chitosan complex B =14.1% labeling: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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Sialic acid complex C with 17.6% labeling also shows no toxicity towards SH-SY5Y 
cells at all the concentrations studied. Similarly, no statistical difference was found at all 
concentrations (in all cases, p > 0.05). (Refer to figure 28). 
 Sialic acid complex D (~24.1% labeling) is non-toxic as seen from the figure 29 as none 
of the concentrations differ significantly than live control. Thus, complex D is non-toxic at all 
concentrations. 
 
Figure 28: Sialic acid-chitosan complex C =17.6% labeling: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
Looking at Figure 30, there is no toxicity seen from the sialic acid complex E. There is a 
dip observed at 1μM point that is inconsistent with the observed trend. However, the most likely 
explanation is biological variability as none of the other complexes show any statistically 
significant toxicity at 1µM concentration compared to control. This indicates that the complex E 
is non-toxic to SH-SY5Y cells. 
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Figure 29: Sialic acid-chitosan complex D = 24.1% labeling: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
 
 
Figure 30: Sialic acid-chitosan complex E = 37.3% labeling: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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From the analysis of the intrinsic toxicity of sialic acid complex F (~40.1% labeling) we 
start observing toxicity towards SH-SY5Y cells (refer to figure 31). At all concentrations except 
5μM, the viabilities are statistically different compared to control. The range of toxicity appears 
to be around ~20% toxicity. This toxicity was not seen from any other compounds with less 
sialic acid labeling than complex F. This also corresponds to the transition seen from increasing 
sialic acid labeling to saturation in labeling as seen from the EDC chemistry curve. Also, at this 
point, we are approaching the limit of sialic acid labeling, which may indicate a likely link 
between molecule rigidity and toxicity. However, no further studies were done to confirm the 
molecule rigidity or its effect on toxicity.   
 
Figure 31: Sialic acid-chitosan complex F = 40.7% labeling: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
Sialic acid complex G has ~48% labeling which is the maximum we could achieve from 
the EDC chemistry. It seems unlikely that any higher labeling of chitosan could be achieved as 
the saturation characteristics were seen from the EDC chemistry curve. This complex is the most 
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bulky among all the other compounds tested and also shows the highest toxicity among all 
complexes. We see that at all concentrations, the viability of cell treated with complex G is 
statistically lower compared to the live control (figure 32). We see viability in the range of ~60% 
after the addition of complex G. This indicates a likely link between higher molecular weight of 
the compound and high toxicity observed to cells in culture. Also, another plausible explanation 
could be that molecular rigidity may be the contributing factor towards toxicity. This issue of 
molecular rigidity was also observed in the case of star-burst shaped dendrimers that exhibited 
high toxicity [8, 26, 160]. However, this needs to be investigated from further studies. 
 
Figure 32: Sialic acid-chitosan complex G=48% labeling: Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
Statistical Analysis Done for Each Concentration 
In this section, the complexes are compared to one another at each concentration. This 
will help us to understand the effect of each complex at a particular concentration. Similar letters 
on complexes on different concentrations are not compared. E.g.: in Figure 33, Chitosan at 1μM 
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has “AB” letter group, which is same as that on chitosan at 3μM. However, those two are not to 
be compared in this section. The letter grouping only refers to comparison at one concentration.  
The results from figure 33 show the statistical analysis for each particular concentration 
1µM, 3µM and 5µM. All complexes are compared among each other at a particular 
concentration. At 1μM, we see that chitosan and complexes A to D shows no significant 
difference. The highest toxicity is observed from complex G followed by complex F at 1μM. At 
3μM and 5μM, unlabeled chitosan and complexes A to E have similar effect on viability of SH-
SY5Y cells. Lower viabilities are observed for sialic acid complex F (~40.1% labeling) and 
complex G (~48% labeling) at these concentrations. Thus, at lower concentrations, it is observed 
that complex F and G consistently have higher toxicities compared to other labeled compounds.  
 
Figure 33: All sialic acid-chitosan complexes: Intrinsic toxicity compared at 1μM, 3μM, 
5μM 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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At lower concentrations from 1μM to 5μM, a broader trend is observed where complexes 
A to E fall in one group which show almost no toxicity and very less variability in between each 
other when the viabilities are compared. On the other hand, complex F and G consistently show 
higher toxicities at these concentrations, and hence this from the other group which is 
consistently different compared to complexes A to E at these concentrations. This analysis 
indicates that, at lower concentrations, chitosan and complexes A to E are non-toxic and show 
the same effect whereas complexes F and G show toxicity. 
 
Figure 34: All sialic acid-chitosan complexes: Intrinsic toxicity compared at 10μM, 20μM, 
30μM 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The comparison for higher concentrations is shown in the figure 34. At 10μM, 20μM and 
30μM unlabeled chitosan and labeling from ~7.8% to ~37.3% show similar effects on SH-SY5Y 
viability. This works in our favor because these complexes are not toxic to cells at even higher 
concentrations. Similar to the trend observed at lower concentrations, complex F (~80% 
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viability) and complex G (~60% to ~70% viability) show higher toxicities compared to all other 
compounds.  
At higher concentrations from 10μM to 30μM, unlabeled chitosan and complexes A to E 
show no difference from live control indicating that they are non-toxic at even higher 
concentrations. Similar grouping can be done for chitosan and complexes A to E (all p-values > 
0.05). Complexes F and G differ significantly from the above group (in all cases, p < 0.05). This 
is not the case for complexes F and G which show higher toxicities at all the concentrations 
compared to other labeled complexes. 
These results indicate that intrinsic toxicity is not observed from 7.8% to 37% of sialic 
acid labeling to chitosan. Studies have shown that ligand has higher affinity to receptor that is 
multivalent or high in labeling. So, the optimum between intrinsic toxicity to SH-SY5Y and 
higher labeling of chitosan by sialic acid can be seen from complex E (has ~37.3% labeling). 
3.4.2. Aβ Toxicity Attenuation Studies of Sialic Acid-Chitosan Complexes and 
Unlabeled Chitosan 
The results in this section show the statistical analysis for unlabeled chitosan, sialic acid 
chitosan complexes (A to G) with 50μM aggregated Aβ in the media. Aggregated Aβ is prepared 
according to established protocols and added to cells in culture and viability assessed after 24h. 
After addition of 50μM aggregated Aβ and no other experimental/test compound/complex, the 
normalized viability obtained is ~20%. This is indicated on the bar chart by point 0μM 
chitosan/complex concentration. This value represents the Aβ control value, so, if our complexes 
are effective, we should see an increase in viability after the addition of the synthesized 
complexes. 
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In each case, viability is represented as mean ± SD with four replicates. Statistical 
analysis was performed by ANOVA followed by Tukey’s test in SAS program. Statistically 
similar means are grouped together and indicated by the same letter or same groups of letters. 
Different letters across the graphs indicate statistically different means as indicated by Tukey’s 
test (at p < 0.05). The macro used to analyze this data is kindly provided by Saxton M.A [244].  
Statistical Analysis Done for Each Compound 
The next set of plots shows the statistical analysis for the Aβ studies with each 
complex/chitosan compared at all concentrations from 1μM to 30μM. Each complex is presented 
separately so that multiple comparisons can be done at all doses studied. 
 
Figure 35: Unlabeled chitosan = 0% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The results in figure 35 show the Aβ toxicity attenuation properties for unlabeled 
chitosan. It is evident that chitosan shows significant protection from Aβ at all concentrations 
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studied. Statistically highest protection can be seen from concentrations of 10μM to 30μM where 
there is almost ~75% cell viability compared to ~20% at Aβ control. As we have already 
discussed earlier, Aβ toxicity is a combination of the effects of electrostatic interactions, 
hydrophobic interactions and binding with sialic acids on cell membranes. Chitosan is a very 
strong polycation due to its protonation of amine groups as physiological pH. Thus, it is likely 
that the protection seen is due to the shielding of the cell from the harmful electrostatic 
interactions of Aβ. This effect of a polcation protection is not uncommon and many studies has 
demonstrated that a strong polycation shows protection from toxic Aβ [8, 26, 162]. In spite of the 
protection shown by chitosan, the mechanism of protection is not a viable option for long term 
effects. Although we see protection in 24h, this shielding of the cells may prove more 
detrimental later on. Additionally, electrostatic protection is unspecific. As we are sequestering 
the cell away, there is a possibility of inhibiting cellular functions due to unspecific electrostatic 
shielding. Our aim is to sequester the Aβ away from the cell (and not vice versa) and that is the 
precise reason why we need sialic acid labeling on chitosan even if chitosan shows protective 
behavior.  
From the above results of Aβ attenuation properties of complex A (figure 36), having 
~7.8% labeling, we see enhanced protection at all concentrations of complex A. The viabilities of 
SH-SY5Y are around ~50% compared to Aβ only at ~20% viability. As it is evident, complex A 
shows less protection than unlabeled chitosan. The most plausible explanation is that only a 
minimum labeling of the amine terminals in chitosan by sialic acid was sufficient to disrupt the 
electrostatic protective effect shown by chitosan.  
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Figure 36: Sialic acid-chitosan complex A = 7.8% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
 
Figure 37: Sialic acid-chitosan complex B = 14.1% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The results for Aβ toxicity attenuation by complex B having ~14.1% labeling is shown in 
the figure 37. Compared to Aβ control, addition of complex B shows around ~70% viability of 
131 
 
SH-SY5Y cells. All concentrations of complex B show similar protection from toxic Aβ. This is 
interesting because unlabeled chitosan was showing highest protection at higher concentrations. 
Also, complex B is showing higher protection compared to complex A at each concentration. 
From the results of Aβ toxicity studies with sialic acid complex C (~17.6% sialic acid 
labeling) we see excellent protective properties at all concentrations studied compared to Aβ 
control (refer figure 38). We see that the highest viability is ~80% and the range of protection is 
~72 to ~80%. 
 
Figure 38: Sialic acid-chitosan complex C = 17.6% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
Sialic acid complex D (~24.1% labeling) also shows significant protective properties 
compared to control. The data is presented in figure 39. The average protection shows around 
~80% SH-SY5Y cell survival after addition of complex to Aβ treated cells. 
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Figure 39: Sialic acid-chitosan complex D = 24.1% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
 
 
Figure 40: Sialic acid-chitosan complex E = 37.3% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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In figure 40, the Aβ toxicity attenuation properties of complex E (~37.3% labeling) are 
presented. At all concentrations tested, SH-SY5Y cells have significantly more survival 
compared to Aβ control cells. At concentration of 1μM we see around ~71% protection which 
increases to ~82% around 20μM. Thus, complex E gives a good balance between intrinsic 
toxicity and high Aβ attenuation properties. This also represents the transition seen in sialic acid 
labeling from the EDC saturation curve, which we believe is the transition to less flexibility of 
the molecule. This observation further supports our theory of a flexible backbone with sialic acid 
labeling, which will present the necessary clustering towards Aβ in solution and therefore 
attenuate toxicity of Aβ in vitro. 
 
Figure 41: Sialic acid-chitosan complex F = 40.7% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
Sialic acid-chitosan complex F (has ~40.7% labeling) also protects SH-SY5Y cells 
significantly from Aβ at all concentrations tested. See figure 41 for the result of complex F. 
However, now, this protection is around ~70 to ~75%, which is less compared to complex E 
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(~37% labeling) which shows around ~82% viability. Now, in spite of the degree of labeling 
increase, we start seeing a decrease in viability of SH-SY5Y cells. 
It can be seen that sialic acid complex G (see figure 42), with 48% labeling of chitosan, 
shows significant protection if compared to Aβ control (at 0µM complex concentration). Also, 
we do not see any significant difference between the protections offered at concentrations from 1 
to 30μM. However, the protection offered by complex G gives around ~60% viability, which is 
less than the protection from complex D, E. One likely explanation that fits the data is that our 
complex backbone is saturated with sialic acid labeling and hence, essentially, it is a bulky 
higher molecule weight molecule that shows sub-optimum sialic acid clustering towards Aβ that 
gives less protection compared to other less percentage labeled chitosan complexes. However, it 
is difficult to address the issue of molecule rigidity or even flexibility in a complex of sialic acid 
and chitosan. 
 
Figure 42: Sialic acid-chitosan complex G = 48% labeling: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference 
between the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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Statistical Analysis Done for Each Concentration 
In the next set of plots, each compound tested, unlabeled chitosan and the different sialic 
acid-chitosan complexes, are compared among each other at every concentration studied. We are 
interested to analyze which compound offers what level of protection at each concentration. 
Similar letters on adjacent concentration do not mean that those viabilities are statistically 
similar. Each complex is only compared at each concentration separately. The Aβ control at 0μM 
chitosan/complex concentration is given for better understanding of the results only. 
 
Figure 43: All sialic acid-chitosan complexes at 1μM, 3μM, 5μM: Aβ toxicity attenuation 
studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The results for all complexes at lower concentrations (i.e. 1µM, 3µM and 5µM) are given 
in figure 43. At a concentration of 1μM, complex D shows the highest protection followed by 
complex C. Chitosan also shows protection, but it is statistically lower compared to protection 
from sialic acid complexes C, D, E, F. Compared to unlabeled chitosan (0% labeling), we see a 
136 
 
sharp drop in viability from complex A. This supports our theory that even small percentage 
labeling of chitosan by sialic acid is sufficient to disrupt the electrostatic protection offered from 
electrostatic shielding. Increasing the labeling from ~7.8% to ~14.1% also increases the 
protection with maximum observed from complex D (~24.4% labeling). After that, as the 
labeling increases, the protection decreases which the least being observed from complex G. At 
5μM complexes C, D, E, F shows the highest protection from 50μM Aβ toxicity. Chitosan offers 
protection, albeit statistically lower compared to complexes C, D, E, F. Again, similar trend is 
observed where complex A shows much lower protection after minimum sialic acid labeling. 
The protection starts increasing with sialic acid labeling and reaches the highest for ~17.6 to 
~37.3% labeling of chitosan. After that, the protection decreases even after the percentage 
labeling (on complexes F and G) of chitosan increases. At 5μM, similar trends are observed with 
highest protection from 17.6 to 37.3% labeling. Chitosan also shows statistically lower 
protection compared to complexes C, D, E.  
Again, broader trends can be observed from the data, at lower concentrations (1µM, 
3µM, 5µM), we see complexes C (17.6%), D (24.2%) and E (37.3%) show no statistical 
difference between one another (p > 0.05) and offer the highest protection from Aβ. Thus, this is 
the highest protection group of complexes. The next highest protective group is unlabeled 
chitosan, complex B (14.1%) and F (40.7). At all concentrations, they are statistically similar 
protection from Aβ. Finally, complexes A (7.8%) and G (48%) show the least protection from 
Aβ. 
In figure 44, the analysis of Aβ studies at higher concentrations, 10μM, 20μM and 30μM 
of chitosan/complex concentration are presented (figure 44). Again, each compound is compared 
to other at a single concentration, with similar letter indicating no statistical difference between 
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the means of the groups. Again, means refer to the normalized viability values. At 10μM as well 
as 20μM, we see highest protection from unlabeled chitosan and complexes C, D, E (~17.6% to 
~37.3%). Only statistical difference is observed from complex A and G compared to the other 
compounds. This trend is also observed at lower concentrations. At 30μM, highest protection is 
observed from complex D, E (~24.5% and ~37% labeling) followed by complex C. Other 
complexes show lower protection.  
 
Figure 44: All sialic acid-chitosan complexes at 10μM, 20μM, 30μM: Aβ toxicity 
attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
At higher concentrations (10µM, 20µM, 30µM) again, the trend continues but with an 
exception. Here, the protection seen from chitosan is similar to the highest protection seen from 
sialic acid complexes C, D, E respectively. Earlier, we have seen that chitosan offer higher 
protection at higher concentration. Next highest protection is from group of complexes B and F 
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followed by the least shown by the group of complex A (in all cases, p < 0.05 compared to other 
groups) and complex G. 
3.4.3. Our Hypothesis for the Observed Results 
Looking at the entire picture, we see similar trends in all the data from Aβ toxicity 
attenuation studies. Below are the likely explanations from these trends. Chitosan being a strong 
polycation (amino groups become protonated at pH 7.0) shows protection due to strong 
electrostatic interactions with the negatively charged cell surface. This interaction of strong 
polycations with the cell surface is well documented in literature. Thus, we believe, chitosan is 
sequestering the cell away from Aβ and that is not the ideal effect/protection. At an extended 
period of time, this unspecific shielding of the cell will actually prove detrimental as this 
protection will start interfering with other intracellular processes of the cell (metabolites, 
hormones, amino acid transport) that depend on the electrostatic interactions with their host 
receptors. Also, as a therapeutic, it is unrealistic to protect each and every cell from the toxic 
effects of Aβ. Our next result also supports our argument. When we label chitosan with just 
~7.8% sialic acid, the protection shown by complex A decreases compared to unlabeled chitosan. 
This decreased protection is seen at all the concentrations of complex A. This may be due to the 
disruption of the protection seen from the electrostatic interactions. This is why Aβ kills more 
cells when complex A is added compared to unlabeled chitosan. Now, as the degree of labeling 
increases, higher viabilities in SH-SY5Y cells are observed. The highest protection can be seen 
for labeling from ~17.6% to ~37.6% of chitosan (i.e. complex C, D, E). This transition may 
indicate that the mechanism of protection has now shifted to our complex sequestering Aβ away 
from the cells. This is a strong possibility, as the biomimetics were synthesized with sialic acids 
labeled on chitosan. On the neuronal membrane, Aβ has affinity towards clustered sialic acids 
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and binds to them. If our complexes are showing toxicity attenuation, it is most likely that the 
protection is due to binding of Aβ to the complex. In the study with sialic acid labeled 
dendrimers, Aβ had binding affinities to the sialic acid dendrimers complexes on the order of 10-
7M to 10-9M[8, 26], which were at least an order of magnitude higher than Aβ binding to 
gangliosides (10-6M [8, 26, 156]) on neuronal membranes.  Looking at the data, it is difficult to 
predict whether one or multiple mimics bind to Aβ. Binding studies should be done to prove the 
exact mechanism of protection (e.g. to prove binding of complex with Aβ). This sequestering of 
the Aβ away from the cell is the mechanism of protection that we aimed for. It is difficult to 
elucidate whether the complex acts via competitive or non-competitive mechanism in attenuating 
the toxicity of Aβ. It is also possible that the complex binds with Aβ, and alters the rate at which 
Aβ interacts with the cells, and induces toxic effect. This may be the reason why we see 
protection at all concentrations studied but not complete protection (or 100% cell survival). 
Additionally, we do not see any type of dose-dependent behavior from the complexes. Thus, the 
mechanism of protection needs to be investigated in much more detail in later studies. 
Nevertheless, this type of protection also works in our favor, that if we can delay or alter the rate 
of toxicity of Aβ towards neurons, we can essentially aim to delay the age of onset or the time of 
progression of Alzheimer’s disease. 
This the reason why we need to investigate structural analogs of sialic acid, to understand 
which groups or subgroups of sialic acid are interacting with or have higher affinity towards Aβ. 
This information coupled with binding studies will prove beneficial from the therapeutic point of 
view. 
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3.4.4. Summary of the Statistical Analysis 
We used ANOVA followed by Tukey’s test (at p <0.05) for the statistical analysis of the 
toxicity studies. A macro was used to group statistically similar means together and assign letter 
groups to them. Thus, similar letters above the bar indicates no statistical difference between 
those means (as given by Tukey’s test at p < 0.05). Each mean the normalized viability at that 
concentration. This grouping allows for multiple comparisons between each and every data point 
on the bar chart. We studied a gradient of 1μM to 30μM of unlabeled chitosan and sialic acid-
chitosan complexes A (~7.8% labeling), B (~14.1%), C (~17.6%), D (~24.5%), E (~37.3%), F 
(~40.7%) to G (~48% labeling) on SH-SY5Y cells.  For the sake of understanding, we will treat 
1µM to 5µM as low concentrations and 10µM to 30µM as high concentrations of compounds for 
this study. The comparison between each data point and the p-values obtained by Tukey’s test 
are attached in the appendix. Also, the output from macro is included along with the means 
compared in the appendix. 
Intrinsic Toxicity Data 
Statistical Analysis Done for Each Compound 
It is observed that unlabeled chitosan does not show any significant toxicity at towards 
SH-SY5Y cells. The only case where difference was observed was at 10µM when compared to 
live control (p=0.0459). This is a significant improvement over other studies where the issue was 
high intrinsic backbone toxicity towards cultured cells [8, 26].  
For complexes A, B, C, D, E, from the statistical analysis, none (except, complex E at 
1µM) of the viabilities at any concentration of the complexes differ significantly from the live 
control (in all cases, p > 0.05). Thus, complexes A (~7.8%) to E (~37.3%) do not show any 
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intrinsic toxicity towards SH-SY5Y cells at all concentrations studied. This indicates that we 
were successful in developing complexes that were non-toxic towards cells. Again, this is an 
improvement over previous works where the issue was high intrinsic toxicity of the complexes 
towards cultured neurons[8, 26, 229]. 
Toxicity is observed starting with complex F (40.7%) and the viability range is around 
~80% at all concentrations of complex F. Viabilities at all concentrations of complex F, except 
5µM, differ significantly from the 0µM live control (in all cases p < 0.05). This follows the 
transition to saturation in sialic acid labeling found from the EDC chemistry curve for chitosan 
(see figure 20 in dissertation). Sialic acid complex G (~48%) is the most toxic and the range of 
viability of cells is around ~60% at higher concentrations of complex G (compared to live 
control, all viabilities for all concentrations are statistically different, in all cases, p <0.001).  
Statistical Analysis Done for Each Concentration 
At lower concentrations from 1μM to 5μM, a broader trend is observed where complexes 
A to E fall in one group which show almost no toxicity and very less variability in between each 
other when the viabilities are compared. On the other hand, complex F and G consistently show 
higher toxicities at these concentrations, and hence, these two complexes from the other group 
which is consistently more toxic compared to group of complexes A to E at lower 
concentrations. This analysis indicates that, at lower concentrations, chitosan and complexes A 
to E are non-toxic and show the same effect whereas complexes F and G show toxicity towards 
cells in culture. 
At higher concentrations from 10μM to 30μM, unlabeled chitosan and complexes A to E 
show no difference from live control indicating that they are non-toxic at even higher 
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concentrations. Similar grouping can be done for chitosan and complexes A to E (all p-values > 
0.05). Complexes F(40.7%) and G(48%) differ significantly from the above group (in all cases, p 
< 0.05) and show consistent higher toxicity at all concentrations. 
This trend of higher toxicity seen above 40% labeling indicates a likely link between 
higher labeling and higher toxicity or higher molecular weight of the complex and higher 
toxicity. 
Aβ Toxicity Attenuation Data 
In this study, along with a gradient of 1μM to 30μM of unlabeled chitosan and complexes 
A to G, a concentration of 50μM aggregated Aβ is added to the cells. The Aβ control value is 
~20% viability compared to live control (100%). 
Statistical Analysis Done for Each Compound 
When viabilities of cells treated with unlabeled chitosan or any of the complexes at any 
concentration (1µM to 30µM) is compared to the Aβ control viability, we see that in all cases the 
p-value is < 0.001. This indicates that all the cells treated with the sialic acid-chitosan complexes 
and unlabeled chitosan have statistically higher viabilities compared to Aβ control. This proves 
that all the complexes synthesized show Aβ toxicity attenuation properties. Unlabeled chitosan 
shows lower protection from 1µM till 5µM after which the protection increases and is 
statistically the same from 10µM to 30µM. 
In all the Aβ studies with sialic acid complexes, a typical dose dependent response is not 
seen. All the complexes, from 1µM to 30µM, do not show any statistical difference between 
each other for all doses. This indicates that the mechanism of protection is not just competitive 
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binding or electrostatic interactions. It is possible that due to strong polycations strength of 
chitosan, electrostatic dominance could be higher. It may be that the binding to Aβ is non-
competitive and the complex of (Aβ)-(sialic acid-chitosan) is still toxic to cells but at a reduced 
rate. A recent publication developed mathematical models to investigate this theory[162]. 
Statistical Analysis Done for Each Concentration 
Unlabeled chitosan shows significant protection from Aβ and the protection is higher at 
10μM to 30μM concentration of chitosan added with Aβ. A likely reason for this protection is 
that the chitosan polycation interacts with the negatively charged cell membrane. This effect of a 
polycation compound protecting cells is seen in other studies with toxic Aβ [8, 26, 162]. Further 
evidence supporting this hypothesis is that complex A (~7.8%) treated cells have ~50% viability 
compared to ~65% in chitosan. This indicates that minimum labeling of the chitosan cations 
were sufficient to disrupt the protection and hence complex A shows less protection. 
As the labeling increases, we see an increase in viabilities and the highest protection is 
seen from complexes C (~17.6%) to E (37.3%) labeling. From intrinsic toxicity studies, the 
toxicity of the complexes are non-existent up to complex E. Thus, the optimum between higher 
sialic acid labeling and non-toxicity can be seen from complex E. After that, the protection starts 
decreasing with the least from complex G. 
Again, broader trends can be observed from the data, at lower concentrations (1µM, 
3µM, 5µM), we see complexes C (17.6%), D (24.2%) and E (37.3%) show no statistical 
difference between one another (p > 0.05) and offer the highest protection from Aβ. Thus, this is 
the highest protection group of complexes. The next highest protective group is unlabeled 
chitosan, complex B (14.1%) and F (40.7). At all concentrations, they are statistically similar 
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protection from Aβ. Finally, complexes A (7.8%) and G (48%) show the least protection from 
Aβ. 
At higher concentrations (10µM, 20µM, 30µM) again, the trend continues but with an 
exception. Here, the protection seen from chitosan is similar to the highest protection seen from 
sialic acid complexes C, D, E respectively. Earlier, we have seen that chitosan offer higher 
protection at higher concentration. Next highest protection is from group of complexes B and F 
followed by the least shown by the group of complex A (in all cases, p < 0.05 compared to other 
groups) and complex G. 
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4. EVALUATION OF SIALIC ACID-ANALOGS FOR THE ATTENUATION OF 
AMYLOID-BETA TOXICITY 
 
4.1. Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder that affects 
almost 5.4 million individuals in the United States alone [245]. The brains of AD patients are 
characterized by the presence of extracellular senile plaques and neurofibrillary tangles. The 
senile plaques are composed primarily of the beta-amyloid peptide (Aβ), and it is hypothesized 
that Aβ plays a crucial role in the neurodegeneration associated with AD [84, 246]. To that end, 
agents which either sequester Aβ or interfere with Aβ interaction/binding to cells have been 
sought after as a means to reduce the pathological effects of Aβ [8, 26, 156, 247]. 
It is generally accepted that Aβ binding to extracellular membranes is a critical step in the 
development of amyloidoses, including AD. There is a variety of evidence suggesting that Aβ 
binds to cell membranes through interaction with cell surface gangliosides or glycoproteins 
containing sialic acids [21, 112-114, 134, 234]. Furthermore, numerous studies have shown that 
Aβ binding affinity is higher when multiple sialic acids are present, either because of clustering 
of the gangliosides or because of the degree of sialylation of the gangliosides[8, 26, 28, 113, 118, 
248]. There is increasing evidence which proves that Aβ binds to gangliosides on the neuronal 
membrane forming a ganglioside-Aβ moiety, which further acts as an endogenous seed for 
amyloid fibril formation [21, 23, 31, 32, 129, 236]. However, to design smart biomimetic 
therapeutics for AD, it is crucial to understand with groups or subgroups within the sialic acid 
have the highest affinity towards Aβ. It is this kind of information that this study will try to 
address.  In a related work, we synthesized membrane mimicking sialic acid conjugated chitosan 
complexes having different degrees of labeling of sialic acid and tested the ability of those 
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complexes to attenuate Aβ toxicity in a neuroblastoma cell line. It was observed that along with 
the labeled compounds, naïve chitosan showed similar protective properties [249].  Therefore, 
the evaluation of unique sialic acid-analogs may prove to be more effective in attenuating Aβ 
toxicity. 
In the current study, four unique biological sugars (see figure 10) were conjugated to 
chitosan via EDC chemistry and the interactions of these complexes with Aβ were studied in 
vitro. Chitosan was used as a backbone to benefit from its protective properties and the sugars 
selected are substructures of sialic acid (N-acetylneuraminic acid). This work addresses whether 
other biological sugars other than sialic acid are effective for use in the design of therapeutics for 
AD. Also, it will help to identify and isolate the unique –R group, or the substructure of sialic 
acid, which is most likely responsible for Aβ toxicity attenuation. By addressing how differences 
in sugar structure alter the binding affinity, mechanism of Aβ binding and differences in toxicity, 
we can contribute to develop a new class of therapeutics aimed at preventing Aβ toxicity 
associated with AD. 
4.2. Materials and Methods 
4.2.1. Materials 
Aβ(1-40).HCl peptide was purchased from Anaspec Inc. (San Jose, CA). Human 
neuroblastoma SH-SY5Y cells were purchased from ATCC (Manassas, VA). Cell dissociation 
buffer and other cell culture reagents were purchased from Gibco-Invitrogen (Grand Island, NY). 
Chitosan powder (MW~15000, DD~84%) was purchased from Polysciences Inc. (Warrington, 
PA). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (Sulfo-NHS) were purchased from Pierce Biotechnology (Rockford, 
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IL). The ultra-filtration membranes were purchased from Millipore (Billerica, MA). 
Tetrahydropyran-2-carboxylic acid (Pyran) was purchased from Ryan Scientific Inc. (Mt. 
Pleasant, SC). Human recombinant nerve growth factor (NGF-β) for SH-SY5Y, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Sialic acid (N-acetylneuraminic acid), 
Keto-deoxynonulosonic acid (KDN), D(+)-galacturonic acid (GA), Cyclohexanecarboxylic acid 
(CHC), chemicals and all other reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
4.2.2. Peptide Preparation 
Stock solutions of Aβ(1-40) at concentrations of 10mg/ml were prepared by dissolving 
the lyophilized peptide in anhydrous dimethyl sulfoxide (DMSO). After incubating for 30min to 
1h at 250C to ensure complete dissolution, the stock solutions of Aβ were diluted directly to their 
final concentration in sterile cell culture media and rotated at 250C for 24h prior to the addition 
to the cells. This method of preparing aggregated Aβ peptide has been found to yield Aβ fibrils 
and other aggregated species that were consistently toxic to cells in vitro at concentrations 
ranging from 20μM to 100μM [8, 249, 250]. 
4.2.3. Cell Culture 
Human neuroblastoma SH-SY5Y cells were cultured in a humidified 5% CO2/air 
incubator at 370C in Minimum Essential Media (MEM), supplemented with 10% (v/v) fetal 
bovine serum, 2.2mg/ml NaHCO3, 100U/ml penicillin, 100μg/ml streptomycin and 2.5μg/ml 
amphotericin B (fungizone). SH-SY5Y cells were NGF differentiated prior to use in toxicity 
studies by the addition of 20ng/ml of NGF-β to cells for 5-7 days in a 96 well plate. All the cells 
used in toxicity studies were under the 10th passage to ensure consistent metabolic response and 
stability. 
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4.2.4. Synthesis and Purification of Sugar-Chitosan Complexes 
KDN, GA, CHC, and Pyran were conjugated to chitosan using EDC chemistry following 
the manufacturer’s suggested protocol with minor modifications. Chitosan (MW~15000, 
DD~84%) at a concentration of 8mg/ml, was dissolved in 1X phosphate buffer solution (PBS) 
and 5% HCl solution. The molar concentrations of the conjugating sugars, EDC and Sulfo-NHS 
were based on the theoretical calculation of the number of primary amines calculated using the 
degree of deacetylation (DD) and the number of glucosamine units in chitosan. In an earlier 
related paper, the EDC chemistry for different percentage labeling of chitosan by sialic acid was 
presented [249].  From that data, saturation characteristics were observed for sialic acid labeling 
of chitosan for the chemistry using two-fold excess of sialic acid to primary amines in chitosan 
with significant decrease in complex toxicity and improved protective properties.  Additionally, 
the observed difference in labeling for four-fold chemistry and two-fold chemistry was nominal, 
with drastic decreased in protective properties for chemistries greater than four-fold excess[249]. 
Hence, for all subsequent sugars, four-fold excess of sugars were used compared to the number 
of primary amines in chitosan to ensure consistent degree of labeling. Thus, four fold excess 
molar concentration of each sugar was dissolved in 1ml of activation buffer (0.1M 2-
(morpholino)ethanesulfonic acid (MES) and 0.5M NaCl at pH 6.0). To this solution, 0.362mM 
EDC (10 fold molar excess to the moles of primary amines in chitosan) and 5mM of Sulfo-NHS 
was added. The pH was maintained in-between 5.0 to 6.0 by the use of 0.1M phosphate buffer. 
After rotating the reaction mixture for 30min at room temperature, 1.4μl of 2-mercaptoethanol 
was added to deactivate the unreacted EDC. After stirring the mixture for 2min, 1ml of chitosan 
solution (8mg/ml) was added and the pH increased again by using phosphate buffer. The total 
reaction mixture was allowed to rotate overnight. After 24h, sample was checked for 
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precipitation. If observed, the resulting precipitate was dissolved by the addition of 10% (v/v) of 
acetic acid solution before purification. 
To remove the unreacted sugars and EDC, the reaction volume was filtered using 10000 
NMWL cutoff Amicon Ultra centrifugal filter unit. At least six washes of de-ionized water were 
performed. This ensured that the final concentration of the free sugars in the reaction mixture 
was less than 6% of the total sugars (free and covalently bound to chitosan). After purification, 
the sugar-chitosan complexes were stored at minus 4oC for later use. 
4.2.5. Quantification of KDN Present in KDN-Chitosan Complex 
The extent of KDN labeling of chitosan was done by the method proposed by Aminoff [251]. 
The following reagents were used for the test: Solution A: 25mM periodic acid in 0.125N 
concentrated H2SO4 at pH 1.2, Solution B: 2% (w/v) solution of sodium arsenite in 0.5N HCl. 
Solution C: 0.1M solution of 2-thiobarbituric acid at pH 9.0 (adjusted with NaOH) in water. 
Solution D: 5% (v/v) solution of 12N HCl in acid butanol. Briefly, the method is as follows: In a 
0.5ml sample of complex, blank or pure chitosan, 0.25ml of periodate reagent (solution A) was 
added, tube shaken and incubated at 37oC for 30min. Then, 0.2ml of arsenite reagent (solution B) 
was added and the sample stirred until the yellow color of liberated iodine disappeared. 
Afterwards, 2ml of thiobarbituric acid reagent (solution C) was added, the tube mixed and 
incubated in a boiling water bath for 7.5min. After cooling to room temperature in an ice-bath, 
5ml of acid butanol (solution D) was added and the contents mixed vigorously. The sample was 
then centrifuged 2000g for 7min at 25oC, to extract the resulting chromophore into butanol. The 
absorbance of the butanol layer was measured at 549nm using a spectrophotometer within 1h.  
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The Aminoff procedure was performed with pure KDN solution to generate a standard 
curve. Pure chitosan solution was also tested to determine whether chitosan interfered with the 
color production. Assuming the KDN-chitosan complex was 100% labeled, a sample containing 
0.3mM of KDN concentration was hydrolyzed with 0.1N HCl at 80oC for 1h before the assay. 
This assumption of 100% labeling was necessary to ensure that the amount of KDN in the 
assayed “KDN-complex sample” would fall under the range of the Aminoff assay. Three or more 
independent measurements were taken in each case. 
4.2.6. Quantification of GA Present in GA-Chitosan Complex 
The quantification of GA present on chitosan was done by the carbazole-sulfuric acid 
method. The following reagents were made fresh each time. Solution E: 4M sulfamic acid-
potassium sulfamate at pH 1.6 (made by adding saturated KOH to sulfamic acid in water), 
Solution F: 0.1% (w/v) of carbazole in ethanol. The protocol is as follows: To a 0.4ml sample of 
complex, blank or chitosan, 40μl of sulfamic acid reagent (solution E) was added. Sample was 
mixed and 2.4ml of concentrated H2SO4 was carefully added. After the sample reached room 
temperature, 100μl of carbazole reagent (solution F) was added and mixed thoroughly. Then, the 
open tube was placed in a boiling water bath for 20min.  After cooling to room temperature, the 
absorbance of the sample was measured at 525nm using a spectrophotometer.  
The assay was run with pure GA for the standard curve. Also, pure chitosan was tested 
for the interference with the assay. Similar assumption about 100% GA labeling was made to 
ensure that the amount of GA in the “GA-complex” sample would fall within the range of the 
carbazole-sulfuric acid assay. Hydrolysis of the GA-complex was done with 0.1N HCl at 80oC 
for 1h prior to its use in the assay. Three or more independent readings were taken in each case. 
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4.2.7. MTT Toxicity Assay 
SH-SY5Y cells were plated at a density of 2x104 cells/well in 96 well plates and then 
NFG differentiated for 5-7 days. After differentiation, the cell medium was replaced with 
medium containing NGF to which the compounds to be tested was added, either Aβ, chitosan, 
sugar-chitosan complex or a combination of the above. Aggregated Aβ peptide at a concentration 
of 50μM was prepared as per the methods described earlier and fresh stock solutions were used 
each time. In all experiments, Aβ was added to the cells approximately 30min prior to the 
addition of chitosan or sugar-chitosan complexes. A gradient of chitosan and sugar-chitosan 
complexes from 0μM to 50μM was applied on the 96 well plates. The plates were incubated in a 
humidified 5% CO2/air incubator at 370C for 24h. The viability of the cells were determined by 
using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The media 
in the wells was then replaced with 100μl of culture media without phenol red. 10μl of freshly 
prepared MTT solution in culture media without phenol red (5mg/ml) was added to all the wells. 
After incubation for 2h, the wells were checked for purple crystals and the media replaced with 
200μl of DMSO. After 20min on the shaker, absorbance at 570nm and 690nm was measured 
using a standard microplate reader. Normalized viability values were obtained by dividing the 
percentage of viable cells in the sample by that of in the control samples with no Aβ or other 
compound added [249, 252, 253]. 
4.2.8. Verification of Sugar Conjugation to Chitosan 
The presence of sugars on chitosan was verified using Thermo Electron Nicolet 380 FTIR with 
Smart Orbit attachment (Thermo Electron Corporation, Waltham, WA). All of the sugar-chitosan 
complexes synthesized were lyophilized using a Labconco FreeZone 1 Liter Benchtop Freeze 
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Dry system. The lyophilized powders were stored at -40C for further use. For the FTIR of 
chitosan, lyophilized powder obtained directly from the manufacturer was used. 
4.2.9. Statistical Analysis 
We used ANOVA followed by the Tukey’s test for the complete analysis of the intrinsic 
toxicity and Aβ studies data. The results were significant if p < 0.05. Detailed statistical analysis 
of the results is presented after results and discussion section. The p-values for every comparison 
are given in the appendix. 
4.3. Results and Discussion 
4.3.1. Verification of Sugar Conjugation to Chitosan 
Multibounce FTIR was used to verify successful attachment of sialic acid-analog to the 
chitosan backbone.  The solid blue line in each FTIR spectra represents pure chitosan, while the 
dashed red line represents sugar chitosan complex.  Each Figure represents a different analog-
chitosan complex, Figure 45: Keto-deoxynonulosonic acid (KDN) complex and unlabeled 
chitosan, Figure 46: D(+)-galacturonic acid (GA) complex and unlabeled chitosan, Figure 47: 
Tetrahydropyran-2-carboxylic acid (Pyran) complex and unlabeled chitosan and Figure 48: 
Cyclohexanecarboxylic acid (CHC) complex and unlabeled chitosan, respectively.  The spectra 
indicate successful conjugation of chitosan by all complexes.  This is evident by the loss of the 
amine doublet at 3300 cm-1 due to amide bond formation, the presence of broad amide stretch at 
3300cm-1 and the appearance of strong double peaks at 1500 – 1700 cm-1 due to the formation of 
the amide linkage. Also, loss of carboxylic acid group which shows a peak around ~1800cm-1 is 
not seen indicating that the sugars have coupled to chitosan via formation of amide linkage. 
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Other spectral changes are unique to each compound and are used for qualitative verification 
only. 
The FTIR spectra verify that the conjugation was successful in the conjugation of sugars 
to chitosan. This is significant in that it validates the EDC technique for future works.  While 
FTIR is not quantitative as performed, the qualitative use of FTIR for this technique supports the 
assertion that the conjugation chemistry was successful. 
 
Figure 45: FTIR spectra for unlabeled chitosan (solid blue line) and KDN-chitosan 
complex (dashed red line) 
Spectral regions of interest: Increases at 1500 to 1700 cm-1 indicates formation of amide linkage, 
loss of doublet at 3300cm-1indicates disappearance of amines, broad stretch around 3300cm-1 
indicates presence of amide linkage 
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Figure 46: FTIR spectra for unlabeled chitosan (solid blue line) and GA-chitosan complex 
(dashed red line) 
 
Figure 47: FTIR spectra for unlabeled chitosan (solid blue line) and Pyran-chitosan 
complex (dashed red line) 
Spectral regions of interest: Increases at 1500 to 1700 cm-1 indicates formation of amide linkage, 
loss of doublet at 3300cm-1indicates disappearance of amines, broad stretch around 3300cm-1 
indicates presence of amide linkage 
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Figure 48: FTIR spectra for unlabeled chitosan (solid blue line) and CHC-chitosan 
complex (dashed red line) 
Spectral regions of interest: Increases at 1500 to 1700 cm-1 indicates formation of amide linkage, 
loss of doublet at 3300cm-1indicates disappearance of amines, broad stretch around 3300cm-1 
indicates presence of amide linkage 
4.3.2. Quantification of Sugar Conjugation to Chitosan 
The results for pure chitosan in the carbazole-sulfuric acid assay and Aminoff assay were 
negative implying that chitosan did not interfere with the assays (results not shown). Figure 49 
shows the results of the Aminoff assay for KDN quantification. Solid diamonds indicate the 
standard curve from pure KDN whereas an open crossmarker shows the quantification of KDN 
present in the 4-fold KDN-chitosan complex. Figure 50 represents the results for the GA 
quantification using the Carbazole-sulfuric acid assay. Solid diamonds represent the standard 
curve of pure GA and open cross marker indicates the sample of GA-chitosan complex 
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quantified. The standard curves are useful to calculate the degree of labeling of chitosan by KDN 
and GA. The degree of labeling was calculated by dividing the observed absorbance of the 
complex sample by the calculated absorbance of the sample with 100% labeling of the amine 
terminals of chitosan by the sugars assayed (based on the standard curve). The Warren assay was 
used to quantify sialic acid labeled to chitosan [241]. The percentage labeling of chitosan by 
sialic acid, KDN and GA by EDC chemistry is shown in Table 9. 
 
 
Figure 49: Results for the quantification of Keto-deoxynonulosonic acid (KDN)-chitosan 
complex 
The Aminoff assay is used for KDN quantification. Filled diamonds represent the standard curve 
from pure KDN assay. Open cross marker represents the KDN-complex quantified using 
Aminoff assay. Data is represented as mean ± SD, n=3 
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Table 9: Percentage labeling of chitosan by different sugars 
Complex [Sugar]:[Primary Amine] 
in reaction solution 
Degree of labeling of chitosan 
Sialic acid-chitosan[249] 4:1 40.70 ± 1.4 
KDN-chitosan 4:1 34.13 ± 2.23 
GA-chitosan 4:1 35.69 ± 1.766 
 
 
 
Figure 50: Results for quantification of Galacturonic acid (GA)-chitosan complex 
 The carbazole-sulfuric acid assay is used for GA quantification. Filled diamonds represent the 
standard curve from pure GA assay. Open cross marker indicates GA-complex quantified. Data 
is represented as mean ± SD, n=3. 
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The results from Table 9 indicate that all the three sugars quantified show around 35-40% 
labeling of chitosan when using the 4:1 ratio of sugars to primary amines in the reaction mixture. 
It is also evident that EDC chemistry can be used with sufficient accuracy to achieve the desired 
percentage labeling of chitosan primary amines. For the CHC and Pyran complexes, all attempts 
to verify the 35%-40% labeling have met with little to no success. Techniques that were 
attempted include colorimetric (total carbohydrate) assays, MALDI-TOF, NMR, Flame 
elemental analysis, HPLC-MS and XPS. Nevertheless, as seen from figure 10, the structures of 
CHC and Pyran attached to chitosan are very similar to that of GA that has been quantified. 
Thus, a reasonable assumption can be made that the remaining two complexes, CHC and Pyran, 
have around 35% to 40% labeling. 
4.3.3. Intrinsic Toxicity of Sugar Analogs and Sugar-Chitosan Complexes 
MTT was used to determine the toxicity of analogs and complexes developed. The 
intrinsic toxicity of pure sugar analogs on SH-SY5Y viability are shown in figure 51. The 
intrinsic toxicity of various sugar-chitosan complexes on SH-SY5Y viability are shown in figure 
52. The toxicity values were normalized to the live control containing no analog or complex.  
The bar at 0μM represents the live control with 100% cells. We observed that KDN and CHC 
display no toxicity, but, GA and Pyran exhibit toxicity towards SH-SY5Y cells.  The range of 
toxicity for analogs ranged from no apparent toxicity (CHC) to 40% toxicity (GA). From these 
results, it is difficult to predict the exact mechanism of toxicity as such sugars have not been 
studied with neuronal cultures to the best of our knowledge.  
The results of the toxicity studies for the complexes are in figure 52.  CHC, KDN, and 
GA showed very little change in toxicity from complexation.  However, Pyran showed a 
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significant improvement in toxicity upon complexation (decrease in toxicity). The complex 
toxicities are as follow:  CHC = Pyran < KDN < GA.  The range of complex toxicity ranged 
from no apparent toxicity (CHC and Pyran) to 40% toxicity (GA). More detailed explanation for 
these results is presented in the statistical analysis section. 
 
 
 
Figure 51: Toxicity of sugar-analogs exposed to SH-SY5Y  
Results of SH-SY5Y viability when exposed to pure sugar analogs. Figure contains results for 
pure compounds, Keto-deoxynonulosonic acid (diagonal bar), D(+)-galacturonic acid (open 
diamond bar), Tetrahydropyran-2-carboxylic acid (wide diagonal bar), Cyclohexanecarboxylic 
acid (horizontal bar). The 0µM concentration represents the normalized control viability with no 
analogs in the system. Error bars represent mean ±SD and n=4 in each case. 
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Figure 52: Toxicity of sugar-chitosan complexes exposed to SH-SY5Y 
Results of SH-SY5Y viability when exposed to sugar-complexes, Figure contains results for pure 
compounds, Keto-deoxynonulosonic acid (Blue bar), D(+)-galacturonic acid (red bar), 
Tetrahydropyran-2-carboxylic acid (orange bar), Cyclohexanecarboxylic acid (green bar). The 
0µM concentration represents the normalized control viability with no complex in the system. 
Error bars represent mean ±SD and n=4 in each case. 
When comparison is made to the control values, only CHC showed no intrinsic toxicity. 
This is significant in that the CHC and Pyran only differ by the presence of the oxygen 
substitution in the ring structure (present in Pyran), indicating that this oxygen substitution is an 
important factor in toxicity. Another comparison between GA and KDN shows a similar 
phenomenon with respect to the multi-OH tail. The loss of –OH tail found in KDN but not in GA 
leads to a significant increase in intrinsic toxicity. This indicates that such decoration of a 
therapeutic may be necessary to prevent toxicity and address its therapeutic effects.  The same 
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argument can be made for avoiding the oxygen substitution in the core ring. It is this type of 
structural impact information that we were attempting to understand and elucidate. 
 
Figure 53: Comparison of the intrinsic toxicity before and after complexation of sugars 
Figure (53.A.) show the results of the intrinsic toxicity of GA analog and GA-chitosan complex 
compared together. Figure (53.B.) shows the result of the intrinsic toxicity of Pyran analog and 
Pyran-chitosan complex compared together. Results show toxicity of Pyran analog is attenuated 
in the Pyran-chitosan complex after conjugation. 
162 
 
Another interesting observation was seen when the intrinsic toxicities of the sugar were 
compared before and after complexation. As seen from the figure below (figure 53), GA analog 
is toxic to SH-SY5Y cells and so is the GA-chitosan complex. This indicates that the toxicity of 
GA is maintained even after complexation. We have already tested chitosan toxicity and seen 
that chitosan is a non-toxic backbone. On the other hand, comparing the intrinsic toxicities of 
Pyran analog before and after complexation presents us with a different picture. It is observed 
that the viabilities of Pyran-complex are higher than the viabilities of Pyran-analog at all 
concentrations studied (in all cases, p < 0.05). As it is evident, Pyran analog was toxic to cells, 
whose toxicity is attenuated after complexation with chitosan backbone. This provides an 
important observation that the toxicity of compounds could be attenuated after complexation. 
This also indicates that we are not limited to just biological sugars and it is possible that a 
potentially know toxic compound can now the complexed and the toxicity attenuated.   
4.3.4. Efficacy of Sugar Analogs and Sugar-Chitosan Complexes to Attenuate Aβ 
Toxicity 
MTT was used to determine the ability of the compounds to attenuate Aβ toxicity of 
analogs and complexes developed.  The toxicity values were normalized to the control 
containing 50μM Aβ with no analog or complex. The dashed line represents the Aβ control value 
used for normalization. Figure 54 shows the ability of the pure sugar analogs to attenuate the 
toxicity of 50µM aggregated Aβ(40).  The analogs, as a group, showed no significant ability to 
attenuate Aβ toxicity.   The results of the attenuation studies for the sugar-chitosan complexes 
are in Figure 55. 
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Figure 54: Attenuation of 50μM Aβ toxicity by sugar analogs 
Results of SH-SY5Y viability when exposed to sugar analogs and 50µM Aβ in media.  Figure 
contains results for pure compounds, Keto-deoxynonulosonic acid (diagonal bar), D(+)-
galacturonic acid (open diamond bar), Tetrahydropyran-2-carboxylic acid (wide diagonal bar), 
Cyclohexanecarboxylic acid (horizontal bar). The 0µM analog concentration represents the 
viability with 50µM Aβ(40) and no analogs in the system. Error bars represent mean ±SD and 
n=4 in each case. 
The result from the KDN analog Aβ attenuation study indicate that, statistically, none of 
the viabilities at any concentrations studied are significantly different from the viability obtained 
from Aβ control (71% viability). This analysis indicates that KDN-analog does not have any 
protective effect on cells from the toxic Aβ.From the study of Pyran analog with 50μM Aβ, it 
can be seen that the viabilities of the wells treated with Pyran are statistically lower compared to 
the Aβ control. Similarly, at all concentration of GA analog studied, we see a decrease in 
viabilities and thus, no protection can be seen from Aβ. The toxicity towards the cells is most 
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likely the combination of aggregated Aβ and GA together. The addition of CHC analog at any 
concentration does not show any protective effect on SH-SY5Y viability. At all concentrations, 
the means were not statistically different from the Aβ control (in all cases, p > 0.05). 
 
Figure 55: Attenuation of 50μM Aβ toxicity by sugar-chitosan complexes 
Results of SH-SY5Y viability when exposed to sugar-complexes and 50µM Aβ in media.  Figure 
contains results for pure compounds, Keto-deoxynonulosonic acid (Blue bar), D(+)-galacturonic 
acid (red bar), Tetrahydropyran-2-carboxylic acid (orange bar), Cyclohexanecarboxylic acid 
(green bar), The 0µM chitosan/complex concentration represents the viability with 50µM Aβ(40) 
and no complex in the system. Error bars represent ±SD and n=4 in each case. 
It can be seen that the viability of SH-SY5Y cells increase after the addition of KDN-
chitosan complex which indicates protection from the complex. For the KDN-complex, the 
highest protection can be seen at concentrations of 5μM, 10μM and 20μM. Other concentrations 
also show protection and the protection increases and then decreases at higher concentrations. It 
is difficult to compare KDN-complex with sialic acid complex as there is a difference in the 
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values of Aβ control. GA-complex does not shown any protective properties at all concentrations 
studied. At 3μM to 10μM, the viabilities are not different than that of Aβ control and then the 
viability decreases. From the results of Pyran-chitosan complex shown in figure 38, we can see 
that the complex offers protection from Aβ. Highest protection can be seen from 5μM and 10μM 
concentration of the complex. CHC-complex offers no protection from Aβ and the viability 
decreases as the concentration of complex increases. None of the viabilities at any concentrations 
are statistically higher compared to those of the Aβ control. 
The two complexes, KDN-complex and Pyran-complex showed significant protective 
properties, while CHC and GA complexes showed no attenuation.  Levels of toxicity attenuation 
of complexes were as follows:  KDN > Pyran > GA = CHC.  The statistical analysis and detailed 
explanation for the results are in the statistical analysis section. 
Since, none of the sugar analogs by themselves showed any significant levels of Aβ 
toxicity attenuation, it supports the works of previous investigators including ourselves that the 
clustering of sugars in the cellular membrane plays a significant role in Aβ binding [8, 26, 162, 
235, 248, 249, 254]. However, the effectiveness of complexes is more pronounced. Using the 
same KDN/GA comparison from the previous section, the role the multi –OH tail plays in the 
binding of Aβ becomes clear.  While GA complex shows no protective properties, the KDN 
complex exhibits the highest levels of protection. Thus, we hypothesize that the multi-OH tail is 
that differentiating factor and this is the target that Aβ recognizes. Revisiting the Pyran/CHC 
comparison displays a contradictory result from the toxicity studies. While it is apparent that the 
oxygen substitution significantly increases toxicity, it also leads to a significant level of toxicity 
attenuation. These two pieces of information lead us to the belief that the oxygen ring 
substitution allows for either cellular or Aβ binding in a competitive, interfering manner. 
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However, the –OH tail shows similar crossreactivity with the cells (indicated by the level of 
neuroprotection and toxicity). In comparison of the two compounds, it is likely that oxygen 
structures are the best target for future therapeutic development. Again, increasing evidence 
suggests that lipid-protein interactions play a crucial role in the aggregation of various 
amyloidogenic proteins. Thus, such kind of structural information will be useful as a general 
guideline for researchers involved in further therapeutic development. Binding studies performed 
on complex will yield definite information on the affinity of Aβ to these –R groups. 
4.4. Statistical Analysis of Intrinsic Toxicity and Aβ Toxicity Attenuation Data 
Every value in the bar charts are expressed as normalized viabilities plotted on the y-axis 
with the test compound concentration on the x-axis. Each mean is calculated from the average of 
the viabilities observed from at least four replicates of each complex/compound concentration. 
For the statistical analysis, we are interested to understand how each compound performed at all 
the concentrations tested. Hence, for each compound, starting with 0μM concentration, the 
viabilities obtained at all concentrations is compared to one another. This is the statistical 
analysis for each compound. Similarly, at each concentration, we wanted to compare the 
viabilities obtained from all compounds tested at that concentration. This will allow us to 
compare the effects of different compounds at the same concentration. This is the statistical 
analysis for each concentration. 
As this is the case of multiple comparisons, we use ANOVA followed by a suitable post-
hoc test. For the post-hoc test Tukey’s Honest Significant Difference (HSD) test (shorthand 
“Tukey’s test” in later texts) is used. For every case or comparison, we are keeping the constant 
error rate of α equal to 0.05. All our measurements are done independently. The two important 
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assumptions of ANOVA test is that the population is normally distributed and the variances for 
all populations are equal. A sample dataset was run with the Levene’s test in SAS to check for 
equality of variances. The output from a sample dataset is presented in the appendix. The output 
from Levene’s test is attached in the Appendix. Thus, the homogeneity of the variance is verified 
and our data fits the requirements for ANOVA. However, this is a common assumptions in such 
kind of toxicity studies [8, 26, 162, 203, 229]. Furthermore, as a post hoc test, the analysis is 
done by Tukey’s test. The null hypothesis is that the two means (i.e. the means of the two 
normalized viabilities being compared) are equal. When the null hypothesis is rejected, post hoc 
comparisons are done using Tukey’s test to investigate further which groups/means differ. 
Tukey’s Test 
Tukey’s test allows for all possible pairwise tests and is based on the studentized range 
statistics. It also keeps a constant experimental error rate (α) for all possible pairwise tests. The 
sample size is equal in Tukey’s method. The differences between the means is calculated and 
compared to the critical value to see if the difference is significant. This critical value is the 
“Honestly Significant Difference” and that value is computed from SAS. The adjusted p-values 
for all pairwise comparisons are given in the output. 
Guide to Interpreting the Statistical Information on the Bar Chart 
Data for normalized viability is presented as mean ±SD of at least four replicates on the 
bar chart. The statistical significance of differences between groups was estimated by ANOVA. 
Further, any differences between the means group were analyzed by Tukey's test. Each graph 
shows the results and the statistical outputs obtained from the Tukey’s test. Different letters 
across the graphs indicate statistically-significant differences (p < 0.05); the same letter indicates 
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no statistical difference between those groups. This assignment of letters is done using a macro 
for SAS program developed by Saxton M.A [244]. This macro is run after the analysis by 
Tukey’s test. The macro groups similar means together and assigns a letter. The figure 56 shows 
the statistical analysis of the KDN-Chitosan complex intrinsic toxicity data. The table (Figure 
56.A.) in the figure below shows the output from the macro by the Tukey’s test (at p < 0.05). The 
means are sorted and ranked starting with the highest to the lowest mean. Each mean represents 
the normalized viability at each concentration of the compound studied. Using SAS, the 
calculation for the critical value of the “Least Significant Difference” (LSD) is done. When the 
analysis is done by the Tukey's test, SAS applies the adjustment on the LSD based on Tukey's 
test and the critical value is adjusted. The highest mean is assigned the letter group A. If the 
critical value of the LSD = “X”, then means below that differ by less than “X” do not differ 
statistically. This is represented by giving them a common letter so that they share a letter. 
 
Figure 56: Grouping example: Statistical analysis and graph for KDN-complex intrinsic 
toxicity data.  
The table (56.A.) represents the output using the macro which gives letter grouping for the 
means by Tukey’s test. The figure (56.B.) represents the normalized viabilities of KDN-complex 
plotted as a function of concentration. The similar letters above the bar indicate no statistical 
difference. Different letters indicates statistical difference at p<0.05 by Tukey’s test. 
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As seen from figure 56.A, the difference between the means of 0μM and 10μM is not 
statistically significant. This is illustrated by same letter A on 0µM and 10µM in Figure 56.B. 
Here, each mean is the normalized viability obtained at each concentration. Hence, they both are 
assigned the letter A. However, the mean of 10μM is less than that of the mean at 0μM. Hence, 
10μM is assigned A and B (i.e. “AB”). Thus, 10µM indicated by “AB” is statistically the same 
as all other means that have the letter A or B above them. Moving on after 10μM, the next 
highest mean is 3μM. SAS determined that the mean of 10μM and 3μM were statistically 
different (working with the adjusted critical value for Tukey’s) and hence it is assigned a 
separate letter group “BC”. Looking at the output data in the appendix, the comparison between 
the 0μM and 10μM gives the p-value of 0.0106 using Tukey’s test. Coming back to 3μM, the 
letter “B” and “C” is shared with 10μM, 5μM, 20μM, 30μM. All these means do not differ 
statistically even if one is lower in value than the other. Looking back at the table, the 
normalized viability at 0μM is statistically different from all the viabilities at all other 
concentrations. Thus, means that share a letter are not statistically different. Example: As seen 
from figure 1-A, the normalized viability at 3μM (indicated by letter group “BC” is statistically 
different from the normalized viabilities at 0μM (indicated by A), 40μM (indicated by D) and 
48μM (indicated by D) as given by Tukey’s test (at p < 0.05). The comparison between each data 
point and the p-values obtained by Tukey’s test are attached in the appendix. Also, the output 
from macro is included along with the means compared in the appendix. 
4.4.1. Intrinsic Toxicity of Pure Sugar Analogs 
The graphs below show the intrinsic toxicity studies for pure analogs KDN, GA, Pyran 
and CHC tested without Aβ in media. In all the graphs below, the normalized viability of 1 at 
0μM analog concentration represents the live control with 100% cells and no other 
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test/experimental compound added to them. Normalized viability values at each concentration 
were obtained by dividing the percentage of viable cells in the sample by that in the live control 
samples. The results are represented as the mean ±SD of at least four replicates. The statistical 
significance of differences between groups was estimated by ANOVA. Further, any differences 
between the means group were analyzed by Tukey's test. Different letters across the graphs 
indicate statistically-significant differences (p < 0.05); the same letter indicates no statistical 
difference between those groups. As an example, in the plot for KDN analog intrinsic toxicity, 
the statistical significance of the live control at 0μM indicated by letter (A). All other 
concentrations which have the letter (A) above them are not statistically significant from one 
another. Thus, in this case, 3μM, 5μM 10μM and 48μM are not statistically different from 0μM 
as all those concentrations have the letter A above each of those concentrations. However, 0μM 
point is statistically different (given by Tukey’s test with p < 0.05) from viabilities at 20μM, 
30μM and 40μM (as they do not contain the letter A). Two or more groups of letters (e.g. AB) 
mean that those means are statistically similar to group A as well as B (although A only and B 
only groups are statistically different from one another). A macro was used in SAS programming 
to convert similar means into groups of letters using the Tukey’s test[244]. In all cases, each 
concentration group is compared to each other. The comparison between each data point and the 
p-values obtained by Tukey’s test are attached in the appendix. Also, the output from macro is 
included along with the means compared in the appendix. 
Statistical Analysis Done for Each Compound  
Looking at figure 57, it can be seen that KDN analogs kills no more than 12% cells at all 
concentrations shows compared to control. This low toxicity from KDN is expected as KDN is a 
biological sugar and is a member of the sialic acid family of compounds. Additionally, KDN is 
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also found throughout the human body. The viability is higher at lower concentrations (from 
3μM to 10μM) whereas it decreases from 20μM to 48μM concentration of pure KDN. 
 
Figure 57: KDN analog- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
From the figure 58, cells treated with GA analog at all concentrations show around ~60% 
viability compared to live control. The exact mode of toxicity cannot be asserted from the 
performed experiments. While GA has not been studied specifically with respect to a neuronal 
cell culture to the best of our knowledge, it is difficult to ascertain the exact mode of toxicity 
from this data. One interesting possibility is the significant difference between KDN and GA 
with respect to the multi-OH tail. Thus, the increased toxicity could be most likely attributed to 
the loss of multi-OH tail in GA.  
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Figure 58: GA analog- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
 
Figure 59: Pyran analog- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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From the intrinsic toxicity of Pyran analog (figure 59), we can see that there is a drop in 
viability after addition of pure Pyran at all concentrations studied. The range of viability 
observed is from ~70% to 80%. Lowest viability is obtained at 3μM whereas highest is seen at 
20μM. Again, the interaction of Pyran structure with respect to neuronal culture has not been 
investigated yet. One possibility is the significant similarity is the presence of oxygen 
substitution between the GA structure and Pyran structure (see figure 10). Also, since CHC does 
not show any toxicity at all concentrations, the only difference being the absence of oxygen 
substitution, the Pyran toxicity can be attributed to the oxygen substitution in the ring structure. 
 
Figure 60: CHC analog- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The addition of pure CHC analog (figure 60) shows no toxicity towards SH-SY5Y cell 
culture at all concentrations studied. Again revisiting the plausible structural difference-activity 
explanation, the only difference in structure between CHC and Pyran is the oxygen substitution 
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in the ring structure. As all other conditions are the same between the two experiments, one 
possibility for lower viability in Pyran analog study could be that oxygen substitution in the ring 
structure contributes to the intrinsic toxicity. 
Statistical analysis done for each concentration 
The next sets of figures (figures 61 and 62) give the statistical comparison between the 
four sugar analogs at a particular concentration. Thus, the four analogs are compared at 
concentrations from 3μM to 48μM. 
 
Figure 61: All sugar analogs at 3μM, 5μM, 10μM- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The figure 61 shows the statistical analysis for pure analogs KDN, GA, Pyran and CHC 
at the concentration of 3μM, 5μM and 10μM. Each sugar analog is compared among themselves 
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at each concentration studied by ANOVA followed by Tukey’s test (at p < 0.05). Analogs are not 
compared between two different concentrations although the graph output shows similar letters 
between adjacent concentrations. Means that do not share the same letters above the error bars 
are statistically different as given by Tukey’s test (p < 0.05) at that particular concentration only. 
At least four replicates were done for each concentration for each compound tested. At 3μM, 
CHC and KDN show no toxicity whereas higher toxicity is observed from Pyran (~67% 
viability) and GA (64%. viability). Such a trend is also seen in the other concentrations 5μM and 
10μM. The results indicate that at lower concentrations, CHC and KDN shows greater than 95% 
viability whereas at the same concentrations, Pyran (less than 74% viability) and GA (less than 
64% viability) show decreased viabilities. 
 
Figure 62: All sugar analogs at 20μM, 30μM, 40μM, 48μM- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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The sugar analogs were also tested for their intrinsic toxicity at higher concentrations 
(20μM, 30μM, 40μM and 48μM) and the results are given in figure 62. Each sugar analog is 
compared among themselves at each concentration studied by ANOVA followed by Tukey’s test 
(with p < 0.05). Means that do not share the same letters above error bars are statistically 
different as given by Tukey’s test (p < 0.05). Similar observations can be seen as compared to 
the results from lower concentrations. Cells treated with pure GA shows lower viability than the 
cells treated with all other pure analogs. Thus, among the four analogs tested, GA shows the 
highest intrinsic toxicity. However, at this point, we are interested in testing the toxicity of each 
complex after conjugation with chitosan. So, since GA is the best structural analog we could find 
that fit our criteria, GA is continued for further Aβ attenuation studies. 
4.4.2. Intrinsic Toxicity of Sugar-Chitosan Complexes 
The graphs show the statistical analysis for the intrinsic toxicity results of KDN-Chitosan 
complex, GA-Chitosan complex, Pyran-Chitosan complex and CHC-Chitosan complex. In all 
the below graphs, the normalized viability of 1 at 0μM represents the 100% live cells and no 
other test/experimental compound added to them. Normalized viabilities are obtained by dividing 
the viable cells in a sample with that of the live control (untreated cells). In each case, viability is 
represented as mean ± SD with four replicates. Statistical analysis was performed by ANOVA 
followed by Tukey’s test in SAS program. Similar means are grouped together and indicated by 
the same letter or same groups of letters. Different letters across the graphs indicates statistically 
different means as indicated by Tukey’s (at p < 0.05) test. The macro used to analyze this data is 
provided by Saxton M.A [244]. The individual p-values are provided in the appendix along with 
the output for the macro.  
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Statistical Analysis Done for Each Compound 
The graphs of the intrinsic toxicity of each sugar-chitosan complex show statistical 
comparisons between all concentrations for that particular complex studied. Each complex is 
presented separately so that multiple comparisons can be done at all the doses. 
 
Figure 63: KDN-chitosan complex- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
Figure 63 shows the intrinsic toxicity of KDN-Chitosan complex. At concentrations from 
3μM to 10μM, we see viability in the range of ~90%. At higher concentrations, the viability 
decreases with the lowest seen at 40μM and 48μM, with the lowest being ~80% viability. Of 
note is the fact that, KDN sugar has the highest molecular weight as compared to the other sugars 
studied in this work. This seems to indicate that there is a possible link between high molecular 
weight of the complex and higher toxicity. Also, there is likely a link between higher toxicity 
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observed at higher concentration of these high M.W complexes applied to cells in culture [8, 
255].  
In the result of GA-Chitosan complex (refer to figure 64), we see viability in the range of 
~70% at lower concentrations (3μM to 10μM) and around ~60% viability towards 48μM 
concentration. However, all the viabilities are statistically different compared to live control. 
Comparing to the KDN structure, the only significant difference between the two complexes is 
the multi –OH tail in KDN. From the analog data and complex data, we can see that GA analog 
and GA-Chitosan complex exhibit higher toxicities compared to KDN analog and KDN-
Chitosan complex. Also, there is no change in toxicity after complexation. This also supports our 
earlier explanation that the loss of multi –OH tail can be the possible cause of intrinsic toxicity 
towards neuronal cells in culture. 
 
Figure 64: GA-chitosan complex- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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Figure 65: Pyran-chitosan complex- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
Figure 65 shows the intrinsic toxicity of Pyran-Chitosan complex. Means are compared 
between all the concentrations applied in the work. We see that Pyran-complex is non-toxic 
(lowest viability is ~92% ± 0.05% at 10μM) at all the concentrations applied, as it is evident that 
none of the means at any concentration are statistically different compared to control. This result 
is significant as Pyran-analog by itself showed viability in the range of ~70% to ~80%. This 
increase in viability seen in Pyran-chitosan indicates that the toxicity of the biological sugar is 
attenuated after complexation. This result indicates that it is possible to evaluate and consider 
compounds that are known to be potentially toxic as their toxicity after complexation could be 
attenuated.  
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Figure 66: CHC-chitosan complex- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
From the figure 66 showing the intrinsic toxicity of CHC-Chitosan complex, we see that 
from concentrations of 3μM to 30μM, the normalized viabilities are not statistically different 
compared to control. This indicates that the CHC complex shows no significant (statistically) 
toxicity at concentration up to 30μM. At higher concentrations, the viability decrease to ~82% at 
48μM. 
Statistical Analysis Done for Each Concentration 
The next set of figures show the comparison between the sugar-chitosan complexes at 
each individual concentration studied. Thus, the effects of the four complexes are compared at 
each concentration from 3μM to 48μM. 
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Figure 67: All sugar-chitosan complexes at 3μM, 5μM, 10μM- Intrinsic toxicity studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
At viability at 0μM represents the live control (untreated cells) and is provided for 
comparison purposes only. From the figure 67, at 3μM, CHC-complex shows no toxicity, 
whereas almost 30% toxicity is observed from GA-complex. Similar trend is seen at the other 
concentrations of 5μM and 10μM. Thus, at all these concentrations, the range of toxicity (from 
highest to lowest toxic) is as follows: GA-complex > KDN-complex = Pyran-complex > CHC-
complex.  
At higher concentrations (20μM to 48μM), the results show that Pyran-complex show no 
toxicity compared to control at all concentrations studied (refer figure 68). At 20μM and 30μM, 
statistically, the order of toxicities (from highest to lowest toxicity) is as follows: GA-complex > 
KDN-complex > CHC-complex = Pyran-complex. At concentrations of 40μM and 48μM, 
statistically, order of toxicities is: GA-complex > KDN-complex = CHC-complex > Pyran-
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complex. It is interesting to note that at all concentrations (3μM to 48μM), GA-complex always 
shows higher toxicity compared to all other complexes.  
 
Figure 68: All sugar-chitosan complexes at 20μM, 30μM, 40μM, 48μM- Intrinsic toxicity 
studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
4.4.3. Aβ Toxicity Attenuation Properties of Pure Sugar Analogs  
The results below show the Aβ toxicity attenuation properties of the pure sugar analogs. 
The concentration of Aβ studied is 50μM. In all the graphs, the normalized viability at 0μM 
analog concentration is the Aβ control value, i.e. viable cells after treatment with only 50μM 
aggregated Aβ with no analog/sugar added. For this study, Aβ control viability was found to be 
71% (± 0.01%).  In all cases, a gradient of pure analogs from 3μM to 48μM was applied and four 
replicates were done for each concentration. Values on graph are represented as means ± SD of 
the normalized viability values. The statistical analysis between the groups was done by 
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ANOVA followed by Tukey’s test in SAS program. Different letters above each bar indicates 
statistically significant difference between the means as given by Tukey’s test at p < 0.05. Same 
letter above the bar chart indicates no statistical difference between those means. To get the 
grouping of letters for similar means, a macro developed by Saxton M.A. was used in SAS [244]. 
Statistical Analysis Done for Each Compound 
 
Figure 69: KDN analog: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The result from the KDN analog Aβ attenuation study (Figure 69) indicate that, 
statistically, none of the viabilities at any concentrations studied are significantly different from 
the viability obtained from Aβ control (71% viability). This analysis indicates that KDN-analog 
does not have any protective effect on cells from the toxic Aβ (figure 69). 
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Figure 70: GA analog: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
 
Similarly, at all concentration of GA analog studied, we see a decrease in viabilities and 
thus, no protection can be seen from Aβ. The toxicity towards the cells is most likely the 
combination of aggregated Aβ and GA together (figure 70).  
From the study of Pyran analog with 50μM Aβ (figure 71), it can be seen that the 
viabilities of the wells treated with Pyran are statistically lower compared to the Aβ control. In 
between 3μM and 48μM, Pyran monomer does not show any type of dose-response relationship. 
The result also indicates that Pyran monomer by itself does not show any Aβ attenuation 
properties. 
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Figure 71: Pyran analog: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
 
Figure 72: CHC analog: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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The addition of CHC analog at any concentration does not show any protective effect on 
SH-SY5Y viability (figure 72). At all concentrations, the means were not statistically different 
from the Aβ control. 
Statistical Analysis Done for Each Concentration 
The following plots show the statistical analysis done for each concentration with 
comparison among the four different sugars studied (figures 73, 74). Thus, here, we are 
comparing each sugar at a particular concentration. Significant here is that none of the sugar 
analogs show any protective effects from toxic Aβ. These results indicates that clustering of the 
sugars in the neuronal membrane play a critical role in Aβ toxicity attenuation and that free 
monomer in solution is insufficient to achieve the necessary clustering. Also, this result justifies 
the need of a suitable backbone that can allow the sugars to effectively cluster.  
 
Figure 73: All sugar analogs at 3μM, 5μM, 10μM: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
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Figure 74: All sugar analogs at 20μM, 30μM, 40μM, 48μM: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
4.4.4. Aβ Toxicity Attenuation Properties of the Sugar-Chitosan Complexes 
In the following section, all the sugars are conjugated with a chitosan backbone and their 
ability to attenuate the toxicity of 50μM aggregated Aβ is investigated. Aggregated Aβ is 
prepared according to established protocols and added to cells in culture and viability assessed 
after 24h. After addition of 50μM aggregated Aβ and no other experimental/test 
compound/complex, the normalized viability obtained around ~71%. This is indicated on the 
plots by the bar chart at point 0μM chitosan/complex concentration. This value represents the Aβ 
control value, so, if the complexes are effective in protection, an increase in viability should be 
observed after the addition of the synthesized complexes. 
In each case, viability is represented as mean ± SD with four replicates. Statistical 
analysis was performed by ANOVA followed by Tukey’s test in SAS program. Statistically 
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similar means are grouped together and indicated by the same letter or same groups of letters. 
Different letters across the graphs indicates statistically different means as indicated by Tukey’s 
(at p < 0.05) test. The macro used to analyze this data is provided by Saxton M.A [244]. 
Statistical Analysis Done for Each Compound 
The next set of plots shows the statistical analysis for the Aβ studies with each sugar- 
complex or unlabeled chitosan compared at all concentrations from 1μM to 30μM. Each 
complex is plotted separately so that multiple comparisons can be done at all doses studied. 
 
Figure 75: KDN-chitosan complex: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
The above plot, figure 75, shows the result for the Aβ toxicity attenuation by KDN-
chitosan complex. KDN differs from sialic acid at the C-5 position. It can be seen that the 
viability of SH-SY5Y cells increase after the addition of KDN-chitosan complex which indicates 
189 
 
protection from the complex. For the KDN-complex, the highest protection can be seen at 
concentrations of 5μM, 10μM and 20μM. Other concentrations also show protection and the 
protection increases and then decreases at higher concentrations. It is difficult to compare KDN-
complex with sialic acid complex as there is a difference in the values of Aβ control. Also, it 
should be noted that KDN is just a substructure of sialic acid, so it is likely that Aβ only 
recognizes a part of the substructure which gives the toxicity attenuation from KDN-complex. 
The difference between GA-complex and KDN-complex is the presence of the multi-OH tail. So, 
the most likely explanation for the protection shown by KDN-complex and none shown by GA-
complex is that the multi-OH chain is involved in Aβ interactions.  
 
Figure 76: GA-chitosan complex: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
From the above result, figure 76, it can be seen that GA-complex does not shown any 
protective properties at all concentrations studied. At 3μM to 10μM, the viabilities are not 
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different than that of Aβ control and then the viability decreases. The difference in the structure 
of KDN and GA is the multi –OH tail. As no protection from GA-complex can be seen, it is 
likely that the loss of –OH tail is the reason for loss of protection. Thus, it is plausible that the 
multi –OH tail of sialic acid is the target that Aβ recognizes.  
 
Figure 77: Pyran-chitosan complex: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
From the results of Pyran-chitosan complex shown in figure 77, we can see that the 
complex offers protection from Aβ. Highest protection can be seen from 5μM and 10μM 
concentration of the complex. The Pyran structure consists of the oxygen substitution in the ring 
structure. The results indicate the possible role of Pyran substitution in Aβ interactions. Such 
type of structural information will be useful in the development of a therapeutic based on 
polysaccharide structures. 
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Figure 78: CHC-chitosan complex: Aβ toxicity attenuation studies 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
From the above results, figure 78, we see that CHC-complex offers no protection from 
Aβ and the viability decreases as the concentration of complex increases. None of the viabilities 
at any concentrations are statistically higher compared to those of the Aβ control. Again, the 
difference between Pyran-complex and CHC-complex is the presence of oxygen substitution. 
Making the same argument, it can be seen that the ring structure does not contribute to Aβ 
toxicity attenuation; whereas the same ring structure with the presence of oxygen substitution 
contributes to Aβ toxicity attenuation. This indicates a possible role of oxygenated saccharide 
structure in Aβ showing affinity towards cell surface sialic acids. Such type of comparisons can 
be made as the backbone chitosan has approximately similar labeling for all sugars. 
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Statistical Analysis Done for Each Concentration 
In this section, each compound tested, the different sugar-chitosan complexes are 
compared among each other at every concentration studied. We are interested to analyze which 
complex offers what level of protection at every concentration applied to the plate with 50μM 
aggregated Aβ added to them. Similar letters on adjacent concentration do not mean that those 
viabilities are statistically similar. Each complex is only compared at each concentration 
separately. The Aβ control at 0μM complex concentration is given for understanding only. 
 
Figure 79: All sugar-chitosan complexes at 3μM, 5μM, 10μM: Aβ toxicity attenuation study 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
In the above plot, each complex (with Aβ media) is compared at 3μM, 5μM and 10μM 
separately (refer figure 79). At 3μM, it can be seen that the viability is higher from KDN-
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complex and Pyran-complex although all the complexes do not differ statistically. But, compared 
to control, KDN-complex shows higher viabilities followed by Pyran-complex. Moving on to 
5μM, we can see that statistically highest viabilities are seen from KDN-complex and Pyran 
complex compared to GA-complex and CHC-complex. This difference in viabilities between the 
two groups is even more pronounced at 10μM. Also, viability with GA-complex did not decrease 
immediately at lower concentrations, which can most likely be attributed to the oxygen 
substitution in GA. Our results indicate that, at all concentrations from 3μM to 10μM, KDN-
complex followed by Pyran-complex show Aβ toxicity attenuation properties.     
 
Figure 80: All sugar-chitosan complexes at 20μM, 30μM, 40μM, 48μM: Aβ toxicity 
attenuation study 
Similar letters or group of letters above the bar chart indicates no statistical difference between 
the normalized viabilities of those concentrations as given by Tukey’s test at p<0.05 
In figure 80, the viabilities of each complex are compared among themselves at 20μM, 
30μM, 40μM and 48μM. Starting at 20μM, we see that KDN-complex shows the highest 
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protection followed by Pyran-complex. Lower viability is seen from GA-complex and CHC-
complex. At 30μM, KDN-complex and Pyran-complex show toxicity attenuation whereas loss of 
viabilities can be seen from GA-complex and CHC-complex. Similar trends are seen at 40μM 
and 48μM. Overall, the results show that KDN-complex and Pyran-complex show higher 
viabilities at all concentration studied compared to GA-complex and CHC-complex. 
Even if we do not expect the same level of protection as sialic acid-labeled chitosan, the 
results show the importance of the structures or –R groups of sialic acid that contribute to Aβ 
toxicity attenuation. This has significance with respect to the understanding of the Aβ-sialic acid 
interaction that takes place in-vivo. The information from such structure-activity experiments 
will aid in the development of smarter therapeutics since we know which groups contribute to 
intrinsic toxicity and which groups are important in Aβ toxicity attenuation.  
4.4.5. Summary of the Statistical Analysis 
We used ANOVA followed by Tukey’s test (at p <0.05) for the statistical analysis of the 
toxicity studies. A macro was used to group statistically similar means together and assign letter 
groups to them. Thus, similar letters above the bar indicates no statistical difference between 
those means (as given by Tukey’s test at p < 0.05). This allows for multiple comparisons 
between each and every data point on the bar chart. We studied a gradient of 3μM to 48μM of 
the pure sugar analogs or the sugar-chitosan complexes on SH-SY5Y cells. For the sake of 
understanding, we will treat 3µM to 10µM as low concentrations and 20µM to 48µM as high 
concentrations of compound in this study. The comparison between each data point and the p-
values obtained by Tukey’s test are attached in the appendix. Also, the output from macro is 
included along with the means compared in the appendix. 
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Intrinsic Toxicity of Pure Sugar Analogs 
Statistical Analysis Done for Each Compound 
KDN analog shows no statistical difference from live control (p  > 0.05) at lower 
concentrations whereas the viability decreases at higher concentrations of KDN compared to live 
control (p < 0.05). Around ~90% cell survival is seen at higher concentrations of pure KDN. 
In case of GA analog and Pyran analog, all the viabilities at all concentrations tested are 
statistically less compared to live control (in all cases, p < 0.05). This indicates that pure GA and 
pure pyran are toxic to cells at all concentrations. The exact mode of toxicity cannot be discerned 
as such compounds have not been evaluated in a system of neuronal cultures to be best of our 
knowledge. 
For CHC analog, none of the viabilities at any concentration are different from live 
control (in all cases, p >0.05). This indicates that CHC is a non-toxic compound. 
Statistical Analysis Done for Each Concentration 
At lower concentrations, two distinct groups can be seen. Pure KDN and pure CHC show 
no toxicity and the highest viabilities. There is no statistical difference in their viabilities except 
at 3µM concentration (in all other cases, p > 0.05). In the second group, pure GA and pure Pyran 
consistently show the lower viabilities. Thus, compared to the KDN-CHC group, all viabilities of 
GA and Pyran are statistically different (in all cases, p < 0.05).  
At higher concentrations, similar groups can be observed with KDN and CHC showing 
highest viabilities. In this, CHC is the least toxic. The second group, GA and Pyran analogs, 
show lower viabilities at higher concentrations. In all cases, the viabilities of CHC and KDN are 
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statistically higher compared to the GA and Pyran group (p < 0.05). The toxicity of pure GA is 
the highest at all concentrations compared to other sugars. 
Intrinsic Toxicity of Sugar-Chitosan Complexes 
Statistical Analysis Done for Each Compound 
At concentrations from 3μM to 10μM, for KDN-complex, we see viability in the range of 
~90%. At higher concentrations, the viability decreases with the lowest seen at 40μM and 48μM. 
This seems to indicate that there is a possible link between high molecular weight of the complex 
and higher toxicity. Also, it is possible that higher toxicity is observed at higher concentration 
due to the higher molecular wright of these complexes. 
GA-complex is consistently toxic to the cells with viabilities in the range of ~70% to 
60%. Compared to live control, the viabilities at all concentrations of GA-complex are lower (in 
all cases, p < 0.0001). Again, at higher concentration, higher toxicity is seen from GA-complex. 
Interestingly, after complexation, the toxicity of Pyran analog is attenuated. The 
viabilities at all concentrations of Pyran-complex are statistically similar to that of live control 
(in all cases, p > 0.05). This indicates that the toxicity of a potentially toxic sugar could be 
attenuated after its complexation.  
CHC-chitosan complex is non-toxic at concentrations from 3 to 30µM, whereas toxicity 
is seen at the remaining concentrations. Again, this can be the result of a high MW complex 
showing toxicity at higher concentrations. 
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Statistical Analysis Done for Each Concentration 
At lower concentrations, 3µM, 5µM and 10µM, the range of toxicity (from highest to 
lowest toxic) is as follows: GA-complex > KDN-complex = Pyran-complex > CHC-complex. At 
these concentrations, the viability shown by GA-complex at all concentrations is the lowest 
compared to the rest of the complexes (in all cases, p < 0.05). 
At higher concentrations (20μM to 48μM), the results show that Pyran-complex show no 
toxicity compared to control at all concentrations studied. At 20μM and 30μM, statistically, the 
order of toxicities (from highest to lowest toxicity) is as follows: GA-complex > KDN-complex 
> CHC-complex = Pyran-complex. At concentrations of 40μM and 48μM, statistically, order of 
toxicities is: GA-complex > KDN-complex = CHC-complex > Pyran-complex. It is interesting to 
note that at all concentrations (3μM to 48μM), GA-complex always shows higher toxicity 
compared to all other complexes (in all cases, p < 0.05).  
Aβ Attenuation Properties of Pure Sugar Analogs  
In this study, along with a gradient of 3μM to 48μM of analogs, a concentration of 50μM 
aggregated Aβ is added to the cells. The Aβ control value is ~71% viability compared to live 
control (100%). 
Statistical Analysis Done for Each Compound 
From the analysis, none of the pure sugars at any concentration show viabilities that are 
statistically higher compared to the Aβ control. This proves that none of the sugars by 
themselves show any Aβ toxicity attenuation properties. These results indicates that clustering of 
the sugars in the neuronal membrane play a critical role in Aβ toxicity attenuation and that free 
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monomer in solution is insufficient to achieve the necessary clustering. Also, this result justifies 
the need of a suitable backbone that can allow the sugars to effectively cluster. 
Statistical Analysis Done for Each Concentration 
None of the sugars show any significant protective property at attenuate Aβ toxicity. 
Again, it indicates that a backbone structure is important for Aβ toxicity attenuation. 
Aβ Attenuation Properties of the Sugar-Chitosan Complexes 
In this study, along with a gradient of 3μM to 48μM of sugar-chitosan complexes, a 
concentration of 50μM aggregated Aβ is added to the cells. The Aβ control value is ~71% 
viability compared to live control (100%). 
Statistical Analysis Done for Each Compound 
It can be seen that the viability of SH-SY5Y cells increase after the addition of KDN-
chitosan complex which indicates protection from the toxic Aβ. For the KDN-complex, the 
highest protection can be seen at concentrations of 5μM, 10μM and 20μM concentration. The 
protection increases from 3µM to 10µM and then again starts decreasing at higher 
concentrations. It is difficult to compare KDN-complex with sialic acid-complex as there is a 
difference in the values of Aβ control. 
For the GA-complex and CHC-complex, at 3μM to 20μM, the viabilities are not different 
than that of Aβ control (p > 0.05) and then the viability decreases.  Thus, GA-complex and CHC-
complex shows no protection from Aβ.  
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In case of Pyran-complex, we see that statistically highest protection is seen at 5µM, 
10µM concentrations when compared to Aβ control. Above 20µM, the viabilities are not 
statistically different from Aβ control (in all cases, p > 0.05).  
Statistical Analysis Done for Each Concentration 
This data is explained better based on the structures of the sugars and these are the trends 
observed from the data.  
At all concentrations, KDN-complex and Pyran-complex offer the highest protection 
from Aβ. In all cases, except at 10µM, the effect seen by KDN-complex and Pyran-complex are 
statistically similar (p > 0.05).  
Now, the difference in the structure of KDN and GA is the multi –OH tail present in 
KDN. In all cases, except at 3µM, all the viabilities of KDN-complex are statistically higher than 
the viabilities of GA-complex (in all cases, p < 0.05). As no protection from GA-complex can be 
seen, it is likely that the loss of –OH tail is the reason for loss of protection. Based on this result, 
we postulated that that the multi-OH group in sialic acid is the likely target that Aβ recognizes on 
the neuronal membrane. 
The difference in the structure of Pyran and CHC is the oxygen substitution in the ring 
structure. Comparing the results of Pyran-complex with CHC-complex, viabilities of Pyran-
complex are statistically higher compared to all concentrations (in all cases, p < 0.05), except 
3µM and 20µM. Based on this result, we postulate that the oxygen atom in the ring structure is 
also a factor in Aβ having affinity towards clustered sialic acids. 
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Even if we do not expect the same level of protection as sialic acid-labeled chitosan, the 
results show the importance of the structures or –R groups of sialic acid that contribute to Aβ 
toxicity attenuation. This has significance with respect to the understanding of the Aβ-sialic acid 
interaction that takes place in-vivo. Also, this will be of importance to groups investigating 
polysaccharide structures for therapeutic development. 
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5. CONCLUSIONS 
5.1. Introduction 
Despite over a century of research, the world’s most prominent neurodegenerative 
disease, Alzheimer’s disease (AD), still does not have clearly defined mechanisms, causes or 
cures. The work presented in this dissertation is a step towards understanding the missing pieces. 
One of the fundamental hallmarks of AD brain is the presence of aggregated amyloid-beta 
peptide (Aβ) deposits and hence Aβ is posited to play a central role in the pathology of the 
disease. One theory is that Aβ toxicity is linked to the formation of toxic species, others believe 
that Aβ acts via association with the cell membrane causing toxicity. There are also several 
theorized environmental conditions that lead to the development of AD. However, it is generally 
agreed upon that, the first step in any of the mechanisms of Aβ action on the cell is Aβ binding to 
the cell membrane. To put this in a different context, there can be several different mechanisms 
or a combination of mechanisms that are causes neurotoxicity, but if the toxic species cannot 
interact with the neurons, there cannot be neurotoxicity associated with it. The understanding is 
that, Aβ has to interact with the cell to cause neurotoxicity, and this interaction occurs through 
the cell membrane in a still unexplained manner.  It is precisely this theoretical bottleneck region 
that we plan to target. 
One of the many goals of this project was to design biomimetic compounds to which Aβ 
will have higher affinity compared to its affinity towards cell membranes. Thus, in an in-vitro 
system with a model neuroblastoma cell line, we can expect excellent toxicity attenuation 
properties from the compounds against Aβ. One of the important observations that made this 
approach feasible is that Aβ shows affinity or binds to the sialic acids that are present on the 
gangliosides in the cell membranes. Particularly, this affinity of Aβ was higher when these 
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surface sialic acid moieties on the gangliosides are clustered together. Another important 
observation in favor of this approach was the observation that removal of cell surface sialic acids 
have been found to attenuate Aβ toxicity. To this end, the dissertation focuses on the synthesis of 
such biomimetics compounds that are multivalent in sugars or sialic acid and the ability of such 
complexes to preferentially interfere with cell-Aβ interactions. Another goal of this project was 
to identify the concentration or the clustering of sialic acids that show the highest toxicity 
attenuation. This will help us to understand the mechanisms behind Aβ-cell membrane 
interactions.  
Earlier works with sialic acid labeled dendrimer complexes [8, 26] have shown limited 
success in attenuating the toxicity of Aβ. However, it was clear that Aβ had higher affinity to 
these labeled dendrimers. As the dendrimers structure was rigid, it would be possible that 
labeling of sialic acids was suboptimum for Aβ binding. Also, the different dendrimers tested 
had different levels of intrinsic toxicity towards the cells, which affected the toxicity attenuating 
properties of these constructs.  
5.2. Sialic Acid Labeled Chitosan for the Attenuation of Aβ Toxicity 
Chitosan is a versatile polysaccharide that has excellent biological properties with host of 
applications. The use of chitosan is a definite improvement over earlier works since chitosan is a 
non-toxic, biocompatible and a FDA approved biopolymer. Also, chitosan provided the amine 
functional group that could be modified without affecting the fundamental linear substructure of 
chitosan, thereby retaining its linearity, flexibility and act as a carrier for sialic acid molecules 
which is critical in order to mimic neuronal membranes and to attenuate toxicity of Aβ. 
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Another important conclusion is the effectiveness of EDC chemistry with Sulfo-NHS to 
successfully couple the carboxylic acid group of sialic acid with the amine group present in the 
chitosan molecule. The amide linkage formed was successfully proved using FTIR results which 
showed the loss of primary amines and the presence of amide linkage in complex spectra that 
could only come from the coupling of sialic acid to chitosan via amide bonds. Thus, by varying 
the ratio of moles of sialic acid added to the reaction mixture compared to the moles of primary 
amines of chitosan, we succeeded in synthesizing sialic acid labeled chitosan complexes with 
varying degree of labeling of sialic acid or varying number of sialic acid residues on chitosan. 
The quantification of the amount of sialic acid present on chitosan was done using the Warren 
Assay which gave a red chromophore whose absorbance could be correlated to the amount of 
sialic acid. This important achievement of different amount of SA labeling (8% to 48%)  table 3, 
allowed us to test the effectiveness of the complexes with different amounts of sialic acid on a 
linear flexible backbone to attenuate toxicity of Aβ in a system of differentiated SH-SY5Y cells. 
We have shown that a linear polysialiated structure that mimics the NCAM of a neuron 
shows significant ability to attenuate Aβ toxicity in vitro. This indicates that to achieve the 
clustering effects shown in previous works does not require an a priori clustered backbone (like 
starburst dendrimers) and that a linear structure with sufficient flexibility will natural achieve the 
clustered state when interacting with Aβ (based on equivalent protective properties). Based on 
the toxicity attenuation results, it can be concluded that all complexes as well as naïve chitosan 
were effective in attenuating the toxicity of Aβ (in all cases, p < 0.01). Using a flexible 
backbone, it was observed that 37% labeling of chitosan by sialic acid shows the optimum 
protective properties, indicating a balance between the degree of sialic acid labeling and 
backbone flexibility (which will allow the sialic acid molecules to effectively cluster). Of more 
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interest is the fact that chitosan showed similar protective properties to the labeled compounds, 
thus indicating that there are other biological cyclic sugars that could prove to be equally or more 
effective that sialic acid in preventing Aβ toxicity. It also suggests that the sialic acid-chitosan 
mimic interaction with Aβ peptide and cells must be more than just competing with each other or 
simply electrostatic interactions. It has been suggested that either the lysines or histidines on the 
toxic Aβ peptide species interacts with the negatively charged sugars present on the cell 
membrane which are detrimental to cell health. Thus, we believe that the introduction of our 
complex with sialic acid residues creates another charged species that attracts Aβ and this could 
shield the cell from the harmful interactions with Aβ. This postulate could explain the toxicity 
attenuation shown by unlabeled chitosan in solution in addition to the complexes.  With the 
technique we have developed to control the degree of labeling of a polyamine using EDC 
chemistry with high repeatability, we will be able to more forward and investigate other sugars in 
a similar way to the study presented here. 
This work thus addresses the question whether biomimetics could be applied successfully 
to reduce the toxicity of Aβ peptide. The use of chitosan made it possible to have a backbone that 
allowed the labeled sialic acids to effectively cluster, which was critical in toxicity attenuation. A 
significant numbers of studies have demonstrated the importance of clustering of sugars; our 
work is successful in predicting the optimum sialic acid concentration that shows highest 
protective properties. 
5.3. Evaluation of Sialic Acid Analogs for the Attenuation of Aβ Toxicity 
From the results of Chapter 3, it is clear that sialic acid (N-acetylneuraminic acid) labeled 
chitosan was effective in attenuating toxicity without the toxicity associated with the backbone 
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molecule. Since, chitosan showed protective properties, it was retained as the backbone molecule 
and the ability of other sugars (than sialic acid) to attenuate the toxicity was investigated keeping 
sialic acid as the benchmark for comparison with other sugars. 
Since we are certain that Aβ binds to sialic acids on the neuronal membrane in the brain, 
the most effective method to design a biomimetic (as a potential therapeutic) would be to 
understand which part of the sialic acid structure does Aβ show the highest affinity or binds to. 
Thus, one of the goals of this work was to identify the core structures or the unique –R groups of 
sialic acid which are critical for toxicity association. Second goal was to determine whether other 
sugars show better or similar protective properties than sialic acid. The selection of different 
sugars was done keeping these criteria in mind.  
We were successful in using EDC chemistry with high accuracy in conjugation of 
different sugars with chitosan. Also, this work demonstrates how EDC chemistry with Sulfo-
NHS can be used with sufficient accuracy to achieve different percentage labeling of carboxylic 
acid containing molecules with an amine containing species. The verification of all conjugated 
complexes was done using FTIR which showed the presence of amide linkage in the complex 
spectra. Quantification of the amount of KDN and GA present on chitosan was done 
calorimetrically using the Aminoff and the carbazole assay methods. 
From the intrinsic toxicity studies, it was evident that oxygen substitution in the ring 
structure (between CHC and Pyran) led to an increase in toxicity. Similar increase in toxicity for 
GA compared to KDN implied the importance of multi –OH tail in the intrinsic toxicity. All 
these point to the conclusion that decoration of therapeutics with such –OH tails may be 
necessary to prevent toxicity and address its therapeutic effects.   
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Since none of the analogs by themselves showed none protective properties, it reinforces 
the conclusion that clustering of sialic acid in the neuronal membranes is a necessary condition 
for Aβ binding. Also, it concludes that simple addition of monomeric sialic acid moieties or 
GM1 molecules to aggregated Aβ in-vitro will not be sufficient to achieve the protection desired 
from Aβ. 
For the complexes, KDN and Pyran complexes showed significant protective properties. 
As GA complex did not show any protection, we can believe that the multi –OH tail is the –R 
group that is involved in Aβ interactions. Similarly, from the Pyran-CHC comparison, we found 
that oxygen substitution leads to increased toxicity attenuation indicating the possible role of 
oxygen in Aβ-sialic acid interactions. This work elucidates the impact that certain structures of 
sialic acid and its analogs can have on Aβ binding. It will allow for more specific and detailed 
improvements in the therapeutic polysaccharide structures that can be developed and modified to 
overcome other shortcomings of AD therapeutic development, particularly of penetrating the 
blood-brain barrier. Now that we know which or what structures are important, molecules could 
be developed that will be small enough the cross the Blood Brain Barrier.  
The most followed approach in therapeutic development is to synthesize hundreds, 
thousands of structures or their analogs and test them brute force against the targets, out of 
which, a promising few advance for further testing.  On an average, 5000 -10000 compounds are 
synthesized and tested over a period of several years out of which a select few make it to 
preclinical trials. Thus, there is no standard roadmap for drug synthesis that is being followed in 
this regard. This approach is costing millions in terms of man hours and money. The method we 
have used to design a therapeutic is focused towards developing the therapeutic in an efficient 
step-by-step way by understanding the role of each structure or functional group involved. This 
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way, we can design a novel drug that has just the structures or groups that are necessary in 
treating the disease. Using the method demonstrated in this research, i.e. to determine which 
substructure or core structure is effective as a possible therapeutic, will help to design therapeutic 
against a number of diseases and disorders more efficiently and smartly. Although we have just 
investigated this approach in the case of aggregated Aβ in Alzheimer’s disease, we can extent 
this approach to a wide variety of disease and applications. For example, there are several human 
protein diseases caused by misfolded or aggregated peptides which form fibrils with morphology 
similar to that observed in AD (see table 1). Most of the mechanisms behind these diseases 
involve membrane, lipid interactions. This is a dedicated approach that can be used for specific 
and targeted therapeutic development against such diseases.  
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6. FUTURE WORK 
As with any research work with time limitations, there are several areas where the work 
done in this dissertation can be extended. 
One of the immediate extensions of the current work is to develop small molecule 
therapeutics for Aβ toxicity attenuation. Focus can be shifted to other more toxic Aβ species 
such as ADDL’s. Based on results from chapter 4, we will have a catalog of sugars or –R groups 
ready, that have shown the highest binding to Aβ or protective effects from Aβ. We can use this 
information to then design small molecule therapeutics which will show highest affinity towards 
Aβ and Aβ toxicity attenuation properties. Since we know the structures that exhibit intrinsic 
toxicity, we can avoid those when developing such a therapeutic. Additionally, we can move 
away from the need of a bulk backbone structure and focus on small molecules. These smart low 
MW biomimetic’s could prove more effective in toxicity attenuation than the bulky polysialated 
materials. Also, based on the success of earlier work we could be able to shift from cyclic sugars 
to aliphatic compounds (such as poly-L-lysine) for the backbone. Other ideas for the backbone 
include diamino-alkanes such as 1,2 Diaminoethane (CAS 107-15-7) or 1,3 Diaminopropane 
(CAS 109-76-2). Other alkanes are available with 2-carbons to 19 carbons in their chains which 
will allow us to investigate the effect of sugar separation and backbone flexibility and how it 
affects therapeutic effectiveness. We have already shown that EDC chemistry can be used with 
sufficient accuracy to conjugate compounds which can be extended here. For other constructs, 
conjugation chemistries such as Thiol, Dicyclohexylcarbodiimide etc. can be investigated. 
Another area to explore can be to use double bonded alkenes instead of the alkanes to examine 
effect of backbone flexibility. This backbone will be more rigid due to the presence of a double 
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bond. This work can help researcher involved in development of polysaccharide molecules as 
possible therapeutic applications.  
There has been no attempt in this work to understand the sites where these molecules are 
binding to the toxic Aβ peptide. Also, we have not quantified the binding affinities of our 
biomaterials to the toxic Aβ species. The binding of Aβ to the complex synthesized should be 
investigated by the use of radiochemical techniques. One such technique, the Bolton Hunter 
method has been described for Aβ in earlier works [8]. This would help in the estimation of the 
equilibrium dissociation constants for our complexes which can be compared with other works. 
Additional area to pursue is to determine which species of Aβ, protofibrils, oligomers are 
toxic to cells in culture. This is an critical missing piece of information in the AD puzzle. Using 
the information from chapter 3, we know which structures show the highest affinity. By 
attaching the novel compounds to an immobilized surface (most commonly used are gold 
surfaces), different species of Aβ can tested to analyze their binding characteristics by techniques 
such as Surface Plasmon Resonance. Results from the binding constants using Bolton Hunter 
method and with particular Aβ species will help us to determine the most toxic species that is 
neurotoxic to the cells. 
One huge avenue that can be explored based on this work is the possibility of testing 
these constructs in-vivo on mouse models. Most of the therapeutics targeting the brain fails due 
to their bulky MW and its inability to cross the blood brain barrier. A small MW compound will 
be much easier to transport across the BBB to target the AβAβ in the brain. This will provide the 
perfect set for in vivo tests later on. Our molecules can be attached to lipid or protein moieties 
that can easily cross the BBB. The efficacy of these constructs can be evaluated in vivo. 
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Extensive studies can be performed with mouse models that will help identify and further narrow 
the structures that show promise in vivo. 
The work described in this dissertation provides a distinct roadmap to follow while 
investigating other diseases (see table 1). The next logical disease to investigate will be the 
aggregation and toxicity of α-synuclein which is implicated in Parkinson’s disease (PD). There is 
a major overlap in the mechanism between the two diseases, AD and PD. Also, α-synuclein 
toxicity is postulated to be the result of the interactions between the aggregated peptide and 
neuronal membranes Thus the same systematic development of therapeutic can be applied to 
investigate PD. Additionally, table 1 provides a number of diseases that are a result of protein 
aggregation or misfolding. This dissertation will provide the directions to investigate these 
diseases from a targeted therapeutic point-of-view. 
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Statistical Output for Sialic Acid-Labeled Chitosan: Intrinsic Toxicity Studies 
 
concentration concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.08216 0.02495 21 3.29 0.0035 Tukey 0.0459
0uM 1uM 0.01586 0.02495 21 0.64 0.5318 Tukey 0.9947
0uM 20uM -0.02601 0.02495 21 -1.04 0.3091 Tukey 0.9377
0uM 30uM 0.0217 0.02495 21 0.87 0.3944 Tukey 0.9734
0uM 3uM 0.02671 0.02495 21 1.07 0.2966 Tukey 0.93
0uM 5uM 0.07228 0.02495 21 2.9 0.0086 Tukey 0.1017
10uM 1uM -0.06629 0.02495 21 -2.66 0.0148 Tukey 0.159
10uM 20uM -0.1082 0.02495 21 -4.33 0.0003 Tukey 0.0046
10uM 30uM -0.06046 0.02495 21 -2.42 0.0245 Tukey 0.2378
10uM 3uM -0.05545 0.02495 21 -2.22 0.0374 Tukey 0.3258
10uM 5uM -0.00988 0.02495 21 -0.4 0.6963 Tukey 0.9996
1uM 20uM -0.04188 0.02495 21 -1.68 0.1081 Tukey 0.6367
1uM 30uM 0.005832 0.02495 21 0.23 0.8175 Tukey 1
1uM 3uM 0.01085 0.02495 21 0.43 0.6682 Tukey 0.9994
1uM 5uM 0.05642 0.02495 21 2.26 0.0345 Tukey 0.3072
20uM 30uM 0.04771 0.02495 21 1.91 0.0696 Tukey 0.4947
20uM 3uM 0.05272 0.02495 21 2.11 0.0468 Tukey 0.3811
20uM 5uM 0.09829 0.02495 21 3.94 0.0008 Tukey 0.0113
30uM 3uM 0.005016 0.02495 21 0.2 0.8426 Tukey 1
30uM 5uM 0.05059 0.02495 21 2.03 0.0555 Tukey 0.4279
3uM 5uM 0.04557 0.02495 21 1.83 0.0821 Tukey 0.5462
Obs concentration Estimate Standard Error Letter Group
1 20uM 1.026 0.01765 A
2 0uM 1 0.01765 AB
3 1uM 0.9841 0.01765 ABC
4 30uM 0.9783 0.01765 ABC
5 3uM 0.9733 0.01765 ABC
6 5uM 0.9277 0.01765 BC
7 10uM 0.9178 0.01765 C
Statistical analysis for unlabled chitosan intrinsic toxicity by Tukey's test
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.04538 0.02495 21 1.82 0.0833 Tukey 0.5508
0uM 1uM 0.02741 0.02495 21 1.1 0.2844 Tukey 0.9216
0uM 20uM -0.0089 0.02495 21 -0.36 0.7248 Tukey 0.9998
0uM 30uM 0.01575 0.02495 21 0.63 0.5348 Tukey 0.9949
0uM 3uM 0.07115 0.02495 21 2.85 0.0096 Tukey 0.1108
0uM 5uM 0.05805 0.02495 21 2.33 0.0301 Tukey 0.2776
10uM 1uM -0.01796 0.02495 21 -0.72 0.4795 Tukey 0.9897
10uM 20uM -0.05428 0.02495 21 -2.18 0.0412 Tukey 0.3487
10uM 30uM -0.02963 0.02495 21 -1.19 0.2483 Tukey 0.8912
10uM 3uM 0.02578 0.02495 21 1.03 0.3133 Tukey 0.9402
10uM 5uM 0.01268 0.02495 21 0.51 0.6167 Tukey 0.9984
1uM 20uM -0.03632 0.02495 21 -1.46 0.1603 Tukey 0.7664
1uM 30uM -0.01166 0.02495 21 -0.47 0.645 Tukey 0.999
1uM 3uM 0.04374 0.02495 21 1.75 0.0942 Tukey 0.5909
1uM 5uM 0.03064 0.02495 21 1.23 0.2331 Tukey 0.8754
20uM 30uM 0.02465 0.02495 21 0.99 0.3344 Tukey 0.9512
20uM 3uM 0.08006 0.02495 21 3.21 0.0042 Tukey 0.0546
20uM 5uM 0.06695 0.02495 21 2.68 0.0139 Tukey 0.1515
30uM 3uM 0.05541 0.02495 21 2.22 0.0375 Tukey 0.3264
30uM 5uM 0.0423 0.02495 21 1.7 0.1048 Tukey 0.6261
3uM 5uM -0.0131 0.02495 21 -0.53 0.605 Tukey 0.9981
Obs concentration Estimate Standard Error Letter
Group
1 20uM 1.0089 0.01764 A
2 0uM 1 0.01764 A
3 30uM 0.9843 0.01764 A
4 1uM 0.9726 0.01764 A
5 10uM 0.9546 0.01764 A
6 5uM 0.9419 0.01764 A
7 3uM 0.9288 0.01764 A
Statistical analysis for complex A 7.8% intrinsic toxicity by Tukey's test
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.03301 0.02781 21 1.19 0.2485 Tukey 0.8914
0uM 1uM 0.06101 0.02781 21 2.19 0.0397 Tukey 0.3396
0uM 20uM 0.01866 0.02781 21 0.67 0.5095 Tukey 0.9929
0uM 30uM 0.0694 0.02781 21 2.5 0.021 Tukey 0.2106
0uM 3uM -0.00362 0.02781 21 -0.13 0.8978 Tukey 1
0uM 5uM 0.008982 0.02781 21 0.32 0.7499 Tukey 0.9999
10uM 1uM 0.02799 0.02781 21 1.01 0.3256 Tukey 0.9468
10uM 20uM -0.01435 0.02781 21 -0.52 0.6113 Tukey 0.9983
10uM 30uM 0.03639 0.02781 21 1.31 0.2048 Tukey 0.8405
10uM 3uM -0.03663 0.02781 21 -1.32 0.202 Tukey 0.8366
10uM 5uM -0.02403 0.02781 21 -0.86 0.3973 Tukey 0.9742
1uM 20uM -0.04234 0.02781 21 -1.52 0.1428 Tukey 0.729
1uM 30uM 0.008398 0.02781 21 0.3 0.7656 Tukey 0.9999
1uM 3uM -0.06462 0.02781 21 -2.32 0.0303 Tukey 0.2789
1uM 5uM -0.05202 0.02781 21 -1.87 0.0754 Tukey 0.5193
20uM 30uM 0.05074 0.02781 21 1.82 0.0823 Tukey 0.5472
20uM 3uM -0.02228 0.02781 21 -0.8 0.432 Tukey 0.9823
20uM 5uM -0.00968 0.02781 21 -0.35 0.7312 Tukey 0.9998
30uM 3uM -0.07302 0.02781 21 -2.63 0.0158 Tukey 0.1681
30uM 5uM -0.06042 0.02781 21 -2.17 0.0414 Tukey 0.3501
3uM 5uM 0.0126 0.02781 21 0.45 0.6552 Tukey 0.9992
Obs concentration Estimate Standard Error Letter
Group
1 3uM 1.0036 0.01966 A
2 0uM 1 0.01966 A
3 5uM 0.991 0.01966 A
4 20uM 0.9813 0.01966 A
5 10uM 0.967 0.01966 A
6 1uM 0.939 0.01966 A
7 30uM 0.9306 0.01966 A
Statistical analysis for complex B 14.1% intrinsic toxicity by Tukey's test
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.03728 0.0397 21 0.94 0.3583 Tukey 0.9614
0uM 1uM -0.08291 0.0397 21 -2.09 0.0491 Tukey 0.394
0uM 20uM 0.04438 0.0397 21 1.12 0.2761 Tukey 0.9154
0uM 30uM 0.02534 0.0397 21 0.64 0.5302 Tukey 0.9946
0uM 3uM -0.08299 0.0397 21 -2.09 0.0489 Tukey 0.3929
0uM 5uM 0.01573 0.0397 21 0.4 0.6958 Tukey 0.9996
10uM 1uM -0.1202 0.0397 21 -3.03 0.0064 Tukey 0.0786
10uM 20uM 0.007103 0.0397 21 0.18 0.8597 Tukey 1
10uM 30uM -0.01194 0.0397 21 -0.3 0.7665 Tukey 0.9999
10uM 3uM -0.1203 0.0397 21 -3.03 0.0064 Tukey 0.0783
10uM 5uM -0.02155 0.0397 21 -0.54 0.593 Tukey 0.9978
1uM 20uM 0.1273 0.0397 21 3.21 0.0042 Tukey 0.0547
1uM 30uM 0.1083 0.0397 21 2.73 0.0126 Tukey 0.1399
1uM 3uM -0.00008 0.0397 21 0 0.9984 Tukey 1
1uM 5uM 0.09865 0.0397 21 2.49 0.0215 Tukey 0.2144
20uM 30uM -0.01905 0.0397 21 -0.48 0.6363 Tukey 0.9989
20uM 3uM -0.1274 0.0397 21 -3.21 0.0042 Tukey 0.0545
20uM 5uM -0.02865 0.0397 21 -0.72 0.4784 Tukey 0.9896
30uM 3uM -0.1083 0.0397 21 -2.73 0.0126 Tukey 0.1394
30uM 5uM -0.0096 0.0397 21 -0.24 0.8112 Tukey 1
3uM 5uM 0.09873 0.0397 21 2.49 0.0214 Tukey 0.2137
Obs concentration Estimate Standard Error Letter
Group
1 3uM 1.083 0.02807 A
2 1uM 1.0829 0.02807 A
3 0uM 1 0.02807 A
4 5uM 0.9843 0.02807 A
5 30uM 0.9747 0.02807 A
6 10uM 0.9627 0.02807 A
7 20uM 0.9556 0.02807 A
Statistical analysis for complex C 17.6% intrinsic toxicity by Tukey's test
Effect=concentration Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.03048 0.03313 21 0.92 0.3679 Tukey 0.965
0uM 1uM 0.008172 0.03313 21 0.25 0.8075 Tukey 1
0uM 20uM 0.01609 0.03313 21 0.49 0.6323 Tukey 0.9988
0uM 30uM 0.02114 0.03313 21 0.64 0.5303 Tukey 0.9946
0uM 3uM -0.0672 0.03313 21 -2.03 0.0553 Tukey 0.427
0uM 5uM -0.06269 0.03313 21 -1.89 0.0723 Tukey 0.5061
10uM 1uM -0.02231 0.03313 21 -0.67 0.508 Tukey 0.9928
10uM 20uM -0.0144 0.03313 21 -0.43 0.6683 Tukey 0.9994
10uM 30uM -0.00934 0.03313 21 -0.28 0.7806 Tukey 0.9999
10uM 3uM -0.09769 0.03313 21 -2.95 0.0077 Tukey 0.0919
10uM 5uM -0.09317 0.03313 21 -2.81 0.0104 Tukey 0.1193
1uM 20uM 0.007914 0.03313 21 0.24 0.8135 Tukey 1
1uM 30uM 0.01297 0.03313 21 0.39 0.6995 Tukey 0.9996
1uM 3uM -0.07538 0.03313 21 -2.28 0.0335 Tukey 0.3005
1uM 5uM -0.07087 0.03313 21 -2.14 0.0443 Tukey 0.3672
20uM 30uM 0.005052 0.03313 21 0.15 0.8803 Tukey 1
20uM 3uM -0.08329 0.03313 21 -2.51 0.0201 Tukey 0.2041
20uM 5uM -0.07878 0.03313 21 -2.38 0.027 Tukey 0.2557
30uM 3uM -0.08834 0.03313 21 -2.67 0.0144 Tukey 0.1561
30uM 5uM -0.08383 0.03313 21 -2.53 0.0194 Tukey 0.1984
3uM 5uM 0.004511 0.03313 21 0.14 0.893 Tukey 1
Obs concentration Estimate Standard Error Letter
Group
1 3uM 1.0672 0.02342 A
2 5uM 1.0627 0.02342 A
3 0uM 1 0.02342 A
4 1uM 0.9918 0.02342 A
5 20uM 0.9839 0.02342 A
6 30uM 0.9789 0.02342 A
7 10uM 0.9695 0.02342 A
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis for complex D 24.5% intrinsic toxicity by Tukey's test
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.00264 0.04919 21 -0.05 0.9577 Tukey 1
0uM 1uM 0.1726 0.04919 21 3.51 0.0021 Tukey 0.029
0uM 20uM -0.00534 0.04919 21 -0.11 0.9146 Tukey 1
0uM 30uM 0.04171 0.04919 21 0.85 0.4061 Tukey 0.9765
0uM 3uM 0.04258 0.04919 21 0.87 0.3965 Tukey 0.9739
0uM 5uM -0.03937 0.04919 21 -0.8 0.4325 Tukey 0.9823
10uM 1uM 0.1752 0.04919 21 3.56 0.0018 Tukey 0.0258
10uM 20uM -0.0027 0.04919 21 -0.05 0.9568 Tukey 1
10uM 30uM 0.04434 0.04919 21 0.9 0.3776 Tukey 0.9683
10uM 3uM 0.04522 0.04919 21 0.92 0.3684 Tukey 0.9652
10uM 5uM -0.03673 0.04919 21 -0.75 0.4635 Tukey 0.9876
1uM 20uM -0.1779 0.04919 21 -3.62 0.0016 Tukey 0.0229
1uM 30uM -0.1309 0.04919 21 -2.66 0.0146 Tukey 0.1578
1uM 3uM -0.13 0.04919 21 -2.64 0.0152 Tukey 0.1629
1uM 5uM -0.212 0.04919 21 -4.31 0.0003 Tukey 0.0049
20uM 30uM 0.04704 0.04919 21 0.96 0.3498 Tukey 0.958
20uM 3uM 0.04792 0.04919 21 0.97 0.3411 Tukey 0.9542
20uM 5uM -0.03403 0.04919 21 -0.69 0.4966 Tukey 0.9917
30uM 3uM 0.00088 0.04919 21 0.02 0.9859 Tukey 1
30uM 5uM -0.08108 0.04919 21 -1.65 0.1142 Tukey 0.6549
3uM 5uM -0.08196 0.04919 21 -1.67 0.1106 Tukey 0.644
Obs concentration Estimate Standard Error Letter
Group
1 5uM 1.0394 0.03478 A
2 20uM 1.0053 0.03478 A
3 10uM 1.0026 0.03478 A
4 0uM 1 0.03478 A
5 30uM 0.9583 0.03478 AB
6 3uM 0.9574 0.03478 AB
7 1uM 0.8274 0.03478 B
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis for complex E 37.3% intrinsic toxicity by Tukey's test
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.1768 0.04366 21 4.05 0.0006 Tukey 0.0088
0uM 1uM 0.2694 0.04366 21 6.17 <.0001 Tukey <.0001
0uM 20uM 0.1954 0.04366 21 4.47 0.0002 Tukey 0.0033
0uM 30uM 0.2152 0.04366 21 4.93 <.0001 Tukey 0.0012
0uM 3uM 0.2973 0.04366 21 6.81 <.0001 Tukey <.0001
0uM 5uM 0.13 0.04366 21 2.98 0.0072 Tukey 0.087
10uM 1uM 0.09263 0.04366 21 2.12 0.0459 Tukey 0.3763
10uM 20uM 0.01857 0.04366 21 0.43 0.6749 Tukey 0.9994
10uM 30uM 0.03845 0.04366 21 0.88 0.3884 Tukey 0.9716
10uM 3uM 0.1205 0.04366 21 2.76 0.0117 Tukey 0.1316
10uM 5uM -0.04682 0.04366 21 -1.07 0.2957 Tukey 0.9294
1uM 20uM -0.07406 0.04366 21 -1.7 0.1046 Tukey 0.6255
1uM 30uM -0.05418 0.04366 21 -1.24 0.2283 Tukey 0.87
1uM 3uM 0.02788 0.04366 21 0.64 0.53 Tukey 0.9946
1uM 5uM -0.1395 0.04366 21 -3.19 0.0044 Tukey 0.0562
20uM 30uM 0.01988 0.04366 21 0.46 0.6535 Tukey 0.9992
20uM 3uM 0.1019 0.04366 21 2.34 0.0295 Tukey 0.2739
20uM 5uM -0.06539 0.04366 21 -1.5 0.1491 Tukey 0.743
30uM 3uM 0.08206 0.04366 21 1.88 0.0741 Tukey 0.5139
30uM 5uM -0.08527 0.04366 21 -1.95 0.0642 Tukey 0.4703
3uM 5uM -0.1673 0.04366 21 -3.83 0.001 Tukey 0.0143
Obs concentration Estimate Standard Error Letter
Group
1 0uM 1 0.03087 A
2 5uM 0.87 0.03087 AB
3 10uM 0.8232 0.03087 BC
4 20uM 0.8046 0.03087 BC
5 30uM 0.7848 0.03087 BC
6 1uM 0.7306 0.03087 BC
7 3uM 0.7027 0.03087 C
Statistical analysis for complex F 40.1% intrinsic toxicity by Tukey's test
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
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concentration concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.3586 0.03665 21 9.78 <.0001 Tukey <.0001
0uM 1uM 0.4832 0.03665 21 13.18 <.0001 Tukey <.0001
0uM 20uM 0.3823 0.03665 21 10.43 <.0001 Tukey <.0001
0uM 30uM 0.282 0.03665 21 7.69 <.0001 Tukey <.0001
0uM 3uM 0.4418 0.03665 21 12.05 <.0001 Tukey <.0001
0uM 5uM 0.3906 0.03665 21 10.66 <.0001 Tukey <.0001
10uM 1uM 0.1245 0.03665 21 3.4 0.0027 Tukey 0.0367
10uM 20uM 0.02373 0.03665 21 0.65 0.5244 Tukey 0.9941
10uM 30uM -0.0766 0.03665 21 -2.09 0.049 Tukey 0.3933
10uM 3uM 0.08321 0.03665 21 2.27 0.0338 Tukey 0.3029
10uM 5uM 0.03203 0.03665 21 0.87 0.392 Tukey 0.9727
1uM 20uM -0.1008 0.03665 21 -2.75 0.012 Tukey 0.134
1uM 30uM -0.2011 0.03665 21 -5.49 <.0001 Tukey 0.0003
1uM 3uM -0.04134 0.03665 21 -1.13 0.2721 Tukey 0.9122
1uM 5uM -0.09251 0.03665 21 -2.52 0.0197 Tukey 0.2007
20uM 30uM -0.1003 0.03665 21 -2.74 0.0123 Tukey 0.1373
20uM 3uM 0.05948 0.03665 21 1.62 0.1195 Tukey 0.6701
20uM 5uM 0.008304 0.03665 21 0.23 0.8229 Tukey 1
30uM 3uM 0.1598 0.03665 21 4.36 0.0003 Tukey 0.0043
30uM 5uM 0.1086 0.03665 21 2.96 0.0074 Tukey 0.0892
3uM 5uM -0.05118 0.03665 21 -1.4 0.1772 Tukey 0.7977
Obs concentration Estimate Standard Error Letter Group
1 0uM 1 0.02592 A
2 30uM 0.718 0.02592 B
3 10uM 0.6414 0.02592 BC
4 20uM 0.6177 0.02592 BCD
5 5uM 0.6094 0.02592 BCD
6 3uM 0.5582 0.02592 CD
7 1uM 0.5168 0.02592 D
Differences of Least Squares Means
Statistical analysis for complex G 48% intrinsic toxicity by Tukey's test
Effect=concentration Method=Tukey(P<.05) Set=1
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 0.03359 0.04147 24 0.81 0.4258 Tukey 0.9908
A7.8 C17.6 -0.1103 0.04147 24 -2.66 0.0137 Tukey 0.1833
A7.8 Chi0 -0.01155 0.04147 24 -0.28 0.783 Tukey 1
A7.8 D24.5 -0.01924 0.04147 24 -0.46 0.6469 Tukey 0.9997
A7.8 E37.3 0.1452 0.04147 24 3.5 0.0018 Tukey 0.033
A7.8 F40.7 0.242 0.04147 24 5.84 <.0001 Tukey 0.0001
A7.8 G48 0.4557 0.04147 24 10.99 <.0001 Tukey <.0001
B14.1 C17.6 -0.1439 0.04147 24 -3.47 0.002 Tukey 0.0353
B14.1 Chi0 -0.04514 0.04147 24 -1.09 0.2871 Tukey 0.9532
B14.1 D24.5 -0.05283 0.04147 24 -1.27 0.2148 Tukey 0.8996
B14.1 E37.3 0.1116 0.04147 24 2.69 0.0128 Tukey 0.1734
B14.1 F40.7 0.2084 0.04147 24 5.03 <.0001 Tukey 0.0009
B14.1 G48 0.4222 0.04147 24 10.18 <.0001 Tukey <.0001
C17.6 Chi0 0.09878 0.04147 24 2.38 0.0255 Tukey 0.2938
C17.6 D24.5 0.09109 0.04147 24 2.2 0.0379 Tukey 0.3879
C17.6 E37.3 0.2555 0.04147 24 6.16 <.0001 Tukey <.0001
C17.6 F40.7 0.3523 0.04147 24 8.5 <.0001 Tukey <.0001
C17.6 G48 0.5661 0.04147 24 13.65 <.0001 Tukey <.0001
Chi0 D24.5 -0.00769 0.04147 24 -0.19 0.8544 Tukey 1
Chi0 E37.3 0.1567 0.04147 24 3.78 0.0009 Tukey 0.0175
Chi0 F40.7 0.2536 0.04147 24 6.11 <.0001 Tukey <.0001
Chi0 G48 0.4673 0.04147 24 11.27 <.0001 Tukey <.0001
D24.5 E37.3 0.1644 0.04147 24 3.97 0.0006 Tukey 0.0114
D24.5 F40.7 0.2612 0.04147 24 6.3 <.0001 Tukey <.0001
D24.5 G48 0.475 0.04147 24 11.45 <.0001 Tukey <.0001
E37.3 F40.7 0.09681 0.04147 24 2.33 0.0283 Tukey 0.3164
E37.3 G48 0.3105 0.04147 24 7.49 <.0001 Tukey <.0001
F40.7 G48 0.2137 0.04147 24 5.15 <.0001 Tukey 0.0006
Obs complex Estimate Standard Error Letter
Group
1 C17.6 1.0829 0.02932 A
2 D24.5 0.9918 0.02932 AB
3 Chi0 0.9841 0.02932 AB
4 A7.8 0.9726 0.02932 AB
5 B14.1 0.939 0.02932 BC
6 E37.3 0.8274 0.02932 CD
7 F40.7 0.7306 0.02932 D
8 G48 0.5168 0.02932 E
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis of SA-Chi complex and chitosan at 1uM concentration by Tukey's test
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complex _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.07477 0.03857 24 -1.94 0.0644 Tukey 0.5399
A7.8 C17.6 -0.1541 0.03857 24 -4 0.0005 Tukey 0.0106
A7.8 Chi0 -0.04444 0.03857 24 -1.15 0.2606 Tukey 0.9377
A7.8 D24.5 -0.1384 0.03857 24 -3.59 0.0015 Tukey 0.0272
A7.8 E37.3 -0.02857 0.03857 24 -0.74 0.4661 Tukey 0.9946
A7.8 F40.7 0.2261 0.03857 24 5.86 <.0001 Tukey 0.0001
A7.8 G48 0.3707 0.03857 24 9.61 <.0001 Tukey <.0001
B14.1 C17.6 -0.07938 0.03857 24 -2.06 0.0506 Tukey 0.4673
B14.1 Chi0 0.03033 0.03857 24 0.79 0.4394 Tukey 0.9923
B14.1 D24.5 -0.06359 0.03857 24 -1.65 0.1123 Tukey 0.7178
B14.1 E37.3 0.0462 0.03857 24 1.2 0.2427 Tukey 0.9248
B14.1 F40.7 0.3009 0.03857 24 7.8 <.0001 Tukey <.0001
B14.1 G48 0.4454 0.03857 24 11.55 <.0001 Tukey <.0001
C17.6 Chi0 0.1097 0.03857 24 2.84 0.009 Tukey 0.1303
C17.6 D24.5 0.01579 0.03857 24 0.41 0.6859 Tukey 0.9999
C17.6 E37.3 0.1256 0.03857 24 3.26 0.0034 Tukey 0.0564
C17.6 F40.7 0.3803 0.03857 24 9.86 <.0001 Tukey <.0001
C17.6 G48 0.5248 0.03857 24 13.61 <.0001 Tukey <.0001
Chi0 D24.5 -0.09392 0.03857 24 -2.43 0.0227 Tukey 0.27
Chi0 E37.3 0.01587 0.03857 24 0.41 0.6843 Tukey 0.9999
Chi0 F40.7 0.2706 0.03857 24 7.02 <.0001 Tukey <.0001
Chi0 G48 0.4151 0.03857 24 10.76 <.0001 Tukey <.0001
D24.5 E37.3 0.1098 0.03857 24 2.85 0.0089 Tukey 0.1297
D24.5 F40.7 0.3645 0.03857 24 9.45 <.0001 Tukey <.0001
D24.5 G48 0.509 0.03857 24 13.2 <.0001 Tukey <.0001
E37.3 F40.7 0.2547 0.03857 24 6.6 <.0001 Tukey <.0001
E37.3 G48 0.3992 0.03857 24 10.35 <.0001 Tukey <.0001
F40.7 G48 0.1445 0.03857 24 3.75 0.001 Tukey 0.0189
Obs complex Estimatetandard Erro Letter
Group
1 C17.6 1.083 0.02727 A
2 D24.5 1.0672 0.02727 A
3 B14.1 1.0036 0.02727 AB
4 Chi0 0.9733 0.02727 AB
5 E37.3 0.9574 0.02727 AB
6 A7.8 0.9288 0.02727 B
7 F40.7 0.7027 0.02727 C
8 G48 0.5582 0.02727 D
Differences of Least Squares Means
Effect=complex Method=Tukey(P<.05) Set=1
Statistical analysis of SA-Chi complex and chitosan at 3uM concentration by Tukey's test
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.04907 0.03983 24 -1.23 0.2299 Tukey 0.9141
A7.8 C17.6 -0.04232 0.03983 24 -1.06 0.2986 Tukey 0.9587
A7.8 Chi0 0.01423 0.03983 24 0.36 0.724 Tukey 1
A7.8 D24.5 -0.1207 0.03983 24 -3.03 0.0058 Tukey 0.09
A7.8 E37.3 -0.09742 0.03983 24 -2.45 0.0221 Tukey 0.2651
A7.8 F40.7 0.07191 0.03983 24 1.81 0.0835 Tukey 0.6225
A7.8 G48 0.3326 0.03983 24 8.35 <.0001 Tukey <.0001
B14.1 C17.6 0.006752 0.03983 24 0.17 0.8668 Tukey 1
B14.1 Chi0 0.0633 0.03983 24 1.59 0.1251 Tukey 0.7518
B14.1 D24.5 -0.07167 0.03983 24 -1.8 0.0845 Tukey 0.6262
B14.1 E37.3 -0.04835 0.03983 24 -1.21 0.2365 Tukey 0.9198
B14.1 F40.7 0.121 0.03983 24 3.04 0.0057 Tukey 0.0889
B14.1 G48 0.3817 0.03983 24 9.58 <.0001 Tukey <.0001
C17.6 Chi0 0.05655 0.03983 24 1.42 0.1685 Tukey 0.8394
C17.6 D24.5 -0.07843 0.03983 24 -1.97 0.0606 Tukey 0.521
C17.6 E37.3 -0.05511 0.03983 24 -1.38 0.1792 Tukey 0.8558
C17.6 F40.7 0.1142 0.03983 24 2.87 0.0085 Tukey 0.1244
C17.6 G48 0.3749 0.03983 24 9.41 <.0001 Tukey <.0001
Chi0 D24.5 -0.135 0.03983 24 -3.39 0.0024 Tukey 0.0423
Chi0 E37.3 -0.1117 0.03983 24 -2.8 0.0099 Tukey 0.1408
Chi0 F40.7 0.05768 0.03983 24 1.45 0.1605 Tukey 0.8259
Chi0 G48 0.3184 0.03983 24 7.99 <.0001 Tukey <.0001
D24.5 E37.3 0.02332 0.03983 24 0.59 0.5637 Tukey 0.9988
D24.5 F40.7 0.1927 0.03983 24 4.84 <.0001 Tukey 0.0014
D24.5 G48 0.4533 0.03983 24 11.38 <.0001 Tukey <.0001
E37.3 F40.7 0.1693 0.03983 24 4.25 0.0003 Tukey 0.0058
E37.3 G48 0.43 0.03983 24 10.8 <.0001 Tukey <.0001
F40.7 G48 0.2607 0.03983 24 6.55 <.0001 Tukey <.0001
Obs complex Estimate Standard ErrorLetter Group
1 D24.5 1.0627 0.02816 A
2 E37.3 1.0394 0.02816 AB
3 B14.1 0.991 0.02816 ABC
4 C17.6 0.9843 0.02816 ABC
5 A7.8 0.9419 0.02816 ABC
6 Chi0 0.9277 0.02816 BC
7 F40.7 0.87 0.02816 C
8 G48 0.6094 0.02816 D
Differences of Least Squares Means
Effect=complex Method=Tukey(P<.05) Set=1
Statistical analysis of SA-Chi complex and chitosan at 5uM concentration by Tukey's test
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.01236 0.03426 24 -0.36 0.7213 Tukey 0.9999
A7.8 C17.6 -0.00809 0.03426 24 -0.24 0.8152 Tukey 1
A7.8 Chi0 0.03678 0.03426 24 1.07 0.2937 Tukey 0.9564
A7.8 D24.5 -0.01489 0.03426 24 -0.43 0.6677 Tukey 0.9998
A7.8 E37.3 -0.04801 0.03426 24 -1.4 0.1739 Tukey 0.8479
A7.8 F40.7 0.1314 0.03426 24 3.84 0.0008 Tukey 0.0154
A7.8 G48 0.3132 0.03426 24 9.14 <.0001 Tukey <.0001
B14.1 C17.6 0.00427 0.03426 24 0.12 0.9018 Tukey 1
B14.1 Chi0 0.04915 0.03426 24 1.43 0.1643 Tukey 0.8325
B14.1 D24.5 -0.00253 0.03426 24 -0.07 0.9418 Tukey 1
B14.1 E37.3 -0.03565 0.03426 24 -1.04 0.3085 Tukey 0.9629
B14.1 F40.7 0.1438 0.03426 24 4.2 0.0003 Tukey 0.0066
B14.1 G48 0.3256 0.03426 24 9.5 <.0001 Tukey <.0001
C17.6 Chi0 0.04488 0.03426 24 1.31 0.2026 Tukey 0.8863
C17.6 D24.5 -0.0068 0.03426 24 -0.2 0.8444 Tukey 1
C17.6 E37.3 -0.03992 0.03426 24 -1.17 0.2554 Tukey 0.9342
C17.6 F40.7 0.1395 0.03426 24 4.07 0.0004 Tukey 0.0088
C17.6 G48 0.3213 0.03426 24 9.38 <.0001 Tukey <.0001
Chi0 D24.5 -0.05168 0.03426 24 -1.51 0.1445 Tukey 0.7957
Chi0 E37.3 -0.0848 0.03426 24 -2.48 0.0208 Tukey 0.2527
Chi0 F40.7 0.09462 0.03426 24 2.76 0.0108 Tukey 0.1522
Chi0 G48 0.2765 0.03426 24 8.07 <.0001 Tukey <.0001
D24.5 E37.3 -0.03312 0.03426 24 -0.97 0.3433 Tukey 0.975
D24.5 F40.7 0.1463 0.03426 24 4.27 0.0003 Tukey 0.0055
D24.5 G48 0.3281 0.03426 24 9.58 <.0001 Tukey <.0001
E37.3 F40.7 0.1794 0.03426 24 5.24 <.0001 Tukey 0.0005
E37.3 G48 0.3613 0.03426 24 10.54 <.0001 Tukey <.0001
F40.7 G48 0.1818 0.03426 24 5.31 <.0001 Tukey 0.0004
Obs complex Estimate Standard Error Letter
Group
1 E37.3 1.0026 0.02423 A
2 D24.5 0.9695 0.02423 A
3 B14.1 0.967 0.02423 A
4 C17.6 0.9627 0.02423 A
5 A7.8 0.9546 0.02423 A
6 Chi0 0.9178 0.02423 AB
7 F40.7 0.8232 0.02423 B
8 G48 0.6414 0.02423 C
Differences of Least Squares Means
Statistical analysis of SA-Chi complex and chitosan at 10uM concentration by Tukey's test
Effect=complex Method=Tukey(P<.05) Set=1
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 0.02757 0.0356 24 0.77 0.4463 Tukey 0.993
A7.8 C17.6 0.05329 0.0356 24 1.5 0.1475 Tukey 0.8017
A7.8 Chi0 -0.01711 0.0356 24 -0.48 0.6352 Tukey 0.9997
A7.8 D24.5 0.02499 0.0356 24 0.7 0.4895 Tukey 0.9961
A7.8 E37.3 0.003566 0.0356 24 0.1 0.9211 Tukey 1
A7.8 F40.7 0.2043 0.0356 24 5.74 <.0001 Tukey 0.0002
A7.8 G48 0.3912 0.0356 24 10.99 <.0001 Tukey <.0001
B14.1 C17.6 0.02572 0.0356 24 0.72 0.477 Tukey 0.9954
B14.1 Chi0 -0.04468 0.0356 24 -1.25 0.2216 Tukey 0.9064
B14.1 D24.5 -0.00258 0.0356 24 -0.07 0.9429 Tukey 1
B14.1 E37.3 -0.024 0.0356 24 -0.67 0.5066 Tukey 0.997
B14.1 F40.7 0.1767 0.0356 24 4.96 <.0001 Tukey 0.001
B14.1 G48 0.3637 0.0356 24 10.22 <.0001 Tukey <.0001
C17.6 Chi0 -0.0704 0.0356 24 -1.98 0.0596 Tukey 0.5159
C17.6 D24.5 -0.0283 0.0356 24 -0.79 0.4345 Tukey 0.9918
C17.6 E37.3 -0.04972 0.0356 24 -1.4 0.1753 Tukey 0.85
C17.6 F40.7 0.151 0.0356 24 4.24 0.0003 Tukey 0.0059
C17.6 G48 0.338 0.0356 24 9.49 <.0001 Tukey <.0001
Chi0 D24.5 0.0421 0.0356 24 1.18 0.2486 Tukey 0.9293
Chi0 E37.3 0.02067 0.0356 24 0.58 0.5668 Tukey 0.9988
Chi0 F40.7 0.2214 0.0356 24 6.22 <.0001 Tukey <.0001
Chi0 G48 0.4084 0.0356 24 11.47 <.0001 Tukey <.0001
D24.5 E37.3 -0.02142 0.0356 24 -0.6 0.5529 Tukey 0.9985
D24.5 F40.7 0.1793 0.0356 24 5.04 <.0001 Tukey 0.0009
D24.5 G48 0.3663 0.0356 24 10.29 <.0001 Tukey <.0001
E37.3 F40.7 0.2007 0.0356 24 5.64 <.0001 Tukey 0.0002
E37.3 G48 0.3877 0.0356 24 10.89 <.0001 Tukey <.0001
F40.7 G48 0.187 0.0356 24 5.25 <.0001 Tukey 0.0005
Obs complex Estimate Standard Error Letter
Group
1 Chi0 1.026 0.02517 A
2 A7.8 1.0089 0.02517 A
3 E37.3 1.0053 0.02517 A
4 D24.5 0.9839 0.02517 A
5 B14.1 0.9813 0.02517 A
6 C17.6 0.9556 0.02517 A
7 F40.7 0.8046 0.02517 B
8 G48 0.6177 0.02517 C
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis of SA-Chi complex and chitosan at 20uM concentration by Tukey's test
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 0.05366 0.03776 24 1.42 0.1682 Tukey 0.8389
A7.8 C17.6 0.00959 0.03776 24 0.25 0.8017 Tukey 1
A7.8 Chi0 0.005949 0.03776 24 0.16 0.8761 Tukey 1
A7.8 D24.5 0.00539 0.03776 24 0.14 0.8877 Tukey 1
A7.8 E37.3 0.02596 0.03776 24 0.69 0.4984 Tukey 0.9966
A7.8 F40.7 0.1995 0.03776 24 5.28 <.0001 Tukey 0.0005
A7.8 G48 0.2663 0.03776 24 7.05 <.0001 Tukey <.0001
B14.1 C17.6 -0.04407 0.03776 24 -1.17 0.2547 Tukey 0.9337
B14.1 Chi0 -0.04771 0.03776 24 -1.26 0.2186 Tukey 0.9034
B14.1 D24.5 -0.04827 0.03776 24 -1.28 0.2134 Tukey 0.8982
B14.1 E37.3 -0.0277 0.03776 24 -0.73 0.4704 Tukey 0.9949
B14.1 F40.7 0.1458 0.03776 24 3.86 0.0007 Tukey 0.0145
B14.1 G48 0.2126 0.03776 24 5.63 <.0001 Tukey 0.0002
C17.6 Chi0 -0.00364 0.03776 24 -0.1 0.924 Tukey 1
C17.6 D24.5 -0.0042 0.03776 24 -0.11 0.9124 Tukey 1
C17.6 E37.3 0.01637 0.03776 24 0.43 0.6686 Tukey 0.9998
C17.6 F40.7 0.1899 0.03776 24 5.03 <.0001 Tukey 0.0009
C17.6 G48 0.2567 0.03776 24 6.8 <.0001 Tukey <.0001
Chi0 D24.5 -0.00056 0.03776 24 -0.01 0.9883 Tukey 1
Chi0 E37.3 0.02001 0.03776 24 0.53 0.6011 Tukey 0.9993
Chi0 F40.7 0.1935 0.03776 24 5.13 <.0001 Tukey 0.0007
Chi0 G48 0.2603 0.03776 24 6.89 <.0001 Tukey <.0001
D24.5 E37.3 0.02057 0.03776 24 0.54 0.591 Tukey 0.9992
D24.5 F40.7 0.1941 0.03776 24 5.14 <.0001 Tukey 0.0007
D24.5 G48 0.2609 0.03776 24 6.91 <.0001 Tukey <.0001
E37.3 F40.7 0.1735 0.03776 24 4.6 0.0001 Tukey 0.0025
E37.3 G48 0.2403 0.03776 24 6.36 <.0001 Tukey <.0001
F40.7 G48 0.06678 0.03776 24 1.77 0.0897 Tukey 0.6455
Obs complex Estimate Standard Error Letter
Group
1 A7.8 0.9843 0.0267 A
2 D24.5 0.9789 0.0267 A
3 Chi0 0.9783 0.0267 A
4 C17.6 0.9747 0.0267 A
5 E37.3 0.9583 0.0267 A
6 B14.1 0.9306 0.0267 A
7 F40.7 0.7848 0.0267 B
8 G48 0.718 0.0267 B
Differences of Least Squares Means
Effect=complex Method=Tukey(P<.05) Set=1
Statistical analysis of SA-Chi complex and chitosan at 30uM concentration by Tukey's test
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.5544 0.02772 21 -20 <.0001 Tukey <.0001
0uM 1uM -0.4382 0.02772 21 -15.81 <.0001 Tukey <.0001
0uM 20uM -0.5596 0.02772 21 -20.19 <.0001 Tukey <.0001
0uM 30uM -0.5205 0.02772 21 -18.78 <.0001 Tukey <.0001
0uM 3uM -0.4198 0.02772 21 -15.15 <.0001 Tukey <.0001
0uM 5uM -0.4632 0.02772 21 -16.71 <.0001 Tukey <.0001
10uM 1uM 0.1162 0.02772 21 4.19 0.0004 Tukey 0.0064
10uM 20uM -0.00522 0.02772 21 -0.19 0.8525 Tukey 1
10uM 30uM 0.03385 0.02772 21 1.22 0.2355 Tukey 0.8781
10uM 3uM 0.1345 0.02772 21 4.85 <.0001 Tukey 0.0014
10uM 5uM 0.09117 0.02772 21 3.29 0.0035 Tukey 0.0462
1uM 20uM -0.1214 0.02772 21 -4.38 0.0003 Tukey 0.0041
1uM 30uM -0.08237 0.02772 21 -2.97 0.0073 Tukey 0.0879
1uM 3uM 0.01831 0.02772 21 0.66 0.5161 Tukey 0.9935
1uM 5uM -0.02506 0.02772 21 -0.9 0.3763 Tukey 0.9679
20uM 30uM 0.03907 0.02772 21 1.41 0.1733 Tukey 0.7909
20uM 3uM 0.1398 0.02772 21 5.04 <.0001 Tukey 0.0009
20uM 5uM 0.09639 0.02772 21 3.48 0.0023 Tukey 0.031
30uM 3uM 0.1007 0.02772 21 3.63 0.0016 Tukey 0.0222
30uM 5uM 0.05732 0.02772 21 2.07 0.0512 Tukey 0.4054
3uM 5uM -0.04337 0.02772 21 -1.56 0.1327 Tukey 0.7048
Obs concentration Estimate Standard Error Letter
Group
1 20uM 0.7599 0.0196 A
2 10uM 0.7547 0.0196 A
3 30uM 0.7208 0.0196 AB
4 5uM 0.6635 0.0196 BC
5 1uM 0.6384 0.0196 BC
6 3uM 0.6201 0.0196 C
7 0uM 0.2003 0.0196 D
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis of unlabeled chitosan by Tukey's test: Abeta studies
Differences of Least Squares Means
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oncentratio  oncentratio  Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.3304 0.02255 21 -14.65 <.0001 Tukey <.0001
0uM 1uM -0.3062 0.02255 21 -13.58 <.0001 Tukey <.0001
0uM 20uM -0.3001 0.02255 21 -13.31 <.0001 Tukey <.0001
0uM 30uM -0.3056 0.02255 21 -13.55 <.0001 Tukey <.0001
0uM 3uM -0.2752 0.02255 21 -12.2 <.0001 Tukey <.0001
0uM 5uM -0.2856 0.02255 21 -12.67 <.0001 Tukey <.0001
10uM 1uM 0.02427 0.02255 21 1.08 0.294 Tukey 0.9283
10uM 20uM 0.03029 0.02255 21 1.34 0.1935 Tukey 0.8242
10uM 30uM 0.02488 0.02255 21 1.1 0.2823 Tukey 0.9201
10uM 3uM 0.05527 0.02255 21 2.45 0.0231 Tukey 0.227
10uM 5uM 0.04478 0.02255 21 1.99 0.0602 Tukey 0.4513
1uM 20uM 0.006019 0.02255 21 0.27 0.7921 Tukey 1
1uM 30uM 0.000611 0.02255 21 0.03 0.9786 Tukey 1
1uM 3uM 0.031 0.02255 21 1.37 0.1837 Tukey 0.8086
1uM 5uM 0.02051 0.02255 21 0.91 0.3733 Tukey 0.9669
20uM 30uM -0.00541 0.02255 21 -0.24 0.8128 Tukey 1
20uM 3uM 0.02498 0.02255 21 1.11 0.2804 Tukey 0.9187
20uM 5uM 0.0145 0.02255 21 0.64 0.5273 Tukey 0.9944
30uM 3uM 0.03039 0.02255 21 1.35 0.1921 Tukey 0.822
30uM 5uM 0.0199 0.02255 21 0.88 0.3874 Tukey 0.9714
3uM 5uM -0.01049 0.02255 21 -0.47 0.6466 Tukey 0.9991
Obs oncentratio Estimate Standard Error Letter
Group
1 10uM 0.5307 0.01594 A
2 1uM 0.5064 0.01594 A
3 30uM 0.5058 0.01594 A
4 20uM 0.5004 0.01594 A
5 5uM 0.4859 0.01594 A
6 3uM 0.4754 0.01594 A
7 0uM 0.2003 0.01594 B
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis of complex A 7.8% by Tukey's test: Abeta studies
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.5056 0.02265 21 -22.32 <.0001 Tukey <.0001
0uM 1uM -0.4914 0.02265 21 -21.7 <.0001 Tukey <.0001
0uM 20uM -0.5006 0.02265 21 -22.1 <.0001 Tukey <.0001
0uM 30uM -0.4836 0.02265 21 -21.35 <.0001 Tukey <.0001
0uM 3uM -0.4939 0.02265 21 -21.81 <.0001 Tukey <.0001
0uM 5uM -0.475 0.02265 21 -20.97 <.0001 Tukey <.0001
10uM 1uM 0.01414 0.02265 21 0.62 0.5392 Tukey 0.9952
10uM 20uM 0.004961 0.02265 21 0.22 0.8287 Tukey 1
10uM 30uM 0.022 0.02265 21 0.97 0.3423 Tukey 0.9548
10uM 3uM 0.01164 0.02265 21 0.51 0.6128 Tukey 0.9983
10uM 5uM 0.03056 0.02265 21 1.35 0.1917 Tukey 0.8213
1uM 20uM -0.00918 0.02265 21 -0.41 0.6894 Tukey 0.9996
1uM 30uM 0.007866 0.02265 21 0.35 0.7318 Tukey 0.9998
1uM 3uM -0.0025 0.02265 21 -0.11 0.9131 Tukey 1
1uM 5uM 0.01642 0.02265 21 0.72 0.4765 Tukey 0.9894
20uM 30uM 0.01704 0.02265 21 0.75 0.4601 Tukey 0.9871
20uM 3uM 0.006674 0.02265 21 0.29 0.7711 Tukey 0.9999
20uM 5uM 0.02559 0.02265 21 1.13 0.2712 Tukey 0.9115
30uM 3uM -0.01037 0.02265 21 -0.46 0.6518 Tukey 0.9991
30uM 5uM 0.008551 0.02265 21 0.38 0.7095 Tukey 0.9997
3uM 5uM 0.01892 0.02265 21 0.84 0.4129 Tukey 0.9781
Obs concentration Estimate Standard Error Letter
Group
1 10uM 0.7059 0.01601 A
2 20uM 0.7009 0.01601 A
3 3uM 0.6942 0.01601 A
4 1uM 0.6917 0.01601 A
5 30uM 0.6838 0.01601 A
6 5uM 0.6753 0.01601 A
7 0uM 0.2003 0.01601 B
Statistical analysis of complex B 14.1% by Tukey's test: Abeta studies
Effect=concentration Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.571 0.01411 21 -40.47 <.0001 Tukey <.0001
0uM 1uM -0.577 0.01411 21 -40.89 <.0001 Tukey <.0001
0uM 20uM -0.5543 0.01411 21 -39.29 <.0001 Tukey <.0001
0uM 30uM -0.5359 0.01411 21 -37.98 <.0001 Tukey <.0001
0uM 3uM -0.5992 0.01411 21 -42.47 <.0001 Tukey <.0001
0uM 5uM -0.5923 0.01411 21 -41.98 <.0001 Tukey <.0001
10uM 1uM -0.00601 0.01411 21 -0.43 0.6744 Tukey 0.9994
10uM 20uM 0.01666 0.01411 21 1.18 0.2509 Tukey 0.8937
10uM 30uM 0.03504 0.01411 21 2.48 0.0215 Tukey 0.215
10uM 3uM -0.02821 0.01411 21 -2 0.0587 Tukey 0.4436
10uM 5uM -0.02138 0.01411 21 -1.52 0.1446 Tukey 0.7331
1uM 20uM 0.02267 0.01411 21 1.61 0.123 Tukey 0.6797
1uM 30uM 0.04105 0.01411 21 2.91 0.0084 Tukey 0.0992
1uM 3uM -0.0222 0.01411 21 -1.57 0.1306 Tukey 0.6995
1uM 5uM -0.01537 0.01411 21 -1.09 0.2884 Tukey 0.9244
20uM 30uM 0.01838 0.01411 21 1.3 0.2067 Tukey 0.8431
20uM 3uM -0.04487 0.01411 21 -3.18 0.0045 Tukey 0.0578
20uM 5uM -0.03804 0.01411 21 -2.7 0.0135 Tukey 0.1481
30uM 3uM -0.06325 0.01411 21 -4.48 0.0002 Tukey 0.0033
30uM 5uM -0.05642 0.01411 21 -4 0.0007 Tukey 0.0098
3uM 5uM 0.00683 0.01411 21 0.48 0.6333 Tukey 0.9988
Obs concentration Estimate Standard Error Letter
Group
1 3uM 0.7994 0.009976 A
2 5uM 0.7926 0.009976 A
3 1uM 0.7772 0.009976 AB
4 10uM 0.7712 0.009976 AB
5 20uM 0.7546 0.009976 AB
6 30uM 0.7362 0.009976 B
7 0uM 0.2003 0.009976 C
Effect=concentration Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis of complex C 17.6% by Tukey's test: Abeta studies
254 
 
 
oncentratio  oncentratio  Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.592 0.01989 21 -29.76 <.0001 Tukey <.0001
0uM 1uM -0.5943 0.01989 21 -29.88 <.0001 Tukey <.0001
0uM 20uM -0.5962 0.01989 21 -29.97 <.0001 Tukey <.0001
0uM 30uM -0.5763 0.01989 21 -28.97 <.0001 Tukey <.0001
0uM 3uM -0.5719 0.01989 21 -28.75 <.0001 Tukey <.0001
0uM 5uM -0.5937 0.01989 21 -29.85 <.0001 Tukey <.0001
10uM 1uM -0.00223 0.01989 21 -0.11 0.9119 Tukey 1
10uM 20uM -0.00415 0.01989 21 -0.21 0.8368 Tukey 1
10uM 30uM 0.01579 0.01989 21 0.79 0.4363 Tukey 0.9831
10uM 3uM 0.0201 0.01989 21 1.01 0.3238 Tukey 0.9459
10uM 5uM -0.00162 0.01989 21 -0.08 0.9358 Tukey 1
1uM 20uM -0.00192 0.01989 21 -0.1 0.924 Tukey 1
1uM 30uM 0.01801 0.01989 21 0.91 0.3755 Tukey 0.9676
1uM 3uM 0.02233 0.01989 21 1.12 0.2743 Tukey 0.914
1uM 5uM 0.000604 0.01989 21 0.03 0.9761 Tukey 1
20uM 30uM 0.01993 0.01989 21 1 0.3277 Tukey 0.9479
20uM 3uM 0.02425 0.01989 21 1.22 0.2363 Tukey 0.879
20uM 5uM 0.002525 0.01989 21 0.13 0.9002 Tukey 1
30uM 3uM 0.004314 0.01989 21 0.22 0.8304 Tukey 1
30uM 5uM -0.01741 0.01989 21 -0.88 0.3914 Tukey 0.9725
3uM 5uM -0.02172 0.01989 21 -1.09 0.2872 Tukey 0.9236
Obs oncentratio Estimate andard Erro Letter
Group
1 20uM 0.7965 0.01407 A
2 1uM 0.7945 0.01407 A
3 5uM 0.7939 0.01407 A
4 10uM 0.7923 0.01407 A
5 30uM 0.7765 0.01407 A
6 3uM 0.7722 0.01407 A
7 0uM 0.2003 0.01407 B
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis of complex D 24.5% by Tukey's test: Abeta studies
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oncentratio  _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.5914 0.02829 21 -20.9 <.0001 Tukey <.0001
0uM 1uM -0.5158 0.02829 21 -18.23 <.0001 Tukey <.0001
0uM 20uM -0.6238 0.02829 21 -22.05 <.0001 Tukey <.0001
0uM 30uM -0.6034 0.02829 21 -21.33 <.0001 Tukey <.0001
0uM 3uM -0.5571 0.02829 21 -19.69 <.0001 Tukey <.0001
0uM 5uM -0.6054 0.02829 21 -21.4 <.0001 Tukey <.0001
10uM 1uM 0.07559 0.02829 21 2.67 0.0143 Tukey 0.1548
10uM 20uM -0.03235 0.02829 21 -1.14 0.2658 Tukey 0.9071
10uM 30uM -0.01202 0.02829 21 -0.42 0.6752 Tukey 0.9994
10uM 3uM 0.03432 0.02829 21 1.21 0.2386 Tukey 0.8813
10uM 5uM -0.01399 0.02829 21 -0.49 0.6262 Tukey 0.9987
1uM 20uM -0.1079 0.02829 21 -3.81 0.001 Tukey 0.0148
1uM 30uM -0.08761 0.02829 21 -3.1 0.0055 Tukey 0.0686
1uM 3uM -0.04127 0.02829 21 -1.46 0.1595 Tukey 0.7648
1uM 5uM -0.08958 0.02829 21 -3.17 0.0047 Tukey 0.0595
20uM 30uM 0.02032 0.02829 21 0.72 0.4805 Tukey 0.9899
20uM 3uM 0.06667 0.02829 21 2.36 0.0282 Tukey 0.2649
20uM 5uM 0.01836 0.02829 21 0.65 0.5235 Tukey 0.9941
30uM 3uM 0.04635 0.02829 21 1.64 0.1163 Tukey 0.661
30uM 5uM -0.00197 0.02829 21 -0.07 0.9452 Tukey 1
3uM 5uM -0.04831 0.02829 21 -1.71 0.1025 Tukey 0.6188
Obs concentration Estimate Standard Error Letter
Group
1 20uM 0.824 0.02001 A
2 5uM 0.8057 0.02001 AB
3 30uM 0.8037 0.02001 AB
4 10uM 0.7917 0.02001 AB
5 3uM 0.7574 0.02001 AB
6 1uM 0.7161 0.02001 B
7 0uM 0.2003 0.02001 C
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis of complexE 37.3% by Tukey's test: Abeta studies
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.5538 0.02184 21 -25.36 <.0001 Tukey <.0001
0uM 1uM -0.5219 0.02184 21 -23.9 <.0001 Tukey <.0001
0uM 20uM -0.5576 0.02184 21 -25.53 <.0001 Tukey <.0001
0uM 30uM -0.493 0.02184 21 -22.57 <.0001 Tukey <.0001
0uM 3uM -0.5285 0.02184 21 -24.2 <.0001 Tukey <.0001
0uM 5uM -0.5289 0.02184 21 -24.22 <.0001 Tukey <.0001
10uM 1uM 0.03191 0.02184 21 1.46 0.1588 Tukey 0.7634
10uM 20uM -0.00377 0.02184 21 -0.17 0.8646 Tukey 1
10uM 30uM 0.06087 0.02184 21 2.79 0.011 Tukey 0.1252
10uM 3uM 0.02536 0.02184 21 1.16 0.2587 Tukey 0.9009
10uM 5uM 0.02489 0.02184 21 1.14 0.2672 Tukey 0.9082
1uM 20uM -0.03568 0.02184 21 -1.63 0.1172 Tukey 0.6636
1uM 30uM 0.02896 0.02184 21 1.33 0.1991 Tukey 0.8324
1uM 3uM -0.00655 0.02184 21 -0.3 0.767 Tukey 0.9999
1uM 5uM -0.00702 0.02184 21 -0.32 0.7512 Tukey 0.9999
20uM 30uM 0.06464 0.02184 21 2.96 0.0075 Tukey 0.09
20uM 3uM 0.02912 0.02184 21 1.33 0.1966 Tukey 0.8288
20uM 5uM 0.02866 0.02184 21 1.31 0.2036 Tukey 0.8388
30uM 3uM -0.03552 0.02184 21 -1.63 0.1188 Tukey 0.6682
30uM 5uM -0.03598 0.02184 21 -1.65 0.1144 Tukey 0.6554
3uM 5uM -0.00046 0.02184 21 -0.02 0.9833 Tukey 1
Obs concentration Estimate Standard Error Letter
Group
1 20uM 0.7579 0.01544 A
2 10uM 0.7541 0.01544 A
3 5uM 0.7292 0.01544 A
4 3uM 0.7287 0.01544 A
5 1uM 0.7222 0.01544 A
6 30uM 0.6932 0.01544 A
7 0uM 0.2003 0.01544 B
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis of complex F 40.7% by Tukey's test: Abeta studies
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.4314 0.02247 21 -19.2 <.0001 Tukey <.0001
0uM 1uM -0.4162 0.02247 21 -18.52 <.0001 Tukey <.0001
0uM 20uM -0.4036 0.02247 21 -17.96 <.0001 Tukey <.0001
0uM 30uM -0.42 0.02247 21 -18.69 <.0001 Tukey <.0001
0uM 3uM -0.4211 0.02247 21 -18.74 <.0001 Tukey <.0001
0uM 5uM -0.3937 0.02247 21 -17.52 <.0001 Tukey <.0001
10uM 1uM 0.01519 0.02247 21 0.68 0.5065 Tukey 0.9926
10uM 20uM 0.02783 0.02247 21 1.24 0.2293 Tukey 0.8712
10uM 30uM 0.01144 0.02247 21 0.51 0.6159 Tukey 0.9984
10uM 3uM 0.01032 0.02247 21 0.46 0.6508 Tukey 0.9991
10uM 5uM 0.03768 0.02247 21 1.68 0.1084 Tukey 0.6376
1uM 20uM 0.01264 0.02247 21 0.56 0.5798 Tukey 0.9973
1uM 30uM -0.00375 0.02247 21 -0.17 0.8692 Tukey 1
1uM 3uM -0.00487 0.02247 21 -0.22 0.8305 Tukey 1
1uM 5uM 0.02249 0.02247 21 1 0.3284 Tukey 0.9482
20uM 30uM -0.01639 0.02247 21 -0.73 0.474 Tukey 0.989
20uM 3uM -0.01751 0.02247 21 -0.78 0.4446 Tukey 0.9846
20uM 5uM 0.00985 0.02247 21 0.44 0.6657 Tukey 0.9993
30uM 3uM -0.00112 0.02247 21 -0.05 0.9606 Tukey 1
30uM 5uM 0.02624 0.02247 21 1.17 0.2561 Tukey 0.8986
3uM 5uM 0.02736 0.02247 21 1.22 0.2369 Tukey 0.8796
Obs concentration Estimate Standard Error Letter
Group
1 10uM 0.6317 0.01589 A
2 3uM 0.6214 0.01589 A
3 30uM 0.6202 0.01589 A
4 1uM 0.6165 0.01589 A
5 20uM 0.6038 0.01589 A
6 5uM 0.594 0.01589 A
7 0uM 0.2003 0.01589 B
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical analysis of complex G 48% by Tukey's test: Abeta studies
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.1853 0.02152 24 -8.61 <.0001 Tukey <.0001
A7.8 C17.6 -0.2708 0.02152 24 -12.58 <.0001 Tukey <.0001
A7.8 Chi0 -0.132 0.02152 24 -6.13 <.0001 Tukey <.0001
A7.8 D24.5 -0.2881 0.02152 24 -13.39 <.0001 Tukey <.0001
A7.8 E37.3 -0.2097 0.02152 24 -9.74 <.0001 Tukey <.0001
A7.8 F40.7 -0.2158 0.02152 24 -10.02 <.0001 Tukey <.0001
A7.8 G48 -0.11 0.02152 24 -5.11 <.0001 Tukey 0.0007
B14.1 C17.6 -0.08552 0.02152 24 -3.97 0.0006 Tukey 0.0112
B14.1 Chi0 0.05329 0.02152 24 2.48 0.0207 Tukey 0.2524
B14.1 D24.5 -0.1028 0.02152 24 -4.78 <.0001 Tukey 0.0016
B14.1 E37.3 -0.02437 0.02152 24 -1.13 0.2687 Tukey 0.9428
B14.1 F40.7 -0.03048 0.02152 24 -1.42 0.1696 Tukey 0.8411
B14.1 G48 0.07523 0.02152 24 3.5 0.0019 Tukey 0.0334
C17.6 Chi0 0.1388 0.02152 24 6.45 <.0001 Tukey <.0001
C17.6 D24.5 -0.01731 0.02152 24 -0.8 0.4293 Tukey 0.9912
C17.6 E37.3 0.06114 0.02152 24 2.84 0.009 Tukey 0.1311
C17.6 F40.7 0.05504 0.02152 24 2.56 0.0173 Tukey 0.22
C17.6 G48 0.1608 0.02152 24 7.47 <.0001 Tukey <.0001
Chi0 D24.5 -0.1561 0.02152 24 -7.25 <.0001 Tukey <.0001
Chi0 E37.3 -0.07766 0.02152 24 -3.61 0.0014 Tukey 0.026
Chi0 F40.7 -0.08377 0.02152 24 -3.89 0.0007 Tukey 0.0135
Chi0 G48 0.02194 0.02152 24 1.02 0.3181 Tukey 0.9667
D24.5 E37.3 0.07845 0.02152 24 3.64 0.0013 Tukey 0.0239
D24.5 F40.7 0.07234 0.02152 24 3.36 0.0026 Tukey 0.0449
D24.5 G48 0.1781 0.02152 24 8.27 <.0001 Tukey <.0001
E37.3 F40.7 -0.00611 0.02152 24 -0.28 0.779 Tukey 1
E37.3 G48 0.09961 0.02152 24 4.63 0.0001 Tukey 0.0023
F40.7 G48 0.1057 0.02152 24 4.91 <.0001 Tukey 0.0012
Obs complex Estimate Standard Error Letter
Group
1 D24.5 0.7945 0.01522 A
2 C17.6 0.7772 0.01522 AB
3 F40.7 0.7222 0.01522 BC
4 E37.3 0.7161 0.01522 BC
5 B14.1 0.6917 0.01522 CD
6 Chi0 0.6384 0.01522 DE
7 G48 0.6165 0.01522 E
8 A7.8 0.5064 0.01522 F
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis for SA-Chi complexes at 1uM conc by Tukey's test : Abeta studies
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.2188 0.02857 24 -7.66 <.0001 Tukey <.0001
A7.8 C17.6 -0.324 0.02857 24 -11.34 <.0001 Tukey <.0001
A7.8 Chi0 -0.1447 0.02857 24 -5.06 <.0001 Tukey 0.0008
A7.8 D24.5 -0.2968 0.02857 24 -10.39 <.0001 Tukey <.0001
A7.8 E37.3 -0.2819 0.02857 24 -9.87 <.0001 Tukey <.0001
A7.8 F40.7 -0.2533 0.02857 24 -8.87 <.0001 Tukey <.0001
A7.8 G48 -0.1459 0.02857 24 -5.11 <.0001 Tukey 0.0007
B14.1 C17.6 -0.1052 0.02857 24 -3.68 0.0012 Tukey 0.0219
B14.1 Chi0 0.0741 0.02857 24 2.59 0.0159 Tukey 0.2066
B14.1 D24.5 -0.07799 0.02857 24 -2.73 0.0117 Tukey 0.1617
B14.1 E37.3 -0.06314 0.02857 24 -2.21 0.0369 Tukey 0.3808
B14.1 F40.7 -0.03453 0.02857 24 -1.21 0.2386 Tukey 0.9215
B14.1 G48 0.07286 0.02857 24 2.55 0.0176 Tukey 0.2227
C17.6 Chi0 0.1793 0.02857 24 6.28 <.0001 Tukey <.0001
C17.6 D24.5 0.02722 0.02857 24 0.95 0.3503 Tukey 0.9769
C17.6 E37.3 0.04208 0.02857 24 1.47 0.1539 Tukey 0.814
C17.6 F40.7 0.07068 0.02857 24 2.47 0.0208 Tukey 0.2534
C17.6 G48 0.1781 0.02857 24 6.23 <.0001 Tukey <.0001
Chi0 D24.5 -0.1521 0.02857 24 -5.32 <.0001 Tukey 0.0004
Chi0 E37.3 -0.1372 0.02857 24 -4.8 <.0001 Tukey 0.0015
Chi0 F40.7 -0.1086 0.02857 24 -3.8 0.0009 Tukey 0.0167
Chi0 G48 -0.00124 0.02857 24 -0.04 0.9658 Tukey 1
D24.5 E37.3 0.01486 0.02857 24 0.52 0.6079 Tukey 0.9994
D24.5 F40.7 0.04346 0.02857 24 1.52 0.1413 Tukey 0.7891
D24.5 G48 0.1509 0.02857 24 5.28 <.0001 Tukey 0.0005
E37.3 F40.7 0.0286 0.02857 24 1 0.3268 Tukey 0.9698
E37.3 G48 0.136 0.02857 24 4.76 <.0001 Tukey 0.0017
F40.7 G48 0.1074 0.02857 24 3.76 0.001 Tukey 0.0184
Obs complex Estimate Standard Error Letter
Group
1 C17.6 0.7994 0.0202 A
2 D24.5 0.7722 0.0202 AB
3 E37.3 0.7574 0.0202 AB
4 F40.7 0.7287 0.0202 AB
5 B14.1 0.6942 0.0202 BC
6 G48 0.6214 0.0202 C
7 Chi0 0.6201 0.0202 C
8 A7.8 0.4754 0.0202 D
Statistical analysis for SA-Chi complexes at 3uM conc by Tukey's test : Abeta studies
Differences of Least Squares Means
Effect=complex Method=Tukey(P<.05) Set=1
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complex _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.1894 0.0239 24 -7.92 <.0001 Tukey <.0001
A7.8 C17.6 -0.3067 0.0239 24 -12.83 <.0001 Tukey <.0001
A7.8 Chi0 -0.1776 0.0239 24 -7.43 <.0001 Tukey <.0001
A7.8 D24.5 -0.308 0.0239 24 -12.89 <.0001 Tukey <.0001
A7.8 E37.3 -0.3197 0.0239 24 -13.38 <.0001 Tukey <.0001
A7.8 F40.7 -0.2433 0.0239 24 -10.18 <.0001 Tukey <.0001
A7.8 G48 -0.1081 0.0239 24 -4.52 0.0001 Tukey 0.003
B14.1 C17.6 -0.1173 0.0239 24 -4.91 <.0001 Tukey 0.0012
B14.1 Chi0 0.01181 0.0239 24 0.49 0.6256 Tukey 0.9996
B14.1 D24.5 -0.1186 0.0239 24 -4.96 <.0001 Tukey 0.001
B14.1 E37.3 -0.1304 0.0239 24 -5.46 <.0001 Tukey 0.0003
B14.1 F40.7 -0.05391 0.0239 24 -2.26 0.0335 Tukey 0.3561
B14.1 G48 0.08131 0.0239 24 3.4 0.0023 Tukey 0.0411
C17.6 Chi0 0.1291 0.0239 24 5.4 <.0001 Tukey 0.0003
C17.6 D24.5 -0.00133 0.0239 24 -0.06 0.956 Tukey 1
C17.6 E37.3 -0.01307 0.0239 24 -0.55 0.5896 Tukey 0.9992
C17.6 F40.7 0.06339 0.0239 24 2.65 0.0139 Tukey 0.1861
C17.6 G48 0.1986 0.0239 24 8.31 <.0001 Tukey <.0001
Chi0 D24.5 -0.1305 0.0239 24 -5.46 <.0001 Tukey 0.0003
Chi0 E37.3 -0.1422 0.0239 24 -5.95 <.0001 Tukey <.0001
Chi0 F40.7 -0.06573 0.0239 24 -2.75 0.0111 Tukey 0.1556
Chi0 G48 0.06949 0.0239 24 2.91 0.0077 Tukey 0.1151
D24.5 E37.3 -0.01173 0.0239 24 -0.49 0.6279 Tukey 0.9996
D24.5 F40.7 0.06472 0.0239 24 2.71 0.0123 Tukey 0.1682
D24.5 G48 0.1999 0.0239 24 8.37 <.0001 Tukey <.0001
E37.3 F40.7 0.07645 0.0239 24 3.2 0.0038 Tukey 0.0636
E37.3 G48 0.2117 0.0239 24 8.86 <.0001 Tukey <.0001
F40.7 G48 0.1352 0.0239 24 5.66 <.0001 Tukey 0.0002
Obs complex Estimatetandard Err Letter
Group
1 E37.3 0.8057 0.0169 A
2 D24.5 0.7939 0.0169 A
3 C17.6 0.7926 0.0169 A
4 F40.7 0.7292 0.0169 AB
5 B14.1 0.6753 0.0169 B
6 Chi0 0.6635 0.0169 BC
7 G48 0.594 0.0169 C
8 A7.8 0.4859 0.0169 D
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis for SA-Chi complexes at 5uM conc by Tukey's test : Abeta studies
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.1752 0.02326 24 -7.53 <.0001 Tukey <.0001
A7.8 C17.6 -0.2405 0.02326 24 -10.34 <.0001 Tukey <.0001
A7.8 Chi0 -0.224 0.02326 24 -9.63 <.0001 Tukey <.0001
A7.8 D24.5 -0.2616 0.02326 24 -11.25 <.0001 Tukey <.0001
A7.8 E37.3 -0.261 0.02326 24 -11.22 <.0001 Tukey <.0001
A7.8 F40.7 -0.2234 0.02326 24 -9.61 <.0001 Tukey <.0001
A7.8 G48 -0.101 0.02326 24 -4.34 0.0002 Tukey 0.0046
B14.1 C17.6 -0.06537 0.02326 24 -2.81 0.0097 Tukey 0.1389
B14.1 Chi0 -0.0488 0.02326 24 -2.1 0.0466 Tukey 0.4436
B14.1 D24.5 -0.08646 0.02326 24 -3.72 0.0011 Tukey 0.0202
B14.1 E37.3 -0.08583 0.02326 24 -3.69 0.0011 Tukey 0.0215
B14.1 F40.7 -0.04825 0.02326 24 -2.07 0.0489 Tukey 0.4574
B14.1 G48 0.07418 0.02326 24 3.19 0.0039 Tukey 0.0649
C17.6 Chi0 0.01657 0.02326 24 0.71 0.4831 Tukey 0.9958
C17.6 D24.5 -0.02109 0.02326 24 -0.91 0.3735 Tukey 0.9825
C17.6 E37.3 -0.02046 0.02326 24 -0.88 0.3878 Tukey 0.9853
C17.6 F40.7 0.01711 0.02326 24 0.74 0.469 Tukey 0.9948
C17.6 G48 0.1395 0.02326 24 6 <.0001 Tukey <.0001
Chi0 D24.5 -0.03766 0.02326 24 -1.62 0.1185 Tukey 0.7349
Chi0 E37.3 -0.03703 0.02326 24 -1.59 0.1245 Tukey 0.7504
Chi0 F40.7 0.000547 0.02326 24 0.02 0.9814 Tukey 1
Chi0 G48 0.123 0.02326 24 5.29 <.0001 Tukey 0.0005
D24.5 E37.3 0.000633 0.02326 24 0.03 0.9785 Tukey 1
D24.5 F40.7 0.0382 0.02326 24 1.64 0.1135 Tukey 0.7213
D24.5 G48 0.1606 0.02326 24 6.91 <.0001 Tukey <.0001
E37.3 F40.7 0.03757 0.02326 24 1.62 0.1193 Tukey 0.737
E37.3 G48 0.16 0.02326 24 6.88 <.0001 Tukey <.0001
F40.7 G48 0.1224 0.02326 24 5.26 <.0001 Tukey 0.0005
Obs complex Estimate Standard Error Letter
Group
1 D24.5 0.7923 0.01645 A
2 E37.3 0.7917 0.01645 A
3 C17.6 0.7712 0.01645 AB
4 Chi0 0.7547 0.01645 AB
5 F40.7 0.7541 0.01645 AB
6 B14.1 0.7059 0.01645 BC
7 G48 0.6317 0.01645 C
8 A7.8 0.5307 0.01645 D
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis for SA-Chi complexes at 10uM conc by Tukey's test : Abeta studies
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.2005 0.0232 24 -8.64 <.0001 Tukey <.0001
A7.8 C17.6 -0.2541 0.0232 24 -10.95 <.0001 Tukey <.0001
A7.8 Chi0 -0.2595 0.0232 24 -11.18 <.0001 Tukey <.0001
A7.8 D24.5 -0.296 0.0232 24 -12.76 <.0001 Tukey <.0001
A7.8 E37.3 -0.3236 0.0232 24 -13.95 <.0001 Tukey <.0001
A7.8 F40.7 -0.2575 0.0232 24 -11.1 <.0001 Tukey <.0001
A7.8 G48 -0.1034 0.0232 24 -4.46 0.0002 Tukey 0.0035
B14.1 C17.6 -0.05367 0.0232 24 -2.31 0.0296 Tukey 0.3269
B14.1 Chi0 -0.05898 0.0232 24 -2.54 0.0179 Tukey 0.2257
B14.1 D24.5 -0.09557 0.0232 24 -4.12 0.0004 Tukey 0.0079
B14.1 E37.3 -0.1231 0.0232 24 -5.31 <.0001 Tukey 0.0004
B14.1 F40.7 -0.05698 0.0232 24 -2.46 0.0217 Tukey 0.2608
B14.1 G48 0.09705 0.0232 24 4.18 0.0003 Tukey 0.0068
C17.6 Chi0 -0.00531 0.0232 24 -0.23 0.8209 Tukey 1
C17.6 D24.5 -0.0419 0.0232 24 -1.81 0.0835 Tukey 0.6224
C17.6 E37.3 -0.06946 0.0232 24 -2.99 0.0063 Tukey 0.0971
C17.6 F40.7 -0.00331 0.0232 24 -0.14 0.8876 Tukey 1
C17.6 G48 0.1507 0.0232 24 6.5 <.0001 Tukey <.0001
Chi0 D24.5 -0.03659 0.0232 24 -1.58 0.1279 Tukey 0.7587
Chi0 E37.3 -0.06415 0.0232 24 -2.77 0.0108 Tukey 0.1513
Chi0 F40.7 0.001996 0.0232 24 0.09 0.9321 Tukey 1
Chi0 G48 0.156 0.0232 24 6.73 <.0001 Tukey <.0001
D24.5 E37.3 -0.02757 0.0232 24 -1.19 0.2464 Tukey 0.9277
D24.5 F40.7 0.03858 0.0232 24 1.66 0.1093 Tukey 0.7093
D24.5 G48 0.1926 0.0232 24 8.3 <.0001 Tukey <.0001
E37.3 F40.7 0.06615 0.0232 24 2.85 0.0088 Tukey 0.1285
E37.3 G48 0.2202 0.0232 24 9.49 <.0001 Tukey <.0001
F40.7 G48 0.154 0.0232 24 6.64 <.0001 Tukey <.0001
Obs complex Estimate Standard Error Letter
Group
1 E37.3 0.824 0.01641 A
2 D24.5 0.7965 0.01641 A
3 Chi0 0.7599 0.01641 AB
4 F40.7 0.7579 0.01641 AB
5 C17.6 0.7546 0.01641 AB
6 B14.1 0.7009 0.01641 B
7 G48 0.6038 0.01641 C
8 A7.8 0.5004 0.01641 D
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis for SA-Chi complexes at 20uM conc by Tukey's test : Abeta studies
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
A7.8 B14.1 -0.178 0.02554 24 -6.97 <.0001 Tukey <.0001
A7.8 C17.6 -0.2304 0.02554 24 -9.02 <.0001 Tukey <.0001
A7.8 Chi0 -0.215 0.02554 24 -8.42 <.0001 Tukey <.0001
A7.8 D24.5 -0.2707 0.02554 24 -10.6 <.0001 Tukey <.0001
A7.8 E37.3 -0.2979 0.02554 24 -11.66 <.0001 Tukey <.0001
A7.8 F40.7 -0.1874 0.02554 24 -7.34 <.0001 Tukey <.0001
A7.8 G48 -0.1144 0.02554 24 -4.48 0.0002 Tukey 0.0033
B14.1 C17.6 -0.05233 0.02554 24 -2.05 0.0516 Tukey 0.4727
B14.1 Chi0 -0.03695 0.02554 24 -1.45 0.1609 Tukey 0.8267
B14.1 D24.5 -0.09268 0.02554 24 -3.63 0.0013 Tukey 0.0248
B14.1 E37.3 -0.1199 0.02554 24 -4.69 <.0001 Tukey 0.002
B14.1 F40.7 -0.00939 0.02554 24 -0.37 0.7165 Tukey 0.9999
B14.1 G48 0.06362 0.02554 24 2.49 0.0201 Tukey 0.2462
C17.6 Chi0 0.01538 0.02554 24 0.6 0.5527 Tukey 0.9985
C17.6 D24.5 -0.04035 0.02554 24 -1.58 0.1273 Tukey 0.7573
C17.6 E37.3 -0.06752 0.02554 24 -2.64 0.0142 Tukey 0.189
C17.6 F40.7 0.04295 0.02554 24 1.68 0.1057 Tukey 0.6984
C17.6 G48 0.116 0.02554 24 4.54 0.0001 Tukey 0.0029
Chi0 D24.5 -0.05573 0.02554 24 -2.18 0.0392 Tukey 0.3961
Chi0 E37.3 -0.0829 0.02554 24 -3.25 0.0034 Tukey 0.0576
Chi0 F40.7 0.02757 0.02554 24 1.08 0.2912 Tukey 0.9552
Chi0 G48 0.1006 0.02554 24 3.94 0.0006 Tukey 0.0121
D24.5 E37.3 -0.02718 0.02554 24 -1.06 0.2979 Tukey 0.9584
D24.5 F40.7 0.08329 0.02554 24 3.26 0.0033 Tukey 0.0558
D24.5 G48 0.1563 0.02554 24 6.12 <.0001 Tukey <.0001
E37.3 F40.7 0.1105 0.02554 24 4.32 0.0002 Tukey 0.0048
E37.3 G48 0.1835 0.02554 24 7.18 <.0001 Tukey <.0001
F40.7 G48 0.07301 0.02554 24 2.86 0.0087 Tukey 0.1268
Obs complex Estimate Standard Error Letter Group
1 E37.3 0.8037 0.01806 A
2 D24.5 0.7765 0.01806 AB
3 C17.6 0.7362 0.01806 ABC
4 Chi0 0.7208 0.01806 ABC
5 F40.7 0.6932 0.01806 BCD
6 B14.1 0.6838 0.01806 CD
7 G48 0.6202 0.01806 D
8 A7.8 0.5058 0.01806 E
Differences of Least Squares Means
Effect=complex Method=Tukey(P<.05) Set=1
Statistical analysis for SA-Chi complexes at 30uM conc by Tukey's test : Abeta studies
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complex concentration _complex _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
KDN-A 0uM KDN-A 10uM 0.03484 0.02624 24 1.33 0.1968 Tukey 0.8793
KDN-A 0uM KDN-A 20uM 0.1161 0.02624 24 4.42 0.0002 Tukey 0.0038
KDN-A 0uM KDN-A 30uM 0.1113 0.02624 24 4.24 0.0003 Tukey 0.0059
KDN-A 0uM KDN-A 3uM 0.0515 0.02624 24 1.96 0.0614 Tukey 0.5251
KDN-A 0uM KDN-A 40uM 0.1006 0.02624 24 3.83 0.0008 Tukey 0.0155
KDN-A 0uM KDN-A 48uM 0.08676 0.02624 24 3.31 0.003 Tukey 0.0507
KDN-A 0uM KDN-A 5uM 0.02761 0.02624 24 1.05 0.3032 Tukey 0.9607
KDN-A 10uM KDN-A 20uM 0.08126 0.02624 24 3.1 0.0049 Tukey 0.0788
KDN-A 10uM KDN-A 30uM 0.0765 0.02624 24 2.91 0.0076 Tukey 0.1135
KDN-A 10uM KDN-A 3uM 0.01666 0.02624 24 0.63 0.5316 Tukey 0.9979
KDN-A 10uM KDN-A 40uM 0.06576 0.02624 24 2.51 0.0194 Tukey 0.2401
KDN-A 10uM KDN-A 48uM 0.05191 0.02624 24 1.98 0.0595 Tukey 0.5154
KDN-A 10uM KDN-A 5uM -0.00723 0.02624 24 -0.28 0.7853 Tukey 1
KDN-A 20uM KDN-A 30uM -0.00476 0.02624 24 -0.18 0.8574 Tukey 1
KDN-A 20uM KDN-A 3uM -0.0646 0.02624 24 -2.46 0.0214 Tukey 0.2584
KDN-A 20uM KDN-A 40uM -0.0155 0.02624 24 -0.59 0.5602 Tukey 0.9987
KDN-A 20uM KDN-A 48uM -0.02935 0.02624 24 -1.12 0.2745 Tukey 0.9463
KDN-A 20uM KDN-A 5uM -0.08849 0.02624 24 -3.37 0.0025 Tukey 0.0439
KDN-A 30uM KDN-A 3uM -0.05984 0.02624 24 -2.28 0.0318 Tukey 0.3436
KDN-A 30uM KDN-A 40uM -0.01074 0.02624 24 -0.41 0.686 Tukey 0.9999
KDN-A 30uM KDN-A 48uM -0.02458 0.02624 24 -0.94 0.3582 Tukey 0.979
KDN-A 30uM KDN-A 5uM -0.08373 0.02624 24 -3.19 0.0039 Tukey 0.0648
KDN-A 3uM KDN-A 40uM 0.0491 0.02624 24 1.87 0.0736 Tukey 0.5818
KDN-A 3uM KDN-A 48uM 0.03526 0.02624 24 1.34 0.1917 Tukey 0.8729
KDN-A 3uM KDN-A 5uM -0.02389 0.02624 24 -0.91 0.3717 Tukey 0.9821
KDN-A 40uM KDN-A 48uM -0.01384 0.02624 24 -0.53 0.6027 Tukey 0.9994
KDN-A 40uM KDN-A 5uM -0.07299 0.02624 24 -2.78 0.0104 Tukey 0.1468
KDN-A 48uM KDN-A 5uM -0.05914 0.02624 24 -2.25 0.0336 Tukey 0.3573
Obs complex oncentratio Estimate Standard Error Letter Group
1 KDN-A 0uM 1 0.01856 A
2 KDN-A 5uM 0.9724 0.01856 AB
3 KDN-A 10uM 0.9652 0.01856 ABC
4 KDN-A 3uM 0.9485 0.01856 ABC
5 KDN-A 48uM 0.9132 0.01856 ABC
6 KDN-A 40uM 0.8994 0.01856 BC
7 KDN-A 30uM 0.8887 0.01856 BC
8 KDN-A 20uM 0.8839 0.01856 C
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis of KDN Analog Intrinsic Toxicity by Tukey's test
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complex oncentratio  _complex oncentratio  Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
GA-A 0uM GA-A 10uM 0.3719 0.02372 24 15.68 <.0001 Tukey <.0001
GA-A 0uM GA-A 20uM 0.4151 0.02372 24 17.5 <.0001 Tukey <.0001
GA-A 0uM GA-A 30uM 0.405 0.02372 24 17.07 <.0001 Tukey <.0001
GA-A 0uM GA-A 3uM 0.3663 0.02372 24 15.44 <.0001 Tukey <.0001
GA-A 0uM GA-A 40uM 0.3536 0.02372 24 14.91 <.0001 Tukey <.0001
GA-A 0uM GA-A 48uM 0.3402 0.02372 24 14.34 <.0001 Tukey <.0001
GA-A 0uM GA-A 5uM 0.3579 0.02372 24 15.09 <.0001 Tukey <.0001
GA-A 10uM GA-A 20uM 0.04316 0.02372 24 1.82 0.0814 Tukey 0.614
GA-A 10uM GA-A 30uM 0.03303 0.02372 24 1.39 0.1766 Tukey 0.852
GA-A 10uM GA-A 3uM -0.00562 0.02372 24 -0.24 0.8149 Tukey 1
GA-A 10uM GA-A 40uM -0.01832 0.02372 24 -0.77 0.4475 Tukey 0.9931
GA-A 10uM GA-A 48uM -0.03177 0.02372 24 -1.34 0.1931 Tukey 0.8747
GA-A 10uM GA-A 5uM -0.01404 0.02372 24 -0.59 0.5596 Tukey 0.9987
GA-A 20uM GA-A 30uM -0.01013 0.02372 24 -0.43 0.6731 Tukey 0.9998
GA-A 20uM GA-A 3uM -0.04877 0.02372 24 -2.06 0.0508 Tukey 0.4684
GA-A 20uM GA-A 40uM -0.06148 0.02372 24 -2.59 0.016 Tukey 0.2073
GA-A 20uM GA-A 48uM -0.07493 0.02372 24 -3.16 0.0042 Tukey 0.0693
GA-A 20uM GA-A 5uM -0.0572 0.02372 24 -2.41 0.0239 Tukey 0.2806
GA-A 30uM GA-A 3uM -0.03864 0.02372 24 -1.63 0.1164 Tukey 0.7293
GA-A 30uM GA-A 40uM -0.05135 0.02372 24 -2.16 0.0406 Tukey 0.4057
GA-A 30uM GA-A 48uM -0.06479 0.02372 24 -2.73 0.0116 Tukey 0.1612
GA-A 30uM GA-A 5uM -0.04706 0.02372 24 -1.98 0.0588 Tukey 0.512
GA-A 3uM GA-A 40uM -0.0127 0.02372 24 -0.54 0.5972 Tukey 0.9993
GA-A 3uM GA-A 48uM -0.02615 0.02372 24 -1.1 0.2812 Tukey 0.9501
GA-A 3uM GA-A 5uM -0.00842 0.02372 24 -0.35 0.7257 Tukey 1
GA-A 40uM GA-A 48uM -0.01345 0.02372 24 -0.57 0.5761 Tukey 0.999
GA-A 40uM GA-A 5uM 0.004283 0.02372 24 0.18 0.8582 Tukey 1
GA-A 48uM GA-A 5uM 0.01773 0.02372 24 0.75 0.4621 Tukey 0.9943
Obs complexoncentratio Estimatetandard Err Letter
Group
1 GA-A 0uM 1 0.01678 A
2 GA-A 48uM 0.6598 0.01678 B
3 GA-A 40uM 0.6464 0.01678 B
4 GA-A 5uM 0.6421 0.01678 B
5 GA-A 3uM 0.6337 0.01678 B
6 GA-A 10uM 0.6281 0.01678 B
7 GA-A 30uM 0.595 0.01678 B
8 GA-A 20uM 0.5849 0.01678 B
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis of GA Analog Intrinsic Toxicity by Tukey's test
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complex concentration _complex _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
Pyran-A 0uM Pyran-A 10uM 0.2819 0.03217 24 8.76 <.0001 Tukey <.0001
Pyran-A 0uM Pyran-A 20uM 0.1456 0.03217 24 4.53 0.0001 Tukey 0.003
Pyran-A 0uM Pyran-A 30uM 0.1891 0.03217 24 5.88 <.0001 Tukey 0.0001
Pyran-A 0uM Pyran-A 3uM 0.3245 0.03217 24 10.09 <.0001 Tukey <.0001
Pyran-A 0uM Pyran-A 40uM 0.1957 0.03217 24 6.08 <.0001 Tukey <.0001
Pyran-A 0uM Pyran-A 48uM 0.1872 0.03217 24 5.82 <.0001 Tukey 0.0001
Pyran-A 0uM Pyran-A 5uM 0.2358 0.03217 24 7.33 <.0001 Tukey <.0001
Pyran-A 10uM Pyran-A 20uM -0.1363 0.03217 24 -4.24 0.0003 Tukey 0.006
Pyran-A 10uM Pyran-A 30uM -0.09271 0.03217 24 -2.88 0.0082 Tukey 0.1211
Pyran-A 10uM Pyran-A 3uM 0.04265 0.03217 24 1.33 0.1974 Tukey 0.8801
Pyran-A 10uM Pyran-A 40uM -0.08617 0.03217 24 -2.68 0.0131 Tukey 0.1774
Pyran-A 10uM Pyran-A 48uM -0.0947 0.03217 24 -2.94 0.0071 Tukey 0.1073
Pyran-A 10uM Pyran-A 5uM -0.04609 0.03217 24 -1.43 0.1648 Tukey 0.8333
Pyran-A 20uM Pyran-A 30uM 0.04356 0.03217 24 1.35 0.1883 Tukey 0.8684
Pyran-A 20uM Pyran-A 3uM 0.1789 0.03217 24 5.56 <.0001 Tukey 0.0002
Pyran-A 20uM Pyran-A 40uM 0.0501 0.03217 24 1.56 0.1325 Tukey 0.7696
Pyran-A 20uM Pyran-A 48uM 0.04158 0.03217 24 1.29 0.2085 Tukey 0.8929
Pyran-A 20uM Pyran-A 5uM 0.09018 0.03217 24 2.8 0.0099 Tukey 0.1408
Pyran-A 30uM Pyran-A 3uM 0.1354 0.03217 24 4.21 0.0003 Tukey 0.0064
Pyran-A 30uM Pyran-A 40uM 0.006535 0.03217 24 0.2 0.8407 Tukey 1
Pyran-A 30uM Pyran-A 48uM -0.00199 0.03217 24 -0.06 0.9512 Tukey 1
Pyran-A 30uM Pyran-A 5uM 0.04662 0.03217 24 1.45 0.1602 Tukey 0.8255
Pyran-A 3uM Pyran-A 40uM -0.1288 0.03217 24 -4 0.0005 Tukey 0.0104
Pyran-A 3uM Pyran-A 48uM -0.1373 0.03217 24 -4.27 0.0003 Tukey 0.0055
Pyran-A 3uM Pyran-A 5uM -0.08874 0.03217 24 -2.76 0.0109 Tukey 0.1532
Pyran-A 40uM Pyran-A 48uM -0.00852 0.03217 24 -0.26 0.7933 Tukey 1
Pyran-A 40uM Pyran-A 5uM 0.04008 0.03217 24 1.25 0.2248 Tukey 0.9094
Pyran-A 48uM Pyran-A 5uM 0.04861 0.03217 24 1.51 0.1439 Tukey 0.7944
Obs complex concentration Estimate andard Erro Letter Group
1 Pyran-A 0uM 1 0.02275 A
2 Pyran-A 20uM 0.8544 0.02275 B
3 Pyran-A 48uM 0.8128 0.02275 BC
4 Pyran-A 30uM 0.8109 0.02275 BC
5 Pyran-A 40uM 0.8043 0.02275 BC
6 Pyran-A 5uM 0.7642 0.02275 BCD
7 Pyran-A 10uM 0.7181 0.02275 CD
8 Pyran-A 3uM 0.6755 0.02275 D
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis of Pyran Analog Intrinsic Toxicity by Tukey's test
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complex oncentratio  _complex oncentratio  Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
CHC-A 0uM CHC-A 10uM 0.01937 0.02177 24 0.89 0.3822 Tukey 0.9842
CHC-A 0uM CHC-A 20uM 0.04671 0.02177 24 2.15 0.0422 Tukey 0.416
CHC-A 0uM CHC-A 30uM 0.02109 0.02177 24 0.97 0.3422 Tukey 0.9747
CHC-A 0uM CHC-A 3uM -0.04842 0.02177 24 -2.22 0.0358 Tukey 0.3726
CHC-A 0uM CHC-A 40uM -0.03364 0.02177 24 -1.55 0.1353 Tukey 0.776
CHC-A 0uM CHC-A 48uM -0.01484 0.02177 24 -0.68 0.5019 Tukey 0.9968
CHC-A 0uM CHC-A 5uM -0.01996 0.02177 24 -0.92 0.3683 Tukey 0.9813
CHC-A 10uM CHC-A 20uM 0.02733 0.02177 24 1.26 0.2212 Tukey 0.906
CHC-A 10uM CHC-A 30uM 0.001714 0.02177 24 0.08 0.9379 Tukey 1
CHC-A 10uM CHC-A 3uM -0.0678 0.02177 24 -3.11 0.0047 Tukey 0.0758
CHC-A 10uM CHC-A 40uM -0.05301 0.02177 24 -2.44 0.0227 Tukey 0.2696
CHC-A 10uM CHC-A 48uM -0.03421 0.02177 24 -1.57 0.1291 Tukey 0.7615
CHC-A 10uM CHC-A 5uM -0.03933 0.02177 24 -1.81 0.0833 Tukey 0.6215
CHC-A 20uM CHC-A 30uM -0.02562 0.02177 24 -1.18 0.2507 Tukey 0.9308
CHC-A 20uM CHC-A 3uM -0.09513 0.02177 24 -4.37 0.0002 Tukey 0.0043
CHC-A 20uM CHC-A 40uM -0.08035 0.02177 24 -3.69 0.0011 Tukey 0.0215
CHC-A 20uM CHC-A 48uM -0.06155 0.02177 24 -2.83 0.0093 Tukey 0.1344
CHC-A 20uM CHC-A 5uM -0.06667 0.02177 24 -3.06 0.0053 Tukey 0.0844
CHC-A 30uM CHC-A 3uM -0.06951 0.02177 24 -3.19 0.0039 Tukey 0.0643
CHC-A 30uM CHC-A 40uM -0.05473 0.02177 24 -2.51 0.019 Tukey 0.2366
CHC-A 30uM CHC-A 48uM -0.03593 0.02177 24 -1.65 0.1118 Tukey 0.7165
CHC-A 30uM CHC-A 5uM -0.04105 0.02177 24 -1.89 0.0715 Tukey 0.5725
CHC-A 3uM CHC-A 40uM 0.01478 0.02177 24 0.68 0.5035 Tukey 0.9968
CHC-A 3uM CHC-A 48uM 0.03358 0.02177 24 1.54 0.1359 Tukey 0.7774
CHC-A 3uM CHC-A 5uM 0.02846 0.02177 24 1.31 0.2034 Tukey 0.8871
CHC-A 40uM CHC-A 48uM 0.0188 0.02177 24 0.86 0.3963 Tukey 0.9867
CHC-A 40uM CHC-A 5uM 0.01368 0.02177 24 0.63 0.5356 Tukey 0.9981
CHC-A 48uM CHC-A 5uM -0.00512 0.02177 24 -0.24 0.816 Tukey 1
Obs complexoncentratio Estimatetandard Err Letter
Group
1 CHC-A 3uM 1.0484 0.01539 A
2 CHC-A 40uM 1.0336 0.01539 A
3 CHC-A 5uM 1.02 0.01539 AB
4 CHC-A 48uM 1.0148 0.01539 AB
5 CHC-A 0uM 1 0.01539 AB
6 CHC-A 10uM 0.9806 0.01539 AB
7 CHC-A 30uM 0.9789 0.01539 AB
8 CHC-A 20uM 0.9533 0.01539 B
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Statistical Analysis of CHC Analog Intrinsic Toxicity by Tukey's test
Differences of Least Squares Means
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oncentratio  complex _concentration _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
3uM CHC-A 3uM GA-A 0.4147 0.02646 12 15.68 <.0001 Tukey <.0001
3uM CHC-A 3uM KDN-A 0.09992 0.02646 12 3.78 0.0026 Tukey 0.0122
3uM CHC-A 3uM Pyran-A 0.3729 0.02646 12 14.1 <.0001 Tukey <.0001
3uM GA-A 3uM KDN-A -0.3148 0.02646 12 -11.9 <.0001 Tukey <.0001
3uM GA-A 3uM Pyran-A -0.0418 0.02646 12 -1.58 0.1401 Tukey 0.4248
3uM KDN-A 3uM Pyran-A 0.273 0.02646 12 10.32 <.0001 Tukey <.0001
mplex Method=Tukey(P<.05) Set=1
Obs oncentratio complex Estimate andard Erro Letter
Group
1 3uM CHC-A 1.0484 0.01871 A
2 3uM KDN-A 0.9485 0.01871 B
3 3uM Pyran-A 0.6755 0.01871 C
4 3uM GA-A 0.6337 0.01871 C
Differences of Least Squares Means
Statistical analysis of sugar analogs intrinsic toxicity at 3uM concentration by Tukey's test
concentrat  complex _concentr  _complex Estimate Standard E  DF t Value Pr > |t| Adjustme  Adj P
5uM CHC-A 5uM GA-A 0.3778 0.02668 12 14.16 <.0001 Tukey <.0001
5uM CHC-A 5uM KDN-A 0.04757 0.02668 12 1.78 0.0999 Tukey 0.3273
5uM CHC-A 5uM Pyran-A 0.2557 0.02668 12 9.59 <.0001 Tukey <.0001
5uM GA-A 5uM KDN-A -0.3303 0.02668 12 -12.38 <.0001 Tukey <.0001
5uM GA-A 5uM Pyran-A -0.1221 0.02668 12 -4.58 0.0006 Tukey 0.0031
5uM KDN-A 5uM Pyran-A 0.2082 0.02668 12 7.8 <.0001 Tukey <.0001
Obs concentratcomplex Estimate Standard ELetter
Group
1 5uM CHC-A 1.02 0.01887 A
2 5uM KDN-A 0.9724 0.01887 A
3 5uM Pyran-A 0.7642 0.01887 B
4 5uM GA-A 0.6421 0.01887 C
Differences of Least Squares Means
Statistical analysis of sugar analogs intrinsic toxicity at 5uM concentration by Tukey's test
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
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oncentratio  complex _concentration _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
10uM CHC-A 10uM GA-A 0.3526 0.02714 12 12.99 <.0001 Tukey <.0001
10uM CHC-A 10uM KDN-A 0.01547 0.02714 12 0.57 0.5794 Tukey 0.9392
10uM CHC-A 10uM Pyran-A 0.2625 0.02714 12 9.67 <.0001 Tukey <.0001
10uM GA-A 10uM KDN-A -0.3371 0.02714 12 -12.42 <.0001 Tukey <.0001
10uM GA-A 10uM Pyran-A -0.09007 0.02714 12 -3.32 0.0061 Tukey 0.0272
10uM KDN-A 10uM Pyran-A 0.247 0.02714 12 9.1 <.0001 Tukey <.0001
Obs oncentratio complex Estimate andard Erro Letter
Group
1 10uM CHC-A 0.9806 0.01919 A
2 10uM KDN-A 0.9652 0.01919 A
3 10uM Pyran-A 0.7181 0.01919 B
4 10uM GA-A 0.6281 0.01919 C
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical analysis of sugar analogs intrinsic toxicity at 10uM concentration by Tukey's test
oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
20uM CHC-A 20uM GA-A 0.3684 0.02836 12 12.99 <.0001 Tukey <.0001
20uM CHC-A 20uM KDN-A 0.06939 0.02836 12 2.45 0.0308 Tukey 0.1205
20uM CHC-A 20uM Pyran-A 0.09888 0.02836 12 3.49 0.0045 Tukey 0.0203
20uM GA-A 20uM KDN-A -0.299 0.02836 12 -10.54 <.0001 Tukey <.0001
20uM GA-A 20uM Pyran-A -0.2695 0.02836 12 -9.5 <.0001 Tukey <.0001
20uM KDN-A 20uM Pyran-A 0.02948 0.02836 12 1.04 0.3191 Tukey 0.7305
Obs oncentratio complex Estimatetandard Err Letter
Group
1 20uM CHC-A 0.9533 0.02006 A
2 20uM KDN-A 0.8839 0.02006 AB
3 20uM Pyran-A 0.8544 0.02006 B
4 20uM GA-A 0.5849 0.02006 C
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical analysis of sugar analogs intrinsic toxicity at 20uM concentration by Tukey's test
Differences of Least Squares Means
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
30uM CHC-A 30uM GA-A 0.3839 0.02413 12 15.91 <.0001 Tukey <.0001
30uM CHC-A 30uM KDN-A 0.09025 0.02413 12 3.74 0.0028 Tukey 0.013
30uM CHC-A 30uM Pyran-A 0.1681 0.02413 12 6.97 <.0001 Tukey <.0001
30uM GA-A 30uM KDN-A -0.2936 0.02413 12 -12.17 <.0001 Tukey <.0001
30uM GA-A 30uM Pyran-A -0.2158 0.02413 12 -8.94 <.0001 Tukey <.0001
30uM KDN-A 30uM Pyran-A 0.07781 0.02413 12 3.23 0.0073 Tukey 0.032
Obs oncentratio complex Estimate andard Err Letter
Group
1 30uM CHC-A 0.9789 0.01706 A
2 30uM KDN-A 0.8887 0.01706 B
3 30uM Pyran-A 0.8109 0.01706 C
4 30uM GA-A 0.595 0.01706 D
Statistical analysis of sugar analogs intrinsic toxicity at 30uM concentration by Tukey's test
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
concentration complex _concentration _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
40uM CHC-A 40uM GA-A 0.3872 0.02901 12 13.35 <.0001 Tukey <.0001
40uM CHC-A 40uM KDN-A 0.1342 0.02901 12 4.63 0.0006 Tukey 0.0028
40uM CHC-A 40uM Pyran-A 0.2293 0.02901 12 7.91 <.0001 Tukey <.0001
40uM GA-A 40uM KDN-A -0.253 0.02901 12 -8.72 <.0001 Tukey <.0001
40uM GA-A 40uM Pyran-A -0.1579 0.02901 12 -5.44 0.0001 Tukey 0.0007
40uM KDN-A 40uM Pyran-A 0.09509 0.02901 12 3.28 0.0066 Tukey 0.0292
Obs concentration complex Estimate Standard Error Letter
Group
1 40uM CHC-A 1.0336 0.02051 A
2 40uM KDN-A 0.8994 0.02051 B
3 40uM Pyran-A 0.8043 0.02051 C
4 40uM GA-A 0.6464 0.02051 D
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical analysis of sugar analogs intrinsic toxicity at 40uM concentration by Tukey's test
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concentration complex _concentration _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
48uM CHC-A 48uM GA-A 0.355 0.03174 12 11.19 <.0001 Tukey <.0001
48uM CHC-A 48uM KDN-A 0.1016 0.03174 12 3.2 0.0076 Tukey 0.0334
48uM CHC-A 48uM Pyran-A 0.202 0.03174 12 6.37 <.0001 Tukey 0.0002
48uM GA-A 48uM KDN-A -0.2534 0.03174 12 -7.98 <.0001 Tukey <.0001
48uM GA-A 48uM Pyran-A -0.153 0.03174 12 -4.82 0.0004 Tukey 0.002
48uM KDN-A 48uM Pyran-A 0.1004 0.03174 12 3.16 0.0082 Tukey 0.0357
Obs oncentratio complex Estimatetandard Err Letter
Group
1 48uM CHC-A 1.0148 0.02244 A
2 48uM KDN-A 0.9132 0.02244 B
3 48uM Pyran-A 0.8128 0.02244 C
4 48uM GA-A 0.6598 0.02244 D
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis of sugar analogs intrinsic toxicity at 48uM concentration by Tukey's test
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Statistical Output for Sugar-Chitosan Complexes: Intrinsic Toxicity Studies 
 
oncentratio  oncentratio  Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.0585 0.02363 24 2.48 0.0207 Tukey 0.2525
0uM 20uM 0.1317 0.02363 24 5.57 <.0001 Tukey 0.0002
0uM 30uM 0.1503 0.02363 24 6.36 <.0001 Tukey <.0001
0uM 3uM 0.09444 0.02363 24 4 0.0005 Tukey 0.0106
0uM 40uM 0.2011 0.02363 24 8.51 <.0001 Tukey <.0001
0uM 48uM 0.2026 0.02363 24 8.57 <.0001 Tukey <.0001
0uM 5uM 0.11 0.02363 24 4.65 <.0001 Tukey 0.0022
10uM 20uM 0.0732 0.02363 24 3.1 0.0049 Tukey 0.0786
10uM 30uM 0.09177 0.02363 24 3.88 0.0007 Tukey 0.0138
10uM 3uM 0.03594 0.02363 24 1.52 0.1414 Tukey 0.7892
10uM 40uM 0.1426 0.02363 24 6.03 <.0001 Tukey <.0001
10uM 48uM 0.1441 0.02363 24 6.1 <.0001 Tukey <.0001
10uM 5uM 0.05149 0.02363 24 2.18 0.0394 Tukey 0.3976
20uM 30uM 0.01857 0.02363 24 0.79 0.4396 Tukey 0.9923
20uM 3uM -0.03726 0.02363 24 -1.58 0.1279 Tukey 0.7587
20uM 40uM 0.06936 0.02363 24 2.94 0.0072 Tukey 0.1091
20uM 48uM 0.0709 0.02363 24 3 0.0062 Tukey 0.0958
20uM 5uM -0.02171 0.02363 24 -0.92 0.3673 Tukey 0.9811
30uM 3uM -0.05583 0.02363 24 -2.36 0.0266 Tukey 0.3028
30uM 40uM 0.05079 0.02363 24 2.15 0.0419 Tukey 0.4141
30uM 48uM 0.05233 0.02363 24 2.21 0.0365 Tukey 0.378
30uM 5uM -0.04028 0.02363 24 -1.7 0.1011 Tukey 0.6843
3uM 40uM 0.1066 0.02363 24 4.51 0.0001 Tukey 0.0031
3uM 48uM 0.1082 0.02363 24 4.58 0.0001 Tukey 0.0026
3uM 5uM 0.01555 0.02363 24 0.66 0.5167 Tukey 0.9974
40uM 48uM 0.001541 0.02363 24 0.07 0.9485 Tukey 1
40uM 5uM -0.09108 0.02363 24 -3.85 0.0008 Tukey 0.0147
48uM 5uM -0.09262 0.02363 24 -3.92 0.0006 Tukey 0.0127
Obs oncentratio Estimate andard ErroLetter Group
1 0uM 1 0.01671 A
2 10uM 0.9415 0.01671 AB
3 3uM 0.9056 0.01671 BC
4 5uM 0.89 0.01671 BC
5 20uM 0.8683 0.01671 BCD
6 30uM 0.8497 0.01671 CD
7 40uM 0.7989 0.01671 D
8 48uM 0.7974 0.01671 D
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical Analysis of KDN-Complex Intrinsic Toxicity by Tukey's test
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.2485 0.0202 24 12.3 <.0001 Tukey <.0001
0uM 20uM 0.3378 0.0202 24 16.72 <.0001 Tukey <.0001
0uM 30uM 0.3658 0.0202 24 18.11 <.0001 Tukey <.0001
0uM 3uM 0.2978 0.0202 24 14.74 <.0001 Tukey <.0001
0uM 40uM 0.3853 0.0202 24 19.07 <.0001 Tukey <.0001
0uM 48uM 0.3916 0.0202 24 19.38 <.0001 Tukey <.0001
0uM 5uM 0.295 0.0202 24 14.6 <.0001 Tukey <.0001
10uM 20uM 0.08925 0.0202 24 4.42 0.0002 Tukey 0.0039
10uM 30uM 0.1173 0.0202 24 5.81 <.0001 Tukey 0.0001
10uM 3uM 0.04924 0.0202 24 2.44 0.0226 Tukey 0.269
10uM 40uM 0.1368 0.0202 24 6.77 <.0001 Tukey <.0001
10uM 48uM 0.143 0.0202 24 7.08 <.0001 Tukey <.0001
10uM 5uM 0.04644 0.0202 24 2.3 0.0305 Tukey 0.3343
20uM 30uM 0.02806 0.0202 24 1.39 0.1776 Tukey 0.8535
20uM 3uM -0.04001 0.0202 24 -1.98 0.0593 Tukey 0.5142
20uM 40uM 0.04753 0.0202 24 2.35 0.0272 Tukey 0.3077
20uM 48uM 0.05379 0.0202 24 2.66 0.0136 Tukey 0.1828
20uM 5uM -0.04281 0.0202 24 -2.12 0.0447 Tukey 0.4317
30uM 3uM -0.06807 0.0202 24 -3.37 0.0025 Tukey 0.0442
30uM 40uM 0.01947 0.0202 24 0.96 0.3448 Tukey 0.9754
30uM 48uM 0.02573 0.0202 24 1.27 0.2151 Tukey 0.8999
30uM 5uM -0.07087 0.0202 24 -3.51 0.0018 Tukey 0.0325
3uM 40uM 0.08754 0.0202 24 4.33 0.0002 Tukey 0.0047
3uM 48uM 0.0938 0.0202 24 4.64 0.0001 Tukey 0.0022
3uM 5uM -0.0028 0.0202 24 -0.14 0.8909 Tukey 1
40uM 48uM 0.006257 0.0202 24 0.31 0.7595 Tukey 1
40uM 5uM -0.09034 0.0202 24 -4.47 0.0002 Tukey 0.0034
48uM 5uM -0.0966 0.0202 24 -4.78 <.0001 Tukey 0.0016
Obs concentration Estimate Standard Error Letter
Group
1 0uM 1 0.01429 A
2 10uM 0.7515 0.01429 B
3 5uM 0.705 0.01429 BC
4 3uM 0.7022 0.01429 BC
5 20uM 0.6622 0.01429 CD
6 30uM 0.6342 0.01429 D
7 40uM 0.6147 0.01429 D
8 48uM 0.6084 0.01429 D
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical Analysis of GA-Complex Intrinsic Toxicity by Tukey's test
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concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM 0.08056 0.02795 24 2.88 0.0082 Tukey 0.121
0uM 20uM 0.04285 0.02795 24 1.53 0.1383 Tukey 0.7826
0uM 30uM 0.01396 0.02795 24 0.5 0.6219 Tukey 0.9996
0uM 3uM 0.03921 0.02795 24 1.4 0.1734 Tukey 0.8471
0uM 40uM 0.01886 0.02795 24 0.67 0.5062 Tukey 0.997
0uM 48uM 0.02842 0.02795 24 1.02 0.3193 Tukey 0.9671
0uM 5uM 0.06601 0.02795 24 2.36 0.0266 Tukey 0.3032
10uM 20uM -0.03771 0.02795 24 -1.35 0.1898 Tukey 0.8705
10uM 30uM -0.06659 0.02795 24 -2.38 0.0254 Tukey 0.2934
10uM 3uM -0.04135 0.02795 24 -1.48 0.152 Tukey 0.8105
10uM 40uM -0.0617 0.02795 24 -2.21 0.0371 Tukey 0.3818
10uM 48uM -0.05213 0.02795 24 -1.87 0.0744 Tukey 0.5853
10uM 5uM -0.01454 0.02795 24 -0.52 0.6075 Tukey 0.9994
20uM 30uM -0.02889 0.02795 24 -1.03 0.3116 Tukey 0.9642
20uM 3uM -0.00364 0.02795 24 -0.13 0.8975 Tukey 1
20uM 40uM -0.02399 0.02795 24 -0.86 0.3992 Tukey 0.9872
20uM 48uM -0.01442 0.02795 24 -0.52 0.6105 Tukey 0.9994
20uM 5uM 0.02316 0.02795 24 0.83 0.4154 Tukey 0.9895
30uM 3uM 0.02525 0.02795 24 0.9 0.3753 Tukey 0.9828
30uM 40uM 0.004897 0.02795 24 0.18 0.8624 Tukey 1
30uM 48uM 0.01446 0.02795 24 0.52 0.6095 Tukey 0.9994
30uM 5uM 0.05205 0.02795 24 1.86 0.0748 Tukey 0.5871
3uM 40uM -0.02035 0.02795 24 -0.73 0.4736 Tukey 0.9952
3uM 48uM -0.01078 0.02795 24 -0.39 0.703 Tukey 0.9999
3uM 5uM 0.0268 0.02795 24 0.96 0.3471 Tukey 0.9761
40uM 48uM 0.009565 0.02795 24 0.34 0.7351 Tukey 1
40uM 5uM 0.04715 0.02795 24 1.69 0.1045 Tukey 0.6949
48uM 5uM 0.03759 0.02795 24 1.34 0.1912 Tukey 0.8723
Obs concentration Estimate Standard Error Letter
Group
1 0uM 1 0.01976 A
2 30uM 0.986 0.01976 A
3 40uM 0.9811 0.01976 A
4 48uM 0.9716 0.01976 A
5 3uM 0.9608 0.01976 A
6 20uM 0.9572 0.01976 A
7 5uM 0.934 0.01976 A
8 10uM 0.9194 0.01976 A
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical Analysis of Pyran-Complex Intrinsic Toxicity by Tukey's test
275 
 
 
concentration _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
0uM 10uM -0.01907 0.02728 24 -0.7 0.4911 Tukey 0.9962
0uM 20uM 0.03016 0.02728 24 1.11 0.2799 Tukey 0.9493
0uM 30uM 0.01208 0.02728 24 0.44 0.6617 Tukey 0.9998
0uM 3uM -0.03866 0.02728 24 -1.42 0.1692 Tukey 0.8405
0uM 40uM 0.1325 0.02728 24 4.86 <.0001 Tukey 0.0013
0uM 48uM 0.1776 0.02728 24 6.51 <.0001 Tukey <.0001
0uM 5uM -0.02486 0.02728 24 -0.91 0.3712 Tukey 0.982
10uM 20uM 0.04923 0.02728 24 1.8 0.0837 Tukey 0.623
10uM 30uM 0.03116 0.02728 24 1.14 0.2646 Tukey 0.9403
10uM 3uM -0.01959 0.02728 24 -0.72 0.4796 Tukey 0.9955
10uM 40uM 0.1515 0.02728 24 5.56 <.0001 Tukey 0.0002
10uM 48uM 0.1967 0.02728 24 7.21 <.0001 Tukey <.0001
10uM 5uM -0.00579 0.02728 24 -0.21 0.8338 Tukey 1
20uM 30uM -0.01807 0.02728 24 -0.66 0.514 Tukey 0.9973
20uM 3uM -0.06882 0.02728 24 -2.52 0.0187 Tukey 0.2332
20uM 40uM 0.1023 0.02728 24 3.75 0.001 Tukey 0.0188
20uM 48uM 0.1475 0.02728 24 5.41 <.0001 Tukey 0.0003
20uM 5uM -0.05501 0.02728 24 -2.02 0.055 Tukey 0.4919
30uM 3uM -0.05075 0.02728 24 -1.86 0.0751 Tukey 0.5884
30uM 40uM 0.1204 0.02728 24 4.41 0.0002 Tukey 0.0039
30uM 48uM 0.1655 0.02728 24 6.07 <.0001 Tukey <.0001
30uM 5uM -0.03694 0.02728 24 -1.35 0.1882 Tukey 0.8684
3uM 40uM 0.1711 0.02728 24 6.27 <.0001 Tukey <.0001
3uM 48uM 0.2163 0.02728 24 7.93 <.0001 Tukey <.0001
3uM 5uM 0.0138 0.02728 24 0.51 0.6175 Tukey 0.9995
40uM 48uM 0.04518 0.02728 24 1.66 0.1107 Tukey 0.7132
40uM 5uM -0.1573 0.02728 24 -5.77 <.0001 Tukey 0.0001
48uM 5uM -0.2025 0.02728 24 -7.42 <.0001 Tukey <.0001
Obs concentration Estimate Standard Error Letter
Group
1 3uM 1.0387 0.01929 A
2 5uM 1.0249 0.01929 A
3 10uM 1.0191 0.01929 A
4 0uM 1 0.01929 A
5 30uM 0.9879 0.01929 A
6 20uM 0.9698 0.01929 A
7 40uM 0.8675 0.01929 B
8 48uM 0.8224 0.01929 B
Differences of Least Squares Means
Effect=concentration Method=Tukey(P<.05) Set=1
Statistical Analysis of CHC-Complex Intrinsic Toxicity by Tukey's test
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
CHC-Cmpl GA-Cmplx 0.3364 0.02769 12 12.15 <.0001 Tukey <.0001
CHC-Cmpl KDN-Cmpl 0.1331 0.02769 12 4.81 0.0004 Tukey 0.0021
CHC-Cmpl Pyran-Cm 0.07787 0.02769 12 2.81 0.0157 Tukey 0.0655
GA-Cmplx KDN-Cmpl -0.2033 0.02769 12 -7.34 <.0001 Tukey <.0001
GA-Cmplx Pyran-Cm -0.2586 0.02769 12 -9.34 <.0001 Tukey <.0001
KDN-Cmpl Pyran-Cm -0.05523 0.02769 12 -1.99 0.0694 Tukey 0.2432
Obs complex Estimate Standard Error Letter
Group
1 CHC-Cmpl 1.0387 0.01958 A
2 Pyran-Cm 0.9608 0.01958 AB
3 KDN-Cmpl 0.9056 0.01958 B
4 GA-Cmplx 0.7022 0.01958 C
Differences of Least Squares Means
Effect=complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar-Complexes Intrinsic Toxicity at 3uM Concentration by Tukey's test
complex _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
CHC-Cmpl GA-Cmplx 0.3198 0.01513 12 21.13 <.0001 Tukey <.0001
CHC-Cmpl KDN-Cmpl 0.1348 0.01513 12 8.91 <.0001 Tukey <.0001
CHC-Cmpl Pyran-Cm 0.09087 0.01513 12 6 <.0001 Tukey 0.0003
GA-Cmplx KDN-Cmpl -0.185 0.01513 12 -12.22 <.0001 Tukey <.0001
GA-Cmplx Pyran-Cm -0.229 0.01513 12 -15.13 <.0001 Tukey <.0001
KDN-Cmpl Pyran-Cm -0.04398 0.01513 12 -2.91 0.0132 Tukey 0.0557
Obs complex Estimate andard Err Letter
Group
1 CHC-Cmpl 1.0249 0.0107 A
2 Pyran-Cm 0.934 0.0107 B
3 KDN-Cmpl 0.89 0.0107 B
4 GA-Cmplx 0.705 0.0107 C
Differences of Least Squares Means
Effect=complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar-Complexes Intrinsic Toxicity at 5uM Concentration by Tukey's test
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
CHC-Cmpl GA-Cmplx 0.2676 0.02609 12 10.26 <.0001 Tukey <.0001
CHC-Cmpl KDN-Cmpl 0.07757 0.02609 12 2.97 0.0116 Tukey 0.0496
CHC-Cmpl Pyran-Cm 0.09963 0.02609 12 3.82 0.0024 Tukey 0.0113
GA-Cmplx KDN-Cmpl -0.19 0.02609 12 -7.28 <.0001 Tukey <.0001
GA-Cmplx Pyran-Cm -0.168 0.02609 12 -6.44 <.0001 Tukey 0.0002
KDN-Cmpl Pyran-Cm 0.02206 0.02609 12 0.85 0.4143 Tukey 0.8319
Obs complex Estimate Standard Error Letter
Group
1 CHC-Cmpl 1.0191 0.01845 A
2 KDN-Cmpl 0.9415 0.01845 B
3 Pyran-Cm 0.9194 0.01845 B
4 GA-Cmplx 0.7515 0.01845 C
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for Sugar-Complexes Intrinsic Toxicity at 10uM Concentration by Tukey's test
complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
CHC-Cmpl GA-Cmplx 0.3076 0.01408 12 21.84 <.0001 Tukey <.0001
CHC-Cmpl KDN-Cmpl 0.1015 0.01408 12 7.21 <.0001 Tukey <.0001
CHC-Cmpl Pyran-Cm 0.01269 0.01408 12 0.9 0.3852 Tukey 0.8044
GA-Cmplx KDN-Cmpl -0.2061 0.01408 12 -14.63 <.0001 Tukey <.0001
GA-Cmplx Pyran-Cm -0.2949 0.01408 12 -20.94 <.0001 Tukey <.0001
KDN-Cmpl Pyran-Cm -0.08885 0.01408 12 -6.31 <.0001 Tukey 0.0002
Obs complex Estimate Standard Error Letter
Group
1 CHC-Cmpl 0.9698 0.009958 A
2 Pyran-Cm 0.9572 0.009958 A
3 KDN-Cmpl 0.8683 0.009958 B
4 GA-Cmplx 0.6622 0.009958 C
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for Sugar-Complexes Intrinsic Toxicity at 20uM Concentration by Tukey's test
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
CHC-Cmpl GA-Cmplx 0.3538 0.02379 12 14.87 <.0001 Tukey <.0001
CHC-Cmpl KDN-Cmpl 0.1382 0.02379 12 5.81 <.0001 Tukey 0.0004
CHC-Cmpl Pyran-Cm 0.001878 0.02379 12 0.08 0.9384 Tukey 0.9998
GA-Cmplx KDN-Cmpl -0.2156 0.02379 12 -9.06 <.0001 Tukey <.0001
GA-Cmplx Pyran-Cm -0.3519 0.02379 12 -14.79 <.0001 Tukey <.0001
KDN-Cmpl Pyran-Cm -0.1363 0.02379 12 -5.73 <.0001 Tukey 0.0005
Obs complex Estimate Standard Error Letter
Group
1 CHC-Cmpl 0.9879 0.01683 A
2 Pyran-Cm 0.986 0.01683 A
3 KDN-Cmpl 0.8497 0.01683 B
4 GA-Cmplx 0.6342 0.01683 C
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for Sugar-Complexes Intrinsic Toxicity at 30uM Concentration by Tukey's test
complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustmen  Adj P
CHC-Cmpl GA-Cmplx 0.2529 0.03405 12 7.43 <.0001 Tukey <.0001
CHC-Cmpl KDN-Cmpl 0.06861 0.03405 12 2.01 0.0669 Tukey 0.236
CHC-Cmpl Pyran-Cm -0.1136 0.03405 12 -3.34 0.0059 Tukey 0.0264
GA-Cmplx KDN-Cmpl -0.1843 0.03405 12 -5.41 0.0002 Tukey 0.0008
GA-Cmplx Pyran-Cm -0.3665 0.03405 12 -10.76 <.0001 Tukey <.0001
KDN-Cmpl Pyran-Cm -0.1822 0.03405 12 -5.35 0.0002 Tukey 0.0009
Effect=complex Method=Tukey(P<.05) Set=1
Obs complex Estimate Standard Error Letter
Group
1 Pyran-Cm 0.9811 0.02408 A
2 CHC-Cmpl 0.8675 0.02408 B
3 KDN-Cmpl 0.7989 0.02408 B
4 GA-Cmplx 0.6147 0.02408 C
Differences of Least Squares Means
Statistical Analysis for Sugar-Complexes Intrinsic Toxicity at 40uM Concentration by Tukey's test
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complex _complex Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
CHC-Cmpl GA-Cmplx 0.2139 0.0351 12 6.1 <.0001 Tukey 0.0003
CHC-Cmpl KDN-Cmpl 0.02497 0.0351 12 0.71 0.4904 Tukey 0.8907
CHC-Cmpl Pyran-Cm -0.1492 0.0351 12 -4.25 0.0011 Tukey 0.0054
GA-Cmplx KDN-Cmpl -0.189 0.0351 12 -5.38 0.0002 Tukey 0.0008
GA-Cmplx Pyran-Cm -0.3631 0.0351 12 -10.35 <.0001 Tukey <.0001
KDN-Cmpl Pyran-Cm -0.1742 0.0351 12 -4.96 0.0003 Tukey 0.0016
Obs complex Estimate Standard Error Letter
Group
1 Pyran-Cm 0.9716 0.02482 A
2 CHC-Cmpl 0.8224 0.02482 B
3 KDN-Cmpl 0.7974 0.02482 B
4 GA-Cmplx 0.6084 0.02482 C
Statistical Analysis for Sugar-Complexes Intrinsic Toxicity at 48uM Concentration by Tukey's test
Effect=complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
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Statistical Output for Sugar-Analogs: Aβ Toxicity Attenuation Studies 
 
complex concentration _complex _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
KDN-A 0uM KDN-A 10uM -0.02577 0.01885 24 -1.37 0.1842 Tukey 0.8629
KDN-A 0uM KDN-A 20uM 0.008042 0.01885 24 0.43 0.6734 Tukey 0.9998
KDN-A 0uM KDN-A 30uM -0.05024 0.01885 24 -2.67 0.0135 Tukey 0.1817
KDN-A 0uM KDN-A 3uM 0.02806 0.01885 24 1.49 0.1495 Tukey 0.8057
KDN-A 0uM KDN-A 40uM -0.0184 0.01885 24 -0.98 0.3388 Tukey 0.9737
KDN-A 0uM KDN-A 48uM 0.006658 0.01885 24 0.35 0.727 Tukey 1
KDN-A 0uM KDN-A 5uM -0.05192 0.01885 24 -2.75 0.011 Tukey 0.1544
KDN-A 10uM KDN-A 20uM 0.03381 0.01885 24 1.79 0.0854 Tukey 0.6297
KDN-A 10uM KDN-A 30uM -0.02447 0.01885 24 -1.3 0.2065 Tukey 0.8907
KDN-A 10uM KDN-A 3uM 0.05384 0.01885 24 2.86 0.0087 Tukey 0.1273
KDN-A 10uM KDN-A 40uM 0.007377 0.01885 24 0.39 0.699 Tukey 0.9999
KDN-A 10uM KDN-A 48uM 0.03243 0.01885 24 1.72 0.0982 Tukey 0.6748
KDN-A 10uM KDN-A 5uM -0.02614 0.01885 24 -1.39 0.1782 Tukey 0.8543
KDN-A 20uM KDN-A 30uM -0.05829 0.01885 24 -3.09 0.005 Tukey 0.0795
KDN-A 20uM KDN-A 3uM 0.02002 0.01885 24 1.06 0.2987 Tukey 0.9587
KDN-A 20uM KDN-A 40uM -0.02644 0.01885 24 -1.4 0.1735 Tukey 0.8473
KDN-A 20uM KDN-A 48uM -0.00138 0.01885 24 -0.07 0.9421 Tukey 1
KDN-A 20uM KDN-A 5uM -0.05996 0.01885 24 -3.18 0.004 Tukey 0.0661
KDN-A 30uM KDN-A 3uM 0.07831 0.01885 24 4.15 0.0004 Tukey 0.0073
KDN-A 30uM KDN-A 40uM 0.03185 0.01885 24 1.69 0.104 Tukey 0.6934
KDN-A 30uM KDN-A 48uM 0.0569 0.01885 24 3.02 0.0059 Tukey 0.0923
KDN-A 30uM KDN-A 5uM -0.00167 0.01885 24 -0.09 0.93 Tukey 1
KDN-A 3uM KDN-A 40uM -0.04646 0.01885 24 -2.46 0.0212 Tukey 0.257
KDN-A 3uM KDN-A 48uM -0.02141 0.01885 24 -1.14 0.2673 Tukey 0.942
KDN-A 3uM KDN-A 5uM -0.07998 0.01885 24 -4.24 0.0003 Tukey 0.0059
KDN-A 40uM KDN-A 48uM 0.02505 0.01885 24 1.33 0.1963 Tukey 0.8787
KDN-A 40uM KDN-A 5uM -0.03352 0.01885 24 -1.78 0.088 Tukey 0.6393
KDN-A 48uM KDN-A 5uM -0.05857 0.01885 24 -3.11 0.0048 Tukey 0.077
Obs complex oncentratio Estimate andard Err Letter
Group
1 KDN-A 5uM 0.764 0.01333 A
2 KDN-A 30uM 0.7623 0.01333 A
3 KDN-A 10uM 0.7378 0.01333 AB
4 KDN-A 40uM 0.7305 0.01333 AB
5 KDN-A 0uM 0.7121 0.01333 AB
6 KDN-A 48uM 0.7054 0.01333 AB
7 KDN-A 20uM 0.704 0.01333 AB
8 KDN-A 3uM 0.684 0.01333 B
Differences of Least Squares Means
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Statistical Analysis of KDN Analog Ab Attenuation Studies by Tukey's test
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complex concentration _complex _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
GA-A 0uM GA-A 10uM 0.06787 0.01863 24 3.64 0.0013 Tukey 0.0239
GA-A 0uM GA-A 20uM 0.08862 0.01863 24 4.76 <.0001 Tukey 0.0017
GA-A 0uM GA-A 30uM 0.06867 0.01863 24 3.69 0.0012 Tukey 0.0217
GA-A 0uM GA-A 3uM 0.002304 0.01863 24 0.12 0.9026 Tukey 1
GA-A 0uM GA-A 40uM 0.0437 0.01863 24 2.35 0.0275 Tukey 0.3107
GA-A 0uM GA-A 48uM -0.01028 0.01863 24 -0.55 0.5862 Tukey 0.9992
GA-A 0uM GA-A 5uM 0.03799 0.01863 24 2.04 0.0526 Tukey 0.4783
GA-A 10uM GA-A 20uM 0.02075 0.01863 24 1.11 0.2763 Tukey 0.9473
GA-A 10uM GA-A 30uM 0.000801 0.01863 24 0.04 0.9661 Tukey 1
GA-A 10uM GA-A 3uM -0.06556 0.01863 24 -3.52 0.0018 Tukey 0.0316
GA-A 10uM GA-A 40uM -0.02416 0.01863 24 -1.3 0.2068 Tukey 0.8911
GA-A 10uM GA-A 48uM -0.07815 0.01863 24 -4.2 0.0003 Tukey 0.0066
GA-A 10uM GA-A 5uM -0.02988 0.01863 24 -1.6 0.1217 Tukey 0.7434
GA-A 20uM GA-A 30uM -0.01995 0.01863 24 -1.07 0.2948 Tukey 0.9569
GA-A 20uM GA-A 3uM -0.08632 0.01863 24 -4.63 0.0001 Tukey 0.0023
GA-A 20uM GA-A 40uM -0.04492 0.01863 24 -2.41 0.0239 Tukey 0.2804
GA-A 20uM GA-A 48uM -0.0989 0.01863 24 -5.31 <.0001 Tukey 0.0004
GA-A 20uM GA-A 5uM -0.05063 0.01863 24 -2.72 0.012 Tukey 0.165
GA-A 30uM GA-A 3uM -0.06637 0.01863 24 -3.56 0.0016 Tukey 0.0287
GA-A 30uM GA-A 40uM -0.02496 0.01863 24 -1.34 0.1927 Tukey 0.8742
GA-A 30uM GA-A 48uM -0.07895 0.01863 24 -4.24 0.0003 Tukey 0.0059
GA-A 30uM GA-A 5uM -0.03068 0.01863 24 -1.65 0.1125 Tukey 0.7185
GA-A 3uM GA-A 40uM 0.0414 0.01863 24 2.22 0.0359 Tukey 0.3737
GA-A 3uM GA-A 48uM -0.01258 0.01863 24 -0.68 0.5058 Tukey 0.9969
GA-A 3uM GA-A 5uM 0.03568 0.01863 24 1.92 0.0674 Tukey 0.5539
GA-A 40uM GA-A 48uM -0.05398 0.01863 24 -2.9 0.0079 Tukey 0.1173
GA-A 40uM GA-A 5uM -0.00572 0.01863 24 -0.31 0.7615 Tukey 1
GA-A 48uM GA-A 5uM 0.04827 0.01863 24 2.59 0.016 Tukey 0.2073
Obs complex oncentratio Estimate tandard Err Letter
Group
1 GA-A 48uM 0.7223 0.01317 A
2 GA-A 0uM 0.7121 0.01317 A
3 GA-A 3uM 0.7098 0.01317 A
4 GA-A 5uM 0.6741 0.01317 AB
5 GA-A 40uM 0.6684 0.01317 AB
6 GA-A 10uM 0.6442 0.01317 B
7 GA-A 30uM 0.6434 0.01317 B
8 GA-A 20uM 0.6234 0.01317 B
Statistical Analysis of GA Analog Ab Attenuation Studies by Tukey's test
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
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complex oncentratio  _complex oncentratio  Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
Pyran-A 0uM Pyran-A 10uM 0.09836 0.02064 24 4.77 <.0001 Tukey 0.0017
Pyran-A 0uM Pyran-A 20uM 0.09312 0.02064 24 4.51 0.0001 Tukey 0.0031
Pyran-A 0uM Pyran-A 30uM 0.1173 0.02064 24 5.69 <.0001 Tukey 0.0002
Pyran-A 0uM Pyran-A 3uM 0.1326 0.02064 24 6.43 <.0001 Tukey <.0001
Pyran-A 0uM Pyran-A 40uM 0.1156 0.02064 24 5.6 <.0001 Tukey 0.0002
Pyran-A 0uM Pyran-A 48uM 0.08357 0.02064 24 4.05 0.0005 Tukey 0.0093
Pyran-A 0uM Pyran-A 5uM 0.1215 0.02064 24 5.89 <.0001 Tukey 0.0001
Pyran-A 10uM Pyran-A 20uM -0.00523 0.02064 24 -0.25 0.802 Tukey 1
Pyran-A 10uM Pyran-A 30uM 0.01898 0.02064 24 0.92 0.367 Tukey 0.9811
Pyran-A 10uM Pyran-A 3uM 0.03426 0.02064 24 1.66 0.1099 Tukey 0.711
Pyran-A 10uM Pyran-A 40uM 0.01724 0.02064 24 0.84 0.4117 Tukey 0.989
Pyran-A 10uM Pyran-A 48uM -0.01479 0.02064 24 -0.72 0.4805 Tukey 0.9956
Pyran-A 10uM Pyran-A 5uM 0.02319 0.02064 24 1.12 0.2723 Tukey 0.945
Pyran-A 20uM Pyran-A 30uM 0.02421 0.02064 24 1.17 0.2523 Tukey 0.932
Pyran-A 20uM Pyran-A 3uM 0.03949 0.02064 24 1.91 0.0677 Tukey 0.5553
Pyran-A 20uM Pyran-A 40uM 0.02247 0.02064 24 1.09 0.287 Tukey 0.9531
Pyran-A 20uM Pyran-A 48uM -0.00956 0.02064 24 -0.46 0.6475 Tukey 0.9997
Pyran-A 20uM Pyran-A 5uM 0.02842 0.02064 24 1.38 0.1811 Tukey 0.8586
Pyran-A 30uM Pyran-A 3uM 0.01528 0.02064 24 0.74 0.4661 Tukey 0.9946
Pyran-A 30uM Pyran-A 40uM -0.00173 0.02064 24 -0.08 0.9337 Tukey 1
Pyran-A 30uM Pyran-A 48uM -0.03376 0.02064 24 -1.64 0.1149 Tukey 0.7251
Pyran-A 30uM Pyran-A 5uM 0.004214 0.02064 24 0.2 0.8399 Tukey 1
Pyran-A 3uM Pyran-A 40uM -0.01702 0.02064 24 -0.82 0.4177 Tukey 0.9898
Pyran-A 3uM Pyran-A 48uM -0.04905 0.02064 24 -2.38 0.0258 Tukey 0.2963
Pyran-A 3uM Pyran-A 5uM -0.01107 0.02064 24 -0.54 0.5966 Tukey 0.9993
Pyran-A 40uM Pyran-A 48uM -0.03203 0.02064 24 -1.55 0.1337 Tukey 0.7724
Pyran-A 40uM Pyran-A 5uM 0.005949 0.02064 24 0.29 0.7756 Tukey 1
Pyran-A 48uM Pyran-A 5uM 0.03798 0.02064 24 1.84 0.0781 Tukey 0.6009
Obs complex oncentratio Estimatetandard Err Letter
Group
1 Pyran-A 0uM 0.7121 0.01459 A
2 Pyran-A 48uM 0.6285 0.01459 B
3 Pyran-A 20uM 0.6189 0.01459 B
4 Pyran-A 10uM 0.6137 0.01459 B
5 Pyran-A 40uM 0.5965 0.01459 B
6 Pyran-A 30uM 0.5947 0.01459 B
7 Pyran-A 5uM 0.5905 0.01459 B
8 Pyran-A 3uM 0.5794 0.01459 B
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis of Pyran Analog Ab Attenuation Studies by Tukey's test
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complex oncentratio  _complex oncentratio  Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
CHC-A 0uM CHC-A 10uM 0.03235 0.02088 24 1.55 0.1345 Tukey 0.7742
CHC-A 0uM CHC-A 20uM 0.03119 0.02088 24 1.49 0.1483 Tukey 0.8033
CHC-A 0uM CHC-A 30uM 0.008342 0.02088 24 0.4 0.6931 Tukey 0.9999
CHC-A 0uM CHC-A 3uM 0.06837 0.02088 24 3.27 0.0032 Tukey 0.0543
CHC-A 0uM CHC-A 40uM 0.001365 0.02088 24 0.07 0.9484 Tukey 1
CHC-A 0uM CHC-A 48uM -0.00045 0.02088 24 -0.02 0.983 Tukey 1
CHC-A 0uM CHC-A 5uM 0.06669 0.02088 24 3.19 0.0039 Tukey 0.0644
CHC-A 10uM CHC-A 20uM -0.00115 0.02088 24 -0.06 0.9565 Tukey 1
CHC-A 10uM CHC-A 30uM -0.024 0.02088 24 -1.15 0.2617 Tukey 0.9384
CHC-A 10uM CHC-A 3uM 0.03603 0.02088 24 1.73 0.0974 Tukey 0.6721
CHC-A 10uM CHC-A 40uM -0.03098 0.02088 24 -1.48 0.151 Tukey 0.8085
CHC-A 10uM CHC-A 48uM -0.0328 0.02088 24 -1.57 0.1294 Tukey 0.7624
CHC-A 10uM CHC-A 5uM 0.03434 0.02088 24 1.64 0.1131 Tukey 0.7202
CHC-A 20uM CHC-A 30uM -0.02285 0.02088 24 -1.09 0.2847 Tukey 0.9519
CHC-A 20uM CHC-A 3uM 0.03718 0.02088 24 1.78 0.0877 Tukey 0.6382
CHC-A 20uM CHC-A 40uM -0.02983 0.02088 24 -1.43 0.1661 Tukey 0.8354
CHC-A 20uM CHC-A 48uM -0.03164 0.02088 24 -1.52 0.1428 Tukey 0.7921
CHC-A 20uM CHC-A 5uM 0.0355 0.02088 24 1.7 0.1021 Tukey 0.6874
CHC-A 30uM CHC-A 3uM 0.06003 0.02088 24 2.87 0.0083 Tukey 0.1229
CHC-A 30uM CHC-A 40uM -0.00698 0.02088 24 -0.33 0.7412 Tukey 1
CHC-A 30uM CHC-A 48uM -0.00879 0.02088 24 -0.42 0.6775 Tukey 0.9999
CHC-A 30uM CHC-A 5uM 0.05835 0.02088 24 2.79 0.0101 Tukey 0.1433
CHC-A 3uM CHC-A 40uM -0.06701 0.02088 24 -3.21 0.0038 Tukey 0.0624
CHC-A 3uM CHC-A 48uM -0.06882 0.02088 24 -3.3 0.003 Tukey 0.0518
CHC-A 3uM CHC-A 5uM -0.00168 0.02088 24 -0.08 0.9365 Tukey 1
CHC-A 40uM CHC-A 48uM -0.00182 0.02088 24 -0.09 0.9315 Tukey 1
CHC-A 40uM CHC-A 5uM 0.06532 0.02088 24 3.13 0.0046 Tukey 0.0738
CHC-A 48uM CHC-A 5uM 0.06714 0.02088 24 3.21 0.0037 Tukey 0.0615
Obs complexoncentratio Estimatetandard Err Letter
Group
1 CHC-A 48uM 0.7125 0.01477 A
2 CHC-A 0uM 0.7121 0.01477 A
3 CHC-A 40uM 0.7107 0.01477 A
4 CHC-A 30uM 0.7037 0.01477 A
5 CHC-A 20uM 0.6809 0.01477 A
6 CHC-A 10uM 0.6797 0.01477 A
7 CHC-A 5uM 0.6454 0.01477 A
8 CHC-A 3uM 0.6437 0.01477 A
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis of CHC Analog Ab Attenuation Studies by Tukey's test
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
3uM CHC-A 3uM GA-A -0.06607 0.01475 12 -4.48 0.0008 Tukey 0.0036
3uM CHC-A 3uM KDN-A -0.04031 0.01475 12 -2.73 0.0182 Tukey 0.0749
3uM CHC-A 3uM Pyran-A 0.06424 0.01475 12 4.36 0.0009 Tukey 0.0045
3uM GA-A 3uM KDN-A 0.02576 0.01475 12 1.75 0.1063 Tukey 0.3437
3uM GA-A 3uM Pyran-A 0.1303 0.01475 12 8.83 <.0001 Tukey <.0001
3uM KDN-A 3uM Pyran-A 0.1046 0.01475 12 7.09 <.0001 Tukey <.0001
Obs oncentratio complex Estimatetandard Err Letter
Group
1 3uM GA-A 0.7098 0.01043 A
2 3uM KDN-A 0.684 0.01043 AB
3 3uM CHC-A 0.6437 0.01043 B
4 3uM Pyran-A 0.5794 0.01043 C
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for Sugar Analogs at 3uM Concentration by Tukey's test
oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
5uM CHC-A 5uM GA-A -0.0287 0.01624 12 -1.77 0.1026 Tukey 0.3344
5uM CHC-A 5uM KDN-A -0.1186 0.01624 12 -7.3 <.0001 Tukey <.0001
5uM CHC-A 5uM Pyran-A 0.05486 0.01624 12 3.38 0.0055 Tukey 0.0245
5uM GA-A 5uM KDN-A -0.0899 0.01624 12 -5.54 0.0001 Tukey 0.0006
5uM GA-A 5uM Pyran-A 0.08356 0.01624 12 5.14 0.0002 Tukey 0.0012
5uM KDN-A 5uM Pyran-A 0.1735 0.01624 12 10.68 <.0001 Tukey <.0001
Obs oncentratio complex Estimatetandard Err Letter
Group
1 5uM KDN-A 0.764 0.01149 A
2 5uM GA-A 0.6741 0.01149 B
3 5uM CHC-A 0.6454 0.01149 B
4 5uM Pyran-A 0.5905 0.01149 C
Statistical Analysis for Sugar Analogs at 5uM Concentration by Tukey's test
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
10uM CHC-A 10uM GA-A 0.03552 0.02533 12 1.4 0.1861 Tukey 0.5212
10uM CHC-A 10uM KDN-A -0.05812 0.02533 12 -2.29 0.0406 Tukey 0.1538
10uM CHC-A 10uM Pyran-A 0.06601 0.02533 12 2.61 0.023 Tukey 0.0926
10uM GA-A 10uM KDN-A -0.09364 0.02533 12 -3.7 0.0031 Tukey 0.014
10uM GA-A 10uM Pyran-A 0.03049 0.02533 12 1.2 0.2519 Tukey 0.6362
10uM KDN-A 10uM Pyran-A 0.1241 0.02533 12 4.9 0.0004 Tukey 0.0018
Obs oncentratio complex Estimatetandard Err Letter
Group
1 10uM KDN-A 0.7378 0.01791 A
2 10uM CHC-A 0.6797 0.01791 AB
3 10uM GA-A 0.6442 0.01791 B
4 10uM Pyran-A 0.6137 0.01791 B
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar Analogs at 10uM Concentration by Tukey's test
oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
20uM CHC-A 20uM GA-A 0.05743 0.01872 12 3.07 0.0098 Tukey 0.0422
20uM CHC-A 20uM KDN-A -0.02315 0.01872 12 -1.24 0.24 Tukey 0.6171
20uM CHC-A 20uM Pyran-A 0.06193 0.01872 12 3.31 0.0063 Tukey 0.0277
20uM GA-A 20uM KDN-A -0.08058 0.01872 12 -4.3 0.001 Tukey 0.0049
20uM GA-A 20uM Pyran-A 0.004503 0.01872 12 0.24 0.814 Tukey 0.9948
20uM KDN-A 20uM Pyran-A 0.08508 0.01872 12 4.54 0.0007 Tukey 0.0033
Obs oncentratio complex Estimatetandard Err Letter
Group
1 20uM KDN-A 0.704 0.01324 A
2 20uM CHC-A 0.6809 0.01324 A
3 20uM GA-A 0.6234 0.01324 B
4 20uM Pyran-A 0.6189 0.01324 B
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis for sugar analogs at 20uM concentration by Tukey's test
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
30uM CHC-A 30uM GA-A 0.06033 0.02173 12 2.78 0.0168 Tukey 0.0696
30uM CHC-A 30uM KDN-A -0.05859 0.02173 12 -2.7 0.0195 Tukey 0.0797
30uM CHC-A 30uM Pyran-A 0.109 0.02173 12 5.02 0.0003 Tukey 0.0015
30uM GA-A 30uM KDN-A -0.1189 0.02173 12 -5.47 0.0001 Tukey 0.0007
30uM GA-A 30uM Pyran-A 0.04866 0.02173 12 2.24 0.0449 Tukey 0.1679
30uM KDN-A 30uM Pyran-A 0.1676 0.02173 12 7.71 <.0001 Tukey <.0001
Obs oncentratio complex Estimate andard Err Letter
Group
1 30uM KDN-A 0.7623 0.01537 A
2 30uM CHC-A 0.7037 0.01537 AB
3 30uM GA-A 0.6434 0.01537 BC
4 30uM Pyran-A 0.5947 0.01537 C
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical analysis for sugar analogs at 30uM concentration by Tukey's test
oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
40uM CHC-A 40uM GA-A 0.04234 0.02412 12 1.76 0.1046 Tukey 0.3395
40uM CHC-A 40uM KDN-A -0.01976 0.02412 12 -0.82 0.4285 Tukey 0.8442
40uM CHC-A 40uM Pyran-A 0.1142 0.02412 12 4.74 0.0005 Tukey 0.0024
40uM GA-A 40uM KDN-A -0.0621 0.02412 12 -2.58 0.0243 Tukey 0.0976
40uM GA-A 40uM Pyran-A 0.07189 0.02412 12 2.98 0.0115 Tukey 0.049
40uM KDN-A 40uM Pyran-A 0.134 0.02412 12 5.56 0.0001 Tukey 0.0006
Obs oncentratio complex Estimate andard Err Letter
Group
1 40uM KDN-A 0.7305 0.01705 A
2 40uM CHC-A 0.7107 0.01705 A
3 40uM GA-A 0.6684 0.01705 A
4 40uM Pyran-A 0.5965 0.01705 B
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical analysis for sugar analogs at 40uM concentration by Tukey's test
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
48uM CHC-A 48uM GA-A -0.00983 0.02367 12 -0.42 0.6853 Tukey 0.9748
48uM CHC-A 48uM KDN-A 0.007108 0.02367 12 0.3 0.7691 Tukey 0.9901
48uM CHC-A 48uM Pyran-A 0.08402 0.02367 12 3.55 0.004 Tukey 0.0182
48uM GA-A 48uM KDN-A 0.01694 0.02367 12 0.72 0.488 Tukey 0.8891
48uM GA-A 48uM Pyran-A 0.09384 0.02367 12 3.96 0.0019 Tukey 0.0088
48uM KDN-A 48uM Pyran-A 0.07691 0.02367 12 3.25 0.007 Tukey 0.0307
Obs oncentratio complex Estimatetandard Err Letter
Group
1 48uM GA-A 0.7223 0.01674 A
2 48uM CHC-A 0.7125 0.01674 A
3 48uM KDN-A 0.7054 0.01674 A
4 48uM Pyran-A 0.6285 0.01674 B
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical analysis for sugar analogs at 48uM concentration by Tukey's test
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complex concentration _complex _concentration Estimate Standard Error DF t Value Pr > |t| Adjustment Adj P
KDN-Cmpl 0uM KDN-Cmpl 10uM -0.1434 0.01944 24 -7.38 <.0001 Tukey <.0001
KDN-Cmpl 0uM KDN-Cmpl 20uM -0.08166 0.01944 24 -4.2 0.0003 Tukey 0.0065
KDN-Cmpl 0uM KDN-Cmpl 30uM -0.04994 0.01944 24 -2.57 0.0168 Tukey 0.2155
KDN-Cmpl 0uM KDN-Cmpl 3uM -0.06473 0.01944 24 -3.33 0.0028 Tukey 0.0481
KDN-Cmpl 0uM KDN-Cmpl 40uM -0.05165 0.01944 24 -2.66 0.0138 Tukey 0.1846
KDN-Cmpl 0uM KDN-Cmpl 48uM 0.02479 0.01944 24 1.28 0.2145 Tukey 0.8992
KDN-Cmpl 0uM KDN-Cmpl 5uM -0.124 0.01944 24 -6.38 <.0001 Tukey <.0001
KDN-Cmpl 10uM KDN-Cmpl 20uM 0.06178 0.01944 24 3.18 0.004 Tukey 0.0665
KDN-Cmpl 10uM KDN-Cmpl 30uM 0.0935 0.01944 24 4.81 <.0001 Tukey 0.0015
KDN-Cmpl 10uM KDN-Cmpl 3uM 0.07871 0.01944 24 4.05 0.0005 Tukey 0.0093
KDN-Cmpl 10uM KDN-Cmpl 40uM 0.09179 0.01944 24 4.72 <.0001 Tukey 0.0018
KDN-Cmpl 10uM KDN-Cmpl 48uM 0.1682 0.01944 24 8.65 <.0001 Tukey <.0001
KDN-Cmpl 10uM KDN-Cmpl 5uM 0.01943 0.01944 24 1 0.3274 Tukey 0.97
KDN-Cmpl 20uM KDN-Cmpl 30uM 0.03171 0.01944 24 1.63 0.1159 Tukey 0.7278
KDN-Cmpl 20uM KDN-Cmpl 3uM 0.01693 0.01944 24 0.87 0.3925 Tukey 0.9861
KDN-Cmpl 20uM KDN-Cmpl 40uM 0.03001 0.01944 24 1.54 0.1358 Tukey 0.7771
KDN-Cmpl 20uM KDN-Cmpl 48uM 0.1064 0.01944 24 5.48 <.0001 Tukey 0.0003
KDN-Cmpl 20uM KDN-Cmpl 5uM -0.04235 0.01944 24 -2.18 0.0394 Tukey 0.3979
KDN-Cmpl 30uM KDN-Cmpl 3uM -0.01478 0.01944 24 -0.76 0.4543 Tukey 0.9937
KDN-Cmpl 30uM KDN-Cmpl 40uM -0.00171 0.01944 24 -0.09 0.9307 Tukey 1
KDN-Cmpl 30uM KDN-Cmpl 48uM 0.07473 0.01944 24 3.84 0.0008 Tukey 0.0151
KDN-Cmpl 30uM KDN-Cmpl 5uM -0.07406 0.01944 24 -3.81 0.0009 Tukey 0.0164
KDN-Cmpl 3uM KDN-Cmpl 40uM 0.01308 0.01944 24 0.67 0.5076 Tukey 0.997
KDN-Cmpl 3uM KDN-Cmpl 48uM 0.08952 0.01944 24 4.6 0.0001 Tukey 0.0025
KDN-Cmpl 3uM KDN-Cmpl 5uM -0.05928 0.01944 24 -3.05 0.0055 Tukey 0.0868
KDN-Cmpl 40uM KDN-Cmpl 48uM 0.07644 0.01944 24 3.93 0.0006 Tukey 0.0123
KDN-Cmpl 40uM KDN-Cmpl 5uM -0.07235 0.01944 24 -3.72 0.0011 Tukey 0.02
KDN-Cmpl 48uM KDN-Cmpl 5uM -0.1488 0.01944 24 -7.65 <.0001 Tukey <.0001
Obs complex concentration Estimate Standard ELetter Group
1 KDN-Cmpl 10uM 0.8555 0.01375 A
2 KDN-Cmpl 5uM 0.8361 0.01375 AB
3 KDN-Cmpl 20uM 0.7937 0.01375 ABC
4 KDN-Cmpl 3uM 0.7768 0.01375 BC
5 KDN-Cmpl 40uM 0.7637 0.01375 CD
6 KDN-Cmpl 30uM 0.762 0.01375 CD
7 KDN-Cmpl 0uM 0.7121 0.01375 DE
8 KDN-Cmpl 48uM 0.6873 0.01375 E
Differences of Least Squares Means
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Statistical Analysis for KDN-Complex Ab Attenuation Studies by Tukey's test
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complex concentrat  _complex _concentr  Estimate Standard Error DF t Value Pr > |t| Adjustmen  Adj P
GA-Cmplx 0uM GA-Cmplx 10uM 0.000569 0.03103 24 0.02 0.9855 Tukey 1
GA-Cmplx 0uM GA-Cmplx 20uM 0.08763 0.03103 24 2.82 0.0094 Tukey 0.1353
GA-Cmplx 0uM GA-Cmplx 30uM 0.09198 0.03103 24 2.96 0.0068 Tukey 0.103
GA-Cmplx 0uM GA-Cmplx 3uM -0.00085 0.03103 24 -0.03 0.9785 Tukey 1
GA-Cmplx 0uM GA-Cmplx 40uM 0.1055 0.03103 24 3.4 0.0024 Tukey 0.0412
GA-Cmplx 0uM GA-Cmplx 48uM 0.0769 0.03103 24 2.48 0.0206 Tukey 0.2514
GA-Cmplx 0uM GA-Cmplx 5uM -0.02335 0.03103 24 -0.75 0.459 Tukey 0.9941
GA-Cmplx 10uM GA-Cmplx 20uM 0.08706 0.03103 24 2.81 0.0098 Tukey 0.1402
GA-Cmplx 10uM GA-Cmplx 30uM 0.09142 0.03103 24 2.95 0.0071 Tukey 0.1068
GA-Cmplx 10uM GA-Cmplx 3uM -0.00141 0.03103 24 -0.05 0.964 Tukey 1
GA-Cmplx 10uM GA-Cmplx 40uM 0.105 0.03103 24 3.38 0.0025 Tukey 0.0429
GA-Cmplx 10uM GA-Cmplx 48uM 0.07633 0.03103 24 2.46 0.0215 Tukey 0.2591
GA-Cmplx 10uM GA-Cmplx 5uM -0.02392 0.03103 24 -0.77 0.4482 Tukey 0.9932
GA-Cmplx 20uM GA-Cmplx 30uM 0.004351 0.03103 24 0.14 0.8896 Tukey 1
GA-Cmplx 20uM GA-Cmplx 3uM -0.08848 0.03103 24 -2.85 0.0088 Tukey 0.1285
GA-Cmplx 20uM GA-Cmplx 40uM 0.0179 0.03103 24 0.58 0.5694 Tukey 0.9989
GA-Cmplx 20uM GA-Cmplx 48uM -0.01073 0.03103 24 -0.35 0.7325 Tukey 1
GA-Cmplx 20uM GA-Cmplx 5uM -0.111 0.03103 24 -3.58 0.0015 Tukey 0.0279
GA-Cmplx 30uM GA-Cmplx 3uM -0.09283 0.03103 24 -2.99 0.0063 Tukey 0.0975
GA-Cmplx 30uM GA-Cmplx 40uM 0.01355 0.03103 24 0.44 0.6663 Tukey 0.9998
GA-Cmplx 30uM GA-Cmplx 48uM -0.01508 0.03103 24 -0.49 0.6313 Tukey 0.9996
GA-Cmplx 30uM GA-Cmplx 5uM -0.1153 0.03103 24 -3.72 0.0011 Tukey 0.0203
GA-Cmplx 3uM GA-Cmplx 40uM 0.1064 0.03103 24 3.43 0.0022 Tukey 0.0388
GA-Cmplx 3uM GA-Cmplx 48uM 0.07775 0.03103 24 2.51 0.0194 Tukey 0.2402
GA-Cmplx 3uM GA-Cmplx 5uM -0.02251 0.03103 24 -0.73 0.4752 Tukey 0.9953
GA-Cmplx 40uM GA-Cmplx 48uM -0.02863 0.03103 24 -0.92 0.3653 Tukey 0.9807
GA-Cmplx 40uM GA-Cmplx 5uM -0.1289 0.03103 24 -4.15 0.0004 Tukey 0.0073
GA-Cmplx 48uM GA-Cmplx 5uM -0.1003 0.03103 24 -3.23 0.0036 Tukey 0.0595
Obs complex concentration Estimate Standard ELetter Group
1 GA-Cmplx 5uM 0.7354 0.02194 A
2 GA-Cmplx 3uM 0.7129 0.02194 AB
3 GA-Cmplx 0uM 0.7121 0.02194 AB
4 GA-Cmplx 10uM 0.7115 0.02194 AB
5 GA-Cmplx 48uM 0.6352 0.02194 ABC
6 GA-Cmplx 20uM 0.6244 0.02194 BC
7 GA-Cmplx 30uM 0.6201 0.02194 BC
8 GA-Cmplx 40uM 0.6065 0.02194 C
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for GA-Complex Ab Attenuation Studies by Tukey's test
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complex concentration _complex _concen Estimate Standard E  DF t Value Pr > |t| Adjustmen  Adj P
Pyran-Cm 0uM Pyran-Cm 10uM -0.08309 0.0211 24 -3.94 0.0006 Tukey 0.0121
Pyran-Cm 0uM Pyran-Cm 20uM -0.00706 0.0211 24 -0.33 0.7409 Tukey 1
Pyran-Cm 0uM Pyran-Cm 30uM -0.03276 0.0211 24 -1.55 0.1336 Tukey 0.7722
Pyran-Cm 0uM Pyran-Cm 3uM -0.03322 0.0211 24 -1.57 0.1285 Tukey 0.7601
Pyran-Cm 0uM Pyran-Cm 40uM -0.00499 0.0211 24 -0.24 0.8149 Tukey 1
Pyran-Cm 0uM Pyran-Cm 48uM -0.01063 0.0211 24 -0.5 0.6188 Tukey 0.9995
Pyran-Cm 0uM Pyran-Cm 5uM -0.107 0.0211 24 -5.07 <.0001 Tukey 0.0008
Pyran-Cm 10uM Pyran-Cm 20uM 0.07603 0.0211 24 3.6 0.0014 Tukey 0.0262
Pyran-Cm 10uM Pyran-Cm 30uM 0.05033 0.0211 24 2.39 0.0253 Tukey 0.2922
Pyran-Cm 10uM Pyran-Cm 3uM 0.04987 0.0211 24 2.36 0.0265 Tukey 0.3025
Pyran-Cm 10uM Pyran-Cm 40uM 0.07809 0.0211 24 3.7 0.0011 Tukey 0.021
Pyran-Cm 10uM Pyran-Cm 48uM 0.07245 0.0211 24 3.43 0.0022 Tukey 0.0383
Pyran-Cm 10uM Pyran-Cm 5uM -0.0239 0.0211 24 -1.13 0.2685 Tukey 0.9427
Pyran-Cm 20uM Pyran-Cm 30uM -0.0257 0.0211 24 -1.22 0.235 Tukey 0.9185
Pyran-Cm 20uM Pyran-Cm 3uM -0.02616 0.0211 24 -1.24 0.227 Tukey 0.9114
Pyran-Cm 20uM Pyran-Cm 40uM 0.002064 0.0211 24 0.1 0.9229 Tukey 1
Pyran-Cm 20uM Pyran-Cm 48uM -0.00358 0.0211 24 -0.17 0.8668 Tukey 1
Pyran-Cm 20uM Pyran-Cm 5uM -0.09993 0.0211 24 -4.74 <.0001 Tukey 0.0018
Pyran-Cm 30uM Pyran-Cm 3uM -0.00046 0.0211 24 -0.02 0.9827 Tukey 1
Pyran-Cm 30uM Pyran-Cm 40uM 0.02776 0.0211 24 1.32 0.2006 Tukey 0.8839
Pyran-Cm 30uM Pyran-Cm 48uM 0.02212 0.0211 24 1.05 0.3048 Tukey 0.9614
Pyran-Cm 30uM Pyran-Cm 5uM -0.07423 0.0211 24 -3.52 0.0018 Tukey 0.0318
Pyran-Cm 3uM Pyran-Cm 40uM 0.02823 0.0211 24 1.34 0.1935 Tukey 0.8752
Pyran-Cm 3uM Pyran-Cm 48uM 0.02258 0.0211 24 1.07 0.2951 Tukey 0.957
Pyran-Cm 3uM Pyran-Cm 5uM -0.07377 0.0211 24 -3.5 0.0019 Tukey 0.0334
Pyran-Cm 40uM Pyran-Cm 48uM -0.00564 0.0211 24 -0.27 0.7914 Tukey 1
Pyran-Cm 40uM Pyran-Cm 5uM -0.102 0.0211 24 -4.83 <.0001 Tukey 0.0014
Pyran-Cm 48uM Pyran-Cm 5uM -0.09635 0.0211 24 -4.57 0.0001 Tukey 0.002
Obs complex conc Estimate Standard Error Letter
Group
1 Pyran-Cm 5uM 0.819 0.01492 A
2 Pyran-Cm 10uM 0.7951 0.01492 AB
3 Pyran-Cm 3uM 0.7453 0.01492 BC
4 Pyran-Cm 30uM 0.7448 0.01492 BC
5 Pyran-Cm 48uM 0.7227 0.01492 C
6 Pyran-Cm 20uM 0.7191 0.01492 C
7 Pyran-Cm 40uM 0.7171 0.01492 C
8 Pyran-Cm 0uM 0.7121 0.01492 C
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for Pyran-Complex Ab Attenuation Studies by Tukey's test
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complex concentration _complex _concentration Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
CHC-Cmpl 0uM CHC-Cmpl 10uM 0.03447 0.02069 24 1.67 0.1087 Tukey 0.7075
CHC-Cmpl 0uM CHC-Cmpl 20uM 0.03417 0.02069 24 1.65 0.1117 Tukey 0.7161
CHC-Cmpl 0uM CHC-Cmpl 30uM 0.09055 0.02069 24 4.38 0.0002 Tukey 0.0043
CHC-Cmpl 0uM CHC-Cmpl 3uM -0.00933 0.02069 24 -0.45 0.6562 Tukey 0.9998
CHC-Cmpl 0uM CHC-Cmpl 40uM 0.1135 0.02069 24 5.48 <.0001 Tukey 0.0003
CHC-Cmpl 0uM CHC-Cmpl 48uM 0.1557 0.02069 24 7.53 <.0001 Tukey <.0001
CHC-Cmpl 0uM CHC-Cmpl 5uM -0.01147 0.02069 24 -0.55 0.5845 Tukey 0.9991
CHC-Cmpl 10uM CHC-Cmpl 20uM -0.0003 0.02069 24 -0.01 0.9885 Tukey 1
CHC-Cmpl 10uM CHC-Cmpl 30uM 0.05608 0.02069 24 2.71 0.0122 Tukey 0.1674
CHC-Cmpl 10uM CHC-Cmpl 3uM -0.04379 0.02069 24 -2.12 0.0448 Tukey 0.4328
CHC-Cmpl 10uM CHC-Cmpl 40uM 0.079 0.02069 24 3.82 0.0008 Tukey 0.016
CHC-Cmpl 10uM CHC-Cmpl 48uM 0.1212 0.02069 24 5.86 <.0001 Tukey 0.0001
CHC-Cmpl 10uM CHC-Cmpl 5uM -0.04593 0.02069 24 -2.22 0.0361 Tukey 0.375
CHC-Cmpl 20uM CHC-Cmpl 30uM 0.05638 0.02069 24 2.73 0.0118 Tukey 0.163
CHC-Cmpl 20uM CHC-Cmpl 3uM -0.04349 0.02069 24 -2.1 0.0462 Tukey 0.4412
CHC-Cmpl 20uM CHC-Cmpl 40uM 0.0793 0.02069 24 3.83 0.0008 Tukey 0.0155
CHC-Cmpl 20uM CHC-Cmpl 48uM 0.1215 0.02069 24 5.88 <.0001 Tukey 0.0001
CHC-Cmpl 20uM CHC-Cmpl 5uM -0.04563 0.02069 24 -2.21 0.0372 Tukey 0.383
CHC-Cmpl 30uM CHC-Cmpl 3uM -0.09987 0.02069 24 -4.83 <.0001 Tukey 0.0014
CHC-Cmpl 30uM CHC-Cmpl 40uM 0.02292 0.02069 24 1.11 0.2788 Tukey 0.9488
CHC-Cmpl 30uM CHC-Cmpl 48uM 0.06517 0.02069 24 3.15 0.0043 Tukey 0.0705
CHC-Cmpl 30uM CHC-Cmpl 5uM -0.102 0.02069 24 -4.93 <.0001 Tukey 0.0011
CHC-Cmpl 3uM CHC-Cmpl 40uM 0.1228 0.02069 24 5.94 <.0001 Tukey <.0001
CHC-Cmpl 3uM CHC-Cmpl 48uM 0.165 0.02069 24 7.98 <.0001 Tukey <.0001
CHC-Cmpl 3uM CHC-Cmpl 5uM -0.00214 0.02069 24 -0.1 0.9185 Tukey 1
CHC-Cmpl 40uM CHC-Cmpl 48uM 0.04225 0.02069 24 2.04 0.0523 Tukey 0.4768
CHC-Cmpl 40uM CHC-Cmpl 5uM -0.1249 0.02069 24 -6.04 <.0001 Tukey <.0001
CHC-Cmpl 48uM CHC-Cmpl 5uM -0.1672 0.02069 24 -8.08 <.0001 Tukey <.0001
Obs complex concentration Estimate tandard Err Letter
Group
1 CHC-Cmpl 5uM 0.7235 0.01463 A
2 CHC-Cmpl 3uM 0.7214 0.01463 A
3 CHC-Cmpl 0uM 0.7121 0.01463 A
4 CHC-Cmpl 20uM 0.6779 0.01463 AB
5 CHC-Cmpl 10uM 0.6776 0.01463 AB
6 CHC-Cmpl 30uM 0.6215 0.01463 BC
7 CHC-Cmpl 40uM 0.5986 0.01463 C
8 CHC-Cmpl 48uM 0.5563 0.01463 C
Differences of Least Squares Means
Statistical Analysis for CHC-Complex Ab Attenuation Studies by Tukey's test
Effect=complex*concentratio Method=Tukey(P<.05) Set=1
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
3uM CHC-Cmpl 3uM GA-Cmplx 0.00848 0.02646 12 0.32 0.7541 Tukey 0.988
3uM CHC-Cmpl 3uM KDN-Cmpl -0.0554 0.02646 12 -2.09 0.0582 Tukey 0.2097
3uM CHC-Cmpl 3uM Pyran-Cm -0.02389 0.02646 12 -0.9 0.3842 Tukey 0.8035
3uM GA-Cmplx 3uM KDN-Cmpl -0.06388 0.02646 12 -2.41 0.0326 Tukey 0.127
3uM GA-Cmplx 3uM Pyran-Cm -0.03237 0.02646 12 -1.22 0.2446 Tukey 0.6245
3uM KDN-Cmpl 3uM Pyran-Cm 0.03151 0.02646 12 1.19 0.2567 Tukey 0.6436
Obs oncentratio complex Estimatetandard Err Letter
Group
1 3uM KDN-Cmpl 0.7768 0.01871 A
2 3uM Pyran-Cm 0.7453 0.01871 A
3 3uM CHC-Cmpl 0.7214 0.01871 A
4 3uM GA-Cmplx 0.7129 0.01871 A
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for Sugar Complex Ab Attenuation Studies at 3uM by Tukey's test
oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
5uM CHC-Cmpl 5uM GA-Cmplx -0.01189 0.02468 12 -0.48 0.6386 Tukey 0.9617
5uM CHC-Cmpl 5uM KDN-Cmpl -0.1125 0.02468 12 -4.56 0.0007 Tukey 0.0032
5uM CHC-Cmpl 5uM Pyran-Cm -0.09552 0.02468 12 -3.87 0.0022 Tukey 0.0103
5uM GA-Cmplx 5uM KDN-Cmpl -0.1006 0.02468 12 -4.08 0.0015 Tukey 0.0072
5uM GA-Cmplx 5uM Pyran-Cm -0.08363 0.02468 12 -3.39 0.0054 Tukey 0.024
5uM KDN-Cmpl 5uM Pyran-Cm 0.01702 0.02468 12 0.69 0.5036 Tukey 0.8991
Obs oncentratio complex Estimatetandard Err Letter
Group
1 5uM KDN-Cmpl 0.8361 0.01745 A
2 5uM Pyran-Cm 0.819 0.01745 A
3 5uM GA-Cmplx 0.7354 0.01745 B
4 5uM CHC-Cmpl 0.7235 0.01745 B
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar Complex Ab Attenuation Studies at 5uM by Tukey's test
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
10uM CHC-Cmpl 10uM GA-Cmplx -0.0339 0.01784 12 -1.9 0.0817 Tukey 0.2783
10uM CHC-Cmpl 10uM KDN-Cmpl -0.1779 0.01784 12 -9.97 <.0001 Tukey <.0001
10uM CHC-Cmpl 10uM Pyran-Cm -0.1176 0.01784 12 -6.59 <.0001 Tukey 0.0001
10uM GA-Cmplx 10uM KDN-Cmpl -0.144 0.01784 12 -8.07 <.0001 Tukey <.0001
10uM GA-Cmplx 10uM Pyran-Cm -0.08366 0.01784 12 -4.69 0.0005 Tukey 0.0025
10uM KDN-Cmpl 10uM Pyran-Cm 0.06035 0.01784 12 3.38 0.0054 Tukey 0.0243
Obs oncentratio complex Estimatetandard Err Letter
Group
1 10uM KDN-Cmpl 0.8555 0.01261 A
2 10uM Pyran-Cm 0.7951 0.01261 B
3 10uM GA-Cmplx 0.7115 0.01261 C
4 10uM CHC-Cmpl 0.6776 0.01261 C
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Differences of Least Squares Means
Statistical Analysis for Sugar Complex Ab Attenuation Studies at 10uM by Tukey's test
oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
20uM CHC-Cmpl 20uM GA-Cmplx 0.05347 0.02558 12 2.09 0.0586 Tukey 0.211
20uM CHC-Cmpl 20uM KDN-Cmpl -0.1158 0.02558 12 -4.53 0.0007 Tukey 0.0033
20uM CHC-Cmpl 20uM Pyran-Cm -0.04122 0.02558 12 -1.61 0.1331 Tukey 0.4087
20uM GA-Cmplx 20uM KDN-Cmpl -0.1693 0.02558 12 -6.62 <.0001 Tukey 0.0001
20uM GA-Cmplx 20uM Pyran-Cm -0.09469 0.02558 12 -3.7 0.003 Tukey 0.0139
20uM KDN-Cmpl 20uM Pyran-Cm 0.0746 0.02558 12 2.92 0.0129 Tukey 0.0548
Obs oncentratio complex Estimatetandard Err Letter
Group
1 20uM KDN-Cmpl 0.7937 0.01809 A
2 20uM Pyran-Cm 0.7191 0.01809 AB
3 20uM CHC-Cmpl 0.6779 0.01809 BC
4 20uM GA-Cmplx 0.6244 0.01809 C
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar Complex Ab Attenuation Studies at 20uM by Tukey's test
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oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
30uM CHC-Cmpl 30uM GA-Cmplx 0.001437 0.03142 12 0.05 0.9643 Tukey 1
30uM CHC-Cmpl 30uM KDN-Cmpl -0.1405 0.03142 12 -4.47 0.0008 Tukey 0.0037
30uM CHC-Cmpl 30uM Pyran-Cm -0.1233 0.03142 12 -3.92 0.002 Tukey 0.0094
30uM GA-Cmplx 30uM KDN-Cmpl -0.1419 0.03142 12 -4.52 0.0007 Tukey 0.0034
30uM GA-Cmplx 30uM Pyran-Cm -0.1247 0.03142 12 -3.97 0.0019 Tukey 0.0087
30uM KDN-Cmpl 30uM Pyran-Cm 0.01719 0.03142 12 0.55 0.5944 Tukey 0.9456
Obs oncentratio complex Estimatetandard Err Letter
Group
1 30uM KDN-Cmpl 0.762 0.02222 A
2 30uM Pyran-Cm 0.7448 0.02222 A
3 30uM CHC-Cmpl 0.6215 0.02222 B
4 30uM GA-Cmplx 0.6201 0.02222 B
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar Complex Ab Attenuation Studies at 30uM by Tukey's test
oncentratio  complex oncentratio  _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
40uM CHC-Cmpl 40uM GA-Cmplx -0.00794 0.02058 12 -0.39 0.7064 Tukey 0.9796
40uM CHC-Cmpl 40uM KDN-Cmpl -0.1651 0.02058 12 -8.02 <.0001 Tukey <.0001
40uM CHC-Cmpl 40uM Pyran-Cm -0.1185 0.02058 12 -5.76 <.0001 Tukey 0.0005
40uM GA-Cmplx 40uM KDN-Cmpl -0.1572 0.02058 12 -7.64 <.0001 Tukey <.0001
40uM GA-Cmplx 40uM Pyran-Cm -0.1105 0.02058 12 -5.37 0.0002 Tukey 0.0008
40uM KDN-Cmpl 40uM Pyran-Cm 0.04666 0.02058 12 2.27 0.0426 Tukey 0.1606
Obs oncentratio complex Estimatetandard Err Letter
Group
1 40uM KDN-Cmpl 0.7637 0.01455 A
2 40uM Pyran-Cm 0.7171 0.01455 A
3 40uM GA-Cmplx 0.6065 0.01455 B
4 40uM CHC-Cmpl 0.5986 0.01455 B
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar Complex Ab Attenuation Studies at 40uM by Tukey's test
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oncentratio  complex _concentration _complex Estimate andard Erro  DF t Value Pr > |t| Adjustment Adj P
48uM CHC-Cmpl 48uM GA-Cmplx -0.07881 0.02636 12 -2.99 0.0113 Tukey 0.0483
48uM CHC-Cmpl 48uM KDN-Cmpl -0.1309 0.02636 12 -4.97 0.0003 Tukey 0.0016
48uM CHC-Cmpl 48uM Pyran-Cm -0.1663 0.02636 12 -6.31 <.0001 Tukey 0.0002
48uM GA-Cmplx 48uM KDN-Cmpl -0.05211 0.02636 12 -1.98 0.0715 Tukey 0.2495
48uM GA-Cmplx 48uM Pyran-Cm -0.08754 0.02636 12 -3.32 0.0061 Tukey 0.0271
48uM KDN-Cmpl 48uM Pyran-Cm -0.03542 0.02636 12 -1.34 0.2039 Tukey 0.5548
Obs concentration complex Estimate tandard Err Letter
Group
1 48uM Pyran-Cm 0.7227 0.01864 A
2 48uM KDN-Cmpl 0.6873 0.01864 AB
3 48uM GA-Cmplx 0.6352 0.01864 B
4 48uM CHC-Cmpl 0.5563 0.01864 C
Differences of Least Squares Means
Effect=concentratio*complex Method=Tukey(P<.05) Set=1
Statistical Analysis for Sugar Complex Ab Attenuation Studies at 48uM by Tukey's test
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